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3 Abstract 
Carotid artery stenosis is a major risk factor of stroke.  Carotid endarterectomy is the 
established treatment of choice for severe carotid stenosis.  Carotid stenting has gained 
widespread acceptance as alternative treatment, although trials of safety and efficacy 
have been inconclusive and contradictory.  
The history of our understanding of stroke and carotid atherosclerotic disease is 
sketched.  Landmark trials of stroke prevention, including the carotid endarterectomy 
trials are discussed.  The long-term results of one of the first trials of endovascular 
treatment, the Carotid And Vertebral Transluminal Angioplasty Study (CAVATAS) are 
presented and the results placed in context of other clinical trials of endovascular 
treatment for carotid stenosis. This Cochrane Review informed the largest completed trial 
of stenting and surgery in symptomatic carotid stenosis, the International Carotid 
Stenting Study (ICSS), whose short-term results up to 120 days after treatment are 
detailed.   
Age-related white matter changes are thought to be associated with an increased risk of 
per-procedural stroke and death.  A study investigating the risk of stroke or death 
associated with age-related white matter changes is presented and discussed.   
CAVATAS has suggested that the risks and benefits of endovascular treatment for 
carotid stenosis may be similar to those of carotid endarterectomy.  The Cochrane review 
revealed variable results of published randomised clinical trials.  ICSS showed that 
carotid stenting was associated with a significantly higher short-term risk of stroke, 
myocardial infarction or death up to 120 days after treatment than carotid 
endarterectomy.  Age-related white matter changes were shown to increase the risk of 
stroke or death in both treatment arms. 
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Carotid endarterectomy should remain the treatment of choice for symptomatic carotid 
stenosis but stenting remains an option for certain patients, especially those less suitable 
for carotid endarterectomy.  Scope for further research remains to improve patient 
selection and to compare invasive treatment to modern medical therapy. 
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8 Introduction 
8.1 Purpose and Outline of the Thesis 
Carotid artery atherosclerosis, a major risk factor for cerebral ischaemia and stroke is the 
topic of this thesis.  Several competing treatment options developed for patients with 
carotid artery atherosclerosis have led to uncertainty as to what the safest and most 
effective way of treating patients with carotid artery disease is and they will be discussed 
in this thesis.   The aim of the thesis is to provide a comprehensive overview of carotid 
artery atherosclerosis, the available treatment options and how these different treatment 
modalities compare.   The thesis will add to the understanding of management and 
treatment of carotid artery atherosclerosis. 
A brief historical overview of major developments in stroke medicine and carotid artery 
atherosclerosis in particular will be followed by a definition of stroke and transient 
ischaemic attack (TIA), which often result from carotid disease.  The main questions of 
pathology (what has happened?) and aetiology (what is the mechanism?) of stroke will 
be addressed followed by a description of the imaging modalities available to confirm the 
diagnosis of stroke.     
The incidence of carotid artery atherosclerosis as one of the main risk factors of stroke 
will be discussed.  The different techniques of diagnosing and measuring carotid 
narrowing will be set out and the treatment options carotid endarterectomy, 
endovascular treatment and medical care will be explained. 
This will be followed by a detailed description, analysis and interpretation of two 
landmark trials of endovascular treatment of carotid artery stenosis.  The thesis covers 
almost two decades of research into carotid artery atherosclerosis starting with the 
Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS).  It was one 
of the earliest and largest trials comparing endovascular treatment to carotid 
endarterectomy in patients suitable for surgery or medical treatment in patients not 
29 
suitable for carotid endarterectomy in a controlled and randomised fashion and spurred 
further trials on the topic.  The International Carotid Stenting Study (ICSS) became the 
largest randomised clinical trial of endovascular treatment for carotid stenosis and 
concluded randomisation 16 years after the first patient was randomised into CAVATAS. 
After the presentation of these two pivotal trials, they will be put into context of other 
randomised clinical trials investigating endovascular treatment of carotid stenosis.  This 
will be in the form of a Cochrane-style review, which is the most respected form of 
reviewing the available evidence of medical interventions or treatments and informs not 
only treatment decisions but also healthcare policy in general. 
The thesis will conclude with a summary discussion of the presented data and an outlook 
for future research. 
8.2 Historic Background 
8.2.1 First Description of Stroke 
The ancient Greek Hippocratic Corpus contains several references to apoplexia, or seizure.  
“The healthy subject is taken with a sudden pain, he immediately loses his speech and 
rattles in the throat” (Littré 1839b) can be construed as a clinical description of stroke 
(Clarke 1963).  The Hippocratic Corpus also contains the statement that “unaccustomed 
attacks of numbness and anaesthesia are signs of impeding apoplexy” (Littré 1839a).  It 
has been suggested that this may have been the first description of transient ischaemic 
attacks. 
The Greek physicians contributing to the Hippocratic Corpus (5th – 4th century B.C.) 
believed that disease was a generalised process.  They did not primarily have diagnostic 
considerations in mind (Clarke 1963). 
8.2.2 First Description of Carotid Disease 
In the 17th century, the Swiss physician Johann Jakob Wepfer (1620 – 1695) and his 
English colleague Thomas Willis (1621 – 1675), both pictured below in Figure 8.1, greatly 
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advanced the understanding of cerebrovascular anatomy.  Willis provided a graphical 
representation of the anastomotic network of arteries at the base of the brain that has 
become known as circle of Willis in his work De cerebri anatome.  However, it was Wepfer 
who provided the first written description of these arteries in his work Historiae 
apoplecticum six years before Willis (Gurdjian 1979; Thompson 1996; Tatu et al. 2005).  It 
appears that Wepfer was well aware that occlusion of the extra-cranial vessels could lead 
to “apoplexy”.  Willis on the other hand was much more interested in showing that the 
many anastomoses between carotid and vertebral arteries were able to forestall 
consequences of carotid occlusion (Gurdjian 1979).  Every year the European Stroke 
Conference honours scientists for their work in the field of stroke with the Johann Jakob 
Wepfer Award. 
Figure 8.1 – Johann Jakob Wepfer (left) and Thomas Willis (right) 
  
Rudolf Virchow (1821 – 1902) described a case of carotid thrombosis and ipsilateral 
monocular blindness in 1856 and Sir William Richard Gowers (1845 – 1915) described a 
case of monocular blindness and contralateral hemiplegia in a patient with mitral valve 
stenosis (Virchow 1856; Gowers 1875).  This created the link between clinical presentation 
and occlusive cerebrovascular disease.  
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Charles Miller Fisher was one of the first to study clinically diagnosed occlusion of the 
internal carotid artery at autopsy in the 1950s and began routine removal of the carotid 
arteries at autopsy.  He was able to show that carotid artery disease was responsible for a 
significant number of strokes (Fisher 2001).  
8.2.3 First Treatment of Carotid Disease 
The first attempted thrombo-endarterectomy reported in an English-language journal is 
credited to Elliott Hurwitt and his colleagues at Montefiore Hospital in New York City.  
In January 1953, a 52-year old man was admitted with headache and weakness down his 
right side of the body with aphasia.  Eight days after the admission, an arteriography 
revealed a left internal carotid artery occlusion.  The surgery carried out on the 11th day of 
the hospital admission removed seven centimetres of blood clot from the extracranial 
portion of the internal carotid artery but failed to remove the intracranial parts of the clot.  
For fear of dislodging the clot to the brain the vessel was ligated (Strully et al. 1953). 
On 19 May 1954, Felix Eastcott and colleagues carried out a landmark operation at St 
Mary’s Hospital in London (Eastcott et al. 1954).  A 66-year old female patient was 
suffering repeat transient ischaemic attacks lasting around 30 minutes each and was 
found to have severe carotid stenosis.  By the time of the surgery she has had 33 such 
events over the course of five months.  The carotid bifurcation where the stenosis was 
located was resected and blood-flow restored by end-to-end anastomosis between the 
common and internal carotid arteries.  The patient was completely relieved of her 
symptoms. 
The first case series of carotid endarterectomy was published eleven years after Eastcott’s 
ground-breaking surgery (Debakey et al. 1965).  This was the starting point for 
widespread carotid surgery to correct carotid stenosis.  Carotid endarterectomy remained 
the only available interventional treatment option that could be offered in addition to 
medical therapy for many years.  Its popularity was somewhat dented when two 
randomised trials raised concerns about the safety of the procedure (Fields et al. 1970; 
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Shaw et al. 1984).  Subsequently, large trials were undertaken in Europe and North 
America that eventually restored the reputation of carotid endarterectomy for 
symptomatic carotid stenosis (Barnett et al. 1998; Farrell et al. 1998) and to a lesser degree 
for asymptomatic carotid stenosis (Toole et al. 1995; Halliday et al. 2004). 
8.2.4 First Human Cardiac Catheterisation 
The German physician Werner Forssmann (1904 – 1979) carried out the first human 
cardiac catheterisation in a daring act of self-experimentation in 1929.  He inserted a 
cannula into his own antecubital vein and passed a 65 cm catheter to the right auricle in 
the heart.  He then walked to the X-ray department to prove the location of the catheter 
tip (Forssmann 1929).  Ferdinand Sauerbruch (1875 – 1951) under whom he started 
training as a surgical assistant at the Charité in Berlin shortly thereafter did not approve 
of his work and fired him upon learning of the publication of the article detailing his 
achievement.  The Nobel Foundation in Stockholm, however, recognised Forssmann’s 
important contribution to medicine and in 1956 he was awarded the Nobel Prize for 
Physiology or Medicine. 
8.2.5 The Birth of Interventional Radiology 
On 16 January 1964, Charles Dotter (1920 – 1985) carried out the first percutaneous 
transluminal angioplasty (PTA).  He used a guide wire and coaxial Teflon catheter to 
dilate the tight, localised stenosis of the superficial femoral artery in a 82-year old woman 
with leg ischaemia and gangrene who had refused amputation (Dotter et al. 1964).  To the 
surprise of the surgical team who had kept the patient in hospital under observation fully 
expecting the dilated artery to thrombose, the artery stayed open until her death from 
pneumonia two-and-a-half years later (Rosch et al. 2003).  This milestone was followed by 
refinements of the technique and instrumentation in the coming years.   
In 1973, the first clinically applicable balloon catheters were introduced (Porstmann 
1973).  Andreas Grüntzig’s polyvinyl chloride balloon catheter was introduced in 1974 
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(Gruntzig et al. 1974) and paved the way to the first coronary artery dilation in 1976 
(Gruntzig 1976). 
8.2.6 Expandable Stents 
Frustrated with frequently occluding arteries following successful recanalisation, Dotter 
introduced transluminally placed ‘coil spring endarterial tube grafts’ in 1969 (Dotter 
1969) and they were first approved for use in the biliary system.  In the mid 1980s, a 
variety of self- or balloon-expandable stents made of stainless-steel alloys or Nitinol, an 
alloy of nickel and titanium were introduced (Rosch et al. 2003), among them three self-
expandable stainless-steel stents: The Gianturco Z stent, Palmaz stent and Wallstent 
(Wright et al. 1985).  Wallstent and Palmaz stents were both used in the Carotid and 
Vertebral Artery Transluminal Angioplasty Study (CAVATAS) (Brown et al. 2001). 
8.2.7 Endovascular Treatment of Carotid Disease 
The history of endovascular treatment of carotid stenosis dates back to 1980, when the 
first percutaneous transluminal angioplasty to treat atherosclerotic stenosis was carried 
out in a 64-year old man (Mathias 1981).  Devices designed to protect the brain from 
debris dislodged during dilation of the atherosclerotic lesion initially required a double 
femoral approach (Theron et al. 1987).  But in 1988, Jacques Théron introduced a new 
triple coaxial balloon catheter for carotid angioplasty that included a guiding catheter for 
an occlusive balloon (Theron et al. 1990).  The first publication from the United Kingdom 
on transluminal angioplasty for carotid artery stenosis in seven patients was published in 
1990 and led directly to the setting up of CAVATAS (Brown et al. 1990).  The first reports 
of the use of stents in the carotid artery were published in 1996 (Theron et al. 1996; Yadav 
et al. 1996).  Nevertheless, The American Heart Association counselled against the 
widespread use of carotid angioplasty and stenting without evidence from randomised 
trials, citing CAVATAS as the only multicentre clinical trial underway at the time 
(Bettmann et al. 1998). 
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8.3 Stroke and Transient Ischaemic Attack 
8.3.1 Definition of Stroke and Transient Ischaemic Attack 
According to the World Health Organisation (WHO) stroke is defined as rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, with 
symptoms lasting 24 hours or longer, or leading to death, with no apparent cause other 
than of vascular origin (Hatano 1976). 
This is a fairly broad definition of stroke as a clinical syndrome.  While it stipulates that 
the onset of symptoms should be rapid and their duration 24 hours or more (or leading to 
death), it offers no further description of the nature of cerebral dysfunction and 
underlying vascular pathology. 
The blood supply to the brain can be adversely affected by virtually any disease that 
affects the blood, the heart or the blood vessels themselves.  The nature and location of 
underlying pathology will determine the clinical pattern and severity of cerebral 
dysfunction. 
Symptoms lasting less than 24 hours but fulfilling all other of the above criteria have been 
excluded from the above definition.  They are defined as transient ischaemic attacks 
(TIA).  While the chosen minimum duration for stroke for the above definition was 
somewhat arbitrary, TIAs in practice last for a few minutes only in most cases (Brown et 
al. 2006).  However, waiting for 24 hours before making the diagnosis of stroke cannot be 
regarded as a viable option, given that no time should be wasted in the acute treatment of 
stroke, a fact that is used to promote stroke awareness in the catchphrase “time is brain”.  
Studies of MRI in patients with transient ischaemic attacks have demonstrated that up to 
50% of patients with the classically defined transient ischaemic attack show abnormalities 
on diffusion-weighted MR imaging (DWI) (Engelter et al. 1999; Kidwell et al. 1999).  
Classically defined TIA with DWI abnormalities was also associated with an increased 
risk of subsequent stroke (Purroy et al. 2004; Prabhakaran et al. 2007).  It has therefore 
been suggested to move away from a definition of TIA based on duration of symptoms 
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alone.  The American Heart Association has endorsed a revised definition of TIA that 
uses tissue as criterion: A transient episode of neurological dysfunction caused by focal 
brain, spinal cord, or retinal ischemia, without acute infarction (Easton et al. 2009).  It 
could be argued against this definition that the required brain imaging will vary greatly 
depending on available resources, particularly on the availability of 24-hour MRI.  If this 
tissue-based definition of TIA was used in research, epidemiological studies carried out 
in a community setting may be more difficult to conduct since MRI to confirm the 
diagnosis will not always be available.   
8.3.2 Pathogenesis of Stroke and TIA 
In order to determine the appropriate management and treatment of stroke patients, the 
underlying pathogenic mechanisms need to be elucidated.  They can be broadly divided 
into two categories: (1) Cerebral infarction and (2) haemorrhage.  The latter can further be 
divided into (a) intracerebral and (b) extracerebral (but intracranial) haemorrhage 
(subarachnoid, subdural, epidural haemorrhage). 
Cerebral infarction accounted for 81%, intracerebral haemorrhage for 10% and 
subarachnoid haemorrhage for 5% of all strokes in the Oxfordshire Community Stroke 
Project (Bamford et al. 1990).  In roughly 5% of patients, the mechanism of stroke 
remained uncertain, largely because these patients were elderly and frail and the 
investigators had refrained from transporting them to hospital to perform a CT of the 
brain (Figure 8.2). 
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Figure 8.2 – Distribution of stroke by diagnosis subtype 
The distribution of stroke in the Oxfordshire Community Stroke Project (OCSP, n = 657 patients), South London Stroke 
Register (SLSR, n = 1,254), and the NINDS Stroke Database (SDB, n = 1,805).  Numbers are percentages. 
 
The South London Stroke Register found slightly different proportions with 69% of 
strokes being confirmed radiologically as infarction, 13% intracerebral haemorrhage, and 
6% subarachnoid haemorrhage (Wolfe et al. 2002).  This may reflect differences in 
demography and racial mix in a mostly rural (Oxfordshire) versus city (South London) 
setting.  The South London Stroke Register findings were similar to the distribution of 
stroke subtype in the NINDS Stroke Data Bank (Foulkes et al. 1988). 
A TIA is presumed to be ischaemic rather than haemorrhagic in nature (Brown et al. 
2006), although a small proportion of about 2% of TIAs demonstrate a small intracerebral 
haemorrhage on imaging. 
8.3.3 Aetiology of Cerebral Infarction and TIA 
Most strokes and transient ischaemic attacks are caused by thrombo-embolism from 
either the heart (cardio-embolic), atherosclerosis in a large extracranial or intracranial 
vessel (atherothrombotic), or disease of the small perforating vessels in the brain (lacunar 
stroke).  Rare causes of ischaemic stroke such as sickle cell disease, dissection, or atrial 
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myxoma may be identified, but in a large proportion of patients the origin of infarction or 
TIA remains elusive or more than one cause can be identified (Figure 8.3). 
A uniform system of classifying ischaemic stroke type has been developed for use in the 
Trial of ORG 10172 in Acute Stroke (TOAST) (Adams et al. 1993).  The TOAST 
classification has gained widespread acceptance in clinical practice.  It divides stroke into 
5 categories:  
(1) Large-vessel atherosclerosis  
(2) Cardio-embolic small-vessel occlusion  
(3) Small-vessel occlusion (lacune) 
(4) Other determined cause  
(5) Undetermined aetiology 
The TOAST classification defines lacunar strokes as a clinical syndrome and emphasises 
size of the infarct.  This may lead to a small deep infarct due to middle cerebral artery 
atherosclerosis falsely being classified as small-vessel occlusion.  Stroke of undetermined 
aetiology is a very inhomogeneous group in the TOAST classification.  It groups patients 
with at least two different causes with those patients in whom work-up did not reveal a 
cause of stroke as well as patients with mild carotid artery stenosis (< 50%) (Amarenco et 
al. 2009a).  This not only has implications for research, where it may lead to inappropriate 
patient selection but also may impact on clinical care.  Grouping these patients together 
in the category of undetermined aetiology may lead to an over-sizing of this group and 
result in inappropriate closure of innocent patent foramen ovale (Amarenco et al. 2009a). 
A new stroke classification taking into account that many patients display more than one 
risk factor has since been proposed.  The A-S-C-O classification grades patients in the 
categories atherosclerosis (A), small vessel disease (S), cardioembolic (C) and other cause 
(O) from 1 (‘definitely a potential cause of the stroke’) to 3 (‘unlikely a direct cause of the 
index stroke, but disease present’) (Amarenco et al. 2009b).  This classification provides a 
more complete picture of a patient’s likely underlying cause of stroke.  It is not very 
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useful in the clinical setting and might be more useful in research where a as precise 
description and categorisation of stroke as possible is required. 
Large-vessel Atherosclerosis 
Large-vessel atherosclerosis is largely associated with stenosis either of the internal 
carotid artery itself or at the site of the carotid bifurcation.  Less frequently it is due to 
stenosis of the large intracerebral arteries.   
Large-vessel atherosclerosis accounts for about 6% of all strokes (Foulkes et al. 1988).  
However, this seems to be an underestimate since 6% was the proportion of stenosis 
greater than 70% where the association with stroke was clear.  Up to 40% of cases have 
some degree of carotid atherosclerosis that may have been responsible for the symptoms 
and the proportion of stroke attributed to large-vessel atherosclerosis varies according to 
the criteria used for making the diagnosis.   
It is thought that rupture of atherosclerotic plaque leads to platelet aggregation at the site 
of rupture and thrombus formation.  This can either lead to local occlusion or 
embolisation to a distal vessel (Rothwell 2007).  Several studies in recent years have 
investigated the link between ruptured atherosclerotic lesions (unstable plaque) and 
cerebral infarction and found a correlation between characteristics of plaque instability 
and recent symptoms, particularly stroke (Clarke et al. 2003; Spagnoli et al. 2004; 
Redgrave et al. 2006). 
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Figure 8.3 – NINDS Stroke Database: Distribution of ischaemic stroke by subtype 
Shown is the proportion of patients (%, n = 1,305) in each category enrolled in the NINDS Stroke Database (Foulkes 
et al. 1988). 
 
Large-vessel stenosis or occlusion may remain asymptomatic if sufficient collateral 
circulation (likely to be congenital) via the external carotid artery or the circle of Willis is 
present (Powers 1991; van Everdingen et al. 1998; Liebeskind 2003) and unpublished 
observations suggest that up to 90% of carotid occlusions are asymptomatic.  The 
collateral circulation is not always adequate to maintain sufficient blood flow to the 
brain.  This haemodynamic failure may lead to ischaemia (Grubb et al. 1998; Derdeyn et 
al. 2007).   
Cardio-embolism 
Patients with arterial occlusions attributed to an embolus arising from the heart fall into 
this category (Adams et al. 1993).  Atrial fibrillation, recent myocardial infarction, 
mechanical prosthetic heart valve and infective endocarditis are among the high-risk 
sources of cardiac emboli.  Cardio-embolism accounts for about 20% of ischaemic strokes 
(Foulkes et al. 1988). 
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Small-vessel Occlusion 
Occlusion of small penetrating branches of the cerebral arteries leads to infarction of deep 
white matter regions of the cerebrum or brainstem and grey matter in the basal ganglia.  
These infarcts are often small in size depending on the size of the affected artery.  Their 
name is derived from the Latin word lacuna (hole) and is a reference to their patho-
histological appearance as fluid-filled cavities (Dechambre 1838; Fisher 1965). 
Depending on the size of the affected penetrating artery, different pathological 
mechanisms are incriminated in the formation of lacunar infarcts.  Lipohyalinosis 
associated with fibrinoid necrosis and infiltration of the vessel wall by macrophages 
leads to occlusion of very small arteries (40 to 200 µm in diameter) (Fisher 1982).  
Intracranial atherosclerosis of the proximal portion of the perforating artery 
(microatheroma), the parent vessel (mural atheroma) or at the origin from the parent 
vessel (junctional atheroma) affects vessels in the range of 200 to 900 µm in diameter and 
leads to larger infarcts (Lammie 2000).  Radiologically, lacunar infarcts are defined as 
discrete areas of decreased attenuation on CT or abnormal signal intensity on MRI of less 
than 1.5 cm in diameter located in the basal ganglia, internal capsule, thalamus, 
brainstem or corona radiata (Brown et al. 1988). 
Charles Miller Fisher was able to connect his pathological findings to several clinical 
syndromes (Fisher 1965) and he described 5 classical clinical syndromes: 
• Pure motor hemiparesis is defined as palsy of the face, arm, leg on one side 
without accompanying sensory disturbances, alterations of the visual field, or 
aphasia (Fisher et al. 1965) 
• Pure sensory stroke is characterised by hypoaesthesia and/or paraesthesia 
• Sensory motor stroke combines features of the pure motor and pure sensory 
stroke syndromes 
• Hemiparesis in association with homolateral “cerebellar” signs characterises the 
ataxic hemiparesis and dysarthria-clumsy-hand syndromes. 
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Other Determined Causes of Stroke 
The list of causes of stroke that do not fall into one of the above categories is vast.  These 
only account for 3% of all strokes (Foulkes et al. 1988) but often require specific treatment.  
They are especially important to consider in young patients in whom the conventional 
risk factors for stroke such as hypertension, atrial fibrillation and atherosclerosis are less 
prevalent.  In many cases the rare causes are systemic diseases and stroke are only one of 
many possible manifestations. 
8.3.4 Epidemiology 
Stroke is one of the leading causes of death and adult disability.  In 2001, almost 10% of 
total deaths worldwide were due to cerebrovascular disease (Lopez et al. 2006).  In high-
income countries, cerebrovascular disease was the second most common cause of disease 
burden and it was among the top five causes of disease burden in low-to-middle-income 
countries as measured by disability adjusted life years (DALY) (Lopez et al. 2006). 
The majority of strokes occur in the age group of over 65 years (Bamford et al. 1990; 
Rothwell et al. 2004a) but can occur at any age from birth onwards.  A quarter of strokes 
occur under the age of 65.  Overall, around 30% of patients will have died after a stroke 
and a further one-third of patients will be dependant on others (Bamford et al. 1990). 
Population-based studies have found incidences of first stroke per 1,000 population of 
1.33 in a multi-ethnic community in South London, 1.45 in Oxfordshire and 1.58 in East 
Lancashire (Du et al. 1997; Wolfe et al. 2002; Rothwell et al. 2004a).  Differences between 
subgroups have been described with respect to different stroke subtypes (Figure 8.4).  In 
South London, cardioembolic stroke was more frequent in White patients than in Black 
African or Black Caribbean patients, while small-vessel disease and intracerebral 
haemorrhage were more common in Black African patients (Markus et al. 2007). 
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Figure 8.4 – Distribution of stroke (ischaemic and haemorrhagic) by TOAST criteria 
Shown are the proportions of Black (n = 600) and White patients (n = 600) with stroke in the South London 
Ethnicity and Stroke Study (Markus et al. 2007). Numbers are percentages. 
 
The rate of recurrent stroke is high.  A population-based study carried out in Southern 
Germany found recurrent stroke in 24% of patients over a period of 5 years (Kolominsky-
Rabas et al. 2006).  Patients with symptomatic carotid stenosis are at an especially high-
risk of recurrent stroke.  In the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET), the risk of fatal or nonfatal ipsilateral stroke was 22.2% over five years in 
patients treated medically and 15.7% in patients treated surgically (Barnett et al. 1998).  
Many patients never got into NASCET because of early recurrence and the true rate of 
recurrent stroke in patients with previously symptomatic carotid artery stenosis is 
undoubtedly higher than reported in NASCET.   
The Oxford Vascular Study (OXVASC) included 38 patients with carotid stenosis greater 
than 50% (Figure 8.5).  The risk of recurrent stroke prior to any endarterectomy in these 
patients was 24% at 14 days and 37% at 12 weeks (Fairhead et al. 2005). 
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Figure 8.5 – Oxford Vascular Study: Risk of recurrent stroke  
Shown is the risk in 38 patients with TIA or non-disabling stroke with ≥ 50% carotid stenosis up to the day of any 
endarterectomy.  Adopted from (Fairhead et al. 2005) with permission from Wolters Kluwer Health. 
 
In asymptomatic carotid stenosis the risk of stroke is lower, with 9.5% of patients 
suffering a stroke in the carotid territory over a 5-year period (Halliday et al. 2004).  
However, medical treatment at the time the surgical trials were carried out differed from 
today’s clinical practice.  Especially lipid-lowering medication was used only in a 
minority of patients (Barnett et al. 1998). 
The cost of stroke to society is considerable.  In the UK, direct stroke costs account for 
about 5.5% of National Health Service expenditure, or £ 4 billion (Saka et al. 2009).  In 
Germany, the direct costs of stroke amount to € 2.5 billion (Statistisches Bundesamt 
2007). 
8.4 Imaging the Brain 
Structural brain imaging is vital in correctly diagnosing cerebral infarction and 
differentiating it from haemorrhage and other pathological processes that may mimic 
stroke and guides further investigations and treatment.  The mainstay imaging technique 
is x-ray computed tomography (CT) because of the speed of study acquisition and wide 
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availability of CT scanners.  It is the diagnostic imaging modality of choice to exclude 
intracerebral haemorrhage.  Magnetic resonance imaging (MRI) has a number of 
advantages but is more expensive, time consuming, and not yet as widely available. 
8.4.1 X-ray Computed Tomography 
Very early changes of cerebral infarction may be very subtle and difficult to pick up on x-
ray computed tomography (CT).  The major early signs of infarction in the territory of the 
middle cerebral artery (MCA) involve blurring of the internal capsule, loss of distinction 
of the insular ribbon, loss of grey and white matter differentiation and effacement of the 
sulci.  They can be identified within the first few hours of a stroke (Beauchamp et al. 
1999).  Acute thrombosis or embolic occlusion of a major vessel may be indicated by a 
hyper-dense appearance of the affected vessel.   
Ischaemia leads to cerebral capillary dysfunction and water influx into the brain (Simard 
et al. 2007).  Over the next 24 hours, these changes evolve into the clearly defined 
hypodense appearance of established infarction (Figure 8.6).   
The Alberta Stroke Project early CT score (ASPECTS) divides the middle cerebral artery 
territory into ten regions that are scored for the presence or absence of ischaemic changes.  
This score was shown to predict poor outcome following thrombolysis (Barber et al. 
2000).  The appearance of ischaemic changes evolve over the next few weeks and 
infracted tissue becomes increasingly hypodense.  However, CT may be normal within 
the first 24 hours if the infarct is small and acute small white matter infarcts may be very 
difficult to diagnose in the presence of leukoaraiosis. 
The high contrast between bone and brain parenchyma in the posterior cerebral fossa 
often causes severe beam-hardening artefacts that make the assessment of the brainstem 
and cerebellum difficult (Merino et al. 2010).   
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Figure 8.6 – X-ray computed tomography of ischaemic stroke 
Serial CT images of a left MCA territory stroke in a 71-year old female patient.  The infarct is already well demarcated 
on the day of stroke onset (left) and 3 days after the event (middle).  However, both studies underestimated the true 
area of damage visible after 10 months (right). Images courtesy R. Jäger 
 
Haemorrhage usually leads within minutes to an increase in density (Figure 8.7).  Over 
time the imaging appearance of haemorrhage changes and an area of haemorrhage will 
appear less dense.  In delayed CT it is often impossible to distinguish between infarction 
and haemorrhage.  This phenomenon has been reported to occur by 14 days for lesions of 
moderate size (Dennis et al. 1987).  Haemorrhagic lesions smaller than 20 mm in diameter 
were reported to be iso-dense in 25% of cases within 9 days of stroke (Wardlaw et al. 
2004). 
Figure 8.7 – X-ray computed tomography of acute intracerebral haemorrhage 
Shown is a CT and CT angiography of an acute intracerebral bleed (left and middle) in a patient with underlying 
arterio-venous malformation (right, arrow).  Images courtesy R. Jäger. 
 
Perfusion CT measures brain haemodynamics by tracking a bolus of i.v. contrast and can 
identify areas of hypoperfusion in the setting of acute stroke (Hoffmann et al. 2012). 
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Cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time (MTT) 
can be calculated. Their relationship is described by CBF = CBV/MTT, known as the 
central volume principle (Muizelaar et al. 1997).   
In stroke patients, perfusion CT aims at distinguishing unsalvageable tissue (infarct core) 
from tissue that may either die or survive, depending on whether timely reperfusion 
occurs (penumbra).  In the infarct core the perfusion pressure is reduced to such extend, 
that autoregulation fails, resulting in reduced CBF and CBV.   
In the penumbra, autoregulation is preserved and induces capillary dilatation in an 
attempt to maintain adequate circulation.  This preserves or increases CBV in the face of 
reduced CBF.  Mean transit time is reduced in the infarct core due to decreased perfusion 
pressure (Hoffmann et al. 2012).  The exact parameters and thresholds that best 
characterise the infarct core and penumbra are yet to be defined (Dani et al. 2011). 
CT angiographic source data provide a qualitative picture of cerebral blood flow and has 
been shown to be superior to non-enhanced brain CT in detecting early changes of 
cerebral ischaemia and in predicting the final extent of the infarct (Ezzeddine et al. 2002; 
Schramm et al. 2002; Camargo et al. 2007).  
A multimodal acute stroke CT protocol should include unenhanced CT, perfusion CT 
and CT angiography. 
8.4.2 Magnetic Resonance Imaging 
Early changes of cerebral infarction are more easily picked up by magnetic resonance 
imaging (MRI) with an overall sensitivity within 6 hours of stroke onset in the region of 
90% (Schellinger et al. 2010).  After a few hours the signal intensity increases on T2-
weighted and decreases on T1-weighted images.  Several special MRI sequences have 
been developed that increase the diagnostic yield compared to CT (Fiebach et al. 2002). 
Diffusion-weighted imaging (DWI) measures the random Brownian motion of water 
molecules due to thermal energy (Hoffmann et al. 2012).  Brain ischaemia causes a 
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shortage of metabolites and results in membrane dysfunction and cytotoxic oedema.  The 
movement of water from the extracellular into the intracellular space in turn leads to a 
narrowing of the extracellular matrix and restriction of molecular movement in the 
extracellular space.  After only a few minutes, ischaemic lesions become apparent on 
DWI as hyperintense signal (Hjort et al. 2005).  Serial diffusion weighted imaging 
demonstrated that in non-treated patients DWI lesions grow in size over hours and days 
(Schwamm et al. 1998).  There has been debate whether DWI lesions represent the infarct 
core and therefore irreversible tissue damage.  Although a small proportion of DWI 
lesions may be reversible, particularly after intra-arterial recanalisation, this reversal is 
often only temporary (Kidwell et al. 2000; Kidwell et al. 2002).  Recent data suggest that 
presence of diffusion restriction can be taken as a clinically reliable indicator of 
irreversible ischaemic damage (Campbell et al. 2012). 
Established infarcts exhibit an increase in signal intensity on T2-weighted images and 
may appear bright on DWI (T2 shine-through).  DWI should therefore always be 
interpreted together with the apparent diffusion coefficient (ADC) maps, which measure 
the change in diffusion more directly.  On ADC maps, acute infarction appears as a 
reduction in signal and thus allows distinguishing acute from established infarction 
(Figure 8.9 and Figure 8.8).  Over the next few days, a pseudo-normalization of ADC 
values takes place before they finally increase. 
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Figure 8.8 – CT and MRI of acute and chronic ischaemic stroke 
Shown are a CT, T2w-MRI, DWI and ADC (from left to right) in a patient with a chronic right-sided (*) and acute left-
sided occipital infarct (arrow).  Images courtesy R. Jäger. 
 
Gradient-recalled echo MRI can accurately exclude intracerebral haemorrhage (Fiebach et 
al. 2004).  The paramagnetic properties of degraded blood products (deoxyhaemoglobin) 
allow their visualisation on MRI in the acute phase as focal hypointensities (Hoffmann et 
al. 2012).   
 
Figure 8.9 – MRI of an acute left MCA territory stroke 
Shown are sagitall T1w, coronal FLAIR (top, left to right), and transverse T2w, DWI, and ADC (bottom, left to right) 
sequences of an acute left MCA territory stroke.  Images courtesy R. Jäger. 
 
*! *! *! *!
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T2-weighted fluid-attenuated inversion recovery sequences (FLAIR) visualise white 
matter and small cortical lesions particularly well due to the suppression of free water 
signal (Beauchamp et al. 1999).  Changes in FLAIR signal intensities are dependent on 
time since symptom onset and were shown to be useful as surrogate marker of stroke age 
(Petkova et al. 2010).  Ischaemic changes are not visible on FLAIR within 6 hours of stroke 
onset (Merino et al. 2010).  Combining DWI and FLAIR has shown to be helpful in timing 
stroke onset.  Positive findings on DWI and absence of hyperintensity on FLAIR indicate 
that the stroke has occurred less than 4.5 hours previously (Thomalla et al. 2011).  
Unwitnessed stroke accounts for more than 20% of all strokes (Maas et al. 2011).  Studies 
are under way investigating the combination of DWI and FLAIR and may in the future 
allow extending thrombolysis to patients who are currently not eligible for thrombolytic 
treatment because of the unknown time of onset of stroke (Thomalla et al. 2011).  
Vessel hyperintensities detected by FLAIR indicate disordered blood flow from collateral 
vessels distal to the arterial occlusion or stenosis and is an indicator for tissue at risk for 
infarction but does not predict response to thrombolysis (Schellinger et al. 2005; Azizyan 
et al. 2010).   
Similar to CT, MR can be used to generate perfusion imaging.  Two methods are 
available.  Arterial spin-labelling relies on the detection of magnetically labelled water 
protons to measure perfusion.  Arterial protons are labelled by applying radiofrequency 
pulses upstream from the imaging plane.  Once labelled blood reaches the imaging 
section, images are obtained in the labelled and unlabelled state.  Perfusion parameters 
are obtained by subtracting the two imaging sets (Pollock et al. 2009; Hoffmann et al. 
2012).  The technique is still at an experimental stage but does not require intravenous 
gadolinium-based contrast agents, which is needed in dynamic susceptibility contrast-
enhanced imaging (DSC-PWI). 
DSC-PWI measures the decrease in T2-signal caused by the susceptibility effect of 
intravascular MR contrast agents. The signal changes during the first pass through the 
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capillary bed are tracked to create time-intensity curves used to calculate the perfusion 
parameters CBF, CBV and MTT. This step is more complicated as is the case in perfusion 
CT because the relationship between signal intensity and gadolinium concentration is not 
linear.  The ideal criteria to describe the infarcted area are yet to be defined (Kane et al. 
2007). 
In combination with DWI, perfusion imaging can be used to estimate the ischaemic 
penumbra, with the DWI lesion representing the infarct core and the PWI lesion 
representing the complete hypoperfused area including the potentially salvageable 
penumbra. 
The major disadvantages of MRI are its high cost, duration of study acquisition and the 
fact that a number of patients with metal implants may be excluded.  MRI may also be 
difficult to carry out in claustrophobic patients. 
A clinical multimodal stroke MRI protocol should include DWI/ADC, gradient-echo, 
FLAIR, MR angiography and perfusion-weighted imaging. 
8.5 Internal Carotid Artery Stenosis 
8.5.1 Incidence of Carotid Artery Stenosis 
Information on the prevalence of carotid stenosis is only available for select patient 
populations.  In a study of 526 subjects the prevalence of stenosis greater than 50% was 
6.1% in men aged 75 years or older (Josse et al. 1987).  In a different study of 
predominantly male patients treated for non-vascular diseases, the prevalence of 
asymptomatic carotid stenosis was 6.5% (Fowl et al. 1991).  A systematic review of 
published literature showed a prevalence of moderate (more than 50%) stenosis of 4.2% 
(de Weerd et al. 2009). 
8.5.2 Carotid Artery Stenosis and the Risk of Stroke 
Carotid stenosis is well recognised as a major risk for stroke.  A study of the natural 
history of asymptomatic patients with extracranial artery disease, the majority of which 
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were carotid stenoses, showed an annual stroke morbidity of 0.4% (Hennerici et al. 1987).  
An analysis carried out in the European Carotid Surgery Trial (ECST) population showed 
a 2.1% overall risk at 3 years of stroke lasting more than 7 days in the territory of mild to 
moderate (0 – 69%) asymptomatic carotid artery stenosis but the risk increased to 9.8% in 
patients with stenosis greater than 80% (Rothwell et al. 1995).  More recently, the annual 
risk of stroke in patients with asymptomatic stenosis greater than 50% was found to be 
0.34% for any ipsilateral ischaemic stroke (Marquardt et al. 2010) and 1.0% for any 
ipsilateral carotid hemispheric stroke in patients with greater than 60% carotid artery 
stenosis (Abbott et al. 2005).  This reduction in annual risk is likely to be at least in part 
due to improved medical therapy, particularly cholesterol and blood pressure control. 
The Asymptomatic Carotid Surgery Trial (ACST) reported a 11.0% 5-year risk of stroke in 
patients allocated deferred surgery, with half of the strokes (62 in 1560 patients) 
occurring in the territory of the ipsilateral carotid artery (Halliday et al. 2004).  But this 
may overestimate the risk in the population as a whole because of selection bias.  Many 
of the patients may also have had previous symptoms from coronary, peripheral or 
contralateral carotid stenosis. 
8.5.3 Imaging the Carotid Artery 
Before the impact and consequences of carotid artery stenosis can be discussed further it 
is important to appreciate how the diagnosis of carotid stenosis is made and how the 
techniques used to measure the degree of narrowing differ.   
Several invasive and non-invasive radiological investigations that allow the degree of 
narrowing to be estimated from the images have emerged over time.  Catheter 
angiography has been established for years as the method of choice in the diagnosis of 
carotid stenosis.  Ultrasound, CT angiography (CTA) and MR angiography with 
(CEMRA) or without contrast agent (MRA) are less invasive imaging modalities.  A 
combination of non-invasive techniques is recommended today to detect carotid stenosis.  
52 
Figure 8.10 shows an example of a carotid artery stenosis on conventional angiography 
and CTA. 
Figure 8.10 – Conventional and CT angiography of carotid stenosis 
Shown is a left carotid artery stenosis on angiography and corresponding CTA.  Images courtesy R. Jäger. 
 
Catheter Angiography 
For many years, catheter angiography was the first-line investigation of carotid stenosis.  
Both the European and North American surgery trials of symptomatic carotid stenosis 
required catheter angiography at baseline.  However, diagnostic angiography in itself 
carries a risk of neurological complications reported in around 1% of patients (Willinsky 
et al. 2003).  It has therefore been largely replaced by non-invasive imaging modalities as 
first choice diagnostic technique and is only used in therapeutic indications or if non-
invasive imaging is inconclusive (Hoffmann et al. 2012).   
The NASCET Method of Measuring Carotid Stenosis 
The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the 
European Carotid Surgery Trial (ECST) used different methods to measure carotid 
stenosis on angiography.  Figure 8.11 illustrates where measurements of the carotid 
artery are taken on angiograms for calculating the degree of carotid stenosis.   
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NASCET measured stenosis as a fraction of the minimum luminal diameter and the 
diameter of the distal internal carotid artery: 
 
  
€ 
Degree of stenosis (%) = B−AB ×100  (1) 
In near occlusions with collapse of the distal carotid artery this method underestimates 
stenosis, but the correct application of the method arbitrarily assigns a stenosis of 95% to 
cases where there is distal collapse. 
The ECST Method of Measuring Carotid Stenosis 
The ECST method requires an estimate of the diameter of the “original”, disease-free 
carotid bulb: 
 
  
€ 
Degree of stenosis (%) = C−AC ×100 (2) 
It is important to be clear which method was used to measure stenosis, because the ECST 
method results in a higher degree of apparent stenosis than the NASCET method 
(Rothwell et al. 2003).  NASCET is the most widely used method and NASCET 
measurements may be converted into ECST stenosis by the following formula (Rothwell 
et al. 1994a): 
 
  
€ 
ECST of% stenosis = 610 ×NASCET% stenosis + 40  (3) 
!
"
#
$
Figure 8.11 – Diagram of three methods of 
measuring carotid stenosis on angiogram.  
The diagram illustrates where measurements for 
equations (1), (2) and (4) are taken. 
A, B and D are measurements made on a visible 
column of x-ray contrast; C is a visual estimate of the 
likely normal lumen diameter before the development 
of the stenosis.  
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The Common Carotid (CC) Method of Measuring Carotid Stenosis 
This third method of measuring of carotid stenosis has also been used in research (Brown 
et al. 2001) and incorporates the diameter of the common carotid artery as the 
denominator: 
 
  
€ 
Degree of stenosis (%) = D−AD ×100  (4) 
This method has the advantage of being easy to use and having a lower intra- and inter-
observer variability than the NASCET and ECST methods (Rothwell et al. 1994b).  The 
results of the common carotid method are very similar to ECST measurements and 
equation (5) may be used to convert NASCET measurements into CC degree of stenosis 
analogous to equation (3): 
 
  
€ 
CC of% stenosis = 610 ×NASCET% stenosis + 40  (5) 
Comparison of the Different Grading Methods 
As laid out above each method of grading carotid stenosis takes a different approach.  A 
study comparing the NASCET, ECST and CC grading methods in 86 patients made 
several interesting observations (Staikov et al. 2000).   
Generally, the inter-observer agreement was good for all three methods.  The Common 
Carotid method appeared to be the most reproducible with 66% of measurements 
showing an inter-observer disagreement of 1% or less and no measurement differed by 
more than 6%.  At the other end of the spectrum, using the NASCET method, 5% of 
measurements differed by 6% or more.   
The study found that the NASCET method underestimated the degree of stenosis 
compared to the ECST and CC methods, while the ECST and CC methods had almost 
identical results (Staikov et al. 2000). 
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A comparison of all three methods in over 1000 patients randomised in ECST found that 
the ECST and CC methods differed from the NASCET method in more than 50% of 
measurements with twice as many stenoses being classified greater than 70% when the 
ECST and CC methods were used (Rothwell et al. 1994a).  Since the relations between 
measurements were approximately linear, they could be converted by a simple equation 
(equations 3 and 5).   
Because the Common Carotid method proved to be the most reproducible of the three it 
was recommended to adopt the CC method as the standard method of measuring the 
degree of carotid stenosis on angiograms (Rothwell et al. 1994b).  However, this view has 
not gained much traction and NASCET remains the method used more widely to 
measure carotid stenosis on angiogram. 
 Ultrasound 
Non-invasive carotid ultrasound has replaced conventional angiography as first-line 
imaging modality for carotid stenosis when CT angiography is not available.  Carotid 
stenosis is best evaluated by a combination of duplex and Doppler techniques.  While the 
stenosis can be visualised using duplex ultrasound, colour-coded Doppler ultrasound 
measures blood-flow velocities (Figure 8.12).   
Figure 8.12 – Carotid Doppler ultrasound of carotid artery stenosis 
Shown are colour Doppler und flow-velocity measurements of a carotid stenosis. Images courtesy P.Sidhu. 
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In the hands of an experienced operator the sensitivity and specificity of carotid 
ultrasound reaches 90% for the presence of severe carotid stenosis.  However, carotid 
ultrasound is very user-dependant and calcifications or tortuous arteries may make an 
accurate measurement of stenosis difficult.  The technique is also limited by the inability 
to insonate the distal internal carotid artery and it may be difficult to know whether 
failure to obtain a good ICA signal is due to occlusion of the vessel or simply technical. 
Flow Velocity Criteria of Measuring Carotid Stenosis  
Neither the NASCET, ECST, nor common carotid method described above are useful in 
measuring carotid stenosis by carotid ultrasound, which has the great advantage of being 
a non-invasive imaging modality.   
Criteria for estimating carotid stenosis by measuring peak systolic and end diastolic flow 
velocities has been established by the Society of Radiologists in Ultrasound Consensus 
Conference (Grant et al. 2003).   
Table 8.1 – Doppler ultrasound flow velocity criteria for estimating the degree of carotid stenosis 
PSV, peak systolic velocity; EDV, end diastolic velocity; ICA, internal carotid artery; CCA, common carotid artery.  
Adopted from (Sidhu et al. 1997) 
Stenosis (%)  PSV ICA (m/s)  EDV ICA (m/s)  PSV ICA/PSV CCA 
0 – 29  < 1.0  < 0.4  < 3.2 
30 – 49  1.1 – 1.3  < 0.4  < 3.2 
50 – 59  > 1.3  < 0.4  < 3.2 
60 – 69   > 1.3  0.4 – 1.1  3.2 – 3.9 
70 – 79   > 2.1  1.2 – 1.4   ≥ 4.0 
80 – 95  > 2.1  > 1.4  ≥ 4.0 
96 – 99  String Flow  String Flow  String Flow 
Occlusion  Occluded  Occluded  Occluded 
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Similar criteria (shown in Table 8.1) are used in the local ultrasound laboratory (Sidhu et 
al. 1997).  The technique relies primarily on the increase in peak systolic velocity with 
increasing stenosis.  PSV is the most accurate parameter for a stenosis between 50% and 
90%.   
Above 90% stenosis, the PSV falls as stenosis approaches occlusion (Brant et al. 2006).  
Carotid occlusion may be difficult to distinguish from severe carotid stenosis using 
carotid ultrasound.  Relying on the lack of pulsation of the vessel wall alone to detect 
carotid occlusion is insufficient (Thiele et al. 1992).  Internal Carotid Stenosis is 
characterised by an increasing spectral broadening, or an increase in the frequency range 
of the Doppler signal.  In expert hands, dolour Doppler ultrasound allows for a narrow 
channel of blood-flow to be identified. 
Carotid ultrasound has been compared to catheter angiography and it has been shown 
that results of carotid Doppler ultrasound correlate well with catheter angiography 
(Eliasziw et al. 1995; Chen et al. 1998; Dinkel et al. 2001).  It has therefore largely replaced 
catheter angiography as first line imaging modality of carotid artery stenosis.  However, 
ultrasound is very subjective and user-dependant.   
MR Angiography With or Without Contrast Agent 
Magnetic resonance angiography allows for imaging of the extracranial and main 
cerebral arteries and can identify the location of a thrombus and visualised recanalisation 
(Blatter et al. 1993; Nederkoorn et al. 2003).  Time-of-flight MRA (TOF-MRA) is used to 
visualise the Circe of Willis, contrast-enhanced MRA (CEMRA) is preferred for the 
imaging of the cervical arteries because it is able to visualise arteries distal to the 
occluded segment (Alfke et al. 2011). 
TOF-MRA is a gradient-echo sequence that relies on the differences in exposure to 
radiofrequency pulses between in-plane saturated stationary tissue protons and blood 
flowing into the plane (Hoffmann et al. 2012).   Slow flow is difficult to differentiate from 
occlusion using TOF-MRA and susceptibility artefacts from vessel wall calcification may 
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limit its use but overall has a similar sensitivity to CEMRA in detecting extracranial 
internal carotid artery stenosis greater than 70% (Debrey et al. 2008). Contrast-enhanced 
MRA relies on intravenous contrast agents to reduce the T1 relaxation time of tissue and 
generates contrast between intravascular lumen and surrounding tissue relatively 
independent from flow dynamics (U-King-Im et al. 2009). 
Subacute intraluminal clots in dissection appear T1 hyperintense and may be mistaken 
for flow on TOF-MRA. When dissection is suspected, a fat-saturated T1-weighted 
sequence may help to distinguish the two. 
The main disadvantages of MR angiography are its cost and the duration of imaging 
acquisition.  Metal implants or claustrophobia may rule it out in a proportion of patients 
and MR scanners are still not available everywhere.  While it is a safe technique, concerns 
have recently been raised about the safety of paramagnetic contrast agents in patients 
with renal impairment (Kuo et al. 2007; Heinz-Peer et al. 2009). 
CT Angiography 
The development of fast spiral CT scanners has added CT angiography to the arsenal of 
imaging modalities available for measuring carotid stenosis and has replaced carotid 
ultrasound as first line imaging modality for carotid stenosis in hyper-acute stroke 
patients.  It can accurately detect large intracranial and extracranial vessel stenosis and 
occlusion (Bash et al. 2005; Tan et al. 2007).  In acute stroke patients this is of prognostic 
importance as terminal carotid T occlusions, proximal MCA occlusion and tandem 
lesions tend to respond poorly to intravenous thrombolysis and may be candidates for 
intra-arterial thrombolysis or mechanical clot removal (Hoffmann et al. 2012).   
CT angiography can also demonstrate collateral blood supply to the ischaemic region, 
with presence of good collateral flow linked to better outcome (Miteff et al. 2009).   
An additional benefit of CTA is its ability to identify other pathologies such as arterio-
venous malformations or cerebral aneurysm.   
59 
Severe renal impairment precludes the inclusion of CTA in the work up of patients due 
to the use of injected iodinated contrast agents.  Of great advantage is the relative speed 
of acquiring images covering a section from the aortic arch to the top of the head.  Speed 
and area covered is dependent on the number of detectors used in the CT scanner and 
will likely increase further in the future. 
8.5.4 Future of Carotid Imaging 
The diagnosis of carotid stenosis in need of treatment is currently primarily based on the 
degree of narrowing and does not take into account lessons from coronary artery stenosis 
in particular.  It is now widely accepted that not necessarily the degree of narrowing but 
the composition of the plaque causing the stenosis determines outcome in coronary 
artery disease (Naghavi et al. 2003).  This has been shown to also apply to the carotid 
artery (Spagnoli et al. 2004).  Histopathological studies identified components of carotid 
atheroma (large lipid core, thin or ruptured fibrous cap, and intra-plaque haemorrhage) 
that are associated with an increased risk of stroke (Spagnoli et al. 2004; Redgrave et al. 
2006).  High-resolution MRI has emerged as a promising technique for in vivo carotid 
atheroma imaging (U-King-Im et al. 2004; Davies et al. 2005; Trivedi et al. 2007; U-King-Im 
et al. 2009).  Several studies have shown that MRI can successfully identify the different 
plaque components associated with an increased risk of stroke (Toussaint et al. 1996; 
Fayad et al. 2000; Clarke et al. 2003; Moody et al. 2003; Trivedi et al. 2004; Yuan et al. 2004; 
Ouhlous et al. 2005; Saam et al. 2005; Takaya et al. 2005; Sadat et al. 2009).  In the future 
these additional factors may play a bigger role in selecting patients for intervention 
(Gillard 2007).  The future role of CT and MR will be to guide therapy by exluding other 
pathology, characterising location and subtype of stroke and assessment of risk of 
haemorrhagic transformation. The challenge will be to minimise the time to reperfusion 
and equipping ambulances with CT scanners may be one way of achieving this (Walter et 
al. 2012). 
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8.6 Treatment of Stroke With Particular Reference to Carotid Artery Stenosis 
8.6.1 Medical Treatment 
Medical treatment of carotid stenosis is aimed at preventing recurrent stroke through 
modification of cardiovascular risk factors.  Apart from life-style changes (diet, exercise, 
smoking), three major risk factors are addressed: hypertension, hypercholesterolaemia 
and risk of atherothrombosis.  Recommendations regarding the management of risk 
factors have changed over the years as insight into disease development and progression 
increased.  This process is likely to continue and the following discussion of the rationale 
of treating risk factors in symptomatic patients (secondary prevention) reflects current 
practice at the time of writing. 
Hypertension 
The European Society of Cardiology (ESC) and the European Society of Hypertension 
(ESH) have defined different grades of hypertension (Table 8.2) and published guidelines 
when and how to treat hypertension (Graham et al. 2007). 
Table 8.2 – Definition and classification of blood pressure levels 
Isolated systolic hypertension should be graded (I, II, III) according to systolic blood pressure values in the ranges 
indicated, provided the diastolic values are < 90 mmHg.  Adopted from (Graham et al. 2007) 
Category  Systolic  (mmHg)    Diastolic (mmHg) 
Optimal  < 120  and  < 80 
Normal  120 – 129  and/or  80 – 84 
High normal  130 – 139  and/or  85 – 89 
Grade 1 hypertension   140 – 159  and/or  90 – 99 
Grade II hypertension   160 – 179  and/or  100 – 109 
Grade III hypertension  ≥ 180  and/or  ≥ 110 
Isolated systolic hypertension  ≥ 140  and  < 90 
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Blood pressure (BP) lowering in patients with transient ischaemia or stroke was found to 
significantly reduce the risk of stroke (Rashid et al. 2003).  This was the case regardless of 
the patient fulfilling criteria for hypertension or not.  The correlation between blood 
pressure and cardiovascular risk appears to be linear with systolic blood pressure being a 
slightly better predictor of outcome than diastolic blood pressure.  A combination of 
angiotensin-converting enzyme (ACE) inhibitors and diuretics seemed to be more 
effective than ACE inhibitors alone or the combination of β-blockers and diuretics 
(Rashid et al. 2003). 
This confirmed findings of the Perindopril Protection Against Recurrent Stroke Study 
(PROGRESS), which tested an ACE inhibitor (perindopril) alone (n = 1,281 patients) and 
in combination with a diuretic (indapamide) (n = 1,770 patients) in hypertensive and 
normotensive patients with TIA or stroke within the preceding 5 years in comparison to 
placebo treatment (n = 3,054 patients) (MacMahon et al. 2001).  Hypertension was 
unusually defined as a blood pressure greater than 160/90 mmHg. 
Figure 8.13 – PROGRESS: Cumulative incidence of stroke 
Cumulative incidence of stroke in patients assigned to active treatment versus placeb. Reprinted from (MacMahon et 
al. 2001) with permission from Elsevier. 
The combination treatment was the most effective in lowering blood pressure.  Active 
treatment reduced the 4-year risk of stroke from 14% to 10% (Figure 8.13).  While double 
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active treatment led to a significant 43% relative risk reduction, perindopril alone was not 
significantly better than placebo in preventing stroke.  This probably reflects the 
difference in blood pressure lowering achieved with different regimes. 
Hypercholesterolaemia 
The Heart Protection Study investigated the long-term effects of cholesterol-lowering 
therapy on mortality and morbidity in patients at high risk of vascular events from a 
wide range of circumstances by comparing 40 mg simvastatin daily (n = 10,232 patients) 
to placebo (n = 10,237 patients) (Collins et al. 2002).  Simvastatin significantly reduced the 
5-year risk of any vascular event from 25.2% to 19.8% (Figure 8.14), and the 5-year risk of 
any stroke more modestly from 5.7% to 4.3% (a 25% relative risk reduction).   
Figure 8.14 – Heart Protection Study: Cumulative incidence of any vascular event 
Shown is the cumulative incidence of any vascular event in patients randomised to 40 mg simvastatin or placebo. 
Reprinted from (Collins et al. 2002) with permission from Elsevier. 
 
The incidence of carotid endarterectomy and angioplasty was halved in the active 
treatment group (from 82 [0.8%] in the placebo group to 42 [0.4%] in the active treatment 
group, p = 0.0003) consistent with findings by other studies that cholesterol lowering 
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reduced the need for coronary artery revascularisation (Pedersen et al. 1994; Sacks et al. 
2000). 
More recently, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) study allocated patients after TIA or stroke to receive either 80 mg atorvastatin 
(n = 2,365 patients) or placebo (n = 2,366 patients) (Amarenco et al. 2006).  High-dose 
atorvastatin reduced the 5-year risk of fatal or non-fatal stroke from 13.1% to 11.2% 
(hazard ratio 0.87, 95% CI 0.71 to 0.99, p = 0.03, Figure 8.15), but there was also a small 
increase in the risk of cerebral haemorrhage associated with statin use (hazard ratio 1.66, 
95% CI 1.08 to 2.55).   
The SPARCL trial also showed a significant reduction in carotid revascularisation from 
7.2% in the placebo group to 3.2% in the active treatment group in patients with carotid 
artery stenosis (HR 0.44, 95% CI 0.24 to 0.79).  The risk of stroke was reduced from 16.1% 
in the placebo group to 11.2% in the active treatment group in the same patients (Sillesen 
et al. 2008). 
Figure 8.15 – SPARCL: Kaplan-Meier plot of fatal or non-fatal stroke 
Shown is the cumulative incidence (%) of fatal or nonfatal stroke in patients randomised to 80 mg atorvastatin or 
placebo. Reprinted from (Amarenco et al. 2006) with permission from The New England Journal of Medicine. 
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Antiplatelets 
Aspirin was originally introduced 113 years ago as pain relief and antipyretic medication.  
More than 70 years later, Sir John Robert Vane (1927 – 2004) discovered the therapeutic 
mechanism of aspirin – the inhibition of prostaglandin synthesis.  For this discovery he 
was honoured with the Nobel Prize for Physiology or Medicine in 1982.  Today aspirin 
has become a mainstay in preventive treatment for heart attack and stroke after clinical 
trials in the 1960s and thereafter had established its efficacy as an anti-clotting agent.  
Although the overall benefit is relatively minor, the low cost of aspirin makes it the most 
widely prescribed drug in secondary prevention of stroke.   
Several meta-analyses have shown that antiplatelets are effective in preventing stroke in 
secondary prevention studies of various vascular diseases (Figure 8.16)  (Collins et al. 
1994; Baigent et al. 2002).  A meta-analysis of placebo-controlled trials of aspirin after TIA 
or stroke revealed a relative risk reduction of vascular death, stroke and MI of 13% (Algra 
et al. 1999).  A small trial in patients with asymptomatic carotid stenosis failed to show 
any long-term protective effect of aspirin (Cote et al. 1995).   
Figure 8.16 – Proportional effects of antiplatelet therapy on stroke and TIA 
Stratified Odds of an event in the treatment groups compared to that in control groups (black square) and its 99% CI 
(horizontal line).  Adjusted controls have been calculated after converting any unevenly randomised trials to even ones 
by counting control groups more than once.  Statistical calculations are based on actual numbers from individual trials.  
Reprinted from (Baigent et al. 2002) with permission from BMJ Publishing Group Ltd. 
 
Medium dose aspirin (75 to 325 mg daily) is the most widely tested regimen and initially 
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1994).  Barnett and colleagues investigated different doses of aspirin in patients 
undergoing carotid endarterectomy and found that in fact a lower dose of aspirin (81 mg 
to 325 mg daily) was associated with a lower risk of stroke, myocardial infarction and 
death within 30 days and three months after endarterectomy than a higher dose of 
aspirin (650 mg and 1300 mg). 
Since then, several other studies have compared different antiplatelet agents.  The 
Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial 
compared clopidogrel (n = 9,599 patients) and aspirin (n = 9,586 patients) in patients with 
MI, stroke or peripheral vascular disease (PVD) (Gent et al. 1996).  Clopidogrel was 
associated with a very modest relative risk reduction of 8.7% for the combined primary 
endpoint of myocardial infarction, stroke or vascular death compared to aspirin.  
However the difference was not statistically significant in patients with stroke.  There 
were less severe side effects associated with clopidogrel. 
The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis 
(CARESS) Trial compared the combination of clopidogrel plus aspirin to aspirin alone in 
patients with recently symptomatic carotid stenosis.  The dual-therapy was more 
effective in preventing the primary endpoint of asymptomatic microembolic signals on 
transcranial Doppler (TCD), a possible marker of future stroke and TIA in these patients 
(Markus et al. 2005).  Microembolic signals were detected in 43.8% of patients taking 
dual-antiplatelet therapy compared to 72.7% with aspirin alone, a relative risk reduction 
of 39.8% (95% CI 31.6 to 78.2, p = 0.0013). 
The Management of Atherothrombosis with Clopidogrel in High-risk Patients (MATCH) 
study sought to investigate if the addition of aspirin to clopidogrel improved the 
beneficial effect of clopidogrel alone (Diener et al. 2004).  The study assigned 3,797 
patients to the combination therapy and 3,802 patients to clopidogrel alone.  The 
investigators found no statistically significant difference for the primary endpoint of 
myocardial infarction, stroke, vascular death or hospitalization.  But the risk of life-
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threatening bleeding was significantly higher in the combined treatment group.  The 
combination of aspirin and clopidogrel is therefore reserved for special indications such 
as failure of other antiplatelet therapy, i.e. in patients suffering a cerebrovascular event 
while on alternative antiplatelet regimen or to cover the periprocedural period of carotid 
endarterectomy or stenting. 
The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) 
was undertaken to resolve uncertainty raised by a Cochrane Review (De Schryver et al. 
2003a; De Schryver et al. 2003b) surrounding the secondary preventive value of combined 
dipyridamole and aspirin (Halkes et al. 2006).  Patients were assigned to a combination of 
30 mg to 325 mg aspirin daily plus 200 mg dipyridamole twice daily (n = 1,363 patients) 
or the same dose of aspirin alone (n = 1,376 patients) and followed up for a mean of 3.5 
years.  The combination therapy reduced the risk of death from all vascular causes, non-
fatal stroke, non-fatal myocardial infarction, or major bleeding complication from 15.7% 
to 12.7%, a 1% reduction per annum (Figure 8.17).   
Figure 8.17 – ESPRIT: Kaplan-Meier plot for the primary outcome measure 
Shown is the cumulative incidence (%) of death from all vascular causes, non-fatal stroke, non-fatal MI and non-fatal 
major bleeding complication.  Reprinted from (Halkes et al. 2006) with permission from Elsevier. 
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This finding was consistent with an update of the Cochrane Review (De Schryver et al. 
2007; De Schryver et al. 2008) and the combination of aspirin plus dipyridamole was 
subsequently recommended by the National Institute for Health and Clinical Excellence 
in secondary prevention of stroke (National Institute for Health and Clinical Excellence 
2008).  
The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study 
compared 25 mg aspirin plus 200 mg extended-release dipyridamole twice daily (n = 
10,181 patients) to 75 mg clopidogrel (n = 10,151 patients) in patients with a recent 
ischaemic stroke (Sacco et al. 2008).  The primary outcome of recurrent stroke was 
recorded in 916 patients (9.0%) receiving aspirin plus dipyridamole and 898 patients 
(8.8%) receiving clopidogrel over a mean follow-up period of 2.5 years (HR 1.01, 95% CI 
0.92 to 1.11).  Figure 8.18 shows the cumulative probability of the primary outcome 
measure in ProFESS.   
Figure 8.18 – ProFESS: Risk of recurrent stroke for clopidogrel and aspirin plus dipyridamole 
Shown is the cumulative probability of recurrent stroke. Reprinted from (Sacco et al. 2008) with permission from The 
New England Journal of Medicine. 
 
In the UK, aspirin plus dipyridamole initially remained the antiplatelet regimen of 
choice.  This was mainly due to cost-effectiveness consideration with clopidogrel being 
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almost five times more expensive than the combination of aspirin plus extended-release 
dipyridamole (£ 1.26 versus £ 0.27 per daily dose).   
However, clopidogrel is now out of licence which has led to it being available at a much 
lower cost (£ 0.11 per daily dose) and NICE has recently recommended that clopidogrel is 
now the antiplatelet agent of choice for stroke prevention, in preference to aspirin, with 
aspirin plus dipyridamole as the second choice in patients unable to tolerate clopidogrel 
(National Institute for Health and Clinical Excellence 2010). 
8.6.2 Surgical Treatment of Internal Carotid Artery Stenosis 
While the secondary prevention measures outlined above should also apply to patients 
with carotid artery stenosis, the high risk of recently symptomatic carotid stenosis 
suggests that they do not work quickly enough.  Data from the large surgery trials seems 
to show that it may take two years for best medical treatment to develop its protective 
potential (Figure 8.19).   
Figure 8.19 – European Carotid Surgery Trial: Kaplan-Meier incidence of major stroke 
This graph shows the cumulative incidence of major stroke in surgery and control patients with 80 to 99% stenosis.  
Note that after 2 years the lines for each treatment start to run roughly parallel suggesting that medical therapy takes 
2 years to develop its full protection.  Reprinted from (Farrell et al. 1998) with permission from Elsevier. 
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stenosis appears to be logical.  The publication of Debakey’s case series of carotid surgery 
in predominantly symptomatic patients (Debakey et al. 1965) created immense interest in 
the technique and after reports that endarterectomy may help prevent stroke in patients 
with asymptomatic carotid stenosis (Thompson et al. 1978), carotid endarterectomy soon 
became one of the most frequently carried out surgical procedures in both asymptomatic 
and symptomatic patients.  Spirits were dampened after concerns were raised about the 
appropriateness of treating symptomatic patients (Fields et al. 1970; Shaw et al. 1984).  
This prompted the setting up of large clinical trials comparing carotid endarterectomy 
and medical therapy.  The Veterans Affairs 309 (VA309) study (Mayberg et al. 1991) was 
prematurely halted after the North American Symptomatic Carotid Endarterectomy 
Study (NASCET) and the European Carotid Surgery Trial (ECST) had published interim 
results in favour of carotid endarterectomy in patients with severe stenosis (North 
American Symptomatic Carotid Endarterectomy Trial Collaborators 1991; Peto et al. 
1991).  Their main results shall now be discussed followed by a discussion of a combined 
analysis of the VA309 study, NASCET and ESCT (Rothwell et al. 2003). 
Symptomatic Carotid Artery Stenosis 
ECST recruited patients who had experienced symptoms attributable to carotid stenosis 
(i.e. TIA, amaurosis fugax, retinal infarction, or non-disabling stroke) in the six months 
leading up to randomisation.  The degree of stenosis had to be confirmed by catheter 
angiography and there had to be “substantial uncertainty” as to whether carotid 
endarterectomy should be recommended (Peto et al. 1991; Farrell et al. 1998).  Patients 
were then randomised to either undergo immediate surgery (n = 1,811 patients) or 
deferred surgery (n = 1,213 patients).  Medical treatment was to be similar in both 
groups.  “Appropriate” medical therapy included aspirin, treatment of definite 
hypertension and advice to stop smoking (Peto et al. 1991).  Unfortunately, the trial 
provided little information on compliance with this treatment regimen.  The trial did not 
specify a minimum degree of stenosis to qualify for participation.  The degree of stenosis 
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was distributed equally between the greater than 70%, 50 to 69% and less than 50% 
stenosis groups, as measured by the ECST criteria.  The mean follow-up was 6.1 years. 
The trial showed that carotid endarterectomy was associated with a substantial 7% risk of 
death and stroke lasting more than 7 days (i.e. major stroke) in the 30 days following 
surgery.  Nevertheless, surgery reduced the risk of ipsilateral major stroke over the 
course of three years from 20.6% to 6.8% (p < 0.0001) and that of any major stroke or 
death from 26.5% to 14.9% (p = 0.001) in patients with stenosis greater than 80% (ECST 
criteria).  No effect of surgery was shown for stenosis below 70 to 80% (ECST criteria).  
Interestingly, the trial showed that age and sex had a significant effect on the frequency 
of major stroke or death.  The conclusions that can be drawn from ECST are that the 
balance of risk and benefit is in favour of surgery with severe stenosis of about 80% 
(ECST criteria) and that surgery is riskier in women than in men (Farrell et al. 1998). 
NASCET was carried out at the same time and had similar inclusion criteria.  Initially, 
patients were eligible if focal cerebral ischaemia in the distribution of the carotid artery 
(i.e. one or more TIA or non-disabling stroke) had occurred no more than 120 days prior 
to randomisation (Barnett et al. 1991), this threshold was raised at some stage to 180 days 
(Barnett et al. 1998).  Confirmation of carotid stenosis was by angiography and the 
minimum stenosis required by the protocol was 30% (NASCET criteria).  Patients were 
randomised between surgery (n = 1,436 patients) and no surgery (n = 1,449 patients).  
Medical treatment in both arms consisted of aspirin and treatment of hypertension and 
(in contrast to ECST) hypercholesterolaemia (Barnett et al. 1991).  The risk of stroke or 
death in the 30 days following surgery was 5.8% in patients with greater than 70% 
stenosis (n = 328, NASCET criteria) and 6.7% in the remaining patients in the surgery 
group.  In the former patient group, surgery reduced the risk of ipsilateral stroke at two 
years by 17%.  The benefit was smaller with less severe stenosis: The absolute risk 
reduction at five years achieved by surgery was 6.5% (p = 0.045) in patients with 50 to 
69% stenosis (NASCET criteria) and a non-significant 3.8% (p = 0.16) in patients with 30 
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to 49% stenosis as measured by NASCET criteria (Barnett et al. 1998).  These results were 
consistent with the ECST data. 
In order to make the trials more easily comparable the ECST angiograms were re-
measured using the NASCET criteria, outcome events re-defined and a combined 
analysis of ECST, NASCET and the VA309 study carried out (Rothwell et al. 2003).  The 
risk of stroke or death in the 30 days following surgery was 7.1% in the combined 
population and 6.4% in patients with stenosis exceeding 70%.   The pooled analysis 
confirmed findings from the individual trials that the benefit gained from carotid 
endarterectomy depends on the degree of stenosis.  The risk of any stroke or 
perioperative death was reduced following surgery by 15.6% in patients with 70 to 99% 
stenosis (Figure 8.20). In patients with 50 to 69% stenosis the risk reduction was a more 
modest 7.8%.  While surgery in carotid near-occlusion and less than 50% stenosis was in 
fact associated with no benefit at all (Figure 8.21). 
Figure 8.20 – NASCET, ECST, and VA study: Risk of any stroke or operative death 
Cumulative incidence of stroke or operative death in patients with 70 to 99% stenosis excluding near occlusions in the 
pooled data.  Reprinted from (Rothwell et al. 2003) with permission from Elsevier. 
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Figure 8.21 – NASCET and ECST: Effect of surgery on the absolute risk of any stroke or operative death 
Absolute risk reduction after 5 years of follow-up by degree of stenosis and intention to treat.  Vertical lines represent 
the 95% CI.  Adopted from (Rothwell et al. 2003). 
 
Various subgroups of patients from NASCET and ECST were also combined to compare 
patients with carotid stenosis ≥ 50% as well as timing of carotid endarterectomy 
(Rothwell et al. 2004b).  It found that men tended to have a greater benefit from surgery 
than women.  In men the absolute reduction in the cumulative 5-year risk of ipsilateral 
carotid ischaemic stroke and any stroke or death within 30 days was 11.0% (95% CI 7.6 to 
14.4%) compared to a non-significant risk reduction of only 2.8% (95% CI -2.2 to 7.8%) in 
women.  Elderly patients older than 75 years (ARR 19.2%, 95% CI 10.2 to 28.2%) also 
benefited more from carotid endarterectomy than patients under the age of 65 years 
(ARR 5.6%, 95% CI 1.6 to 9.6%).  Figure 8.22 illustrates that the benefit of surgery 
decreased with time since last symptoms (Rothwell et al. 2004b).   
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Figure 8.22 – NASCET and ECST: Absolute reduction in the risk of ipsilateral carotid ischaemic stroke 
and any stroke or death within 30 days after trial surgery 
Shown is the absolute risk reduction with surgery in the 5-year cumulative risk of ipsilateral carotid ischaemic stroke 
and any stroke or death within 30 days after trial surgery in patients with 50 – 69% stenosis and ≥ 70% stenosis 
depending on time since event.  Vertical lines indicate 95% confidence intervals.  Reprinted from (Rothwell et al. 
2004b) with permission from Elsevier. 
 
These findings have restored the confidence in carotid endarterectomy and firmly 
established carotid endarterectomy as treatment of choice in patients with symptomatic 
severe carotid stenosis.  One peri-operative death or stroke for every six patients with 
carotid stenosis ≥ 70% undergoing carotid endarterectomy is prevented by carotid 
endarterectomy.  Twice as many patients with moderate carotid stenosis (50 to 69%) need 
to undergo carotid endarterectomy to prevent one peri-operative death or stroke. 
Asymptomatic Carotid Artery Stenosis 
Similar trials to the symptomatic surgery trials described above were carried out in 
patients in whom the carotid stenosis had not yet caused stroke or TIA (Diener et al. 1991; 
Mayo Asymptomatic Carotid Endarterectomy Study Group 1992; Hobson et al. 1993; 
Toole et al. 1995; Halliday et al. 2004).   
Two trials will not be discussed in great detail because of shortcomings in study design.  
The Carotid Artery Stenosis with Asymptomatic Narrowing: Operation versus Aspirin 
study (CASANOVA) compared 410 patients (Diener et al. 1991).  However, it did not 
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strictly compare surgery to medical treatment because patients with bilateral stenosis did 
have surgery on the more affected side and there were large numbers of cross-overs.  The 
Mayo Asymptomatic Carotid Endarterectomy (MACE) Study did not include aspirin as 
regular treatment in the surgery arm (Mayo Asymptomatic Carotid Endarterectomy 
Study Group 1992). 
The Veterans Affair (VA) study compared carotid endarterectomy in male patients with 
arteriographically proven carotid stenosis greater than 50% (Hobson et al. 1993).  A total 
of 444 patients (mean age 64.5 years) were randomised to either undergo carotid 
endarterectomy plus aspirin or medical therapy alone, including aspirin.  The authors 
did not further elaborate on the exact nature of medical treatment.  Surgery led to a 
significant reduction in the absolute risk of stroke, TIA and monocular blindness of 12.6% 
(relative risk 0.38, 95% confidence interval 0.22 to 0.67), but the combined incidence of 
stroke or death did not differ between the two groups during the mean follow-up of two 
years. 
The studies making the biggest impact on treatment of asymptomatic carotid stenosis 
and shaping today’s approach to the condition were the Asymptomatic Carotid 
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial (ACST) 
(Toole et al. 1995; Halliday et al. 2004).   
ACAS recruited 1,662 patients who were diagnosed with asymptomatic carotid stenosis 
greater than 60% (Toole et al. 1995).  The degree of stenosis was confirmed by formal 
angiography using the NASCET criteria to measure stenosis.  Medical treatment 
consisted of 325 mg aspirin plus risk factor modification; surgery was carried out by the 
preferred method of the surgeon as soon as possible after randomisation.  Patients were 
followed up for a median 2.7 years.  ACAS showed a significant reduction in the 
estimated 5-year risk of ipsilateral stroke or death (including any perioperative stroke or 
death) in the surgery group from 11% to 5.1%.  This equates to a very small reduction in 
absolute annual risk over five years of 1.2%.  However, the reduction in stroke only 
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became apparent in the fifth year of follow-up and other endpoints did not show any 
significant difference between the two groups. 
ACST was an even bigger study of 3,120 patients (Halliday et al. 2004).  Patients were 
included if the carotid stenosis was narrowed to less than 60% of its luminal diameter as 
measured by ultrasound.  They were randomised between immediate and delayed 
surgery.  Therefore some patients in the latter group had an endarterectomy if they 
became symptomatic or developed another definite reason for surgery during follow-up 
(Halliday et al. 2004).  Unfortunately, the spectrum of “definite” indications for surgery 
where not provided.  No specific medical regimen was prescribed by the study protocol 
and surgeons chose their preferred method of carrying out the carotid endarterectomy as 
soon as possible after randomisation.  Surgery led to a significantly reduced 5-year risk of 
any type of stroke or perioperative death from 11.8% to 6.4% (Figure 8.23), equating to a 
small annual reduction in absolute risk of about 2%. 
Figure 8.23 – ACST: Any type of stroke or perioperative death 
Shown is the cumulative incidence of any stroke or perioperative death.  Reprinted from (Halliday et al. 2004) with 
permission from Elsevier. 
 
While these results may be perceived as headline-grabbing figures promoting carotid 
endarterectomy in healthy and asymptomatic patients it is important to keep some 
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important findings in mind.  ACAS showed that only men benefited from surgery and in 
ACST the benefit for women was much smaller than in men.  Additionally, the benefit 
was greater in younger patients and a large number of patients had unnecessary surgery.  
In ACST, 50 patients needed to be treated in order to prevent one stroke or peri-operative 
death per year.  In ACAS, the number needed to treat in order to prevent one ipsilateral 
stroke death was 83. 
Note of Caution 
Impressive and compelling as the results of the surgery trials may appear to be, a note of 
caution has to be sounded.  In all these trials surgery was compared to a medical 
treatment that by today’s standards could very well be regarded as substandard.  Current 
guidelines for secondary prevention of stroke differ greatly to those in existence at the 
time of ECST, NASCET, ACAS, and ACST.  Aspirin had already found its way into the 
secondary prevention arsenal of medications at the time of the surgery trials.  The benefit 
of lipid-lowering drugs, which are now a mainstay of medical therapy in stroke 
prevention, only became fully apparent after the publication of the Heart Protection 
Study (Collins et al. 2002).  It could be argued that the benefit of carotid endarterectomy 
over medical therapy would be much lower today, especially in asymptomatic patients.  
Since statins take up to one year to develop their protective potential it is less likely that 
medical treatment has a big influence on the outcome of symptomatic stenosis given the 
high early risk of recurrence associated with this disease. 
8.6.3 Endovascular Treatment of Internal Carotid Artery Stenosis 
Non-randomised case series, non-randomised trials and registries were the only source of 
data providing some evidence on the risks and benefits of endovascular treatment prior 
to the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS).  
However, they were based on small numbers that prohibit drawing firm conclusions 
from them and they will not be discussed in detail but briefly summarised in the 
following chapter. 
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8.7 Hypotheses Tested in This Thesis 
The studies described within this thesis had been designed to investigate several aspects 
regarding the safety and efficacy of endovascular treatment of carotid artery stenosis in 
patients with recent symptoms in comparison to carotid endarterectomy in those patients 
suitable for surgery and medical treatment in patients not suitable for surgery.  The work 
attempted to identify factors that may be associated with particular risks of one 
procedure.  Particular emphasis was placed on identifying radiological parameters that 
may help to identify patient groups more suitable for one treatment or the other.  The 
studies were large randomised, multi-centre clinical trials.   
The main null hypothesis of this thesis is that endovascular treatment is of similar safety 
and efficacy than carotid endarterectomy in patients with symptomatic carotid stenosis 
suitable for either treatment.  This null hypothesis is tested by 
• Comparing the short-term risk of endovascular treatment with or without 
stenting to carotid endarterectomy within 30 days after the procedure 
• Comparing the long-term durability of endovascular treatment with or without 
stenting in terms of preventing stroke with carotid endarterectomy. 
Not all patients are suitable for surgery for various reasons.  The null hypothesis that 
endovascular treatment of carotid stenosis was superior to medical therapy alone in these 
patients is tested by 
• Comparing the short-term risk and long-term effectiveness of endovascular 
treatment and medical therapy alone. 
Pre-existing small vessel disease may be a risk factor for procedural stroke following 
surgery or endovascular treatment.  The null hypothesis that small vessel disease poses a 
risk for stroke after treatment that is similar in both treatment groups is tested by 
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• Comparing the risk of stroke associated with and without small vessel after 
endovascular treatment and carotid endarterectomy in patients with 
symptomatic carotid stenosis disease. 
Published evidence of randomised clinical trials of endovascular treatment is thoroughly 
reviewed and combined in a meta-analysis in order to place the findings of the trials 
presented in this thesis into their wider context. 
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9 The Carotid And Vertebral Artery Transluminal Angioplasty 
Study 
9.1 Rationale for CAVATAS 
After Klaus Mathias had carried out the first carotid angioplasty to treat atherosclerotic 
stenosis successfully in 1981 (Mathias 1981), anxieties about the risks associated with 
carotid angioplasty persisted and it was not recommended to carry out the procedure in 
the carotid artery (Perry et al. 1983).  Cerebral embolism caused by dislodged 
atheromatous material or thrombus from the vessel wall or as a result of dissection of the 
carotid artery at the time of balloon inflation with subsequent thromboembolism was 
considered to be the major risk of percutaneous transluminal angioplasty (PTA).  
Cerebral ischaemia caused by hypo perfusion during the time of balloon inflation was 
thought to be another potential mechanism of causing damage to the brain.  Also of 
concern was the risk of restenosis, a well-recognised risk of PTA at other sites. 
However, by 1992, the time the first patient was randomised in CAVATAS several case 
series of endovascular treatment of carotid artery stenosis had been published 
(Bockenheimer et al. 1983; Wiggli et al. 1983; Tsai et al. 1986; Freitag et al. 1987; Brown et al. 
1990; Theron et al. 1990; Kachel et al. 1991; Munari et al. 1992).  These case series reported 
not a single case of minor non-disabling or major stroke in over 100 patients and it was 
thought that endovascular treatment might be an alternative to carotid endarterectomy, 
which had been firmly established as treatment of choice by the large surgical trials. 
Encouraged by these preliminary findings, albeit in a very small number of patients and 
thus acutely aware of the need for randomised data from a much larger patient 
population to assess the safety of carotid balloon angioplasty, the Carotid and Vertebral 
Artery Transluminal Angioplasty Study (CAVATAS) was set up and registered with the 
International Standard Randomised Controlled Trial Number Register (ISRCTN Register, 
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No. 01425573).  Its initial aim was to provide information about the safety of 
endovascular treatment compared to carotid endarterectomy within 30 days after the 
procedure.  In addition and even more importantly, it aimed at collecting long-term 
follow-up data about the efficacy and durability of endovascular treatment. 
CAVATAS consisted of three distinct trials.  The largest trial compared endovascular 
treatment and carotid endarterectomy in patients suitable for surgery (Brown et al. 2001).  
This study is the one most often referred to as CAVATAS.  A second trial compared 
endovascular treatment and stand-alone medical therapy in patients with vertebral artery 
stenosis (Coward et al. 2007).  A third trial compared endovascular treatment to stand-
alone medical therapy in patients with carotid stenosis not suitable for surgery and 
became known as CAVATAS-MED.   
CAVATAS and CAVATAS-MED will be described and discussed in detail in this chapter.  
Parts of the work have been presented at the European Stroke Conferences 2007 (Ederle 
et al. 2007b) and 2008 (Ederle et al. 2008a) and aspects of both bodies of work have been 
published in peer-reviewed journals (Brown et al. 2001; McCabe et al. 2005; Bonati et al. 
2009; Ederle et al. 2009a; Ederle et al. 2009b). 
9.2 Endovascular Treatment versus Surgery in Patients Suitable for Surgery 
9.2.1 Methods and Patients 
Trial Centres 
Centres wishing to participate in CAVATAS were required to have a team in place 
consisting of a neurologist or physician with an interest in stroke medicine, a vascular 
surgeon or neurosurgeon experienced in carotid endarterectomy, and a radiologist 
trained in neuroradiology and the technique of angioplasty.  The experience of each 
participating investigator was assessed by a credentials subcommittee to ensure that each 
centre had sufficient expertise to join the trial.  Radiologists from experienced centres 
provided training to centres with little experience in cerebrovascular angioplasty.  
81 
CAVATAS was a collaboration of 22 centres in Europe, Australia and Canada.  The 
collaborating centres are listed in the Appendix. 
Patients 
Patients were eligible for inclusion in CAVATAS if they had stenosis of the common 
carotid artery, carotid bifurcation or internal carotid artery that was thought by the 
investigators to require treatment.  Patients had to be equally suitable for both carotid 
endarterectomy and endovascular treatment and they were only included if the local 
investigators were unsure of the best treatment option. 
Patients were excluded from the trial if they were unwilling or unable to provide 
informed consent, if angiography demonstrated a thrombus or if the patient had suffered 
a major stroke with no useful recovery of function in the territory of the treatable artery.  
The presence of intracranial stenosis beyond the skull base and stenosis unsuitable for 
endovascular treatment also excluded patients from participating in CAVATAS.  No age 
limits were specified in the inclusion criteria. 
Investigations prior to Randomisation 
Investigators were allowed to use their local protocol to investigate patients and establish 
the degree of carotid stenosis.  Most centres used ultrasound in the first instance 
confirmed by conventional angiography before randomisation.  Centres that were able to 
provide data from audits showing a high degree of accuracy compared to conventional 
angiography were allowed to randomise patients on the basis of non-invasive techniques 
(MRA, CTA, or ultrasound).  Non-invasive imaging techniques were usually carried out 
in combination. 
Copies of angiographic or non-invasive imaging were submitted to the central office 
where concealed assessment and measurement of stenosis was carried out.  Stenosis of 
both carotid arteries was measured using the Common Carotid Method on the best 
available angiogram.  In the patients in whom only ultrasound measurements were 
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available (n = 7) flow-velocity criteria (Sidhu et al. 1997) were used to estimate the degree 
of stenosis. 
Randomisation 
Randomisation was carried out by telephone or fax to the randomisation centre at the 
Clinical Trial Service Unit in Oxford, UK after informed consent was obtained.  A 
computerised minimisation algorithm was used for random treatment allocation.  It took 
into account centre and timing of symptoms (symptoms within six months prior to 
randomisation and more distant symptoms) to achieve balanced numbers of patients in 
both groups. 
Treatment 
Surgery 
The allocated treatment was to be carried out as soon as possible after randomisation.  
Surgeons were allowed to use their preferred technique.  No requirements with regards 
to anaesthesia, the use of shunts or patches, or use of heparin during the procedure were 
specified by the trial protocol. 
Endovascular Treatment 
Angioplasty was carried out using percutaneous transluminal interventional techniques 
as soon as possible after randomisation.  Before 1994, this was done by balloon 
angioplasty.  Stents suitable for the carotid artery became available in 1994 and their use 
was allowed if the interventionist carrying out the procedure believed this to be 
necessary.  They could be used either as primary technique or secondary after balloon 
inflation.  Cerebral protection devices were allowed but not mandatory.  No 
requirements with regards to guide wires, catheters, premedication, local anaesthesia, or 
atropine use were set by the protocol.  The protocol did specify that all patients 
randomised to endovascular treatment should receive 150 mg of aspirin or an alternative 
antiplatelet agent for at least 24 hours prior to the procedure.  Patients were systemically 
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anticoagulated with 5,000 units of heparin during and for 24 hours after the procedure.  
Antiplatelet therapy was to be continued throughout follow-up. 
Medical Treatment 
The CAVATAS protocol did not specify a specific medical treatment regimen for risk 
factor control.  It was left to the discretion of the individual centres to manage patients’ 
cardiovascular risk factors according to local guidelines and protocols.  Hypertension, 
diabetes mellitus and hypercholesterolaemia were identified in the protocol as the risk 
factors to be addressed as part of the medical treatment regimen in addition to an 
antiplatelet agent or anticoagulant as appropriate. 
Follow-up 
Patients randomised to surgery and endovascular treatment were followed up at one 
month after treatment.  Further follow-up was carried out six months and yearly after 
randomisation for at least five years in both treatment groups.  An independent clinician 
not directly involved in surgery or endovascular treatment carefully conducted follow-
up.  Ultrasound was used to assess the patency of the treated carotid artery but this was 
not compulsory because ultrasound was not available at all participating centres at the 
start of the trial.  Annual ultrasound follow-up was encouraged where it was available.   
Peak systolic velocities (PSV) in the common carotid artery (CCA) and internal carotid 
artery (ICA), and end diastolic velocity (EDV) in the ICA were recorded and reported to 
the central office.  Pre-defined standardised flow velocity criteria were used to estimate 
the degree of stenosis (Table 8.1, page 56). 
Stenosis was classified as not significant (0 to 49%), moderate (50 to 69%), severe (70 to 
99%), or occluded (100%).  In the small number of centres, where individual velocity 
measurements were not reported the local ultrasonographer’s estimate of stenosis was 
used. 
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All outcome events were reported to the central trial office where researchers unaware of 
allocated treatment independently adjudicated outcome events by reviewing all available 
clinical information. 
Definition of Outcome Events 
Stroke was classified as fatal if death occurred as a direct result of stroke at any time after 
the event.  Stroke leading to patients requiring help from another person in carrying out 
activities of daily living (corresponding to a modified Rankin score of three or more) was 
classified as disabling.  The remaining stroke events were classified as non-disabling and 
divided into those that lasted for fewer than 7 days and those that lasted for more than 7 
days.  This classification matched the criteria used in ECST, which only reported strokes 
lasting more than 7 days (Farrell et al. 1998).   
Strokes that lasted for fewer than 7 days and transient ischaemic attacks were not 
included in the primary analysis to avoid a bias due to under-reporting of minor 
symptoms in patients operated under general anaesthesia and returned to intensive care 
units or surgical wards where they were not routinely seen by a neurologist.  Long-term 
outcome measures did include TIA and minor strokes because it was thought that any 
under-reporting of minor events would be balanced in both groups since an independent 
clinician followed up all patients. 
Death occurring from any cardiovascular-related illness other than stroke was classified 
as other vascular death.  Death caused by non-vascular-related illness was classified as 
non-vascular.  If no information about the cause of death was available it was classified 
as undetermined.  UK patients were registered with the General Register Office (GRO) to 
identify deaths in all patients randomised within the UK. 
Outcome events were classified as perioperative if they occurred at the time of treatment 
or within 30 days after treatment.  The date of crossover to medical treatment in patients 
who did not undergo their allocated treatment was defined as proxy-treatment date for 
the purpose of statistical analysis. 
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Outcome Measures 
Primary Outcome Measure 
The primary outcome measure of CAVATAS was defined by the protocol as 
• Long-term period free of disabling stroke or death from the time of 
randomisation.   
The trial was designed to provide information to inform the clinician about the value of 
the different treatment options to the patient and the health service.  Death was included 
in the primary outcome measure because it has direct bearing on the cost-effectiveness of 
treatment, which was regarded as an important issue to be addressed.  It was anticipated 
that the trial would include mainly elderly patients and mortality was thought to be 
particularly important.  This was to be investigated by comparing the differences in life 
years free of disability and hence the rate of disabling stroke or death was chosen as 
primary outcome measure. 
Secondary Outcome Measures 
The trial protocol did not pre-specify any additional outcome measures.  Many aspects 
are worth taking into account when trying to assess the safety and efficacy of 
endovascular treatment compared to surgery and a number of secondary endpoints were 
defined prior to the analysis of data.  They were: 
• Stroke lasting more than 7 days or death 
• Any stroke or perioperative death 
• Stroke lasting more than 7 days or perioperative death. 
Further secondary analyses excluded perioperative events and death of non-stroke 
related causes to assess the long-term efficacy of endovascular treatment compared to 
surgery: 
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• Stroke or TIA occurring more than 30 days after treatment 
• Stroke occurring more than 30 days after treatment 
• Ipsilateral stroke or TIA occurring more than 30 days after treatment 
• Ipsilateral stroke occurring more than 30 days after treatment 
• Contralateral stroke more than 30 days after treatment. 
• Any cause of death  
Any cause of death was analysed separately because it was anticipated that most 
outcome events over such a long time of follow-up would be due to death rather than 
stroke. 
Restenosis was a well-recognised problem of endovascular treatment.  It was unclear if 
restenosis was a benign occurrence or associated with an increase risk in stroke.  A 
separate analysis was performed to shed light on this issue. 
Subgroup Analyses 
Several subgroups were defined prior to the analysis.  Patients who received a stent were 
compared to those who underwent balloon angioplasty alone to investigate how the use 
of stents influenced the rate of stroke lasting more than 7 days or perioperative death. 
Additionally, several baseline characteristics were chosen that might influence outcome 
based on findings from other studies and knowledge about risk factors for stroke.  Those 
were age (dichotomized at the median), sex, severity of ipsilateral and contralateral 
stenosis, severity of qualifying event, hypertension, diabetes mellitus, smoking, history of 
ischaemic heart disease, and previous myocardial infarction. 
The combined endpoint of stroke lasting more than 7 days or perioperative death was 
chosen to carry out the subgroup analyses.   
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Statistical Methods 
CAVATAS was an exploratory trial and no formal sample size calculation had been 
carried out.  The duration of recruitment was determined by availability of funding.  All 
data were analysed using standard statistical software (SPSS for Macintosh, SPSS Inc., 
Chicago, Illinois, USA).   
The log rank test was used to compare the survival free experience in the two treatment 
arms.  The treatment effect was estimated using a Cox proportional hazard model to 
calculate hazard ratios and 95% confidence intervals (CI).  The carotid endarterectomy 
group was used as the reference group throughout.  The proportional hazards 
assumption was tested with a graphical log-minus-log method.  All outcome events up to 
the last available follow-up or death of the patient were included in the calculation of 
hazard ratios.   
The number of patients followed up for more than eight years dropped to less than 50 
and Kaplan-Meier curves were therefore only plotted up to eight years after 
randomisation.  Patients experiencing more than one event were only counted once in 
each category with the first corresponding event, whenever it occurred. 
Primary and secondary outcome measures were analysed by intention to treat, i.e. 
patients were analysed in their randomly allocated treatment group regardless of 
whether they received the allocated treatment or not.  Additionally, all outcome 
measures were analysed by allocated treatment received, i.e. only patients who received 
their allocated treatment were included in the analysis (per-protocol analysis). 
The exploratory subgroup analyses were done by intention to treat.  The comparison of 
stenting, balloon angioplasty alone and carotid endarterectomy was based on the 
allocated treatment received (per protocol).  Cox regression was used to test for treatment 
effect interaction within the subgroups. 
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Restenosis data were analysed by intention to treat but a secondary per-protocol analysis 
was also carried out.  For the comparison of restenosis after angioplasty alone versus 
stenting the per-protocol data set was used.  Time to censoring was compared with a log 
rank test to reveal differences in duration of ultrasound follow-up between the groups.  
Since the exact date on which restenosis had occurred was unknown, a generalised non-
linear model was used to compare the groups.  Patients free of restenosis were censored 
at the time of the last ultrasound investigation and censoring was assumed to be non-
informative.  The proportionality of hazards was assessed via interactions with follow-up 
time periods.  Hazard ratios and corresponding 95% confidence intervals were calculated 
for the entire duration of follow-up.  Life-table analyses estimated the cumulative 
incidences of restenosis at the scheduled ultrasound investigation after treatment, with a 
pre-defined interest in the incidences after one and five years of follow-up.  In cases of 
restenosis and missing data from the preceding follow-up appointment, restenosis was 
arbitrarily assumed to have occurred mid way between the date the diagnosis of 
restenosis was made and the last available ultrasound investigation showing no stenosis. 
To test if ≥ 70% restenosis during follow-up is associated with pre-defined covariates 
multivariable generalised non-linear models adjusted for treatment were used.  The 
calculation of hazard ratio was subsequently adjusted for age, sex, and independent 
predictors of restenosis as identified by the above-mentioned analysis.  Cox regression 
analyses were used to compare time until occurrence of ipsilateral cerebrovascular events 
between patients with and without ≥ 70% carotid stenosis adjusted for allocated 
treatment, age and sex. 
9.2.2 Results 
Baseline Characteristics 
Between 1 March 1992 and 31 July 1997 a total of 505 patients were randomly assigned to 
undergo endovascular treatment (n = 252) or carotid endarterectomy (n = 253).  One 
patient was found to have an occluded carotid artery after randomisation but before 
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angioplasty was attempted.  The decision was taken to exclude this patient from further 
analysis.  This left 251 patients allocated to endovascular treatment and 253 patients 
allocated to carotid endarterectomy for the intention-to-treat analysis (Figure 9.1). 
Figure 9.1 – CAVATAS: Trial profile 
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Almost 90% of patients included in the study had experienced cerebrovascular symptoms 
attributable to the carotid artery in the six months preceding randomisation, the majority 
of which were transient symptoms (Table 9.1).   
Table 9.1 – CAVATAS: Cerebrovascular events within 6 months before randomisation per allocated 
treatment. 
Data are number of events (% of known data).  EVT, endovascular treatment; CEA, carotid endarterectomy 
  EVT  
(n = 251) 
 CEA  
(n = 253) 
Transient ischaemic attack  94 (37%)  98 (39%) 
Amaurosis fugax  60 (24%)  63 (25%) 
Hemisphere stroke     
Minor  19 (8%)  20 (8%) 
Major, non-disabling  32 (13%)  28 (11%) 
Major, disabling  11 (4%)  18 (7%) 
Retinal infarct  5 (2%)  3 (1%) 
 
More than 50% of patients were considered hypertensive and roughly 75% had a history 
of smoking.  Cholesterol was elevated in just over one third of all patients (Table 9.2). 
Roughly 85% of the patients had a baseline carotid stenosis greater than 70% measured 
using the Common Carotid Method.  Contralateral carotid stenosis greater than 70% was 
only found in just under one third of all patients.  In general, baseline characteristics were 
well balanced (Figure 9.2).
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Table 9.2 – CAVATAS: Patient characteristics at baseline per allocated treatment 
Data are number of patients (%) of known data), unless otherwise indicated.  EVT, endovascular treatment; CEA, 
carotid endarterectomy; SD, standard deviation; IQR, interquartile range. 
  EVT  
(n = 251) 
 CEA  
(n = 253) 
Age (median [IQR], years)  68 [62 – 73]  68 [62 – 73] 
Sex     
Women  77 (31%)  75 (30%) 
Men  174 (69%)  178 (70%) 
Vascular risk factors     
Hypertension  132 (53%)  144 (58%) 
Systolic blood pressure (mean [SD], mmHg)  151.8 [21.8]  152.6 [20.1] 
Diastolic blood pressure (mean [SD], mmHg)  83.5 [11.8]  83.9 [10.7] 
Diabetes mellitus  35 (14%)  32 (13%) 
Cholesterol > 6.5 mmol/L  67 (34%)  62 (32%) 
Smokers, past or present  191 (77%)  192 (78%) 
Prior history of cardio-/cerebrovascular disease     
Myocardial infarction  43 (19%)  40 (17%) 
Ischaemic heart disease  95 (39%)  92 (37%) 
Atrial fibrillation  12 (5%)  12 (5%) 
Peripheral vascular disease  60 (24%)  51 (20%) 
Cerebrovascular symptoms > 6 months before 
randomization 
 21 (8%)  15 (6%) 
Treatments used at randomisation     
Antiplatelet  216 (86%)  230 (91%) 
Warfarin  23 (10%)  28 (11%) 
Time from randomisation to treatment (median [IQR], 
days) 
 20 [8 – 32]  27 [14 – 41] 
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Table 9.3 – CAVATAS: Follow-up characteristics per allocated treatment 
Data are number of patients (% of known data) unless otherwise indicated.  EVT, endovascular treatment; CEA, 
carotid endarterectomy; IQR, interquartile range; SD, standard deviation.  †The first line for each characteristic is taken 
from the 1-year follow-up, and the second line from the 6-year follow-up data. 
  EVT  
(n = 251) 
 CEA  
(n = 253) 
Follow-up median [IQR], years)  5 [2 – 6]  5 [2 – 6] 
Total person years of follow-up  1098  1083 
Use of treatments, blood pressure and smoking status during follow-up† 
Antiplatelet  202 (92%) 
43 (86%) 
 209 (90%) 
47 (90%) 
Warfarin  12 (6%) 
4 (8%) 
 12 (5%) 
2 (4%) 
Systolic blood pressure (mean [SD], mmHg)  151.0 [21.0] 
153.9 [23.2] 
 151.0 [23.4] 
147.6 [26.5] 
Diastolic blood pressure (mean [SD], mmHg)  83.0 [10.1] 
78.3 [12.3] 
 82.7 [10.2] 
77.6 [14.0] 
Smokers, past or present  48 (23%) 
5 (11%) 
 50 (22%) 
12 (27%) 
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Figure 9.2 – CAVATAS: Baseline degree of stenosis per allocated treatment 
Degree of stenosis (%, per decile) in the randomised ipsilateral internal carotid artery (upper graph) and the 
contralateral internal carotid artery (lower graph).  EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Delay to Treatment 
Patients allocated to endovascular treatment had a significantly shorter wait before 
treatment was administered than the patients allocated to surgery: The median delay 
between randomisation and endovascular treatment was 20 days (IQR 8 to 32 days) and 7 
days shorter than in the surgery group (IQR 14 to 41 days, p < 0.001, Figure 9.3).   
Figure 9.3 – CAVATAS: Delay of treatment per allocated treatment 
Shown is the time between date of randomisation and date of treatment in days.  EVT, endovascular treatment; CEA, 
carotid endarterectomy. 
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The per-protocol analysis therefore included the 240 patients who received the allocated 
endovascular treatment and 246 patients who received the allocated carotid 
endarterectomy (Figure 9.1). 
 Follow-up 
Follow-up of patients was terminated in 2007 providing up to 11 years of follow-up in 
some patients.  The median length of follow-up was identical in both treatment groups (5 
years, IQR 2 to 6 years, Table 9.3). 
Patients in the endovascular and endarterectomy group were followed up for a total of 
1098 and 1083 person-years, respectively.  Information for eight years of follow-up was 
available in 12.5% of the patients (Figure 9.4). 
Figure 9.4 – CAVATAS: Number of patients available for follow-up per allocated treatment 
Absolute number of patients available for follow-up per month, regardless of an outcome event.  The red (CEA) and 
blue (EVT) bars add up to the total number of patients. EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Intention-to-treat Analyses 
Primary Outcome 
Disabling Stroke or Death 
Disabling stroke or death had been defined as the primary outcome measure and 
occurred in 117 patients in the endovascular treatment group and 121 patients in the 
endarterectomy group over the course of the trial. 
The majority of outcome events in the primary outcome cluster were non-stroke deaths 
(84 in the endovascular group and 94 in the surgery group, Table 9.4).  Fatal stroke was 
more common in the endovascular group (15 versus six, respectively). 
The cumulative incidence of disabling stroke or death was virtually identical up to five 
years after randomisation and was recorded in 26.5% (SE 2.9%) of patients in the 
endovascular group and 27.5% (SE 3.0%) of patients in the endarterectomy group.  
Beyond five years the cumulative incidence of disabling stroke or death started to 
diverge and by eight years after randomisation it reached 45.2% (SE 4.0%) in the 
endovascular group and 50.4% (SE 4.1%) in the surgery group (Figure 9.5).  However, the 
cumulative incidence subsequently converged again and the hazard ratio based on all 
available follow-up data showed no significant difference between endovascular 
treatment and surgery (HR 1.02, 95% CI 0.79 to 1.32, Figure 9.6). 
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Table 9.4 – CAVATAS: Major long-term outcome events 
Data are number of patients.  Numbers in brackets indicate contribution of individual outcomes to the composite 
endpoint.  All non-perioperative strokes lasted for more than 7 days.  EVT, endovascular treatment; CEA, carotid 
endarterectomy.  *6 patients had a subsequent non-perioperative stroke (1 fatal, 2 disabling, 3 non-disabling).  †5 
patients had a subsequent non-perioperative stroke (1 fatal, 3 disabling, 1 non-disabling).  ‡4 patients had a 
subsequent non-perioperative ipsilateral stroke (1 disabling, 3 non-disabling).  §2 patients had a subsequent non-
perioperative ipsilateral stroke (1 disabling, 1 non-disabling). 
 Intention to treat  Per protocol 
 EVT 
(n = 251) 
CEA 
(n = 253) 
 EVT 
(n = 240) 
CEA 
(n = 246) 
Disabling stroke or death (disabling stroke, fatal stroke, non-stroke death) 
 117 
(18, 15, 84) 
121 
(21,6, 94) 
 110 
(18, 11, 81) 
114 
(19, 6, 89) 
Stroke lasting more than 7 days or death (fatal stroke, disabling stroke, non-disabling stroke, 
perioperative non-stroke death, non-perioperative non-stroke death) 
 134 
(14, 17, 28, 0, 75) 
131 
(6, 19, 22, 3, 81) 
 127 
(11, 16, 28, 0, 72) 
124 
(6, 17, 22, 3, 76) 
Any stroke or perioperative death (fatal stroke, disabling stroke, non-disabling stroke > 7 days, non-
disabling stroke < 7 days, vascular non-stroke death, non vascular death) 
 67 
(14, 17, 28, 8, 0, 0) 
51 
(6, 19, 22, 1, 2, 1) 
 63 
(11, 16, 28, 8, 0, 0) 
49 
(6, 17, 22, 1, 2, 1) 
Non-perioperative stroke or TIA (fatal stroke, disabling stroke, non-disabling stroke, TIA) 
 67 
(6, 7, 18, 36*) 
51 
(4, 5, 9, 33†) 
 65 
(6, 7, 17, 35*) 
51 
(4, 5, 9, 33†) 
Non-perioperative ipsilateral stroke or TIA (fatal stroke, disabling stroke, non-disabling stroke, TIA) 
 34 
(1, 3, 8, 22‡) 
27 
(1, 2, 8, 16§) 
 33 
(1, 3, 8, 21‡) 
27 
(1, 3, 8, 16§)  
Non-perioperative non-ipsilateral stroke (fatal, disabling, non-disabling) 
 24 
(8, 5, 11) 
13 
(4, 6, 3) 
 24 
(8, 5, 11) 
13 
(4, 6, 3) 
Death (stroke, vascular non-stroke, non vascular, undetermined) 
 112 
(16, 43, 44, 9) 
113 
(6, 53, 46, 8) 
 105 
(14, 39, 43, 9) 
107 
(6, 49, 44, 8) 
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Figure 9.5 – CAVATAS: 8-year cumulative incidence of disabling stroke or death (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of disabling stroke or death up to 8 years after 
randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-
year cumulative incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.6 – CAVATAS: Hazard ratios for various outcome measures in (ITT) 
Hazard ratios (HR) are calculated based on the intention-to-treat data.  CI, confidence interval. 
0!
10!
20!
30!
40!
50!
60!
0! 1! 2! 3! 4! 5! 6! 7! 8!
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
%
)!
Follow-up (Years)!
EVT!
CEA!
Patients at risk:!
CEA !253 !223 !206 !182 !166 !144 !90 !69 !48!
EVT !251 !225 !209 !193 !174 !148 !100 !72 !53!
HR 1.02 (95% CI 0.79 – 1.32), p = 0.891!
45.2%!
50.4%!
Outcome Measure! HR (95 % CI)! P value!
Disabling stroke or death! 1.02 (0.79 – 1.32)! 0.891!
Stroke lasting > 7 days or death! 1.08 (0.85 – 1.38)! 0.513!
Any stroke or perioperative death! 1.35 (0.94 – 1.93)! 0.129!
Stroke lasting > 7 days or perioperative death! 1.19 (0.82 – 1.72)! 0.368!
Non-perioperative stroke or TIA! 1.37 (0.95 – 1.97)! 0.090!
Non-perioperative stroke! 1.66 (0.99 – 2.80)! 0.054!
Non-perioperative ipsilateral stroke or TIA! 1.29 (0.78 – 2.14)! 0.323!
Non-perioperative ipsilateral stroke! 1.22 (0.59 – 2.54)! 0.591!
Non-perioperative contralateral stroke! 1.90 (0.97 – 3.73)! 0.058!
Any cause of death! 1.07 (0.82 – 1.40)! 0.611!
0! 1! 2! 3! 4!
Favours endovascular treatment! Favours endarterectomy!
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Secondary Outcome Measures 
Safety 
Following convention, albeit a rather arbitrary one, the 30-day period following 
treatment has been chosen to compare the safety of endovascular treatment and carotid 
endarterectomy.  The rate of disabling stroke or death within 30 days after first treatment 
was similar in both groups (6% in both treatment arms, p = 0.8, Table 9.5).   
While all seven deaths within 30 days after endovascular treatment were fatal strokes, 
only one in four deaths following surgery were attributed to stroke.  The other causes of 
death following surgery were ruptured aortic aneurysm, pulmonary embolism and 
respiratory arrest secondary to neck haematoma.  In each treatment group, one patient 
died of non-stroke-related vascular causes without having undergone treatment.  Stroke 
that lasted for more than seven days occurred within 30 days after endovascular 
treatment in 25 patients (including fatal stroke).  They were 22 ischaemic strokes and 
three fatal haemorrhagic strokes.  In 24 patients the stroke was ipsilateral to the treated 
artery.  Following surgery, 20 ischaemic strokes lasting more than seven days and two 
non-disabling haemorrhagic strokes were recorded, all of which were ipsilateral to the 
treated vessel.   
Patients appeared to be at highest risk of treatment-related stroke on the day of treatment 
with 16 strokes lasting longer than seven days occurring on the treatment day in either 
group.  All but one stroke took place within two weeks after treatment (Figure 9.7).  Non-
disabling stroke that lasted for fewer than seven days was more common in the 
endovascular treatment group compared to surgery (eight vs. one event, respectively). 
Cranial nerve injury was completely avoided by endovascular treatment.  As a result of 
surgery it occurred in 22 patients (p < 0.0001).  All but one cranial nerve injuries resolved 
completely within 30 days.  One cranial nerve injury did not resolve until after six 
months.   
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Haematoma requiring intervention or leading to an extended hospital stay was caused by 
endovascular treatment in three patients and by surgery in 17 patients (p < 0.0015).  The 
groin haematomas in the endovascular treatment group did not require surgery while 14 
neck haematomas in the surgery group did. 
Table 9.5 – CAVATAS: Outcome events within 30 days after treatment 
Data are number of patients (%).  Stroke refers to events in any territory.  None of the differences were statistically 
significant except for cranial nerve palsies (p < 0.0001) and haematoma (p < 0.0015).  EVT, endovascular 
treatment; CEA, carotid endarterectomy. 
  Intention to treat  Per protocol 
  EVT 
(n = 251) 
CEA 
(n = 253) 
 EVT 
(n = 240) 
CEA 
(n = 246) 
Fatal stroke  7  
(3%) 
1 
(0.3%) 
 6 
(3%) 
1 
(0.4%) 
Non-stroke death  0 3 
(2%) 
 0 3 
(2%) 
Disabling stroke  9  
(4%) 
11  
(4%) 
 9 
(4%) 
10 
(4%) 
Non-disabling stroke lasting more than 
7 days 
 9 
(4%) 
10 
(4%) 
 9 
(4%) 
10 
(4%) 
Non-disabling stroke lasting less than 
7 days 
 8  
(3%) 
1 
(0.3%) 
 8 
(3%) 
1 
(0.4%) 
       
Disabling stroke or death  16  
(6%) 
15 
(6%) 
 15 
(6%) 
14 
(6%) 
Stroke lasting more than 7 days or 
death 
 25 
(10%) 
25 
(10%) 
 24 
(10%) 
24 
(10%) 
       
Cranial nerve palsy  0 22 
(9%) 
 0 22 
(9%) 
Haematoma (requiring surgery or 
extending hospital stay) 
 3 
(1%) 
17  
(7%) 
 3 
(1%) 
17 
(7%) 
Myocardial infarction  0 3 
(1%) 
 0 3 
(1%) 
Pulmonary embolus  0 2 
(1%) 
 0 2 
(1%) 
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Figure 9.7 – CAVATAS: Timing and pathology of strokes lasting more than 7 days occurring within 12 
days after treatment 
‘H’ represents a cerebral haemorrhage.  Day 1 denotes the day of treatment. 
 
Efficacy 
All strokes occurring more than 30 days after first treatment were recorded as lasting 
longer than seven days.  The number of outcome events are summarised in Table 9.4. 
Any stroke or death occurred in 134 patients in the endovascular treatment group and in 
131 patients in the surgery group.  Stroke contributed to this outcome cluster 59 events in 
the endovascular group (14 fatal, 17 disabling, and 28 non-disabling) and 47 events (six 
fatal, 19 disabling, 22 non-disabling) in the surgery group.   
The estimated 8-year cumulative incidence of any stroke or death was 54.4% (SE 4.0%) in 
the surgery group and 52.9% (SE 4.0%) in the endovascular group (Figure 9.8).  The 
estimated hazard ratio including all available follow-up information was in favour of 
surgery, though not statistically significant (1.08, 95% CI 0.85 to 1.38, Figure 9.6). 
Stroke of any duration or perioperative death occurred more often in patients allocated 
endovascular treatment (n = 67) than in patients allocated surgery (n = 51).  After eight 
years, the cumulative incidence was 29.7% (SE 3.4%) in the endovascular treatment group 
and 23.5% (SE 3.5%) in the surgery group (Figure 9.9).  No significant difference between 
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endovascular treatment and surgery was detected by the end of follow up (HR 1.35, 95% 
CI 0.94 to 1.93, Figure 9.6). 
The 8-year estimated cumulative incidence of any stroke that lasted for more than 7 days 
or perioperative death was higher in the endovascular group (26.6%, SE 3.4%) than in the 
surgery group (23.1%, SE 3.5%, Figure 9.10) but the hazard ratio showed no significant 
difference between the groups (HR 1.19, 95% CI 0.82 to 1.72, Figure 9.6). 
Non-perioperative stroke or TIA occurred in 67 patients in the endovascular group and 
51 patients in the endarterectomy group.  The 8-year cumulative incidence was higher in 
the endovascular group (36.9%, SE 5.0%) than in the surgery group (30.2%, SE 4.7%, 
Figure 9.11), but the estimated hazard ratio was not significantly different (HR 1.37, 95% 
CI 0.95 to 1.97, Figure 9.6). 
Non-perioperative stroke occurred more frequently in the endovascular group than in 
the surgery group.  The estimated 8-year cumulative incidence was 21.1% (SE 4.1%) in 
the former and 15.4% (SE 4.3%) in the latter group (Figure 9.12).  However, this absolute 
risk reduction of 5.7% translating into a hazard ratio of 1.66 (95% CI 0.99 to 2.80) failed to 
reach statistical significance (Figure 9.6). 
Ipsilateral stroke or TIA was more frequent in the endovascular treatment group 
compared to surgery (n = 34 versus n = 27, respectively) and the 8-year estimated 
cumulative incidence was 19.3% (SE 4.0%) after endovascular treatment and 17.9% (SE 
3.8%) after carotid endarterectomy (Figure 9.13).  The hazard ratio showed no significant 
difference between the two treatments (HR 1.29, 95% CI 0.78 to 2.14, Figure 9.6). 
The 8-year cumulative incidence of ipsilateral stroke occurring more than 30 days after 
treatment was very similar in both groups.  Eight years after randomisation, 11.3% (SE 
3.7%) of patients in the endovascular treatment group had experienced an ipsilateral 
stroke compared to 8.6% (SE 3.1%) of patients in the surgery group (Figure 9.14).  The 
increase in risk after endovascular treatment compared to surgery was not statistically 
significant (HR 1.22, 95% CI 0.59 to 2.54, Figure 9.6). 
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Contralateral stroke, i.e. stroke in a vascular territory other than that supplied by the 
randomised carotid artery, was almost twice as common following endovascular 
treatment (n = 24) than after surgery (n = 13) over the whole length of the trial but the 
estimated 8-year cumulative incidence of 11.6% (SE 2.5%) in the former and 11.2% (SE 
4.2%) in the latter treatment group was almost identical (Figure 9.15).  The hazard ratio 
calculated based on all available follow-up data showed an increased risk after 
endovascular treatment, albeit not a statistically significant one (HR 1.90, 95% CI 0.97 to 
3.73, Figure 9.6). 
It was mentioned above that death was the most commonly observed outcome event.  By 
the end of follow-up 112 patients in the endovascular group and 118 patients in the 
surgery group had died.  Almost half of patients had died by eight years of follow-up.  
The cumulative 8-year mortality was 43.0% (SE 4.0%) in the endovascular group and 
48.6% (SE 4.2%) in the surgery group (Figure 9.16).  The hazard ratio showed no 
significant difference between endovascular treatment and surgery (HR 1.07, 95% CI 0.82 
to 1.40, Figure 9.6). 
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Figure 9.8 – CAVATAS: 8-year cumulative incidence of stroke lasting more than 7 days or death (ITT) 
Shown is the Kaplan-Meier curve for any stroke or death up to 8 years after randomisation in the intention-to-treat 
analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.9 – CAVATAS: 8-year cumulative incidence of any stroke or perioperative death (ITT) 
Shown is the Kaplan-Meier curve for any stroke or perioperative death up to 8 years after randomisation in the 
intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative 
incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.10 – CAVATAS: 8-year cumulative incidence of stroke lasting more than 7 days or perioperative 
death (ITT) 
Shown is the Kaplan-Meier curve for stroke that lasted for more than 7 days or perioperative death up to 8 years 
after randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 
8-year cumulative incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.11 – CAVATAS: 8-year cumulative incidence of non-peiroperative stroke or TIA (ITT) 
Shown is the Kaplan-Meier curve for non-perioperative stroke or TIA up to 8 years after randomisation in the intention-
to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.12 – CAVATAS: 8-year cumulative incidence of non-perioperative stroke (ITT) 
Shown is the Kaplan-Meier curve for non-perioperative stroke up to 8 years after randomisation in the intention-to-
treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.13 – CAVATAS: 8-year cumulative incidence of ipsilateral non-perioperative stroke or TIA (ITT) 
Shown is the Kaplan-Meier curve for ipsilateral non-perioperative stroke or TIA up to 8 years after randomisation in 
the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative 
incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
0!
10!
20!
30!
40!
50!
60!
0! 1! 2! 3! 4! 5! 6! 7! 8!
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
%
)!
Follow-up (Years)!
EVT!
CEA!
Patients at risk:!
CEA !248 !215 !186 !167 !142 !103 !59 !42 !25!
EVT !241 !212 !186 !162 !142 !98 !58 !40 !23!
HR 1.66 (95% CI 0.99 – 2.80), p = 0.054!
21.1%!
15.4%!
0!
10!
20!
30!
40!
50!
60!
0! 1! 2! 3! 4! 5! 6! 7! 8!
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
%
)!
Follow-up (Years)!
EVT!
CEA!
Patients at risk:!
CEA !248 !212 !181 !162 !133 !95 !54 !38 !24!
EVT !241 !206 !178 !159 !136 !94 !58 !40 !23!
HR 1.29 (95% CI 0.78 – 2.14), p = 0.323!
19.3%!
17.9%!
107 
Figure 9.14 – CAVATAS: 8-year cumulative incidence of ipsilateral non-perioperative stroke (ITT) 
Shown is the Kaplan-Meier curve for ipsilateral non-perioperative stroke up to 8 years after randomisation in the 
intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative 
incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.15 – CAVATAS: 8-year cumulative incidence of contralateral non-perioperative stroke (ITT) 
Shown is the Kaplan-Meier curve for contralateral non-perioperative stroke up to 8 years after randomisation in the 
intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative 
incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
0!
10!
20!
30!
40!
50!
60!
0! 1! 2! 3! 4! 5! 6! 7! 8!
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
%
)!
Follow-up (Years)!
EVT!
CEA!
Patients at risk:!
CEA !248 !218 !187 !167 !142 !103 !58 !42 !24!
EVT !241 !216 !195 !171 !148 !104 !62 !43 !25!
HR 1.22 (95% CI 0.59 – 2.54), p = 0.591!
11.3%!
8.6%!
0!
10!
20!
30!
40!
50!
60!
0! 1! 2! 3! 4! 5! 6! 7! 8!
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
%
)!
Follow-up (Years)!
EVT!
CEA!
Patients at risk:!
CEA !248 !219 !192 !173 !149 !108 !61 !43 !26!
EVT !241 !214 !191 !169 !148 !104 !61 !43 !28!
HR 1.90 (95% CI 0.97 – 3.73), p = 0.058!
11.6%!
11.2%!
108 
Figure 9.16 – CAVATAS: Mortality (ITT) 
Shown is the Kaplan-Meier for death up to 8 years after randomisation in the intention-to-treat analysis.  The vertical 
bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, endovascular treatment; CEA, 
carotid endarterectomy. 
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Per-protocol Analyses 
Primary Outcome 
The per-protocol analyses included only patients who received their allocated treatment.  
This was the case in 240 patients in the endovascular treatment group and 246 patients in 
the surgery group (see Table 9.4 for a summary of outcome events per treatment group). 
The 8-year cumulative incidence of disabling stroke or death was higher after surgery 
(50.0%, SE 4.2%) than after endovascular treatment (45.5%, SE 4.1%, Figure 9.17), but the 
hazard ratio showed no significant difference between endovascular treatment and 
carotid endarterectomy (HR 1.03, 95% CI 0.79 to 1.34, Figure 9.18). 
Figure 9.17 – CAVATAS: 8-year cumulative incidence of disabling stroke or death (PP) 
Shown is the Kaplan-Meier curve for disabling stroke or death up to 8 years after randomisation in the per-protocol 
analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.18 – CAVATAS: Hazard ratios for various outcome measures (PP) 
Hazard ratios (HR) are calculated based on the intention-to-treat data.  CI, confidence interval. 
 
Efficacy 
The estimated 8-year cumulative incidence of stroke that lasted for more than 7 days or 
death in patients who received the allocated carotid surgery was 54.2% (SE 4.1%).  In 
patients who received the allocated endovascular treatment the incidence of any stroke or 
death was 52.6% (SE 4.1%, Figure 9.19).  The estimated hazard ratio including all 
available follow-up information was 1.10 (95% CI 0.86 to 1.41) in favour of surgery 
(Figure 9.18). 
Stroke of any duration or perioperative death was more common after endovascular 
treatment than after surgery.  After 8 years, the cumulative incidence was 29.7% (SE 
3.6%) in the endovascular treatment group and 21.9% (SE 3.1%) in the surgery group 
(Figure 9.20).  This did not translate into a significant difference in risk (HR 1.35, 95% CI 
0.93 to 1.96, Figure 9.18). 
Outcome Measure! HR (95 % CI)! P value!
Disabling stroke or death! 1.03 (0.79 – 1.34)! 0.856!
Stroke lasting > 7 days or death! 1.10 (0.86 – 1.41)! 0.465!
Any stroke or perioperative death! 1.35 (0.93 – 1.96)! 0.145!
Stroke lasting > 7 days or perioperative death! 1.17 (0.80 – 1.73)! 0.422!
Non-perioperative stroke or TIA! 1.34 (0.93 – 1.93)! 0.116!
Non-perioperative stroke! 1.63 (0.97 – 2.76)! 0.063!
Non-perioperative ipsilateral stroke or TIA! 1.27 (0.76 – 2.10)! 0.364!
Non-perioperative ipsilateral stroke! 1.16 (0.55 – 2.43)! 0.698!
Non-perioperative contralateral stroke! 1.92 (0.98 – 3.77)! 0.054!
Any cause of death! 1.07 (0.81 – 1.40)! 0.644!
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The 8-year estimated cumulative incidence of any stroke lasting more than 7 days or 
perioperative death was higher in the endovascular group (25.8%, SE 3.4%) than in the 
surgery group (22.6%, SE 3.6%, Figure 9.21) but the hazard ratio showed no significant 
difference between the groups (HR 1.17, 95% CI 0.80 to 1.73, Figure 9.18). 
Restricting the analysis to cerebrovascular events occurring more than 30 days after 
treatment showed that non-perioperative stroke or TIA was more frequent in patients 
who received the allocated endovascular treatment than in those patients who received 
the allocated endarterectomy.  The 8-year cumulative incidence was higher in the 
endovascular group (34.9%, SE 4.6%) than in the surgery group (30.9%, SE 4.9%, Figure 
9.22), but the estimated hazard ratio was not significantly different (HR 1.34, 95% CI 0.93 
to 1.93, Figure 9.18). 
The per-protocol analysis of non-perioperative stroke alone showed no significant 
difference between endovascular treatment and carotid endarterectomy (HR 1.63, 95% CI 
0.97 to 2.76, Figure 9.23), although the estimated 8-year cumulative incidence was higher 
in the former group (19.0%, SE 3.3% versus 15.8%, SE 4.4%, Figure 9.18). 
In patients who received the allocated endovascular treatment, ipsilateral stroke or TIA 
was more frequent than in the patients who underwent the allocated carotid 
endarterectomy.  The 8-year cumulative incidence was 17.5% (SE 3.9%) after 
endovascular treatment and 17.0% (SE 3.0%) after carotid endarterectomy (Figure 9.24).  
The hazard ratio showed no significant difference between the two treatments (HR 1.27, 
95% CI 0.76 to 2.10, Figure 9.18). 
The 8-year cumulative incidence of ipsilateral stroke occurring more than 30 days after 
treatment was very similar in the patients undergoing the allocated endovascular 
treatment and carotid endarterectomy.  After eight years, 8.7% (SE 2.6%) of patients 
allocated to and receiving endovascular treatment group had experienced an ipsilateral 
stroke compared to 8.9% (SE 3.3%) of patients in the surgery group (HR 1.16, 95% CI 0.55 
to 2.43, Figure 9.18 and Figure 9.25). 
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The estimated 8-year cumulative incidence of non-perioperative stroke in a vascular 
territory other than that supplied by the randomised carotid artery was 12.0% (SE 2.5%) 
after endovascular treatment and 11.5% (SE 4.3%) after carotid surgery (Figure 9.26).  The 
hazard ratio calculated based on all available follow-up showed an increased risk after 
endovascular treatment that approached statistical significance (HR 1.92, 95% CI 0.98 to 
3.77, Figure 9.18). 
The cumulative 8-year mortality was 42.2% (SE 4.2%) in the endovascular group and 
48.1% (SE 4.3%) in the surgery group (Figure 9.27).  The hazard ratio showed no 
significant difference between endovascular treatment and surgery (HR 1.07, 95% CI 0.81 
to 1.40, Figure 9.18). 
Figure 9.19 – CAVATAS: 8-year cumulative incidence of stroke lasting more than 7 days or death (PP) 
Shown is the Kaplan-Meier curve for any stroke that lasted more than 7 days or death up to 8 years after 
randomisation in the per-protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year 
cumulative incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.20 – CAVATAS: 8-year cumulative incidence of any stroke or perioperative death (PP) 
Shown is the Kaplan-Meier curve for any stroke or perioperative death up to 8 years after randomisation in the per-
protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.21 – CAVATAS: 8-year cumulative incidence of stroke that lasted more than 7 days of 
perioperative death (PP) 
Shown is the Kaplan-Meier curve for stroke that lasted more than 7 days or perioperative death up to 8 years after 
randomisation in the per-protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year 
cumulative incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.22 – CAVATAS: 8-year cumulative incidence of non-perioperative stroke or TIA (PP) 
Shown is the Kaplan-Meier curve for non-perioperative stroke or TIA up to 8 years after randomisation in the per-
protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.23 – CAVATAS: 8-year cumulative incidence of non-perioperative stroke (PP) 
Shown is the Kaplan-Meier curve for  non-perioperative stroke up to 8 years after randomisation in the per-protocol 
analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.24 – CAVATAS: 8-year cumulative incidence of ipsilateral non-perioperative stroke or TIA (PP) 
Shown is the Kaplan-Meier curve for ipsilateral non-perioperative stroke or TIA up to 8 years after randomisation in 
the per-protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative 
incidence.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.25 – CAVATAS: 8-year cumulative incidence of ipsilateral non-perioperative stroke (PP) 
Shown is the Kaplan-Meier curve for ipsilateral non-perioperative stroke up to 8 years after randomisation in the per-
protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.26 – CAVATAS: 8-year cumulative incidence of contralateral non-perioperative stroke (PP) 
Shown is the Kaplan-Meier curve for any stroke or perioperative death up to 8 years after randomisation in the per-
protocol analysis.  The vertical bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, 
endovascular treatment; CEA, carotid endarterectomy. 
 
Figure 9.27 – CAVATAS: Mortality (PP) 
Shown is the Kaplan-Meier curve for death up to 8 years after randomisation in the per-protocol analysis.  The vertical 
bars represent the standard errors of the estimated 8-year cumulative incidence.  EVT, endovascular treatment; CEA, 
carotid endarterectomy. 
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Subgroup analyses 
The majority of patients assigned to endovascular treatment were treated by angioplasty 
alone.  Only 55 patients (22.5%) of those who received the allocated endovascular 
treatment underwent stenting and 185 patients were treated with balloon angioplasty 
alone.  The 8-year cumulative incidence of stroke lasting more than seven days or 
perioperative death was highest in the patients who received a stent (34.1%, SE 9.0%, 
Figure 9.28).  Patients who were treated with balloon angioplasty alone had an 8-year 
cumulative incidence of stroke lasting more than seven days or perioperative death of 
24.0% (SE 3.8%) and surgically treated patients a risk of 22.6% (SE 3.6 5). 
Figure 9.28 – CAVATAS: 8-year cumulative incidence of stroke that lasted more than 7 days or 
perioperative death (PP) 
Shown is the Kaplan-Meier curve for stroke that lasted for more than 7 days or perioperative death up to 8 years 
after randomisation in the per-protocol analysis.  Patients allocated to endovascular treatment are divided into those 
receiving stenting and those undergoing balloon angioplasty alone.  The vertical bars represent the standard errors of 
the estimated 8-year cumulative incidence.  AN, balloon angioplasty; CAS, carotid stenting; CEA, carotid 
endarterectomy. 
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The higher risk of stenting compared to balloon angioplasty did not reach statistical 
significance in the within-subgroup analysis (HR 1.37, 95% CI 0.74 to 2.52).  Compared to 
surgery, the higher risk of stenting was also not statistically significant (HR 1.41, 95% CI 
0.78 to 2.56). 
The exploratory subgroup analyses examining the influence of baseline variables on the 
long-term rate of stroke lasting more than seven days or perioperative death showed no 
significant interaction with treatment effect of any of the variables tested (Figure 9.29).   
The risk of stroke lasting more than seven days or perioperative death after endovascular 
treatment in patients younger than 68 years appeared to be similar to the risk in patients 
undergoing surgery (HR 1.05, 95% CI 0.61 to 1.83) but there was a trend in favour of 
surgery in those patients older than 68 years (HR 1.32, 95% CI 0.79 to 2.20).   
In patients with ischaemic heart disease at time of randomisation there was also a strong 
trend in favour of endarterectomy over endovascular treatment (HR 1.88, 95% CI 1.00 to 
3.54). 
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Figure 9.29 – CAVATAS: Subgroup analyses to compare the rates of the outcome event of stroke in 
territory that lasted more than 7 days or perioperative death, according to various baseline characteristics 
P values are associated with treatment-covariate interaction tests.  Analyses are by intention to treat.  N, number of 
patients in each group; n, number of events; EVT, endovascular treatment; CEA, carotid endarterectomy; HR, hazard 
ratio; TIA, transient ischaemic attack; MI, myocardial infarction. 
 
Number of events 
(n/N)! HR (95 % CI)! P Value!
EVT! CEA!
Sex!
Women! 21/77! 12/75! 1.63 (0.80 – 3.33)! 0.30!
Men! 39/174! 39/178! 1.04 (0.67 – 1.63)!
Age!
< 68 years! 27/120! 24/115! 1.05 (0.61 – 1.83)! 0.56!
! 68 years! 33/131! 27/138! 1.32 (0.79 – 2.20)!
Qualifying event!
Stroke! 21/62! 18/66! 1.23 (0.65 – 2.31)! 0.99!
TIA! 28/94! 24/98! 1.24 (0.72 – 2.13)!
Ocular! 7/65! 6/66! 1.20 (0.40 – 3.58)!
Severity of stenosis!
< 70%! 2/15! 4/22! 0.64 (0.12 – 3.47)! 0.46!
! 70%! 58/236! 47/231! 1.22 (0.83 – 1.79)!
Contralateral stenosis!
<50%! 25/112! 19/117! 1.32 (0.72 – 2.39)! 0.67!
! 50%! 35/139! 32/136! 1.11 (0.69 – 1.80)!
Hypertension!
No! 23/117! 19/106! 1.10 (0.60 – 2.01)! 0.71!
Yes! 37/132! 32/144! 1.27 (0.79 – 2.04)!
Diabetes!
No! 51/211! 42/215! 1.24 (0.83 – 1.87)! 0.93!
Yes! 9/35! 7/32! 1.18 (0.44 – 3.18)!
Smoking!
No! 11/56! 10/57! 1.04 (0.44 – 2.45)! 0.73!
Yes! 49/191! 41/192! 1.23 (0.81 – 1.86)!
Ischaemic heart disease!
No! 32/152! 36/157! 0.88 (0.54 – 1.41)! 0.06!
Yes! 27/95! 15/92! 1.88 (1.00 – 3.54)!
Previous MI!
No! 43/187! 40/193! 1.07 (0.70 – 1.65)! 0.39!
Yes! 12/43! 7/40! 1.69 (0.67 – 4.30)!
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Restenosis 
In 200 patients who completed endovascular treatment and 213 patients who completed 
carotid endarterectomy ultrasound follow-up was available for analysis (median follow-
up 4 years, Table 9.6).  The ultrasound criteria are summarised in Table 8.1, page 56.   
Table 9.6 – CAVATAS restenosis study: Patient characteristics at baseline per allocated treatment 
Data are number of patients (% of known data), unless otherwise indicated.  EVT, endovascular treatment; CEA, 
carotid endarterectomy; SD, standard deviation; IQR, interquartile range. 
  EVT  
(n = 200) 
 CEA  
(n = 213) 
Age (mean [SD], years)  67 [8.5]  67 [8.3] 
Sex     
Women  48 (29%)  69 (32%) 
Men  142 (71%)  144 (68%) 
Vascular risk factors     
Hypertension  103 (52%)  121 (57%) 
Diabetes mellitus  28 (14%)  29 (14%) 
Cholesterol > 6.5 mmol/L  53 (27%)  54 (25%) 
Smokers, past or present  151 (76%)  156 (73%) 
Prior history of cardio-/cerebrovascular disease     
Ischaemic heart disease  78 (39%)  77 (36%) 
Peripheral vascular disease  42 (21%)  44 (21%) 
Ipsilateral cerebrovascular events within 6 months 
before randomisation 
 192 (96%)  202 (95%) 
Degree of ipsilateral carotid stenosis (mean [SD])  77 [14.2]  77 [14.5] 
 
Restenosis ≥ 70% occurred significantly more often in patients randomised to 
endovascular treatment (n = 53) compared to patients randomised to surgery (n = 20).  
Restenosis occurred within the first year after treatment in the majority of cases.  One 
year after treatment, the cumulative incidence of stenosis ≥ 70% was 21.7% (SE 3.0%) in 
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the endovascular treatment arm and 7.5% (SE 1.9%) in the surgery arm.  Five years after 
treatment, the cumulative incidence of carotid restenosis ≥ 70% was 30.7% (SE 3.7%) after 
endovascular treatment and 10.5% (SE 2.4%) after surgery (HR 3.17, 95% CI 1.89 to 5.32, p 
< 0.0001, Table 9.7 and Figure 9.30). 
Restenosis ≥ 50% was also more frequent in the endovascular treatment group compared 
to surgery (109 versus 59 patients, respectively).  One year after treatment the cumulative 
incidence of this outcome was 48.5% (SE 3.6%) in the endovascular treatment group and 
20.7% (SE 2.9%) in the surgery group.  After 5 years the cumulative incidence had 
increased to 58.6% (SE 3.9%) after endovascular treatment and to 31.5% (SE 3.5%) after 
surgery (HR 2.58, 95% CI 1.87 to 3.55, p < 0.0001, Figure 9.30).   
Patients receiving a stent had a lower risk of developing ≥ 50% stenosis (HR 0.37, 95% CI 
0.21 to 0.62, p = 0.0003) and ≥ 70% stenosis than patients undergoing balloon angioplasty 
alone (HR 0.43, 95% CI 0.19 to 0.97, p = 0.042, Figure 9.31). 
Table 9.7 – CAVATAS: Carotid restenosis or occlusion after treatment 
Data are number of patients.  Numbers in brackets indicate contribution of individual outcomes to the composite 
endpoint.  All non-perioperative strokes lasted for more than 7 days.  EVT, endovascular treatment; AN, balloon 
angioplasty; CAS, carotid stenting; CEA, carotid endarterectomy. 
 Intention to treat  Per protocol (endovascular treatment 
only) 
 
EVT 
(n = 200) 
CEA 
(n = 213) 
HR (95% CI) 
 
CAS 
(n = 50) 
AN 
(n = 145) 
HR (95% CI) 
Restenosis ≥ 70% or occlusion (1-year cumulative incidence, 5-year cumulative incidence) 
 
53 
(21.7, 30.7) 
20 
(7.5, 10.5) 
3.17  
(1.89 – 5.32) 
 
7  
(13.1, 16.6) 
46  
(25.3, 36.2) 
0.43  
(0.19 – 0.97) 
Restenosis ≥ 50% or occlusion 
 
109  
(48.5, 58.6) 
59  
(20.7, 31.5) 
2.58  
(1.87 – 3.55) 
 
16  
(23.0, 36.6) 
93  
(58.8, 68.1) 
0.37  
(0.21 – 0.62) 
122 
Figure 9.30 – CAVATAS: 5-year cumulative incidence of carotid restenosis 
Shown is the cumulative incidence of restenosis ≥ 70% (upper graph) and ≥ 50% (lower graph) using life-table 
analysis.  EVT, endovascular treatment; CEA, carotid endarterectomy. 
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Figure 9.31 – CAVATAS: 5-year cumulative incidence of restenosis in patients allocated to endovascular 
treatment 
Shown is the cumulative incidence of restenosis ≥ 70% (upper graph) and ≥ 50% (lower graph) using life-table 
analysis.  AN, balloon angioplasty; CAS, carotid stenting. 
 
!"##"$%&'()*+,-./
0
&
1
&
# ,
2 3
4 +
( 5
6
7 3
8
+ 6
7 +
( )
9
/
:,23+62.(,2(-3.;<
=>
0=?
!"# $# %# &' "$ (!
#) (" '% '! !* !!
=>
0=?
@A
BA
CA
DA
EA
FA
GA
HA
A
@ B C D EA
(&+',
!&+&,
-./)+"(/0$#,/12/)+!$/3/)+$%45/6/7/)+)"'
!"##"$%&'()*+,-./
0
&
1
&
# ,
2 3
4 +
( 5
6
7 3
8
+ 6
7 +
( )
9
/
:,23+62.(,2(-3.;<
=>
0=?
!"# #$ %& %! $# !&
#' %' $$ !& !% (
=>
0=?
@
A B C D E@
A@
B@
C@
D@
E@
F@
G@
H@
')%&*+,#-*./*')$!*0*')1$23*4*5*')'''%
%1)1-
1()!-
124 
Smoking at the time of randomisation or in the past independently predicted restenosis ≥ 
70% (HR 2.32, 95% CI 1.19 to 4.54, p = 0.014) without significant interaction between 
smoking history and allocated treatment. 
Recurrent or residual stenosis between 50 and 69% within 60 days after treatment was 
associated with a significant increase in the risk of the stenosis progressing to ≥ 70% (HR 
3.76, 95% CI 1.88 to 7.52, p = 0.0002).   
In turn, Restenosis ≥ 70% diagnosed within the first year after treatment carried a higher 
risk of ipsilateral non-perioperative stroke or TIA.  The 5-year cumulative incidence was 
22.7% in patients with ≥ 70% stenosis compared to 10.9% with less than 70% stenosis (HR 
2.18, 95% CI 1.04 to 4.54, p = 0.038, Figure 9.32).   
Figure 9.32 – CAVATAS restenosis study: 5-year cumulative incidence of ipsilateral stroke or TIA 
Shown is the Kaplan-Meier cumulative incidence of ipsilateral stroke or TIA during 5 years of follow-up in patients with 
70% or more restenosis in the first year after treatment compared with patients with less than 70% restenosis in the 
first year after treatment.  Time is from the first ultrasound examination done within the first year after treatment that 
confirmed restenosis. 
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The 5-year risk of ipsilateral stroke was also greater in patients with at least 70% 
restenosis (9.7% versus 5.4%, although it did not reach statistical significance (HR 1.67, 
95% CI 0.54 to 5.11, p = 0.4, Figure 9.33). 
Figure 9.33 – CAVATAS restenosis study: 5-year cumulative incidence of ipsilateral stroke 
Shown is the Kaplan-Meier cumulative incidence of ipsilateral stroke or TIA during 5 years of follow-up in patients with 
70% or more restenosis in the first year after treatment compared with patients with less than 70% restenosis in the 
first year after treatment.  Time is from the first ultrasound examination done within the first year after treatment that 
confirmed restenosis. 
 
9.2.3 Discussion 
CAVATAS was the first large randomised clinical trial comparing endovascular 
treatment and carotid endarterectomy for mainly symptomatic carotid stenosis.  It 
addressed two main questions concerning endovascular treatment of atherosclerotic 
carotid artery stenosis.   
The primary outcome measure defined as disabling stroke or death reflected the main 
aim of the trial to provide data on the long-term effectiveness of endovascular treatment 
compared to surgery and inform on the value of treatment to the patient and the health 
service.  The trial showed a very small and non-significant increase in risk of disabling 
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stroke or death over the whole course of the trial in the endovascular treatment group 
compared to the surgery group.  The majority of events contributing to this outcome 
cluster were non-stroke-related deaths (72% in the endovascular group and 77% in the 
surgery group).  The number of disabling strokes was virtually identical, but more than 
twice as many patients in the endovascular group suffered a fatal stroke than patients in 
the surgery group.  NASCET only reported risks up to five years after randomisation 
(Barnett et al. 1998).  The 5-year rate of disabling stroke or death of any cause after carotid 
endarterectomy reported there was 18.3% and thus slightly higher than the 5-year risk of 
16.5% following endovascular treatment and 17.5% following carotid endarterectomy in 
CAVATAS. 
Since non-stroke-related mortality dominated the primary outcome cluster, excluding 
long-term mortality that is not directly attributable to stroke may provide a better 
estimate of the long-term effectiveness of endovascular treatment and surgery.  The risk 
of any stroke or perioperative death was also higher in the endovascular group than in 
the surgery group but the difference in risk failed to reach statistical significance (HR 
1.35, 95% CI 0.94 to 1.93). 
The CAVATAS steering committee had decided prospectively to exclude stroke that 
lasted for fewer than seven days from the analysis of short-term outcome data.  There 
was concern that minor short-lived events were more likely to be detected in patients 
who were returned to a neurological ward and looked after by a team trained in 
diagnosing stroke, as it was mainly the case in patients undergoing endovascular 
treatment.  Surgical patients were generally returned to an intensive care setting before 
moving to a surgical ward.  Moreover, ECST, the European benchmark for CAVATAS at 
the time the trial was initiated had also excluded minor stroke from its analysis (Farrell et 
al. 1998).  The incidence of minor procedural strokes that lasted for fewer than seven days 
was analysed for the first time for this thesis and the associated publications (Bonati et al. 
2009; Ederle et al. 2009a).  Non-disabling stroke lasting less than seven days was more 
frequent in the endovascular group compared to surgery (eight versus one event, 
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respectively).  Notable is the fact that all non-disabling stroke that lasted for fewer than 
seven days occurred within 30 days of the procedure.  All strokes occurring more than 30 
days after treatment reported to the central trial office lasted for more than seven days.  
This finding of excess in minor strokes in the endovascular treatment group is not 
necessarily because of an underreporting in the surgery group as the Trial Steering 
Committee envisaged it.  Six out of eight non-disabling strokes that lasted for fewer than 
seven days in the endovascular treatment group occurred on the day of treatment and it 
is possible that manipulation of the stenosis with the angioplasty equipment caused some 
sort of instability in the plaque that directly led to a minor stroke. 
ECST has published long-term results and reported a 10-year risk of ipsilateral stroke 
after carotid endarterectomy of 9.7% (Cunningham et al. 2002).  This is similar to the 8-
year risk of 8.6% following surgery and 11.3% after endovascular treatment found in 
CAVATAS. 
Neither the primary outcome nor any of the secondary outcome measures showed a 
definite benefit of either treatment compared to the other in the long-term.  More 
importantly, all outcome measures consistently showed a trend towards more events in 
patients allocated endovascular treatment.  This is consistent with findings of SPACE and 
EVA-3S.  These trials also found little difference in the rates of ipsilateral non-
perioperative stroke more than 30 days after carotid stenting and endarterectomy over a 
shorter period of up to two and four years of follow-up, respectively (Eckstein et al. 2008; 
Mas et al. 2008), but both trials found an excess of events in stenting versus surgery in 
their overall analysis for time since randomisation. 
Cranial nerve injury was significantly more frequent after surgery than after 
endovascular treatment.  Not always are these benign and quickly resolving adverse 
events.  One patient had only recovered from a cranial nerve injury by the 6-month 
follow-up.  But it is very difficult to weigh cranial nerve injury against cerebrovascular 
events, which are much more likely to cause disability.  Because of brain damage caused 
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by even a small procedural stroke, a patient may be less able to compensate for any 
future loss of function caused by subsequent strokes.  Also, the fact that a particular 
patient has suffered a procedural stroke in the first place may point towards a lower 
tolerance of disturbances in blood supply and thus increasing the risk of future stroke.  
Stroke is also associated with an increased risk of dementia.  Hospital-based series 
excluding pre-existing dementia reported a prevalence of post-stroke dementia at three 
months ranging from 6% (Madureira et al. 2001) to 28% (Pohjasvaara et al. 1997).  A recent 
review reported a pooled prevalence of post-stroke dementia within three to six months 
of 18%, when pre-existing dementia was excluded (Pendlebury et al. 2009b).  Cranial 
nerve palsies and stroke are therefore not readily comparable. 
The exploratory subgroup analyses of patients treated with stenting compared to those 
treated with balloon angioplasty alone showed a higher risk of stroke that lasted for more 
than seven days or perioperative death in stented patients compared to those treated by 
balloon angioplasty alone, but the difference was not statistically significant (HR 1.37, 
95% CI 0.74 to 2.52).  The higher rate of events after stenting reflects the fact that in four 
out of 55 stented patients, stenting was performed as a secondary, rescue procedure after 
the onset of stroke caused by balloon dilation.  Hence, this result does not reflect the 
current practice of carotid stenting as a primary procedure avoiding full balloon dilation.  
When perioperative events were excluded and thus the long-term efficacies of stenting 
and balloon angioplasty alone were compared, the risk of non-perioperative stroke or 
TIA was lower after stenting than after balloon angioplasty (HR 0.67, 95% CI 0.34 to 1.32) 
but this did not reach statistical significance. 
CAVATAS was not sufficiently powered to show definite effects in any subgroup 
analysis.  They were exploratory in nature and may inform future analysis carried out in 
much larger patient populations.  None of the subgroup analyses of major risk factors 
conclusively favoured endovascular treatment over surgery.  Endovascular treatment 
was somewhat safer in patients with less than 70% stenosis of the treated artery but the 
number of patients in this category was very small, resulting in a very wide confidence 
129 
interval.  In patients with a history of ischaemic heart disease, the rate of stroke that 
lasted for more than seven days or perioperative death after carotid endarterectomy was 
lower than in patients without ischaemic heart disease, whereas after endovascular 
treatment the rate of this outcome measure was higher in the former patients compared 
to latter.  The treatment-covariate interaction test approached statistical significance.  This 
result may become significant with larger patient numbers or the apparent correlation 
could simply be due to chance since no correction for multiple comparisons was made. 
The long-term risk of developing restenosis ≥ 70% was higher after endovascular 
treatment than after surgery with smoking independently predicting severe carotid 
restenosis during follow-up.  Moreover, restenosis ≥ 70% was associated with an 
increased risk of ipsilateral cerebrovascular events during long-term follow-up.   
Smoking is a recognised risk factor for stroke and guidelines uniformly advise smoking 
cessation as stroke preventive measure (Goldstein et al. 2006).  Inflammatory mediators 
like CRP, interleukin-6 and white blood cells are raised in smokers.  In turn, these 
inflammatory mediators are linked to atherosclerosis.   
Smoking is also directly linked to endothelial dysfunction that can lead to atherosclerosis.  
However, the exact pathways of a causal relationship between smoking and 
cardiovascular risk factors is still unclear (Yanbaeva et al. 2007).  The fact that smoking 
predicted severe carotid restenosis in both treatment groups is therefore plausible.  To 
continue smoking after carotid surgery or endovascular treatment can be regarded 
counterproductive and patients should be strongly encouraged to stop smoking.  Other 
mechanisms may also contribute to restenosis.  Surgical and endovascular intervention 
only deal with the immediate consequences of atherosclerosis and not its underlying 
causes.  It is therefore not surprising should the processes that led to the stenosis 
continue after plaque removal or stent insertion.  In addition, the “damage” caused to the 
vessel wall by either plaque removal or balloon inflation and/or stent insertion may 
provide a stimulus for smooth muscle proliferation and intima-media thickening, which 
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in turn might lead to restenosis.  This was shown to be the case in a patient with 
recurrent restenosis after angioplasty who underwent carotid endarterectomy, which 
showed prolific smooth muscle hypertrophy at the site of the previous angioplasty 
(Crawley et al. 1998).  Accompanying long-term medical therapy has an important role to 
play in preventing restenosis. 
The risk of restenosis ≥ 70% was lower after stenting than after balloon angioplasty alone 
but still higher than in case series of primary stenting, which have reported severe 
restenosis in 6% of patients after five years and moderate restenosis in up to 16% of 
patients (Lal et al. 2003; Wholey et al. 2003; Bergeron et al. 2005).  Better ascertainment in 
the context of a clinical trial and differences in patient selection and criteria for grading 
restenosis may explain this difference.  Stenting techniques also differed: Stenting in 
CAVATAS was primarily carried out after unsatisfactory balloon angioplasty.  Only one 
other randomised clinical trial investigated the incidence of restenosis following stenting 
and carotid endarterectomy.  After a relatively short follow-up of two years, the 
cumulative risk of severe restenosis or occlusion in that trial was reported as 10.7% after 
stenting and 4.6% after endarterectomy (Eckstein et al. 2008). 
Severe carotid restenosis diagnosed within the first year following treatment was 
associated with an increased risk of subsequent ipsilateral cerebrovascular events.  The 
risk of ipsilateral stroke in patients with ≥ 70% restenosis was not significantly increased 
from the risk in patients with < 70% restenosis, albeit with wide confidence intervals due 
to the small number of patients reaching this endpoint.  Nevertheless, the increased 
incidence of restenosis ≥ 70% in the endovascular group may explain the increase in non-
perioperative ipsilateral stroke and TIA after endovascular treatment. 
A history of smoking independently predicted restenosis in CAVATAS and has been 
previously identified as predictor of restenosis after endarterectomy (Lattimer et al. 1997).  
The lack of interaction between treatment received and smoking in the prediction of 
restenosis suggests that the effect of smoking is similar in both treatment arms. 
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More than half of the recurrent cerebrovascular events in patients with severe restenosis 
were transient in nature.  Any decision to re-treat patients with severe asymptomatic 
carotid stenosis based on ultrasound findings needs to take into account the relatively 
low risk of ipsilateral stroke in these patients, which was about 2% per year in 
CAVATAS. 
No broadly accepted ultrasound criteria exist for the diagnosis of de novo restenosis.  The 
same criteria used for calculating stenosis were used for establishing restenosis in 
CAVATAS, which may have led to an overestimate of restenosis in stented patients due 
to reduced vessel wall compliance (Nederkoorn et al. 2009). 
Overall, the results of CAVATAS do not support a change in clinical practice away from 
carotid endarterectomy as treatment of choice but they support the use of endovascular 
treatment to prevent long-term stroke in patients in whom carotid endarterectomy is 
contraindicated or who prefer to undergo the possibly greater hazard of endovascular 
treatment in preference to surgery.  Because none of the performed analyses favoured 
endovascular treatment over surgery and uncertainty regarding the long-term durability 
of endovascular treatment persists, it would be unjustified to recommend endovascular 
treatment as first-line treatment.  It remains to be seen if changes in technology improve 
the safety of endovascular treatment.  However, both EVA-3S with a definite benefit of 
surgery and SPACE with an inconclusive result cast some doubt on this assumption and 
the results of ICSS should provide more insight. 
The results emphasise the need for further data from short and long-term comparisons of 
endovascular treatment with endarterectomy to clarify if the small differences between 
the treatments become significant with larger numbers of patients.  While restenosis was 
more frequent following endovascular treatment further data are needed to confirm if 
stenting is superior to balloon angioplasty alone and comparable to surgery in 
preventing restenosis and if re-treatment of asymptomatic restenosis is justified.
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9.3 Endovascular Treatment in Patients Not Suitable for Surgery – Comparison 
with Medical Care 
Treating symptomatic carotid stenosis poses a dilemma in patients who are not well 
enough to undergo surgery or in whom surgery is thought to carry too high a risk of 
complications.  Before endovascular treatment was available, patients not fit for surgery 
were treated medically.  The advent of endovascular treatment with balloon angioplasty 
and stenting was a welcome addition to the management of these patients and quickly 
gained widespread acceptance.  Endovascular treatment was thought to be suitable for 
patients not well enough for surgery and superior to medical treatment alone in 
preventing stroke recurrence.  But there is little evidence from randomised controlled 
trials of the safety and long-term effectiveness of this treatment. 
CAVATAS therefore contained a randomised trial comparing the long-term outcome of 
endovascular treatment of carotid stenosis compared to medical therapy alone.  This 
study was called CAVATAS-MED. 
9.3.1 Methods and Patients 
Patients 
Patients with carotid stenosis who were considered not suitable for carotid 
endarterectomy were randomly allocated to receive either endovascular treatment or 
medical therapy alone.  Twelve centres enrolled patients into CAVATAS-MED.  These 
centres are listed in the Appendix. 
Other inclusion criteria and a detailed description of baseline investigations, 
randomisation, definition of outcome, treatment, and follow-up are set out above and 
will not be repeated here.  Arrangements for follow-up differed in so far as patients 
randomised to medical therapy alone had the initial follow-up appointment one month 
after randomisation. 
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Outcome Measures 
Stroke or death during follow-up was chosen as primary outcome measure.  Since the 
study sample was very small, only one further outcome measure was analysed and 
included all cerebrovascular events (Amaurosis fugax, retinal infarct, TIA and stroke). 
Statistical Analysis 
Data were analysed based on intention to treat using standard statistical software (SPPS 
for Macintosh, SPSS Inc., Chicago, Illinois, USA).  The log rank test was used to compare 
the survival free experience in the two treatment arms.  The treatment effect was 
estimated using a Cox proportional hazard model to calculate hazard ratio and 95% 
confidence intervals.  The medical therapy group was used as the reference group.  The 
proportional hazards assumption was tested with a graphical log-minus-log method.  All 
outcome events up to the last available follow-up or death of the patient were included in 
the calculation of hazard ratios.  To be consistent with the CAVATAS data presentation, 
Kaplan-Meier curves were only plotted up to eight years of follow-up. 
9.3.2 Results 
Baseline Characteristics 
The first patient not suitable for surgery was randomised on 29 April 1992.  By the time 
the last patient was randomised on 16 May 1997, a total of 40 patients not suitable for 
surgery were randomly assigned to endovascular treatment (n = 20 patients) or medical 
therapy alone (n = 20 patients).   
In 31 patients the reasons for being considered unsuitable for carotid endarterectomy 
were either surgical (n = 17) or medical (n = 14) contraindications.  Seven patients 
fulfilling the inclusion criteria for the main CAVATAS study had refused surgery and 
were therefore included in this study and in two patients no reason for being unsuitable 
for surgery was recorded. 
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Four patients in the endovascular group did not undergo their allocated treatment: Two 
patients crossed over to medical therapy after it proved impossible to cross the lesion 
with the guide wire.  One patient refused endovascular treatment after randomisation 
and had carotid endarterectomy instead.  One patient was randomised based on an 
angiogram prior to study entry suggesting greater than 50% stenosis.  At the time of 
endovascular treatment the angiogram did not confirm this but showed a stenosis < 40% 
and treatment was not carried out.  One patient in the medical therapy group underwent 
endovascular treatment at the patient’s request but the treatment failed to dilate the 
stenosis (Figure 9.34). 
Figure 9.34 – CAVATAS-MED: Trial profile 
 
The majority of patients (62.5%) had experienced cerebrovascular symptoms in the six 
months leading up to randomisation (Table 9.8).  Patients allocated to endovascular 
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treatment were younger than the patients assigned to medical therapy and more patients 
in the latter group had a history of ischaemic heart disease or previous myocardial 
infarction.  Cholesterol was elevated in more patients in the endovascular treatment 
group.  Other baseline patient characteristics did not differ between the two groups 
(Table 9.9 and Figure 9.35).   
Blood pressure control during the course of the trial was similar in both treatment groups 
(Figure 9.36) as was the number of patients receiving anti-platelet therapy. 
Data on the use of cholesterol-lowering and anti-hypertensive medication was not 
collected. 
Table 9.8 – CAVATAS-MED: Cerebrovascular symptoms prior to randomisation per allocated treatment 
Data are number of patients (% of known data), unless otherwise indicated.  EVT, endovascular treatment; MED, 
medical treatment. 
  EVT  
(n = 20) 
 MED  
(n = 20) 
Transient ischaemic attack  6 (30%)  3 (15%) 
Amaurosis fugax  0  3 (15%) 
Hemisphere stroke     
Minor  2 (10%)  0 
Major, non-disabling  4 (20%)  0 
Major, disabling  1 (5%)  1 (5%) 
Asymptomatic  5  (25%)  10 (50%) 
Unknown  2 (10%)  3 (15%) 
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Table 9.9 – CAVATAS-MED: Patient characteristics at baseline per allocated treatment 
Data are number of patients (% of known data), unless otherwise indicated.  EVT, endovascular treatment; MED, 
medical treatment; SD, standard deviation; IQR, interquartile range. 
  EVT  
(n = 20) 
 MED  
(n = 20) 
Age (median [IQR], years)  67 [59 – 72]  71.5 [69 – 79] 
Sex     
Women  16 (80%)  15 (75%) 
Men  4 (20%)  5 (25%) 
Vascular risk factors     
Hypertension  14 (70%)  13 (65%) 
Systolic blood pressure (mean [SD], mmHg)  147 [21]  151 [21] 
Diastolic blood pressure (mean [SD], mmHg)  83 [6]  82 [9] 
Diabetes mellitus  6 (30%)  6 (30%) 
Cholesterol > 6.5 mmol/L  13 (65%)  3 (15%) 
Smokers, past or present  17 (85%)  13 (65%) 
Prior history of cardiovascular disease     
Myocardial infarction  1 (5%)  4 (20%) 
Ischaemic heart disease  5 (25%)  8 (40%) 
Atrial fibrillation  0  0 
Peripheral vascular disease  4 (20%)  3 (15%) 
Treatments used at randomisation     
Antiplatelet  19 (95%)  20 (100%) 
Warfarin  2 (10%)  1 (5%) 
Time from randomisation to treatment (median [IQR], 
days) 
 39 [23 – 72]  – 
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Figure 9.35 – CAVATAS-MED: Baseline degree of stenosis per allocated treatment 
Shown is the degree of stenosis (%, per decile) in the randomised ipsilateral internal carotid artery (upper graph) and 
the contralateral internal carotid artery (lower graph).  EVT, endovascular treatment; MED, medical treatment. 
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Figure 9.36 – CAVATAS-MED: Blood pressure during follow-up per allocated treatment 
Shown is the mean blood pressure at randomisation (mmHg).  The bottom of each bar indicates the diastolic BP, the 
top of each bar represents the systolic blood pressure 
 
Delay to Treatment 
The median delay between randomisation and first endovascular treatment was 27 days 
(IQR 8 to 49 days).  One patient suffered a retinal infarct while awaiting endovascular 
treatment. 
Follow-up 
Patients were followed up for up to ten years.  The median length of follow-up was 4.5 
years (IQR 1.25 to 7 years) in the endovascular treatment group and 3.5 years (IQR 1 to 8 
years) in the medical treatment group. 
Primary Outcome 
Stroke or death occurred in nine patients in each treatment group.  Stroke contributed 
five events in the endovascular treatment group and four events in the medical therapy 
group to this outcome cluster.  One fatal haemorrhagic stroke occurred one day after 
endovascular treatment in addition to a retinal infarct that occurred between 
randomisation and angioplasty. 
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The 3-year cumulative incidence of stroke or death was 36.0% (SE 10.9%) after 
endovascular treatment and 35.4% (SE 10.8%) after medical therapy.  Eight years after 
randomisation, the cumulative incidence of stroke or death was 52.0% (SE 13.0%) in the 
former and 41.3% (SE 11.3%) in the latter treatment group (Figure 9.37). 
The hazard ratio based on all available follow-up data showed no difference between 
endovascular treatment and medical therapy (HR 1.02, 95% CI 0.41 to 2.57, Figure 9.38). 
Figure 9.37 – CAVATAS-MED: 8-year cumulative incidence of stroke or death 
Shown is the Kaplan-Meier cumulative incidence of stroke or death during 8 years of follow-up.  The vertical bars at 
the end of each line represent the standard errors of the 8-year cumulative incidence.  EVT, endovascular treatment; 
MED, medical treatment. 
 
Figure 9.38 – CAVATAS-MED: Hazard ratios for outcome measures (ITT) 
HR, hazard ratio; CI, confidence interval.   
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Secondary Outcome Measure 
The combined outcome of TIA, stroke, amaurosis fugax, and retinal infarct occurred in 
seven patients in the endovascular treatment group and in ten patients in the medical 
therapy group.   
The 8-year cumulative incidence of any cerebrovascular event was 37.0% (SE 11.4%) after 
endovascular treatment and 52.6% (SE 11.6%) with medical therapy alone (Figure 9.39).  
All events occurred within three years after randomisation.  The reduction in risk after 
endovascular treatment was not statistically significant (HR 0.79, 95% CI 0.27 to 1.83, 
Figure 9.38). 
Figure 9.39 – CAVATAS-MED: 8-year cumulative incidence of any cerebrovascular event (ITT) 
Shown is the Kaplan-Meier cumulative incidence of any cerebrovascular event (amaurosis fugax, retinal infarct, 
transient ischaemic attack, or stroke) during 8 years of follow-up.  The bars at the end of each line represent the 
standard errors of the 8-year cumulative incidence. 
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9.3.3 Discussion 
Endovascular treatment by balloon angioplasty or stenting was associated with a 5% 
(95% CI 0.1 to 24.9%) risk of stroke or death within 30 days after treatment.  Thereafter, 
the risk of stroke was 10% (95% CI 0.1 to 43.7%) in patients allocated endovascular 
treatment.  However, the rate of stroke with medical therapy alone over the whole study 
was only 20% (95% CI 0.1 to 31.6%) and the number of events prevented by endovascular 
treatment did not make up for the initial risk of the procedure.  CAVATAS-MED 
therefore failed to conclusively show superiority of endovascular treatment over medical 
therapy for carotid stenosis in patients not suitable for carotid endarterectomy. 
Because CAVATAS-MED had a very small sample size it would be wrong to form any 
firm conclusions about the lack of benefit of endovascular treatment.  The wide 
confidence intervals and large standard errors surrounding the calculated risks and 
hazard ratios show that the study was underpowered to show any effect of treatment.  It 
remains possible that endovascular treatment could be superior or indeed worse than 
medical therapy alone in the kind of patients randomised to CAVATAS-MED. 
The small sample size reflects the fact that there are few patients with carotid stenosis 
who are not suitable for surgery but still appropriate for endovascular treatment.  Over 
500 patients were randomised between carotid endarterectomy and endovascular 
treatment but only 40 patients were considered unsuitable for surgery at the same centres 
(of which 7 were included on the grounds of having refused surgery and 1 underwent 
surgery despite having been considered unsuitable).  This may reflect the practice that 
was common during randomisation in CAVATAS of only investigating patients for 
carotid stenosis and referring them to the CAVATAS centres if they were initially 
considered suitable for surgery.  Moreover, reasons for considering patients unsuitable 
for surgery are very poorly defined and with carotid endarterectomy increasingly being 
carried out under local anaesthesia few contraindications for surgery other than 
anatomical reasons (stenosis too high to be accessible by surgery) exist. 
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Patients assigned to endovascular treatment were considerably younger and more 
patients in this treatment group had elevated cholesterol levels at time of randomisation 
compared to those allocated medical therapy alone.  It could have been anticipated that 
the age profile would favour endovascular treatment but this is not reflected by the trial 
results.  Modern medical therapy might have reduced the rate of stroke and rendered 
endovascular treatment even less effective. 
The trial protocol did not specify targets for blood pressure control or cholesterol levels.  
Antiplatelet therapy was widely implemented but no data relating to the use of lipid-
lowering or anti-hypertensive medication during follow-up were collected.  This makes it 
difficult to assess the quality of medical therapy in the trial and compare it to modern 
treatment regimes. 
The median delay between randomisation and endovascular treatment was longer than 
in the CAVATAS study described in the beginning of this chapter and one patient 
suffered a retinal infarct while awaiting endovascular treatment.  This may be a result of 
more investigations being carried out to establish the suitability for surgery in more 
severely ill patients and thus delaying treatment. 
Interventionists may take some encouragement from the fact that of the seven patients 
treated with stenting only one had a non-disabling stroke during follow-up, while eight 
primary outcome events were recorded in the remaining patients in the endovascular 
treatment group.  Stenting technology has evolved since CAVATAS was conducted, 
although the rate of stroke within 30 days after carotid stenting was still higher than that 
after carotid endarterectomy in the recent trials (Mas et al. 2006; Ringleb et al. 2006). 
Only one other randomised trial has compared endovascular treatment to medical 
therapy for carotid stenosis in patients not suitable for carotid endarterectomy and was 
similarly hampered by a very small sample size.  This study randomised 21 patients with 
bilateral carotid stenosis between stenting and medical care (Zhao et al. 2003).  After 18 
months of follow-up, one in eight patients had suffered a stroke or had died after stenting 
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(12.5%) compared to nine in 13 medically treated patients (69.2%).  The higher rate of 
stroke or death in the Chinese study may reflect the fact that these patients had severe 
bilateral carotid stenosis.  Alternatively, differences in risk factor profile or the quality of 
medical therapy may account for the difference in risk of stroke or death between the 
Chinese study and CAVATAS-MED. 
CAVATAS-MED represents the largest randomised body of data comparing 
endovascular treatment to medical therapy alone although it failed to recruit sufficient 
numbers of patients to show any effect of interventional treatment with a sufficient level 
of certainty.  Medical therapy has evolved since the trial was conducted.  Especially the 
use of cholesterol-lowering statins and better control of hypertension have undoubtedly 
improved medical therapy.  It remains uncertain what the best management of patients 
not suitable to undergo carotid endarterectomy should be and more information on how 
interventional treatment, be it surgical or endovascular, compares to modern medical 
therapy would be desirable.  It could even be argued that another trial in symptomatic 
patients that includes modern medical therapy as a separate arm with a pre-defined 
medical regimen to be followed by participants is needed.  The cholesterol and blood 
pressure trials have shown that the preventive effect of the tested medication went 
beyond mere blood pressure and cholesterol lowering and it would therefore be difficult 
to define the medical regimen by its control of target parameters.  With the positive 
publicity of carotid endarterectomy it is also unclear how such a trial would be accepted 
by patients and clinicians, potentially making recruitment very difficult.  One such trial is 
underway in asymptomatic patients (Reiff et al. 2009). 
144 
10 Putting CAVATAS in the Context of Other Trials – A Cochrane 
Systematic Review 
10.1 Introduction 
 The first Cochrane Review comparing endovascular treatment and endarterectomy for 
carotid artery stenosis was carried out in 1997.   At that time data on the safety and 
efficacy of endovascular treatment was scarce and the review did not identify any 
completed randomised trials (Crawley et al. 2000).  The only sources of data were non-
randomised case series, registries or case reports (Wiggli et al. 1983; Tsai et al. 1986; 
Theron et al. 1987; Brown et al. 1990; Theron et al. 1990; Kachel et al. 1991; Munari et al. 
1992; Eckert et al. 1996; Gil-Peralta et al. 1996; Theron et al. 1996).    
CAVATAS was one of the earliest randomised clinical trials of endovascular treatment of 
carotid stenosis and the first to indicate than endovascular treatment may be comparable 
to endarterectomy with regards to safety and efficacy in preventing stroke.   By the time 
the early results of CAVATAS were published in 2001, primary stenting had largely 
replaced balloon angioplasty alone.  The rationale for this change in technique was that 
stenting might avoid the consequences of carotid dissection caused by balloon dilation by 
maintaining laminar flow across the stenosis and sealing the site of dissection and thus 
preventing a free intimal flap from which thromboembolism might originate (Diethrich et 
al. 1996; Roubin et al. 2001).  The hope was that results from intervention in the coronary 
artery circulation, where stenting had been shown to be superior to balloon angioplasty 
alone could be mirrored in the carotid artery (Fischman et al. 1994; Serruys et al. 1994). 
The changes in technology of endovascular treatment and remaining uncertainty about 
safety and efficacy of endovascular treatment highlighted by the initial Cochrane review 
led to other trials being conducted in the years following CAVATAS.  Neither of them 
provided sufficient evidence on their own that would have settled the debate as to the 
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ideal treatment of patients with symptomatic stenosis.  Combining results from similar 
trials in a meta-analysis is one way of trying to increase the certainty about available 
evidence and different attempts at such combined analyses have been made. 
Before discussing the Cochrane Review on endovascular treatment of carotid stenosis 
carried out in 2007 in particular, it is useful to provide a brief overview of what sets 
Cochrane Reviews apart from other reviews. 
10.2 Cochrane Review Explained 
Healthcare research provides unmanageable amounts of information.  Cochrane reviews 
aim at bringing together all available evidence for and against the appropriateness of 
particular treatments or interventions in the absence of definitive randomised trials.  
These reviews are published quarterly in the Cochrane Library by the Cochrane 
Collaboration and provide up-to-date information for healthcare professionals and are 
influential in shaping policies for healthcare provision.  Information gained from such 
reviews help to formulate research questions for trials and determine the sample size 
needed to answer any question posed by the review in the absence of definitive clinical 
trials.  Most funding bodies require researchers to carry out a Cochrane-style review 
prior to applying for funding. 
A systematic review is focused on a specific research question.  Evidence from research is 
collated, analysed, and interpreted based on pre-defined inclusion criteria.  Bias is 
minimized by using systematic methods in order to provide reliable findings and 
conclusions.   
Cochrane reviews are characterised by clearly stated objectives and pre-defined inclusion 
criteria and a reproducible methodology.  A comprehensive search strategy is aimed at 
identifying all studies meeting the inclusion criteria published in the international 
literature.  The identified studies are assessed for the validity of their findings and 
characteristics and findings of included studies are presented in a systematic fashion. 
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Cochrane reviews often contain meta-analyses using statistical methods to summarize 
the results of independent studies (Glass 1976).  Two different methods (fixed effect and 
random effects method) were used for the meta-analysis for dichotomous outcomes in 
the review discussed below.  In meta-analyses that bring together studies of small sample 
size or with low event rate, the Mantel-Haenszel method has better statistical properties 
than the inverse variance method sometimes used for meta-analyses and was the method 
chosen for the review. 
The random effects method assumes that different studies are estimating different, yet 
related intervention effects.  When heterogeneity is absent, the fixed effect and random 
effects methods will give identical results.  With heterogeneity present, the confidence 
intervals will be wider in the random effects model and corresponding claims of 
statistical significance therefore more conservative. 
This systematic and comprehensive approach sets Cochrane reviews apart from other 
reviews that are very often limited to publications in English identified by a cursory 
search on Medline and restricted by a mere meta-analysis of the main findings without a 
detailed assessment of the individual trials’ quality. 
10.3 The Evidence for Endovascular Treatment vs. Surgery for Carotid Stenosis 
10.3.1 Objective of Review 
The purpose of this Cochrane review was to bring together the published evidence from 
clinical trials comparing endovascular treatment of internal carotid artery stenosis 
compared to surgery or medical treatment in the absence of definitive clinical trials.  The 
main work was published in the Cochrane Library (Ederle et al. 2007a) and presented at 
the Autumn Meeting of the Association of British Neurologists (Ederle et al. 2008b).  
Aspects of the work have been published elsewhere (Ederle et al. 2009c).  Since the 
Cochrane review was conducted, one further trial that was listed in the Cochrane review 
as ‘ongoing’ has published 30-day safety results.  This trial will be discussed in detail in 
the next section and is not included in this chapter’s review. 
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10.3.2 Outcome Measures 
It was planned to analyse outcomes with intention to treat.  In order to compare safety 
and efficacy of endovascular treatment to surgery or medical treatment alone, two main 
hypotheses were investigated: 
• Whether endovascular treatment for carotid artery stenosis has a significantly 
different risk of periprocedural stroke or death compared to surgery or medical 
treatment 
• Whether endovascular treatment for carotid artery stenosis is effective in 
preventing stroke ipsilateral to the procedure and in other territories in the long 
term 
Secondary analyses were carried out to examine whether 
• Endovascular treatment reduces the risk of cranial neuropathy 
• Treatments differed in terms of any death within 30 days of procedure, any 
stroke within 30 days of procedure and any death of any cause following 
treatment 
• The rates of other vascular complications (myocardial infarction, pulmonary 
embolism, haematoma) differ between endovascular treatment and surgery 
• There is a significant difference in the restenosis rates following endovascular 
treatment or carotid endarterectomy and whether restenosis leads to recurrent 
stroke 
• In patients unsuitable for surgery, carotid angioplasty and stenting are more 
effective in preventing stroke compared to medical therapy 
• There is a learning curve, i.e. whether the event rate changes over time within 
trials and from trial to trial 
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• The endovascular treatment or carotid endarterectomy arm is responsible for 
heterogeneity among the trials 
• Stenting with cerebral protection devices has a lower rate of treatment-related 
ischaemic events than stenting without cerebral protection devices 
• Endovascular treatment is as safe as surgery in asymptomatic patients. 
10.3.3 Selection of Studies 
Un-confounded truly randomised trials comparing carotid angioplasty or stenting (or 
both) with conventional carotid endarterectomy or medical therapy alone were included 
in the review.  Trials including patients of any age or sex with either symptomatic or 
asymptomatic carotid stenosis were considered.  Any acceptable technique for carotid 
endarterectomy and any acceptable endovascular technique for treatment of carotid 
stenosis were allowed and trials of patients with bilateral as well as unilateral procedures 
were reviewed. 
The Cochrane Stroke Group trials register was searched in March 2007 in addition to the 
Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 
1, 2007), MEDLINE (1950 to March 2007), EMBASE (1980 to March 2007), and Science 
Citation Index (1945 to March 2007).  The detailed search strategy for MEDLINE (Ovid) 
was adopted for the other databases and can be found in the Appendix.  In an effort to 
identify further published, unpublished and ongoing trials, reference lists of relevant 
articles were reviewed and individuals active in the field were contacted. 
All articles identified by the different database searches were reviewed for their 
suitability to be included in the review and pre-specified data were extracted: 
• The method of randomisation and whether the randomising doctor was blinded 
to the treatment allocated 
• The number of patients originally allocated to each treatment group.  This was 
done to enable an intention-to-treat analysis 
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• The method of measuring outcome and whether outcome assessment was 
independent or blinded or both 
• The number of exclusions and losses to follow up 
• Intervention characteristics 
• Outcome measures as outlined above 
A number of subgroup analyses were identified prior to data collection and relevant 
information was also extracted from the published articles: 
• The number of patients given antiplatelet or anticoagulant drugs within the 
treatment period 
• The proportion of symptomatic versus asymptomatic patients in each treatment 
group 
• The degree of baseline stenosis in each treatment group 
• Stents versus no stents 
• The use of cerebral filter devices versus no cerebral filter device. 
Heterogeneity among trials was tested using a standard χ2 test and P = 0.1 was chosen as 
level of statistical significance as far as heterogeneity tests were concerned.  The odds of 
an unfavourable outcome in patients treated by endovascular intervention compared to 
the corresponding odds in patients treated medically or surgically (odds ratio) with 
corresponding 95% confidence interval were calculated using the Mantel-Haenszel fixed 
effect method.  In light of anticipated heterogeneity among trials, the odds ratio was also 
calculated using the Mantel-Haenszel random effects model.  P = 0.05 was chosen as level 
of statistical significance. 
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10.3.4 Description of Studies 
The characteristics of the studies included in this review are summarised in Table 10.1. 
Included Studies 
Seven completed randomised trials were identified comparing endovascular treatment 
with surgery or medical care, involving 941 patients (Brooks et al. 2001; Brown et al. 2001; 
Brooks et al. 2004; Hoffmann et al. 2006; Ederle et al. 2007b). 
The majority of patients (n = 2,286) were however contributed from five further 
randomised trials that had been stopped early (Naylor et al. 1998; Alberts 2001; Yadav et 
al. 2004; Mas et al. 2006; Ringleb et al. 2006). 
Completed Trials 
The multi-centre trial CAVATAS was described in detail in the previous section.  The 
initial analysis of the 505 patients allocated to either endovascular treatment or surgery 
was presented in 2001 and the analysis of the 40 patients unsuitable for surgery and 
randomised between endovascular and medical treatment was first presented at the 
European Stroke Conference in 2007 (Ederle et al. 2007b). 
A group that had collaborated in CAVATAS continued randomisation after CAVATAS 
and presented the local results of 20 patients randomised between carotid 
endarterectomy and endovascular treatment in 2006 (Hoffmann et al. 2006).  This trial 
will be called BACASS in this review. 
A single centre study carried out in Kentucky, USA compared carotid endarterectomy 
with carotid angioplasty and stenting in 104 symptomatic patients and published in 2001 
(Brooks et al. 2001).  The same group subsequently published a similar study in 85 
asymptomatic patients (Brooks et al. 2004). 
Two trials were indentified that had been carried out in China.  The multicentre trial of 
endarterectomy versus stenting for treatment of carotid atherosclerotic stenosis in China 
(TESCAS-C) reported the results of 166 patients randomised between carotid stenting 
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and surgery for symptomatic carotid stenosis (Ling et al. 2006).  The other single centre 
trial compared endovascular treatment and medical care in 21 patients with bilateral 
carotid stenosis and was carried out in Beijing (Zhao et al. 2003). 
Stopped Trials 
A trial of endovascular treatment versus surgery was started at Leicester Royal Infirmary, 
UK, around the same time as CAVATAS but was suspended after only 23 patients had 
been randomly allocated to treatment and only 17 patients had proceeded to treatment.  
No complications occurred in the ten carotid endarterectomies but five of the seven 
patients undergoing endovascular treatment suffered a stroke.  Three patients were 
excluded from the trial after randomisation: One patient due for surgery 
asymptomatically occluded the carotid artery before treatment could be carried out and 
one patient in each group refused treatment.  The remaining three patients were awaiting 
hospital admission at the time the trial was stopped. 
A multicentre trial of carotid stenting versus endarterectomy (Wallstent) in the USA was 
also suspended early after enrolling 219 patients.  Reportedly, this was because of a 
significant lower complication rate in the stenting group compared to endarterectomy 
(4.5% versus 21.1%, P = 0.049), but no results were ever published in a peer-reviewed 
journal (Alberts 2001). 
The randomised Stenting and angioplasty with protection in patients at high risk for 
endarterectomy (SAPPHIRE) trial of stenting using a single device (Angioguard XP 
emboli protection guide wire) compared to endarterectomy in 334 high surgical risk was 
stopped after a drop in recruitment numbers (Yadav et al. 2004). 
Similar reasons led to the early termination of the Stent-Protected Angioplasty versus 
Carotid Endarterectomy study (SPACE) in symptomatic patients.  Interim-analysis of the 
1,183 patients randomised at the time revealed that almost twice as many patients were 
required for a statistically significant result and the investigators decided to stop 
randomisation (Ringleb et al. 2006). 
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The Endarterectomy Versus Angioplasty in patients with Symptomatic Severe carotid 
Stenosis (EVA-3S) was a multicentre trial in France and randomised 527 patients before it 
was stopped due to safety and futility concerns.  The 30-day risk of stroke or death was 
significantly higher after stenting than after surgery (9.6% versus 3.9%) and the Safety 
Committee recommended stopping the trial (Mas et al. 2006). 
Ongoing Trials 
Several trials comparing endovascular treatment to carotid endarterectomy or medical 
therapy were ongoing at the time of this review: 
A trial comparing stenting and carotid endarterectomy within one month of TIA or 
stroke was initiated in 2005 (Agostoni et al. 2005). 
The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST, 
NCT00004732) is comparing endovascular treatment and carotid endarterectomy in 
symptomatic and asymptomatic patients and was still recruiting patients in the United 
States of America and Canada at the time of this review (Hobson 2002). 
A study in Germany with the aim of recruiting 200 patients with symptomatic carotid 
stenosis and comparing carotid stenting and endarterectomy was under way (Link et al. 
2000). 
A commercially sponsored multi-centre trial called ‘Carotid Angioplasty and Stenting 
Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid 
Endarterectomy With Significant Extracranial Carotid Stenotic Disease’ (ACT I, 
NCT00106938) is enrolling patients in the USA. 
The Asymptomatic Carotid Surgery Trial-2 (ACST-2, ISRCTN 21144362) was about to 
start enrolment. 
The International Carotid Stenting Study (ICSS) was still ongoing but has since 
completed randomisation.  It will be discussed in the following chapter. 
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Methodological Quality of Included Studies 
Centre and patient requirements 
CAVATAS was a multicentre trial with long-term follow-up beyond five years.  Each 
centre had to have a team consisting of a neurologist or physician interested in stroke 
medicine for follow-up, an experienced vascular surgeon to perform the 
endarterectomies and either a vascular radiologist with angioplasty experience or 
interventional neuroradiologist to perform carotid angioplasty and stenting.  In 
CAVATAS, patients with symptomatic or asymptomatic carotid stenosis with any degree 
of stenosis equally suitable for surgery or endovascular treatment were eligible provided 
the clinician was substantially uncertain about the best treatment.  No specific technique 
was prescribed for surgical treatment and all endovascular techniques were allowed.   
Patients unsuitable for surgery were randomised in CAVATAS-MED between 
endovascular treatment and medical therapy. 
BACASS recruited patients with symptomatic carotid stenosis greater than 70% and 
suitable for both surgery and endovascular treatment.  Patients had to be willing and 
available to be followed up for two years and each case was discussed in a multi-
disciplinary meeting prior to randomisation. 
The Kentucky study was a single centre trial and only included symptomatic patients 
with symptoms or signs of cerebra ischaemia confined to the ipsilateral carotid artery 
within three months prior to randomisation.  The degree of stenosis had to be greater 
than 70%. 
The same group carried out a single centre study in patients who did not have signs or 
symptoms of cerebral ischaemia and a degree of carotid stenosis of at least 80%, 
documented by digital subtraction angiography. 
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TESCAS-C enrolled patients with severe symptomatic or asymptomatic carotid stenosis.  
No further details regarding exact degree of stenosis, centre requirements and further 
inclusion criteria were available from the abstract of the Chinese publication. 
Patients with severe carotid stenosis on one side and contralateral occlusion as 
demonstrated on duplex ultrasound or cerebral angiography were eligible to join the 
single centre study carried out in Beijing, China.  This study did not publish further 
centre requirements or inclusion criteria. 
The study carried out in Leicester, UK recruited patients with symptomatic severe 
internal carotid artery stenosis greater than 70%.  Endarterectomy was carried out by 
standardised operative technique by a single consultant vascular surgeon.  Endovascular 
treatment was carried out by a single consultant vascular radiologist using stents in all 
patients. 
Patients with symptomatic carotid artery stenosis greater than 60% with transient 
ischaemic attacks or completed strokes within 120 days prior to randomisation were 
randomised in the Wallstent study.  Each participating centre had to demonstrate that it 
had the personnel, technical experience and infrastructure to support the study.  This 
included an interventionist, surgeon, neurologist, ultrasonographer and study co-
ordinator.  The study was only presented at a conference and no further details regarding 
centre or patient requirements were available from the abstract.  Controversially, the 
study sponsor directly intervened in the conduct of the trial and terminated the trial 
prematurely. 
SAPPHIRE randomised symptomatic and asymptomatic patients who were perceived to 
have a high surgical risk to either protected stenting or endarterectomy.  The degree of 
carotid stenosis had to be greater than 50% in symptomatic patients and greater than 80% 
in asymptomatic patients.  In addition, high surgical risk was determined by the presence 
of at least one of the following co-morbidity conditions: congestive heart failure, left 
ventricular dysfunction, recent myocardial infarction or severe pulmonary disease.  A 
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consensus decision to offer inclusion in the study was reached by a neurologist, surgeon 
and interventionist. 
The multi-centre EVA-3S study recruited patients with recently (within 120 days prior to 
randomisation) symptomatic carotid stenosis greater than 60%.  Patients were only 
included in the trial if they had made a useful recovery from their stroke (modified 
Rankin Score less than 3).  Participating surgeons were required to have the experience of 
at least 25 carotid endarterectomies in the year before joining the trial.  The 
interventionist had to have performed at least 12 carotid stenting procedures or at least 
25 stenting procedures of the supra-aortic trunks including five carotid stents.  Less-
experienced operators and interventionists were allowed to join but procedures had to be 
carried out under supervision.  The trial briefly interrupted randomisation and the use of 
cerebrovascular filter devices were made compulsory in the endovascular treatment arm. 
SPACE recruited recently (180 days prior to randomisation) symptomatic patients with 
carotid stenosis greater than 70% on carotid ultrasound (equivalent to greater than 50% 
by NASCET criteria).  As in EVA-3S, patient had to have made a useful recovery from 
their stroke, expressed by a modified Rankin score of less than 3.  Surgeons had to have 
the experience of at least 25 carotid endarterectomies and interventionists were required 
to show proof of 25 successful angioplasty or stent procedures. 
Method of Randomisation 
Two trials (CAVATAS and CAVATAS-MED) used the randomisation service at the 
Clinical Trial Service Unit in Oxford, UK to randomly assign patients to either treatment 
group.  A computerised minimisation algorithm was used that took into account centre 
and timing of symptoms.   
Wallstent used a computerised number-generator for randomisation.  Assignment to 
treatment was provided in sequentially numbered sealed envelopes.  Each centre was 
assigned its own randomisation sequence. 
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In the Leicester study patients were assigned to treatment on a consecutive basis from 
300 random treatment methods numbered and sealed opaque envelopes.  Sealed 
envelopes were also used for randomisation in BACASS. 
An automated, centralised telephone response system was used for randomisation in 
SAPPHIRE while EVA-3S and SPACE used computer-based systems for randomly 
assigning treatment.  In the case of EVA-3S this was a sequence involving randomised 
blocks of two, four, or six and in the case of SPACE a random allocation schedule. 
The Chinese study of endovascular versus medical therapy used a random number table 
for randomisation but it was not entirely clear from the publication if treatment allocation 
was concealed. 
The randomisation method in the above nine trials was considered to be adequate.  In the 
remaining three trials no information regarding the method of randomisation was 
available and thus judged to be unclear. 
Due to the nature of the interventions, it was not feasible to blind health workers, 
patients, or assessors to treatment or outcome in any of the trials. 
Follow up 
The formal follow up schedule differed between the different trials.  CAVATAS and 
CAVATAS-MED followed up patients 30 days after treatment and then at 6 months, 12 
months and yearly after randomisation.  Follow up was carried out by an independent 
neurologist or clinician not directly involved in the actual trial treatment.  The mean 
duration of follow up in CAVATAS was 1.95 years at the time of the original publication 
and 4.3 years in CAVATAS-MED.  A similar follow up schedule was used in BACASS 
with follow up dates calculated from treatment date and provided a mean duration of 
follow up of 2 years.  SPACE also followed up patients 30 days after treatment, at six 
months, one year and planned to conclude follow up two years after treatment.  
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SAPPHIRE followed the same schedule but the last follow up was conducted one year 
after treatment. 
The Kentucky study of symptomatic patients had a more frequent follow up schedule 
with the first follow up taking place 48 hours after the procedure and again at one, three, 
six, 12, and 24 months.  The asymptomatic Kentucky study used the same follow up 
schedule, plus an additional follow up visit 48 months after treatment. 
EVA-3S also conducted the first follow up 48 hours after the procedure.  The next follow 
up visits were then scheduled at 30 days, six months after treatment and every 6 months 
thereafter. 
The first follow up was conducted even sooner in the Leicester and Wallstent studies 24 
hours after treatment.  In the Leicester study the next follow up was scheduled at 30 days 
and patients were followed up for two years, but the follow up intervals were not stated.  
Wallstent conducted a further follow up at six months, 12 months and annually 
thereafter. 
TESCAS-C limited follow-up to 30 days and one year after treatment and the other 
Chinese study of endovascular versus medical treatment only reported results at 1.5 
years after treatment. 
Assessment of Functional Outcome 
Only in five trials was the method of assessing functional outcome given in the relevant 
publications.  The Leicester study used the Oxford Handicap Stroke score.  The 
symptomatic Kentucky study and Wallstent used the Barthel score and modified Rankin 
scale to measure outcome.  Wallstent and BACASS assessed functional outcome using the 
National Institute of Health Stroke Scale (NIHSS). 
CAVATAS divided non-disabling strokes into those lasting fewer than seven days and 
those lasting for seven days or more.  CAVATAS-MED included strokes of any duration.  
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If help was required to undertake activities of daily living for more than 30 days after the 
stroke it was classified as disabling. 
In EVA-3S, SPACE, SAPPHIRE, Kentucky (asymptomatic trial), TESCAS-C, and the 
Chinese study of endovascular versus medical treatment, the method of assessing 
functional outcome was unspecified. 
Analysis of Data 
CAVATAS, CAVATAS-MED, BACASS and SPACE specified that data analyses were by 
intention to treat.  EVA-3S analysed the 30-day results based on treatment received and 
the 6-months results by intention to treat.  The Leicester study only reported results of 
patients who underwent treatment. 
It was possible to extract the number of patients originally allocated to each treatment 
and the outcome of all patients from the publications for an intention-to-treat analysis. 
SAPPHIRE included both symptomatic and asymptomatic patients and the majority of 
patients were in fact asymptomatic.  Because it did not provide details of outcome events 
in asymptomatic patients it was not possible to analyse the symptomatic and 
asymptomatic patients separately. 
Table 10.1 – Cochrane Review: Summary of the characteristics of included studies 
AF, atrial fibrillation; bd, twice daily; CEA, carotid endarterectomy; ICA, internal carotid artery; LOS, low output 
syndrome; LV, left ventricular; MI, myocardial infarction; NIH, National Institutes of Health; TIA, transient ischaemic 
attack. 
Study Leicester 1998 
Method Single centre, randomisation by sequentially numbered sealed opaque envelopes 
containing treatment methods  
2 patients randomised in the surgical arm were not included in the analysis: 1 patient 
spontaneously occluded the relevant ICA, the other patient refused to undergo 
treatment after admission  
4 patients in the endovascular group were not included in the analysis: 1 refused 
treatment after admission, the other 3 were awaiting admission for treatment when 
the trial was suspended  
Follow up at 24 hours and 30 days  
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Participants 23 patients with symptomatic carotid stenosis of 70% to 99% assigned to optimal 
medical treatment with either CEA or carotid angioplasty and stenting  
Patients with asymptomatic disease, symptomatic 0% to 69% stenosis, crescendo 
TIA or stroke in evolution and vertebrobasilar or non-hemispheric symptoms were 
excluded 
Interventions Patients assigned to CEA or carotid angioplasty and stenting  
Aspirin therapy was not stopped before treatment  
All patients received intravenous heparin at the time of the procedure  
In addition, any patient with evidence of more than 25 emboli during any 10 minute 
period of transcranial doppler monitoring was given an incremental intravenous 
infusion of dextran 40 
Outcomes Death and ipsilateral stroke at 30 days post procedure  
Secondary outcome included median number of cerebral emboli detected on 
transcranial doppler 
Notes Terminated prematurely due to safety concerns 
Allocation concealment A – Adequate 
Study CAVATAS 2001 
Method Multicentre, central telephone randomisation  
Follow up at 1, 6, 12 months then annually by independent neurologist  
Intention-to-treat analysis  
Participants 505 patients of any age with symptomatic or asymptomatic carotid artery stenosis 
suitable for surgery or endovascular treatment  
Patients unsuitable for surgery because of medical or surgical risk factors, who were 
unable to give informed consent, unwilling to undergo either procedure or if they 
had a disabling stroke with no useful recovery of function within the region supplied 
by the treatable artery were excluded  
40 patients with carotid artery stenosis who were not suitable for surgery were 
randomised to receive best medical treatment alone or in combination with 
endovascular treatment (see CAVATAS-MED 2007) 
Interventions Patients fit for surgery assigned to endovascular treatment or CEA  
Those unfit for surgery assigned to endovascular treatment or medical care  
Patients in the endovascular group given minimum 150 mg aspirin daily for at least 
24 hours prior to the procedure  
Heparin given at the time of procedure and for the following 24 hours  
Outcomes The primary outcome was specified as disabling stroke or death within 30 days of 
treatment  
The secondary outcome measure was ipsilateral stroke lasting more than 7 days 
Notes  
Allocation concealment A – Adequate 
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Study Kentucky (symptomatic) 2001 
Method Single centre, randomised (method not known)  
Follow up at 1, 3, 6, 12 and 24 months 
Participants 104 patients with symptomatic carotid stenosis > 70% (events within 3 months of 
evaluation)  
Patients with NIH score > 4, cardiac arrhythmia, sensitivity to aspirin, other 
antiplatelets or heparin or with recent intracranial haemorrhage were excluded 
Interventions Patients assigned to carotid angioplasty and stenting or surgery  
All patients received 325 mg aspirin and 75 mg clopidogrel before the procedure 
and patients in the endovascular group received heparin at the time of the 
procedure 
Outcomes Death and stroke following the procedure  
Secondary measures: restenosis rate, length of hospital stay, and relative costs of 
each procedure 
Notes  
Allocation concealment B – Unclear 
Study Wallstent 2001 
Method Multicentre, randomisation performed using a computerised random number 
generator, assignment by sequentially-numbered sealed envelopes; each centre 
assigned its own sequence  
Participants 219 patients aged > 18 years with symptomatic (> 60%) ICA stenosis with events in 
the last 120 days were included  
Patients with ipsilateral arterial stenosis greater than the target lesion, NIH score > 
15, Rankin score > 2, Barthel score < 60, AF, LV thrombus, endocarditis, heparin 
sensitivity, not suitable for surgery, moderate or severe dementia, bleeding diathesis 
or coagulopathy, history of intracranial haemorrhage were excluded  
Interventions Patients assigned to CEA or endovascular treatment  
All patients in the endovascular group given aspirin 325 mg bd and ticlopidine 250 
mg bd for 3 days prior to treatment  
Following carotid angioplasty and stenting all patients treated with aspirin and 
ticlopidine for 4 weeks then aspirin only (325 mg bd)  
For the CEA group use of ticlopidine was optional  
All surgical patients were treated with aspirin 325 mg bd following the procedure 
for the duration of the study 
Outcomes The primary endpoint for the study was the cumulative occurrence of any ipsilateral 
stroke, periprocedure death within 30 days or vascular death within one year of 
treatment  
Secondary outcomes included time to major stroke, patency of the treated artery, 
time to contralateral stroke, time to death, and the occurrence of a TIA  
Notes Terminated prematurely by the sponsor 
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Allocation concealment A – Adequate 
Study Beijing 2003  
Method Single centre, randomised by random number table  
Follow up at 1.5 years after treatment 
Participants 21 patients with severe bilateral carotid stenosis 
Interventions Patients assigned to carotid stenting or medical care alone  
Outcomes Cerebrovascular symptoms since start of treatment 
Notes  
Allocation concealment B – Unclear 
Study Kentucky (asymptomatic) 2004 
Method Single centre, randomised (method not known)  
Follow up at 1, 3, 6, 12, 24, and 48 months 
Participants 85 patients with asymptomatic carotid stenosis > 80% documented by digital 
subtraction angiography 
Interventions Patients assigned to carotid angioplasty and stenting or surgery  
All patients received 325 mg aspirin and 75 mg clopidogrel before the procedure 
and patients in the endovascular group received heparin at the time of the 
procedure  
Outcomes Death and stroke following the procedure  
Secondary measures: perception of perioperative pain, length of hospital stay, and 
relative costs of each procedure  
Notes  
Allocation concealment B – Unclear 
Study SAPPHIRE 2004  
Method Multicentre, randomisation by pseudo-random-number generator and distributed by 
an automated, centralised telephone response system 
Participants 334 patients with > 50% symptomatic carotid stenosis with one or more 
comorbidity criteria (i.e. high surgical risk group) 
Interventions Patients assigned to CEA or carotid stenting with cerebral protection  
All patients received aspirin prior to and following treatment  
In addition, the stented group received clopidogrel pre and post procedure  
All patients were given heparin during the procedure  
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Outcomes Death, any stroke, and MI within 30 days of procedure  
Death of ipsilateral stroke between 31 days and 1 year post procedure plus 30 day 
major adverse clinical event rate 
Notes Terminated prematurely due to a drop in randomisation 
Allocation concealment A – Adequate  
Study BACASS 2006 
Method Single centre, randomised by sealed envelopes  
Follow up at 1, 6, 12 months and yearly thereafter conducted between 1998 and 
2002 
Participants 20 patients with symptomatic carotid stenosis > 70%  
Patients were excluded if they were unwilling to participate, unavailable for at least 2 
years for follow up, or presented with ICA occlusion or free floating thrombus 
Interventions Patients were assigned to either stenting or CEA 
Outcomes Primary outcome measures were periprocedural stroke, death or MI  
Secondary outcome measures were peri-interventional TIA, haematoma, cranial 
nerve paralysis and LOS 
For the follow up, secondary outcome measures were patency of the treated vessel 
and stroke prevention related to the treated side  
Notes  
Allocation concealment A – Adequate 
Study SPACE 2006 
Method Multicentre, randomised by computer-generated random allocation schedule  
Follow up at 7 and 30 days, and after 6, 12, and 24 months 
Participants 1,183 patients with symptomatic carotid stenosis > 70% on duplex ultrasound in the 
previous 180 days of enrolment  
Patients had to be older than 50 years 
Interventions Patients assigned to stenting or CEA, patients had to be treated within 14 days of 
randomisation  
All patients in the stenting group had to be given 100 mg aspirin plus 75 mg 
clopidogrel daily for 3 days before and 30 days after treatment  
CEA patients had to be given 100 mg aspirin before, during, and after surgery 
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Outcomes Ipsilateral stroke or death of any cause between randomisation and 30 days after 
treatment  
Disabling ipsilateral stroke or death from any cause since randomisation  
Any stroke up to days after treatment  
Procedural failure including inability to treat with allocated technique, remaining 
stenosis > 50% or vessel occlusion assessed up to 30 days after treatment 
Notes Terminated prematurely after futility analysis 
Allocation concealment A – Adequate 
Study EVA-3S 2006 
Method Multicentre, randomisation by computer-generated sequence, involving randomised 
blocks of 2, 4, or 6  
Patients stratified by centre and degree of stenosis  
Follow up at 48 hours, 30 days and 6 months after treatment 
Participants 527 patients with symptomatic carotid stenosis between 60% and 99% within 120 
days before enrolment  
Patients had to be fit to undergo either surgery or stenting  
Patients with Rankin score > 3, severe tandem lesions, previous revascularisation of 
the symptomatic stenosis were excluded  
Interventions Patients assigned to stenting or surgery  
After the study was started, use of cerebral protection devices became mandatory 
in the stenting group  
It was recommended to use between 100 mg and 300 mg of aspirin daily in all 
patients, and 75 mg clopidogrel or 500 mg ticlopidine for 3 days before and 30 days 
after stenting  
Outcomes Any stroke or death within 30 days after treatment  
MI, TIA, cranial nerve injury, major local complications, and systemic complications 
within 30 days after treatment  
Any stroke or death within 30 days of treatment plus ipsilateral stroke, any stroke, 
or any stroke or death within 31 days through end of follow up  
Notes Study terminated prematurely due to safety and futility concerns 
Allocation concealment A – Adequate  
Study TESCAS-C 2006 
Method Multicentre, randomised (method not known)  
Follow up at 1 and 6 months 
Participants 166 patients with severe symptomatic or asymptomatic carotid stenosis 
Interventions Patients assigned to carotid stenting or CEA 
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Outcomes Death, stroke or MI at 30 days after treatment  
Death or ipsilateral stroke between 31 days and 6 months after treatment  
Notes Publication in Chinese with English abstract only, data presented in review taken 
from abstract 
Allocation concealment B – Unclear 
Study CAVATAS-MED 2007 
Method Trial methods were the same as in CAVATAS-CEA 2001  
Participants 40 patients with carotid artery stenosis who were not suitable for surgery were 
randomised to receive best medical treatment alone or in combination with 
endovascular treatment 
Interventions Patients were assigned to receive either endovascular or medical treatment  
Patients in the endovascular group given minimum 150 mg aspirin daily for at least 
24 hours prior to the procedure  
Heparin given at the time of procedure and for the following 24 hours  
Outcomes The primary outcome was specified as disabling stroke or death within 30 days of 
treatment  
The secondary outcome measure was ipsilateral stroke lasting more than 7 days 
Notes  
Allocation concealment A – Adequate 
 
10.3.5 Meta-analysis 
Endovascular Treatment versus Carotid Endarterectomy 
Safety 
Death or any stroke within 30 days after treatment 
Death or any stroke within 30 days after treatment was reported by eight trials.  The χ2-
test for heterogeneity did not suggest underlying heterogeneity (χ2 = 11.81, p = 0.11).  
Death or any stroke was significantly more frequent in the endovascular treatment group 
using the fixed effect model (odds ratio [OR] 1.39, 95% CI 1.05 to 1.84, p = 0.02, Figure 
10.1).  The random effects model widened the 95% confidence interval and the statistical 
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significance disappeared (OR 1.44, 95% CI 0.91 to 2.26, p = 0.12, see Appendix for forest 
plots of all random effects model calculations). 
Figure 10.1 – Cochrane Review: Meta-analysis of death or any stroke within 30 days after treatment in 
the fixed-effect model 
Odds ratio for death or any stroke within 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is 
based on published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The 
summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the 
point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number 
of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
 
!"#$% &'$()*+,#-*.
'/0
!#.12,*-
'/0
3$$+45*"2(467289$:
;<4=4>?
@921A"
6=:
3$$+45*"2(467289$:
;<4=4>?
!"#$%&'(%)"$"('*"+",$-%.),/#012("%3%445647%8&%3%97%:%3%;544%
!"#$%&'(%'<"(2==%"&&".$%>%3%?5@;7%:%3%;5;?
BCBD BCD D DB DBB
E92,9+"9.4D;;F ;5@ ?454A%B45;47%CCA5;;DAE44 ;E4?
>GHGIG!4JBBD ?95; 45;;%B;5AF7%456;D?AE?A? ?AE?A@
K9'"#,L%46+%MN"C:4JBBD 456 ;5@4%B;5;47%95G;D;EA@ 4EA4
!GOOP?5&4JBBQ 4;5@ ;566%B;5@@7%?5@AD6E4F9 GE4F9
RG>G!!4JBBS 459 ;5@;%B;5;47%65@@D;E4; 4E4;
!OG>&4JBBS C?59 45?;%B;5997%4569DCFEAGG @6EA6C
&HGTU!4JBBS 445; ?5F@%B45?@7%A5A6D?AE?FA 4;E?F?
I("*-46;<4=4>?: DBBCB DCU;4VDCB<W4DCFQXDJJ/DQSQ F;/DQ<D
@*--+"9'"4JBBD A5? ?5GF%B45;?7%65F4D4@E4;9 AE44?
Y*)(#.+49'$()*+,#-*. Y*)(#.+4+#.19.%
166 
Death or disabling stroke within 30 days after treatment 
Only seven trials distinguished between disabling and non-disabling stroke and no 
significant heterogeneity among trials was suggested (χ2 = 5.16, p = 0.40).  Disabling 
stroke or death was more frequent following endovascular treatment, but this result was 
statistically significant neither using the fixed effect model (OR 1.22, 05% CI 0.83 to 1.79, 
p = 0.31, Figure 10.2) nor in the random effects model (OR 1.20, 95% CI 0.80 to 1.80, p = 
0.39). 
Figure 10.2 – Cochrane Review: Meta-analysis of disabling stroke or death within 30 days after treatment 
in the fixed-effect model 
Odds ratio for disabling stroke or death within 30 days after treatment.  The ends of the lines are the 95% CI.  
Analysis is based on published results.  The large diamond represents the odds ratio and 95% CI of the combined 
data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the 
diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for 
heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees 
of freedom. 
 
!"#$% &'$()*+,#-*.
'/0
!#.12,*-
'/0
3$$+45*"2(467289$:
;<4=4>?
@921A"
6=:
3$$+45*"2(467289$:
;<4=4>?
BCBD BCD D DB DBB
E92,9+"9.4D;;F !"# $!"%&'(!")#*'%%+"&,-,.$$ !.$%
>GHGIG!4JBBD %&", $"!/'(!"+%*'%",,-$0.%+% $+.%+,
K9'"#,L%46+%MN"C:4JBBD ,"% !",$'(!"!$*'#"&!-!.+, $.+$
1234'567'82427692:2;4<'=8;>3?@A72'B'+"$0*'C5'B'#*'D'B'!")!'
1234'567'6E27AFF'2552=4'G'B'$"!%*'D'B'!",!
!GOOP?5&4JBBQ $)", !"+0'(!"$0*'$"&+-).$0# #.$0#
RG>G!!4JBBS !"! :64'234;HAIF2!.$! !.$!
!OG>&4JBBS ))") $"%+'(!"#$*'%"%%-%/.+&& %%.+/)
&HGTU!4JBBS /"$ %"%#'(!"0&*'#")0-&.%0+ ).%0%
I("*-46;<4=4>?: DBBCB DCJJ4VBCFUW4DCX;YSB/DU<X Q;/DUU;
Z*)(#.+49'$()*+,#-*. Z*)(#.+4+#.19.%
167 
Death within 30 days after treatment 
No significant heterogeneity among the seven trials reporting death within 30 days after 
treatment (χ2 = 2.27, p = 0.69).  The risk of death was not different in either treatment 
group using both the fixed effect model (OR 0.99, 95% CI 0.50 to 1.97, p = 0.98, Figure 
10.3) and the random effects model (OR 1.00, 95% CI 0.49 to 2.04, p = 0.99). 
Figure 10.3 – Cochrane Review: Meta-analysis of death within 30 days after treatment in the fixed-effect 
model 
Odds ratio for death within 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is based on 
published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The summary 
estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the point 
estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number of 
patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Stroke within 30 days after treatment 
The same seven trials showed a significantly different effect for stroke within 30 days 
after treatment in favour of carotid endarterectomy.  The fixed effect model’s odds ratio 
was 1.40 (95% CI 1.02 to 1.91, p = 0.04, Figure 10.4).  However, there was significant 
heterogeneity among the trials (χ2 = 10.65, p = 0.06) and using the random effects model 
widened the confidence interval and rendered the result not statistically significant (OR 
1.47, 95% CI 0.81 to 2.67, p = 0.20). 
Figure 10.4 – Cochrane Review: Meta-analysis of stroke within 30 days after treatment in the fixed-effect 
model 
Odds ratio for any stroke within 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is based on 
published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The summary 
estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the point 
estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number of 
patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Cranial neuropathy within 30 days after treatment 
The rate of cranial neuropathy within 30 days after treatment was reported in six trials 
without significant heterogeneity among the studies (χ2 = 1.87, p = 0.60).  The result 
significantly favoured endovascular treatment using both the fixed effect model (OR 0.07, 
95% CI 0.03 to 0.20, p < 0.00001) and the random effects model (OR 0.09, 95% CI 0.04 to 
0.25, p < 0.00001, Figure 10.5). 
Figure 10.5 – Cochrane Review: Meta-analysis of cranial neuropathy within 30 days after treatment in 
the fixed-effect model 
Odds ratio for cranial neuropathy within 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is 
based on published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The 
summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the 
point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number 
of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Death or neurological complications within 30 days after treatment 
Data from six trials were available that allowed for death and neurological complications 
(stroke and cranial neuropathy) to be combined.  This combined outcome significantly 
favoured endovascular treatment in the fixed effect model (OR 0.62, 95% CI 0.45 to 0.86, p 
= 0.004, Figure 10.6).  However, there was significant heterogeneity among the included 
trials (χ2 = 11.06, p = 0.05) and the random effects model produced a non-significant 
result in favour of endovascular treatment (OR 0.60, 95% CI 0.31 to 1.17, p = 0.13). 
Figure 10.6 – Cochrane Review: Meta-analysis of death or neurological complications within 30 days after 
treatment in the fixed-effect model 
Odds ratio for death or neurological complications (cranial neuropathy, stroke) within 30 days after treatment.  The 
ends of the lines are the 95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio 
and 95% CI of the combined data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect 
model, the centre of the diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength 
of evidence for heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence 
interval; df, degrees of freedom. 
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Death or stroke or myocardial infarction within 30 days after treatment 
Six trials allowed for combining death, stroke and myocardial infarction in one outcome 
measure.  No significant difference was found between treatments in both the fixed effect 
model (OR 1.11, 95% CI 0.77 to 1.60, p = 0.57) and the random effects model (OR 1.06, 
95% CI 0.48 to 2.38, p = 0.88, Figure 10.7).  There was significant heterogeneity among 
trials (χ2 = 12.90, p = 0.02). 
Figure 10.7 – Cochrane Review: Meta-analysis of death or stroke or myocardial infarction within 30 days 
after treatment in the fixed-effect model 
Odds ratio for death or stroke or myocardial infarction within 30 days after treatment.  The ends of the lines are the 
95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio and 95% CI of the 
combined data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre 
of the diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for 
heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees 
of freedom. 
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Death, stroke, cranial neuropathy or myocardial infarction within 30 days after treatment 
The same six studies were combined for analysing death, stroke, cranial neuropathy and 
myocardial infarction in one outcome measure.  While there was significant 
heterogeneity among the trials (OR 41.46, p < 0.00001), little difference was found 
between endovascular treatment and endarterectomy in both the fixed effect model (OR 
0.87, 95% CI 0.67 to 1.14, p = 0.32, Figure 10.8) and the random effects model (OR 1.16, 
95% CI 0.41 to 3.24, p = 0.78). 
Figure 10.8 – Cochrane Review: Meta-analysis of death, stroke, cranial neuropathy or myocardial 
infarction within 30 days after treatment in the fixed-effect model 
Odds ratio for death, stroke, cranial neuropathy or myocardial infarction within 30 days after treatment.  The ends of 
the lines are the 95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio and 
95% CI of the combined data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect 
model, the centre of the diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength 
of evidence for heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence 
interval; df, degrees of freedom. 
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Efficacy 
Long-term efficacy was difficult to assess because trials reported outcome after different 
time intervals.  Two trials reported six months’ results, two trials reported outcome 
events 12 months after randomisation and one trial each presented results after 2 and 
after 3 years of follow up. 
Death or any stroke during follow-up, including the initial 30-day post treatment period 
Heterogeneity among the six trials reporting death or stroke during follow up was 
significant (χ2 = 14.05, p = 0.02).  Discounting different lengths of follow up, the excess of 
death or stroke during follow up in the endovascular treatment group was not 
statistically significant in the fixed effect model (OR 1.13, 95% CI 0.81 to 1.58, p = 0.47, 
Figure 10.9) and the random effects model (OR 1.18, 95% CI 0.61 to 2.28, p = 0.62). 
Figure 10.9 – Cochrane Review: Meta-analysis of death or stroke during follow-up in the fixed-effect 
model 
Odds ratio for death or stroke during follow up, including the 30-day post-treatment period.  The ends of the lines are 
the 95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio and 95% CI of the 
combined data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre 
of the diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for 
heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees 
of freedom. 
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Death occurring later than 30 days after treatment 
Three trials provided data on death occurring more than 30 days after treatment and 
there was no significant heterogeneity among these trials (χ2 = 1.27, p = 0.53).  Neither the 
fixed effect model (OR 0.58, 95% CI 0.30 to 1.13, p = 0.11, Figure 10.10) nor the random 
effects model (OR 0.57, 95% CI 0.29 to 1.12, p = 0.53) revealed a significant difference 
between treatments. 
Figure 10.10 – Cochrane Review: Meta-analysis of death occurring more than 30 days after treatment in 
the fixed-effect model 
Odds ratio for death occurring more than 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is 
based on published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The 
summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the 
point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number 
of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Stroke occurring later than 30 days after treatment 
The effect for stroke occurring later than 30 days after treatment in the same three trials 
was significantly different in neither the fixed effect (OR 1.00, 95% CI 0.47 to 2.14, p = 
0.99, Figure 10.11) nor the random effects model (OR 0.99, 95% CI 0.46 to 2.14, p = 1.00).  
No significant heterogeneity among trials was detected (χ2 = 0.82, p = 0.36). 
Figure 10.11 – Cochrane Review: Meta-analysis of stroke occurring more than 30 days after treatment in 
the fixed-effect model 
Odds ratio stroke occurring more than 30 days after treatment.  The ends of the lines are the 95% CI.  Analysis is 
based on published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The 
summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the 
point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number 
of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Protected versus Unprotected Endovascular Treatment 
Death or stroke within 30 days after treatment 
Data from two trials were obtainable to compare endovascular treatment with and 
without cerebral protection devices, with significant heterogeneity between trials (χ2 = 
4.53, p = 0.03).  The use of protection devices was not favoured statistically significant in 
either the fixed effect (OR 0.77, 95% CI 0.41 to 1.46, p = 0.43, Figure 10.12) or random 
effects model (OR 0.57, 95% CI 0.14 to 2.33, p = 0.43). 
Figure 10.12 – Cochrane Review: Meta-analysis of protected versus unprotected endovascular treatment 
in the fixed-effect model 
Odds ratio for protected versus unprotected endovascular treatment.  The ends of the lines are the 95% CI.  Analysis 
is based on published results.  The large diamond represents the odds ratio and 95% CI of the combined data.  The 
summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect model, the centre of the diamond is the 
point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, number 
of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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10.3.6 Endovascular Treatment versus Carotid Endarterectomy in Asymptomatic 
patients 
Three trials allowed for asymptomatic patients to be included in the study according to 
their study protocol.  However, in only two trials, the number of asymptomatic patients 
and corresponding event rate was available for analysis in this Cochrane review. 
Death or stroke within 30 days after treatment 
Death or stroke only occurred in one trial.  There was no difference between 
endovascular treatment and carotid endarterectomy and the fixed effect and random 
effects model both produced the same odds ratio (OR 1.06, 95% CI 1.06 to 6.94, p = 0.96, 
Figure 10.13). 
Figure 10.13 – Cochrane Review: Meta-analysis of death or stroke within 30 days after treatment in 
asymptomatic patients 
Odds ratio for death or stroke within 30 days after treatment in asymptomatic patients.  The end of the lines are the 
95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio and 95% CI of the 
combined data.  The summary estimate statistic is a Mantel-Haenszel (fixed-effect model), the centre of the diamond 
is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength of evidence for heterogeneity.  N, 
number of patients in each treatment group; n, number of events; CI, confidence interval; df, degrees of freedom. 
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Endovascular Treatment versus Medical Care 
Death or stroke occurring later than 30 days after treatment/randomisation 
Only the results of two very small trials were available for the analysis of death or stroke 
occurring later than 30 days after treatment or randomisation and heterogeneity between 
these two trials was significant (χ2 = 3.30, p = 0.07).  And neither the fixed effect model 
(OR 0.39, 95% CI 0.14 to 1.14, p = 0.09, Figure 10.14) nor the random effects model (OR 
0.28, 95% CI 0.02 to 3.23, p = 0.30) significantly favoured endovascular treatment over 
medical management alone. 
Figure 10.14 – Cochrane Review: Meta-analysis of death or stroke occurring later than 30 days after 
endovascualar treatment or randomisation in the fixed-effect model 
Odds ratio for death or stroke occurring more than 30 days after endovascular treatment or randomisation.  The ends 
of the lines are the 95% CI.  Analysis is based on published results.  The large diamond represents the odds ratio and 
95% CI of the combined data.  The summary estimate statistic is calculated using a Mantel-Haenszel fixed-effect 
model, the centre of the diamond is the point estimate, and its width the 95% CI.  The χ2 test indicates the strength 
of evidence for heterogeneity.  N, number of patients in each treatment group; n, number of events; CI, confidence 
interval; df, degrees of freedom. 
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the rate of ipsilateral stroke in the survival analysis up to 3 years after randomisation was 
not significantly different.  BACASS reported one patient in each treatment arm with a 
restenosis between 30% and 49% and one patient in the surgery group with a stenosis 
between 50% and 69% at the time of the 2-year follow up. 
The Kentucky study in symptomatic patients reported that the patency of treated arteries 
remained ‘acceptable’ two years after treatment in both groups but did not provide 
specific restenosis rates nor did it define ‘acceptable’. 
Source of heterogeneity and learning curve 
Not enough individual patient data were available to further investigate the source of 
heterogeneity among trials.  The analysis of a potential learning curve in carotid stenting 
was not able to proceed because of a lack of individual patient data. 
No information regarding ipsilateral stroke during long term follow up was extractable 
from the individual trial publications and this analysis was therefore not carried out. 
10.3.7 Discussion of Results 
This review and meta-analysis of randomised clinical trials showed a significant 
difference in the risk of stroke or death between patients treated endovascularly and 
those patients treated with surgery using the fixed effect model, favouring carotid 
endarterectomy.  There was no difference in the risk of death between the two treatment 
groups and the increase in risk of death or stroke was primarily driven by the difference 
in the risk of stroke.  However, using the random effects model to calculate the odds ratio 
led to a widening of the 95% confidence interval and rendered the difference in risk not 
statistically significant.  This suggests that the results of this analysis are not very robust.  
Most likely the number of patients and events in each treatment group are not sufficient 
to provide a robust estimate of the overall risk difference. 
No significant difference in the risk of death or disabling stroke within 30 days after 
treatment were found, suggesting that non-disabling stroke are the driving force behind 
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any difference between endovascular treatment and carotid endarterectomy, although 
this specific analysis was not possible due to lack of information in the individual trial 
publications. 
Centres taking part in the randomised trials had a specific interest in secondary 
prevention of stroke and care must be taken when extrapolating the data into routine 
clinical practice in less specialist centres.  Furthermore, three of the included trials were 
stopped early because of an excess event rate in the endovascular treatment group.  
Therefore, the overall result might well be biased because of this.  This fact needs to be 
kept in mind when interpreting the results of the meta-analysis. 
Little doubt remains about the significant reduction in peri-procedural cranial 
neuropathy in patients undergoing endovascular treatment compared to those who 
underwent carotid endarterectomy.  Potentially, cranial neuropathy can have a 
devastating impact on the quality of life of affected patients.  It may require the 
placement of a percutaneous endogastric tube or greatly impair speech.  It is difficult to 
adequately take cranial neuropathy into account when balancing the risks and benefits of 
endovascular treatment over carotid endarterectomy.  While including cranial 
neuropathy in a combined outcome measure together with death and stroke off-set the 
increased risk of stroke after endovascular treatment and tended to favour endovascular, 
adding myocardial infarction to this outcome showed no significant difference between 
the treatments.  This was because of an increase in myocardial infarction in the 
endovascular treatment group. 
Only one of the trials included in this review concluded from their individual results that 
endovascular treatment was not inferior to carotid endarterectomy.  All other trials were 
much more cautious in the interpretation of safety data and either concluded that carotid 
endarterectomy was the safer option or that not sufficient evidence would justify a shift 
of clinical practice away from carotid endarterectomy as the treatment of choice of 
symptomatic carotid stenosis.  This view has to be supported by the meta-analysis that 
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overall showed a tendency towards carotid endarterectomy being superior to 
endovascular treatment in short term outcome, but the number of patients and the 
number of observed events was too small to provide a robust estimate of the overall odds 
ratio. 
At the time of this review very little information about long term efficacy of endovascular 
treatment compared to endarterectomy was available and only 4 trials provided at least 
1-year follow up data and the reported length of follow up differed greatly.  There 
appears to be consensus in the carotid stenosis research community what the important 
short-term outcome data are.  The initial 30 days after treatment have been identified as 
of particular interest and the vast majority of trials report this data and are also 
surprisingly consistent in their selection of outcome measures for this time period.   
Unfortunately, there is a complete breakdown in consensus beyond the 30-day safety 
period.  The reported outcome measures are as numerous as there are trials and the trial 
publications make it very difficult to identify outcome measures that all trials have in 
common without the knowledge of individual patient data.  But not only do long-term 
outcome measures differ, there is also no uniformity on the length of reported follow up.  
Most likely, this lack of consistency in reporting is owed to funding since it is quite 
expensive to keep a trial running for a long period of time.  However, the question must 
be allowed, why trialists ignore previous publications in their field and do not report the 
same outcome events, even if their trials provide longer follow up.  This could be easily 
done in addition to their own pre-specified analyses and would make comparison of 
trials much easier. 
On this basis it is very difficult to form a firm conclusion about the long-term efficacy of 
treatment.  It appears that the effects of death and stroke during follow up are very 
similar beyond the initial 30-day peri-procedural period.  And the overall differences 
between endovascular treatment and endarterectomy appear to be determined by 
differences in the 30-day outcomes. 
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Cerebral filter devices are marketed actively as a major improvement in endovascular 
treatment.  The idea of a filter catching any debris dislodged from the site of stenosis by 
balloon inflation or stent placement may be appealing but it must not be forgotten that 
they require passing of the stenosis in the first place and thus pose a potential risk of 
embolism to the distal vasculature.  Filter devices may catch larger debris but may also 
lead to the splitting of soft material into many small parts that may pass through the filter 
mesh and cause multiple areas of ischaemic damage in the brain.  It was the hope that the 
review might shed some light on the usefulness of cerebral filter devices but only two 
trials included data on the use of these devices in their publications.  Their use was not 
allocated randomly and selection bias might have been operating.  No conclusions 
should therefore be drawn from this subgroup analysis, which did not favour one 
method over the other. 
Only two trials investigated endovascular treatment compared to surgery in 
asymptomatic patients.  The numbers of patients and observed events were rather small 
and no conclusion can be drawn from this analysis.  One further trial included larger 
numbers of asymptomatic patients but failed to report these results separately making it 
impossible to separate symptomatic from asymptomatic patients.  The same was true for 
the comparison of endovascular treatment and medical therapy alone.  Only two trials 
were identified and included in the review but both contained very small numbers of 
patients. 
There are several reasons that would explain any underlying heterogeneity among trials.  
The endovascular technique used by the trials evolved over time.  While CAVATAS 
started as a trial of balloon angioplasty, it allowed stenting as it become more widely 
available.  The later trials exclusively used primary stenting as endovascular technique of 
choice.  Devices available early on in the development of stenting have either undergone 
changes or are no longer available.  This is a disadvantageous position for endovascular 
treatment, which has to compete with a technique that was able to evolve for many years 
relatively un-scrutinised before being tested and compared in the large clinical trials. 
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Heterogeneity may also stem from differences in baseline patient characteristics.  Not all 
trials strictly recruited symptomatic patients only.  In CAVATAS 12% asymptomatic 
patients were recruited in the endovascular treatment and 9% in the endarterectomy arm.  
The proportion of asymptomatic patients in SAPPHIRE was even larger with 68% of 
patients in the stenting group and 71% of patients in the surgery group being 
asymptomatic, making this effectively a trial in asymptomatic carotid stenosis.  
Moreover, patients were selected specifically with a high surgical risk.  Given that those 
patients were thought to be at high risk of surgery, it may come as a surprise that 
SAPPHIRE reported an event rate of stroke or death within 30 days after the procedure 
plus ipsilateral stroke or death between 31 days and 1 year after treatment of ‘only’ 8.4%.  
However, as pointed out above, the majority of the patients in SAPPHIRE were 
asymptomatic and therefore, if they had had medical treatment, one would have 
expected an event rate of no more than 4%.  Hence, 8.4% is a high event rate and in fact 
indicates that the patient should never have had revascularisation either by surgery or 
carotid stenting.  CAVATAS did not specifically aim at recruiting high-risk patients but 
baseline patient characteristics suggest that patients in CAVATAS selected a higher 
proportion of patients at high surgical risk compared to NASCET or ECST.  But what 
constitutes a high-risk patient remains poorly defined. 
Baseline carotid stenosis also differed between the trials, which may account for 
differences in outcome and heterogeneity among trials.  The surgical trials NASCET and 
ECST have shown that the risk of stroke is not independent of the degree of carotid 
stenosis. 
Completed and stopped trials were included in this review, which may provide another 
source of heterogeneity among trials.  Three of the included studies were terminated 
prematurely because of concerns over the safety of stenting.  The Wallstent trial was 
stopped after a total of 210 patients had been enrolled.  The primary endpoint of 
cumulative occurrence of ipsilateral stroke, procedure-related death or vascular death 
within one year was reported in 12.1% of patients in the stenting group and 3.6% of 
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patients in the endarterectomy group (p = 0.02).  The 30-day rate of death or stroke was 
12.1% after stenting and 4.4% after endarterectomy (p = 0.049).  Based on this data and a 
futility analysis the study sponsor rather than the Data Safety and Monitoring Board 
intervened and stopped the trial.  This was very controversial because the study sponsor 
took the decision despite of outcome events not having been validated in all patients and 
because there were concerns regarding the competence and experience of those 
undertaking stenting.  No further publication has come forth since the presentation at the 
meeting of the American Stroke Association and it was not possible to further assess the 
trial.   
The Leicester study was stopped after referral to the Data Monitoring Committee who 
invoked the stopping rule after only 17 patients had received the allocated treatment.  
Five of seven patients undergoing endovascular treatment suffered a stroke compared to 
ten uncomplicated carotid endarterectomies (p = 0.003).  The investigators felt that the 
trial could not be restarted even in an amended form because of difficulties with 
informed consent. 
EVA-3S was stopped early following a pre-planned interim analysis after 527 patients 
had been randomised showed a significantly higher risk of 30-day stroke or death in the 
stenting arm compared to surgery (9.6% vs. 3.9%). 
Evidence for long-term efficacy was very limited by only short periods of available 
follow up.  Similar safety and potential advantages of endovascular treatment seem to 
justify carrying on with the randomised trials already underway.  They will provide large 
numbers of patients that will help to resolve uncertainties.   
The analyses of endovascular treatment versus endarterectomy in asymptomatic patients 
and endovascular treatment versus medical care in patients not suitable for surgery were 
based on very small numbers of patients and it would not be justified to form conclusions 
based on these findings. 
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The results of this Cochrane Review did not support a change in clinical practice away 
from carotid endarterectomy as the treatment of choice and strongly supported 
continuation of the ongoing trials. 
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11 The International Carotid Stenting Study 
11.1 Rationale for ICSS 
As demonstrated in the previous chapter, the Cochrane Systematic Review did not 
conclusively favour endovascular treatment over carotid endarterectomy (or vice versa) 
but strongly supported the continued randomisation of patients into the ongoing clinical 
trials.  One of these trials concerned was the International Carotid Stenting Study (ICSS).   
While CAVATAS showed similar outcomes after endovascular treatment compared to 
surgery, it was acknowledged that both techniques did carry a significant risk of causing 
a stroke (Brown et al. 2001).  Technology particularly in the field of endovascular 
treatment had moved on since CAVATAS was conducted and the use of stents in 
addition or in place of balloon angioplasty became standard practice in endovascular 
management of carotid stenosis.  Moreover, CAVATAS did not include enough patients 
(or observed sufficient numbers of outcome events) to show a statistically significant 
difference between treatments.   
Encouraged by the findings of CAVATAS and taking into account the shortcomings of 
CAVATAS and changes in technology, ICSS was set up with the aim of investigating the 
risks and benefits of primary carotid stenting compared to surgery in what would 
eventually become the largest trial of carotid stenting in symptomatic stenosis to date. 
11.2 Methods and Patients 
11.2.1 Trial Centres 
ICSS is an international collaboration of 50 centres in Europe, Canada, Australia and New 
Zealand.  The collaborating centres are listed in the Appendix.  The trial was designed to 
compare the safety and long-term efficacy of carotid stenting and endarterectomy.  The 
trial was approved by the Northwest Multicentre Research Ethics Committee in the UK.  
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Participating centres had the obligation to obtain site-specific approval from their local 
ethics committees.   
Each centre wishing to participate in ICSS had to have a team in place consisting of at 
least a neurologist or physician with a special interest in stroke to see patients before 
randomisation and for follow-up, a designated surgeon with experience in carotid 
endarterectomy and a designated interventionist with expertise in carrying out 
angiography, angioplasty, and stenting.  Centres were required to hold regular 
multidisciplinary meetings between the investigators to discuss management of patients 
with carotid artery stenosis.  Investigators submitted their curricula vitae and audit data 
that documented satisfactory training and results of carotid treatment to the credential 
committee. 
Centres were either enrolled as experienced or supervised centres, depending on the 
experience of the personnel carrying out the carotid surgery or intervention.  Centres 
qualified as experienced if the surgeon had performed at least 50 carotid surgeries with a 
rate of ten cases per year and if the interventionist had performed a minimum of 50 
stenting procedures with at least ten cases in the carotid artery.  Centres not fulfilling 
either of these criteria were able to join as supervised centre and the trial procedures at 
these centres were proctored by an outside surgeon or interventionist who was 
appointed by the Trial Steering Committee to ensure that the centres became proficient in 
carrying out the procedure. 
After completion of 20 cases with results deemed acceptable by the proctor and the 
credential committee centres were promoted to ‘experienced’ status.  All patients 
enrolled in a centre after it was promoted were identified as such while patients enrolled 
prior to the centre’s promotion were identified as ‘supervised’.  This was done to allow 
for investigating the influence of experience on outcome.  While theoretically this policy 
applied to surgery and stenting, all centres classified as ‘supervised’ in ICSS were so 
because of a lack of experience in carotid stenting. 
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An independent Data Monitoring Committee that met on a regular basis monitored trial 
safety and advised the Trial Steering Committee. 
11.2.2 Patients 
Patients over the age of 40 years with symptomatic atheromatous disease of the 
extracranial internal carotid artery or at the level of the carotid bifurcation resulting in a 
stenosis measuring more than 50% using the NASCET criteria (Barnett et al. 1998) or non-
invasive equivalent were eligible to join the trial.  The multi-disciplinary team had to 
deem patients suitable for both surgery and stenting and in need of invasive treatment.  
No upper age limit was set by the protocol.  Patients should only be randomised if the 
local investigators were uncertain which of the two treatments was best for the particular 
patient at the time. 
The trial protocol specified that symptoms had to have occurred within 12 months prior 
to randomisation although it was recommended that the time between symptoms and 
randomisation should be less than six months.  Patients had to be clinically stable and 
willing to have either treatment and participate in follow-up. 
Patients unwilling or unable to provide written informed consent were excluded from 
the trial, as were patients who had a major stroke with no useful recovery of function 
within the territory of the treatable artery.  Patients with stenosis that was known to be 
unsuitable for stenting (tortuous anatomy, visible thrombus present, proximal common 
carotid artery stenosis, pseudo-occlusion) or surgery (high stenosis, rigid neck) were 
excluded from participating in ICSS.  Previous endarterectomy or stenting in the treatable 
artery, planned common carotid surgery, planned coronary artery bypass grafting or 
other major surgery within one month of carotid surgery or stenting also excluded 
patients from participation in the trial, as did a limited life expectancy (less than two 
years) due to a pre-existing condition. 
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11.2.3 Investigations Prior to Randomisation 
Several investigations were required before entry into the study.  They included routine 
haematology (full blood count, platelets), blood biochemistry (renal function, blood 
sugar, cholesterol), chest x-ray, and ECG.  A brain scan (CT or MRI) was required to rule 
out any other pathology and to identify existing infarcts.  It also served as baseline 
reference in case of subsequent cerebral infarction or haemorrhage. 
The severity of carotid artery stenosis in the vessel to be treated had to be established and 
the contralateral carotid artery had to be assessed prior to randomisation.  Several 
modalities were acceptable: 
• Arch arteriogram showing both carotid bifurcations 
• Selective catheter angiogram showing the carotid artery targeted for treatment 
AND non-invasive investigation of the contralateral carotid bifurcation 
• Bilateral MR or CT carotid angiogram AND concordant ultrasound investigation. 
Bilateral duplex and Doppler ultrasound alone was acceptable if it was standard practice 
at the centre to treat patients on the basis of ultrasound alone and the centre was able to 
provide proof of their ultrasound imaging’s reliability through a clinical audit.  It was 
recommended that patients allocated to stenting on the basis of non-invasive imaging 
and in whom subsequent angiography as part of the stenting procedure revealed one or 
more exclusion criteria crossed over to surgery or medical care as appropriate.  Follow-
up of these patients continued and they were included in the intention-to-treat analysis.  
A similar approach was recommended for patients allocated to surgery. 
Baseline data including patient demographic data, blood results, existing medical risk 
factors, disability assessed with the modified Rankin scale (see appendix) and pre-
randomisation imaging films or reports were reported to the Central Trial Office. 
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11.2.4 Randomisation 
Eligible patients were randomised in 1:1 ratio to receive carotid artery stenting or carotid 
endarterectomy by telephone call to a computerised service provided by the Oxford 
Clinical Trials Service Unit whose staff had no further role in the trial.  The allocated 
treatment was communicated to the local research team by either telephone or fax.  
Randomisation was stratified by centre with minimisation of sex, age, contralateral 
occlusion, and side of randomised artery.  Minimisation was conducted separately for 
each centre and balanced between the two arms of the study.  Patients in whom both 
carotid arteries needed treatment were randomised for the carotid artery to be treated 
first.  Investigators were kept masked about the randomisation program to prevent them 
anticipating the next assignment.  Patients and individuals delivering the treatment were 
not masked to treatment assignment.  Apart from the trial statistician and the data 
monitoring committee, all investigators including the chief investigator remained 
masked to the results of the trial until recruitment was completed. 
11.2.5 Treatment 
Surgery 
Carotid endarterectomy was carried out as soon after randomisation as possible by a 
designated surgeon.  The protocol did not prescribe a specific surgical technique and 
individual centres were allowed to use whichever technique was their standard 
procedure including the use of local or general anaesthesia, shunts or patches, and 
standard or eversion endarterectomy. 
Stenting 
The protocol prescribed that carotid stenting should be carried out as soon as possible 
after randomisation using a percutaneous transluminal interventional technique from the 
femoral, brachial or common carotid artery by a designated interventional consultant and 
using an appropriate stent.  Cerebral protection devices were recommended when the 
operator thought they could be safely deployed.  Stents and other devices used for 
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carotid stenting were chosen at the discretion of the interventionist but had to be CE 
marked. 
The combination of clopidogrel and aspirin was recommended to cover the period of 
stenting and for at least four weeks after the procedure.  Heparin was mandatory during 
the procedure and discretionary thereafter. 
Stenting and carotid endarterectomy were considered to have been initiated once 
anaesthesia (general or local) in preparation of the procedure was administered even if 
the procedure was subsequently abandoned before stent deployment or endarterectomy. 
Medical Treatment 
The study protocol refrained from prescribing a specific medical treatment regimen.  All 
patients were expected to receive ‘best medical care’ including antiplatelet therapy or 
anticoagulation and control of medical risk factors (hypertension, hyperlipidaemia, 
smoking) before treatment and throughout follow-up. 
11.2.6 Follow-up 
Patients were followed up by a neurologist or physician with a special interest in stroke 
medicine at each participating centre 30 days after treatment, six months after 
randomisation and annually thereafter.  Carotid ultrasound using the methods explained 
in the earlier chapters of this thesis was carried out 30 days after treatment and yearly 
after randomisation to assess the patency of the treated carotid artery. 
Neurological status, complications, and results of ultrasound investigations were 
reported in detail to the Central Trial Office.  Two investigators reviewed the submitted 
data and requested further information as appropriate from the individual centres.  One 
of two independent adjudicators further adjudicated all outcome events.  Remaining 
differences were resolved by agreement. 
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11.2.7 Definitions of Outcome Events 
Stroke was defined as an acute disturbance of focal neurological function with symptoms 
lasting more than 24 hours resulting from intracranial vascular disturbance.  Visual loss 
resulting from embolic or haemodynamic retinal ischaemia lasting longer than 24 hours 
was included in this category.  Events leading to a modified Rankin score of 3 or greater 
for longer than 30 days after onset were classified as disabling and the remaining events 
were classified as non-disabling.  Events leading to death within 30 days after onset were 
classified as fatal. 
An acute disturbance of focal neurological function with symptoms lasting less than 24 
hours attributed to cerebrovascular disease defined a transient ischaemic attack (TIA).  
This category included acute total or partial loss of vision in one eye with recovery within 
24 hours attributed to vascular disease (amaurosis fugax). 
Cranial nerve palsies were defined as weakness or sensory impairment in the distribution 
of one of the cranial nerves attributed to the treatment.  The degree of disability caused 
by cranial nerve palsies was assessed using the modified Rankin score. 
Haematoma was defined as bleeding attributed to the treatment of carotid narrowing 
requiring evacuation, blood transfusion or prolonged hospital stay. 
Myocardial infarction (MI) was defined by the presence of two out of three of the 
following criteria: 
• Specific cardiac enzymes more than twice the upper limit of normal 
• A history of chest discomfort for at least half an hour 
• The development of specific abnormalities on a standard 12-lead ECG (e.g. Q 
waves) 
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11.2.8 Outcome Measures 
The primary analysis specified in the protocol was the difference between groups in long-
term rate of fatal or disabling stroke in any territory.  Long-term was defined as 3 years 
and therefore data are not yet available for the analysis discussed here.  The first 
secondary analysis specified in the protocol is discussed in this chapter: The differences 
in mortality and morbidity between groups within 30 days of carotid treatment.  The 
main endpoint for the analysis of short-term safety data was defined prior to the analysis 
as: 
• Any stroke or death or procedural myocardial infarction (MI) 
Several additional secondary endpoints were also defined prior to the analysis of data: 
• Any stroke 
• Any stroke or death 
• Any stroke or procedural death 
• Disabling stroke or death (including fatal stroke) 
• All cause death 
Events relating to the various components of the primary endpoint, cranial nerve palsies, 
haematomas and Rankin score 30 days after treatment were also analysed. 
Several pre-defined subgroup analyses were carried out.  They were exploratory in 
nature and investigated the influence of various baseline characteristics on outcome. 
11.2.9 Statistical Methods 
A large difference in outcomes between the stenting and endarterectomy groups was not 
expected and the sample size was calculated to provide a reasonable estimate of the 
treatment effect.  A sample size of 1500 patients from experienced centres was chosen on 
the basis that this would allow a 95% confidence interval to be measured with a width of 
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± 3.3% for the difference in risk of disabling stroke or death between treatment groups, 
based on an average of 12.5% of patients having the outcome.  It was also calculated that 
this sample size would allow a 95% CI to be measured with a width of ± 3.0% for the 
secondary short-term outcome of 30-day stroke, death, or procedural MI, on the basis of 
an average of 10% of patients having the outcome.   
Because some patients did not receive their allocated treatment and the timing of 
treatment after randomisation varied, two main analyses of short-term safety data were 
carried out.   
A 120-day intention-to treat (ITT) analysis included all randomised patients and 
compared those allocated to endarterectomy to those allocated to stenting irrespective of 
whether they actually received the allocated treatment.  An arbitrary cut-off point 120 
days post randomisation was pre-defined for event-free patients.  Patients with less than 
120 days of follow-up were censored on the date of last known status.  Censoring was 
assumed to be non-informative, i.e. a censored patient was assumed to have the same 
risk of an outcome event as those who had complete 120-day follow-up.  Kaplan-Meier 
methods were used to estimate 120-day probabilities of an outcome event and 
subsequently the absolute difference between the two treatment groups and 
corresponding 95% confidence intervals.  Cox proportional hazard methods were used to 
calculate the relative difference between treatment groups (hazard ratio) and 
corresponding 95% confidence intervals.  Carotid endarterectomy was the reference 
group.  Log rank tests were used to compare the survival curves.  All events between 
randomisation up to 120 days thereafter were included in the analyses whether 
procedural or not.  This analysis thus compared the policy of carotid stenting with 
endarterectomy on the short-term post-randomisation risk of an event. 
The second analysis was a 30-day per-protocol analysis and evaluated the procedural 
risk.  It included only those patients who received their allocated treatment.  Patients 
who crossed over to an alternative treatment were excluded from the analysis.  Only 
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events occurring after treatment and up to 30 days thereafter (procedural events) were 
included.  Binominal regression methods were used to estimate the 30-day absolute risk 
difference and relative risk ratios and corresponding 95% confidence intervals.  Chi-
squared (χ2) tests were used to test for differences between the two treatment groups.  
Only the first initiated ipsilateral treatment was considered but this could occur at any 
time after randomisation.  A small number of procedures took place more than 120 days 
after randomisation.   
Several pre-defined exploratory subgroup analyses were carried out to investigate 
whether the relative treatment effect for the 120-day intention-to-treat composite 
outcome of stroke, death, or procedural MI differed across various patient risk factor 
groups.  Interaction tests were performed using Cox proportional hazard models.  The 
subgroup analyses were based on the primary outcome measure.  Stata release 11 was 
used for all analysis except the meta-analysis, which was done with ReviewManager 
version 5. 
11.3 Results 
11.3.1 Baseline Characteristics 
Between 21st May 2001 and 20th October 2008, 1713 patients from 50 academic centres (see 
Appendix for list of participating centres) were randomly assigned to either carotid 
stenting (n = 855 patients) or carotid endarterectomy (n = 858).  Three patients withdrew 
consent immediately after randomisation and were excluded from any further analysis.  
The remaining 1710 patients (stenting n = 853, surgery n = 857) were included in the 
analysis (Figure 11.1).  751 (88%) of patients assigned to stenting and 760 (89%) of 
patients assigned to endarterectomy were randomised at centres classified as 
experienced.  Monitoring of adverse events led to concern about the stenting results of 
two investigators at supervised centres.  These investigators were stopped from treating 
further patients within the trial and their centres were suspended from randomisation.  
All the patients at these centres allocated to stenting (n = 11, five with disabling stroke or 
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death) or endarterectomy during the same time period (n = 9, one with fatal stroke) were 
included in the analyses.  One of the two centres subsequently restarted randomisation 
with a different investigator performing stenting. 
The degree of stenosis in the randomised carotid artery exceeded 70% in the vast majority 
of patients.  Contralateral stenosis greater than 50% was found in about one-third of the 
patients in both groups.  Baseline patient characteristics were well balanced between the 
groups (Table 11.1). 
11.3.2 Delay to treatment 
Patients allocated to carotid stenting received the allocated treatment with significantly 
shorter delay after randomisation than patients allocated to and receiving surgery 
(median 9 versus 11 days, p < 0.001).  While 70% of patients in the stenting group had to 
wait less than 14 days for treatment, only 57% patients received carotid endarterectomy 
within 14 days after randomisation (Figure 11.2). 
The delay between the most recent event and treatment was also significantly shorter for 
patients allocated to carotid stenting: The median delay was 35 days for carotid stenting 
and 40 days for carotid endarterectomy (p = 0.013).  While 25% of patients were receiving 
their allocated stent within 14 days after the most recent event, only 18% of patients 
allocated to surgery were treated within this timeframe. 
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Figure 11.1 – ICSS: Trial profile 
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Table 11.1 – ICSS: Patient characteristics at baseline per allocated treatment 
Data are number of patients (%) or mean (SD).  CEA, carotid endarterectomy; SD, standard deviation; CABG, 
coronary artery bypass graft.  *Degree of stenosis measured by NASCET method at randomising centre.  †If two 
events were reported on the same day, the more serious of the two was counted (stroke>retinal infarct>TIA>A 
fugax).  ‡Some Rankin scores ≥ 3 were due to non-stroke disability (table continued on next page). 
  Stenting 
(n = 853) 
 CEA  
(n = 857) 
Randomised at experienced centre  751 (88%)  760 (89%) 
Age (mean [SD], years)  70 [9]  70 [9] 
Sex     
Women  252 (30%)  251 (29%) 
Men  601 (70%)  606 (71%) 
Vascular risk factors     
Hypertension  587 (69%)  595 (69%) 
Systolic blood pressure (mean [SD], mmHg)  147 [24]  146 [24] 
Diastolic blood pressure (mean [SD], mmHg)  79 [12]  78 [13] 
Diabetes mellitus  184 (22%)  187 (22%) 
Treated hyperlipidaemia  522 (61%)  562 (66%) 
Cholesterol (mean [SD], mmol/L)  4.8 [1.3]  4.9 [1.3] 
Current smoker  205 (24%)  198 (23%) 
Past smoker  408 (48%)  424 (49%) 
Prior history of cardiovascular disease     
Myocardial infarction  151 (18%)  156 (18%) 
Atrial fibrillation  57 (7%)  59 (7%) 
Cardiac Failure  23 (3%)  47 (5%) 
Angina in previous 6 months  83 (10%)  77 (9%) 
Previous CABG  109 (13%)  116 (14%) 
Other cardio-embolic source  19 (2%)  16 (2%) 
Peripheral artery disease  139 (16%)  136 (16%) 
Degree of symptomatic carotid stenosis*     
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  Stenting 
(n = 853) 
 CEA  
(n = 857) 
50-69%  92 (11%)  76 (9%) 
70-99%  761 (89%)  781 (91%) 
Degree of contralateral stenosis*     
<50%  565 (66%)  561 (65%) 
50-69%  128 (15%)  142 (17%) 
70-99%  105 (12%)  110 (13%) 
Occluded  49 (6%)  37 (4%) 
Unknown  6 (1%)  7 (1%) 
Most recent ipsilateral event†     
Amaurosis fugax  148 (17%)  142 (17%) 
Transient ischaemic attack  273 (32%)  303 (35%) 
Ischaemic hemispheric stroke  393 (46%)  376 (44%) 
Retinal infarct  26 (3%)  23 (3%) 
Unknown  13 (2%)  13 (2%) 
Event <6 months before randomisation  826 (97%)  816 (95%) 
Event 6-12 months before randomisation  27 (3%)  36 (4%) 
Multiple ipsilateral symptoms prior to randomisation  330 (39%)  317 (37%) 
Ipsilateral stroke prior to most recent ipsilateral event  131 (15%)  106 (12%) 
Modified Rankin Score at Randomisation     
0-2  756 (89%)  744 (87%) 
3-5‡  81 (10%)  99 (12%) 
Unknown  16 (2%)  14 (2%) 
Table 11.1 continued 
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Figure 11.2 – ICSS: Delay between randomisation and treatment 
Cumulative number of patients in whom allocated treatment was initiated per protocol plotted as a proportion (%) of 
the total number randomised in each treatment group (vertical axis), against the delay in days between the dates of 
randomisation and treatment (horizontal axis).  CAS, carotid artery stenting; CEA, carotid endarterectomy. 
 
11.3.3 Compliance with Allocated Treatment 
Most patients had the treatment initiated that they were allocated.  In the stenting group, 
nine patients crossed to surgery, of whom one patient refused stenting.  A further 16 
crossed to medical therapy.  Of these, one patient had suffered a stroke prior to treatment 
and five patients were found to have an occluded carotid artery.  This left 828 patients in 
the stenting group for the per-protocol analysis.   
Of these 828 patients, 64 (8%) had their procedure aborted before the insertion of a stent 
(38 procedures were aborted because of difficulty gaining access to the stenosis, 15 were 
aborted because of the finding of an occluded artery, one patient had a fatal stroke, one 
patient had a fatal MI before completion of treatment, two had other medical 
complications, and further investigation in seven patients showed the artery to be < 50% 
stenosed).  Of the 62 patients whose stenting procedure was aborted after initiation and 
who did not have a fatal event, 37 went on to have an ipsilateral endarterectomy, 
whereas 25 patients continued on medical therapy alone. 
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In the surgery group, 15 patients crossed to stenting.  Of these, three patients refused 
surgery and in one patient it was impossible to gain access to the stenosis.  An additional 
21 patients crossed to medical therapy.  Of these patients, one died before treatment, two 
suffered a disabling stroke before treatment, nine had an occluded carotid artery, and one 
patient refused invasive treatment.  The remaining 821 patients were included in the per-
protocol analysis. 
Only 2 of the 821 patients whose allocated endarterectomy was initiated had their 
procedure aborted (one patient had an allergic reaction during general anaesthesia, the 
other became distressed and the endarterectomy had to be abandoned).  Both patients 
had subsequent ipsilateral stenting. 
11.3.4 Intention-to-treat Analysis 
Main Outcome Measure 
Stroke, Death or Procedural Myocardial Infarction 
The main outcome of stroke, death or procedural MI was recorded in 72 patients 
allocated to carotid stenting and 43 patients allocated to carotid endarterectomy (Table 
11.2). 
The 120-day risk of stroke, death or procedural MI in patients allocated to carotid 
stenting was significantly higher than in the group of patients allocated to carotid 
endarterectomy (8.5% versus 5.2%, respectively).  The absolute risk difference at 120 days 
was 3.3% (95% CI 0.9 to 5.7) and the hazard ratio was 1.69 (95% CI 1.16 to 2.45, p = 0.006) 
in favour of carotid endarterectomy (Table 11.2 and Table 11.3). 
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Table 11.2 – ICSS: Main outcome measures (Intention-to-treat analysis) 
Data are number of first events (Kaplan-Meier estimate at 120 days), hazard ratios or risk differences (95% CI).  Risk 
differences are calculated from Kaplan-Meier estimates at 120 days.  CAS, carotid artery stenting; CEA, carotid 
endarterectomy; MI, myocardial infarction; HR, hazard ratio; RD, risk difference; CI, confidence interval.  *Log-rank test. 
 CAS  
n = 853 
CEA  
n = 857 
HR (95% CI) RD (95% CI) P-
value* 
Primary outcome      
Stroke, death or 
procedural MI 
72 (8.5%) 44 (5.2%) 1.69 (1.16, 2.45) 3.3 (0.9, 5.7) 0.006 
Secondary outcomes      
Any stroke 65 (7.7%) 35 (4.1%) 1.92 (1.27, 2.89) 3.5 (1.3, 5.8) 0.002 
Any stroke or death 72 (8.5%) 40 (4.7%) 1.86 (1.26, 2.74) 3.8 (1.4, 6.1) 0.001 
Any stroke or 
procedural death 
68 (8.0%) 36 (4.2%) 1.95 (1.30, 2.92) 3.8 (1.5, 6.0) 0.001 
Disabling stroke or 
death 
34 (4.0%) 27 (3.2%) 1.28 (0.77, 2.11) 0.8 (-0.9, 2.6) 0.34 
All cause death 19 (2.3%) 7 (0.8%) 2.76 (1.16, 6.56) 1.4 (0.3, 2.6) 0.017 
 
Figure 11.3 – ICSS: 120-day cumulative incidence of stroke, death or procedural MI (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of stroke, death or procedural MI up to 120 days 
after randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 
120-day cumulative incidence.  CAS, carotid stenting; CEA, carotid endarterectomy. 
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Most of the short-term outcome events occurred within 30 days of the first ipsilateral 
procedure.  This was the case in 61 patients in the stenting group and 31 patients in the 
endarterectomy group (Figure 11.4).  However, two events in the stenting group and one 
event in the surgery group occurred prior to the allocated treatment and six events in 
each group occurred more than 30 days after treatment but before the 120-day cut off.  
Three patients in the stenting group and six patients in the surgery group who had no 
attempted ipsilateral procedure experienced an event.   
In 23 patients in the stenting arm and six patients in the surgery arm, the stroke occurring 
on the same day of the procedure was thought to be directly related to the procedure.   
Figure 11.4 – ICSS: Timing of first stroke after allocated procedure 
23 strokes in the stenting arm and 6 strokes in the surgery arm were directly related to the procedure and classified 
‘procedural’.  Day 0 indicates the day of the procedure.  CAS, carotid stenting; CEA, carotid endarterectomy. 
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Additional Outcome Measures 
Stroke 
Stroke was recorded in 65 patients (58 ipsilateral strokes) allocated to stenting and 35 
patients (30 ipsilateral strokes) allocated to carotid endarterectomy (Table 11.2 and Table 
11.3).  The 120-day risk of stroke was 7.7% in patients allocated to stenting and 4.0% in 
patients allocated to surgery, a 3.6% (95% CI 1.4 to 5.9) absolute risk difference.  The 
hazard ratio was 1.97 (95% CI 1.30 to 2.99, p = 0.001) in favour of carotid endarterectomy. 
In both groups the majority of strokes were non-disabling lasting more than 7 days.  In 
the stenting group 39 strokes were non-disabling of which 31 lasted more than 7 days.  
Fourteen strokes in the surgery group were non-disabling of which nine lasted more than 
7 days. 
Fatal stroke occurred more frequently in the carotid stenting group (n = 9) than in the 
surgery group (n = 2).  The number of disabling stroke was similar in both groups, with 
17 disabling strokes in the stenting group and 20 disabling strokes in the surgery group.
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Table 11.3 – ICSS: Number of outcome events recorded between randomisation and 120 days in the 
intention-to-treat (ITT) analysis and between initiation of treatment and 30 days after treatment in the 
per-protocol analysis. 
Data are number of first events of each type.  *In 2 patients this was a retinal infarct.  One patient had both an 
ischaemic and a haemorrhagic stroke.  †1 patient had a subsequent fatal MI and 1 patient also had a non-disabling 
stroke that lasted for more than 7 days.  ‡1 patient had a subsequent disabling stroke.  ||2 patients subsequently died 
of non-stroke, non-MI cause.  ¶The cranial nerve palsy in this patient allocated CAS, which was initiated but aborted, 
occurred after CEA carried out within 30 days of attempted but abandoned stent procedure.  §One patient had a 
non-fatal myocardial infarction within 30 days of the first procedure, which was undertaken more than 120 days after 
randomisation.  This MI was therefore excluded from the ITT analysis but was included in the per-protocol analysis.  
**Severe haematoma was defined as one that required surgical evacuation or blood transfusion or resulted in 
prolonged hospital stay. 
 ITT analysis Per-protocol analysis 
 Stenting 
n=853 
Endarterectomy 
n=857 
Stenting 
n=828 
Endarterectomy 
n=821 
Any stroke 65* 35 58* 27 
Ipsilateral stroke 58 30 52 25 
Ischaemic stroke 63 28 56 21 
Haemorrhagic stroke 3 5 2 5 
Uncertain pathology 0 2 0 1 
Non-disabling stroke 39 14 36 11 
Lasting fewer than 7 days 9† 5‡ 8† 5‡ 
Lasting more than 7 days 31 9 29 6 
Disabling stroke 17|| 20 14 14 
Fatal stroke 9 2 8 3 
Procedural MI 3 4 3 5 
Non-fatal MI 0 4 0 5§ 
Fatal MI 3 0 3 0 
Non-stroke, Non-MI death 7 5 1 1 
Cranial nerve palsy 1¶ 45 1¶ 45 
Disabling cranial nerve palsy 1¶ 1 1¶ 1 
Haematoma 31 50 30 50 
Severe haematoma** 9 28 8 28 
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Any Stroke or Death 
The combined outcome of any stroke or death was also more frequent in the stenting 
group and was recorded in 72 patients allocated to this treatment and in 40 patients 
allocated to carotid endarterectomy.  The 120-day risk was 8.5% for patients allocated to 
carotid stenting and 4.7% for patients allocated to surgery.  The absolute risk difference 
was 3.8% (95% CI 1.4 to 6.1) and the hazard ratio was 1.86 (95% CI 1.26 to 2.74, p = 0.001) 
in favour of carotid endarterectomy (Table 11.2 and Figure 11.6). 
Stroke or Procedural Death 
Disabling stroke or procedural death was recorded in 68 patients in the stenting group 
and 36 patients in the surgery group.  The rate of any stroke or procedural death was 
significantly higher in the stenting group than in the carotid endarterectomy group (8.0% 
versus 4.2%, HR 1.95, 95% CI 1.30 to 2.92, p = 0.001, Table 11.2). 
Disabling Stroke or Death 
This combined outcome was recorded in 34 patients allocated to carotid stenting and 27 
patients allocated to carotid endarterectomy.  The 120-day risks in both arms were not 
significantly different (4.0% versus 3.2%, respectively).  The hazard ratio did not 
significantly favour either treatment (HR 1.28, 95% CI 0.77 to 2.21, p = 0.34, Table 11.2 
and Figure 11.7). 
All Causes of Death 
Nineteen patients allocated to stenting and 7 patients allocated to carotid endarterectomy 
died between randomisation and 120 days thereafter.  The 120-day risk was estimated at 
2.3% in the stenting group and 0.8% in the surgery group, a 1.4% (95% CI 0.3 to 2.6) 
absolute risk difference.  The hazard ratio was 2.76 (95% CI 1.16 to 6.56, p = 0.0167) in 
favour of carotid endarterectomy (Table 11.2 and Figure 11.8). 
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Figure 11.5 – ICSS: 120-day cumulative incidence of any stroke (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of any stroke up to 120 days after randomisation 
in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 120-day cumulative 
incidence.  CAS, carotid stenting; CEA, carotid endarterectomy. 
 
Figure 11.6 – ICSS: 120-day cumulative incidence of stroke or death (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of stroke or death up to 120 days after 
randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 120-
day cumulative incidence.  CAS, carotid stenting; CEA, carotid endarterectomy. 
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Figure 11.7 – ICSS: 120-day cumulative incidence of disabling stroke or death (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of disabling stroke or death up to 120 days after 
randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 120-
day cumulative incidence.  CAS, carotid stenting; CEA, carotid endarterectomy. 
 
Figure 11.8 – ICSS: Any cause of death 120-day cumulative incidence of any cause of death (ITT) 
Shown is the Kaplan-Meier curve for the primary outcome measure of any cause of death up to 120 days after 
randomisation in the intention-to-treat analysis.  The vertical bars represent the standard errors of the estimated 120-
day cumulative incidence.  CAS, carotid stenting; CEA, carotid endarterectomy. 
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Other Peri-procedural Complications 
Cranial Nerve Palsy 
While 45 patients allocated to carotid endarterectomy suffered a cranial nerve palsy, this 
was also the case in one patient allocated to carotid stenting.  However, this patient 
required carotid endarterectomy within 30 days after attempted carotid stenting and the 
cranial nerve palsy was a result of the surgery.  Since it occurred within 30 days of 
stenting, it had to be counted against carotid stenting.  This cranial nerve palsy and an 
additional one in the carotid surgery group was disabling, i.e. the patient required the 
placement of a percutaneous endogastric tube. 
Myocardial infarction 
Procedural myocardial infarction was recorded in three patients allocated to carotid 
stenting and four patients allocated to carotid endarterectomy.  All three MIs in the 
former group and none in the latter group were fatal. 
Haematoma 
Haematoma was more frequently observed in patients allocated to carotid 
endarterectomy and was recorded in 50 patients in this treatment group, of which 28 
required surgical evacuation, blood transfusion or resulted in a prolonged hospital stay 
(severe haematoma).  In patients allocated to stenting, this outcome was recorded in only 
31 cases, of which nine were classified severe. 
Subgroup Analyses 
A number of pre-defined subgroup analyses were carried out based on the main short-
term endpoint using the intention-to-treat dataset.  The results are summarised in Figure 
11.9. 
The analyses carried out failed to identify a subgroup in which stenting was significantly 
favoured over surgery.  Patients without treated hypertension (HR 3.25, 95% CI 1.46 to 
7.20) derived a greater benefit from surgery than patients with treated hypertension (HR 
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1.29, 95% CI 0.83 to 2.00) and the interaction test showed a significant interaction between 
risk factor and treatment (p = 0.039). 
The benefit of surgery was also more pronounced in men (HR 2.17, 95% CI 1.35 to 3.50) 
compared to women (HR 1.05, 95% CI 0.56 to 1.97), but the treatment interaction test 
failed to reach statistical significance (p = 0.071). 
The recent frequency of ipsilateral symptoms appeared to influence the outcome.  
Patients with only a single event benefited from surgery to a greater extent than those 
patients with multiple events (HR 2.22, 95% CI 1.38 to 3.58 versus HR 1.03, 95% CI 0.55 to 
1.92).  But the treatment interaction test did not reach statistical significance (p = 0.055). 
There was no evidence that the relative increase in the hazard of an event in the stenting 
arm compared to the surgery arm differed significantly across the other subgroups, 
although there were trends towards the risk of stenting being less in patients under the 
age of 70, those with stenosis of 50 to 69% compared to 70 to 99%, patients presenting 
with amaurosis fugax and in centres recruiting more than 50 patients to the trial.  There 
was no significant difference between the results in supervised centres and experienced 
centres (stenting risk 6.9% versus 8.7% respectively).  There was also no difference in 
risks depending on whether patients were treated within 14 days of the index event or 
not.
211 
Figure 11.9 - ICSS: Subgroup analysis of the rates of the primary outcome measure 
Subgroups are defined according to baseline characteristics and analysed by intention to treat, *with the exception of 
time from index event to treatment, which is analysed per-protocol.  N, number of patients; n, number of events; HR, 
hazard ratio.  P values are associated with treatment-covariate interaction tests.  CAS, carotid artery stenting; CEA, 
carotid endarterectomy; TIA, transient ischaemic attach; AFx, amaurosis fugax 
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Treated hypertension!
No! 25/256! 8/255! 3.25 (1.46 – 7.20)! 0.039!
Yes! 45/587! 36/595! 1.29 (0.83 – 2.00)!
Diabetes!
No! 51/659! 32/663! 1.64 (1.05 – 2.55)! 0.97!
Yes! 19/184! 12/187! 1.67 (0.81 – 3.43)!
Multiple ipsilateral symptoms!
No! 52/523! 25/540! 2.22 (1.38 – 3.58)! 0.055!
Yes! 20/330! 19/317! 1.03 (0.55 – 1.92)!
Centre experience!
Experienced! 65/751! 38/760! 1.78 (1.19 – 2.65)! 0.444!
Supervised! 7/102! 6/97! 1.13 (0.38 – 3.35)!
Centre recruitment!
< 50 pts! 33/302! 14/307! 2.51 (1.35 – 4.70)! 0.102!
! 50 pts! 39/551! 30/550! 1.32 (0.82 – 2.12)!
Time from event to procedure*!
" 14 days! 15/205! 5/151! 2.21 (0.82 – 5.95)! 0.68!
> 14 days! 46/623! 28/668! 1.76 (1.12 – 2.78)!
Favours stenting! Favours carotid endarterectomy!
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11.3.5 Per-protocol Analysis 
Only events occurring within 30 days after the procedure were considered in this 
analysis. 
Main Outcome Measure 
Stroke, Death or Procedural Myocardial Infarction 
The combined primary outcome measure was recorded in twice as many patients in 
whom the allocated carotid stenting procedure was initiated (n = 61) than in patients in 
the allocated surgery had been initiated (n = 31).  The 30-day procedural risk was 7.4% 
after stenting and 4.0% after surgery.  The absolute difference in risk was 3.3% (95% CI 
1.1 to 5.6) and the hazard ratio significantly favoured carotid endarterectomy (HR 1.83, 
95% CI 1.21 to 2.77, p = 0.0034, Table 11.4). 
Table 11.4 - ICSS: Main outcome measures between initiation of treatment and 30 days after treatment 
(Per-protocol analysis) 
Data are number of first events (%), risk ratios or risk differences (95% CI).  See text for definition of per-protocol.  
CAS, carotid artery stenting; CEA, carotid endarterectomy; MI, myocardial infarction; RD, risk difference. 
 CAS  
n = 828 
CEA  
n = 821 
Risk ratio 
(95% CI) 
RD (95% CI) P-
value* 
Primary outcome      
Stroke, death or MI 61 (7.4%) 33 (4.0%) 1.83 (1.21, 2.77) 3.3 (1.1, 5.6) 0.003 
Secondary outcomes      
Any stroke 58 (7.0%) 27 (3.3%) 2.13 (1.36, 3.33) 3.7 (1.6, 5.8) 0.001 
Any stroke or death 61 (7.4%) 28 (3.4%) 2.16 (1.40, 3.34) 4.0 (1.8, 6.1) 0.0004 
Disabling stroke or 
death 
26 (3.1%) 18 (2.2%) 1.43 (0.79, 2.59) 0.9 (-0.6, 2.5) 0.23 
All cause death 11† (1.3%) 4 (0.5%) 2.73 (0.87, 8.53) 0.8 (-0.1, 1.8) 0.072 
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Additional Outcome Measures 
Stroke 
Any stroke was recorded in 58 patients after the allocated stenting procedure was 
initiated and 27 patients after the allocated carotid endarterectomy was carried out.  The 
30-day procedural risk was 7.0% in the former group and 3.3% in the latter.  The absolute 
risk difference was 3.7% (95% CI 1.6 to 5.8%) and the hazard ratio 2.13 (95% CI 1.36 to 
3.33, p = 0.0006) in favour of endarterectomy (Table 11.4). 
Non-disabling stroke was the main contributor to this outcome, with 36 events in the 
stenting group and 11 events in the endarterectomy group falling into this category 
(Table 11.3). 
Fatal stroke was more common after stenting.  While eight patients suffered a fatal stroke 
after stenting, only one patient suffered a fatal stroke after the allocated carotid 
endarterectomy had been initiated. 
Disabling stroke occurred 14 times within 30 days of the allocated procedure in both 
treatment groups. 
All Causes of Death 
Eleven patients in the carotid stenting group and four patients in the surgery group died 
within 30 days after the allocated treatment had been attempted.  The 30-day risk was 
estimated as 1.3% after stenting and 0.5% after surgery, equivalent to an absolute risk 
difference of 0.8% (95% CI -0.1 to 1.8).  The hazard ratio was 2.73 (95% CI 0.87 to 8.53) and 
did not significantly favour either treatment (p = 0.0720, Table 11.4). 
Any Stroke or Death 
Any stroke or death was recorded in 61 patients in the carotid stenting group and 28 
patients in the surgery group.  The 30-day risk of any stroke or death was 7.4% in the 
former treatment group and 3.4% in the latter group.  The absolute risk difference was 4.0 
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(95% CI 1.8 to 6.1).  The hazard ratio was 2.16 (95% CI 1.40 to 3.34, p = 0.0004) and 
significantly favoured carotid endarterectomy (Table 11.4). 
Disabling or Fatal Stroke or Non-stroke Death 
This outcome was observed in 26 patients following carotid stenting and 18 patients after 
endarterectomy.  The 30-day procedural risks were 3.1% and 2.2%, respectively, an 
absolute risk difference of 0.9% (95% CI -0.6 to 2.5).  The hazard ratio was 1.43 (95% CI 
0.79 to 2.59, p = 0.23) and did not favour either treatment (Table 11.4). 
Other Peri-procedural Complications 
Cranial Nerve Palsy 
The same distribution and number of cranial nerve palsies as in the intention-to-treat 
analysis were observed when using the criteria for the per-protocol analysis (44 cranial 
nerve palsies in the carotid endarterectomy group versus one in the stenting group).  The 
cranial nerve palsy attributed to carotid stenting occurred in a patient, in whom carotid 
endarterectomy carried out shortly after unsuccessful stenting caused a cranial nerve 
palsy within 30 days of the originally attempted stenting procedure. 
Myocardial infarction 
The per-protocol analysis attributed five non-fatal and no fatal myocardial infarctions to 
the carotid surgery group.  All three recorded myocardial infarctions in the stenting 
group were fatal. 
Haematoma 
Eight of 30 haematomas in the carotid stenting group required surgical evacuation, blood 
transfusion or prolonged hospital stay.  The same was true for 28 out of 50 haematomas 
attributed to carotid surgery. 
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11.4 Discussion 
The International Carotid Stenting Study is the largest randomised clinical trial of carotid 
stenting and endarterectomy to date and the first completed trial to show a significantly 
higher short-term risk of stroke, death or peri-procedural myocardial infarction in 
patients allocated stenting (3.3% absolute risk difference in favour of endarterectomy).   
The excess of non-disabling stroke and a higher number of fatal strokes in patients 
allocated to carotid stenting were the main driving forces behind the difference in the 
120-day risk between stenting (8.5%) and carotid endarterectomy (5.2%) in the main 
short-term outcome.  The risk of death not related to stroke or myocardial infarction was 
similar in both groups as was the overall number of myocardial infarctions.   
The results of the per-protocol analysis reinforce the findings of the intention-to-treat 
analysis.  The fact that (with the exception of all-cause death) the per-protocol and 
intention-to-treat analyses provided similar results, suggest that the overall findings are 
reliable and robust.  The difference between groups in the per-protocol analysis was 
mainly attributable to an excess of non-disabling stroke in the stenting group compared 
with the endarterectomy group, but there were also more fatal strokes and fatal 
myocardial infarctions in the stenting group.  By contrast, the numbers of disabling 
strokes in the two groups were identical and the rate of disabling stroke or death was not 
significantly different between the groups. 
All myocardial infarctions recorded in the stenting group were fatal while all myocardial 
infarctions in the surgery group were non-fatal.  The overall number of heart attacks was 
small and not too much weight should be attached to this observation.   
The distribution of stroke severity is interesting in that the number of disabling strokes 
exceeded the number of non-disabling strokes in the carotid endarterectomy group (n = 
19 versus n = 14).  No other randomised clinical trial of carotid stenting or surgery has 
found more disabling than non-disabling strokes in either the stenting or the surgery 
group. This may suggest that non-disabling strokes may have been missed in the surgery 
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group in ICSS.  However, it may be a chance finding and should not distract from the 
overall result.   
Investigators who undertook follow-up assessments were not masked to treatment 
allocation, leading to the possibility of ascertainment bias of minor events.  A post-
analysis audit has confirmed that all but 77 patients were seen for follow-up by a 
neurologist or stroke physician, or by research staff not directly involved in the 
revascularisation procedures.  A sensitivity analysis excluded the 77 patients seen for 
follow-up by a surgeon only and provided similar results to those of the full analysis, 
making it unlikely that biased reporting affected the results.  This is supported by the 
results of a blinded MRI sub analysis of ICSS (Bonati et al. 2010b).  This sub analysis 
showed a significantly higher proportion of patients with new ischaemic lesions on MRI 
in the stenting group than in the endarterectomy group (50% versus 17%, adjusted odds 
ratio 5.21, 95% CI 2.78 – 9.79, p < 0.0001).  The most likely explanation for the excess risk 
of non-disabling stroke associated with stenting is that it is related to instrumentation of 
the carotid stenosis, given that most strokes occurred on the day of treatment. 
ICSS confirmed previous findings that cranial nerve palsy and haematoma were both 
more common after carotid endarterectomy than after stenting.  The cranial nerve palsy 
attributed to stenting in this trial in fact occurred following surgery.  Timing of the 
surgery and occurrence of the nerve injury within 30 days after attempted stenting meant 
that the cranial nerve palsy had to be attributed to the stenting group.  Two cranial nerve 
palsies were considered to be disabling and this should serve as a reminder that they are 
an important complication of carotid surgery.  In almost 25% of patients, cranial nerve 
palsy was associated with haematoma.  However, the long-term outcome of non-
disabling stroke might be worse than that of non-disabling cranial nerve palsy.  A recent 
symptomatic review has highlighted the increased risk of dementia associated with 
recurrent stroke (Pendlebury et al. 2009a).  The long-term consequences of the non-
disabling stroke in ICSS may only become evident with further follow-up, which will 
include measures of disability and quality of life. 
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Patients who received a stent had a shorter wait from the most recent stroke or TIA to 
treatment than did those who received endarterectomy.  But even so only 25% of patients 
in the stenting group were treated within 14 days of symptoms, compared to 18% of 
those in the endarterectomy group.  However, there was no difference in the risks of 
stenting compared with endarterectomy whether or not patients were treated within 14 
days of symptoms or later.  Several strokes occurred before treatment was initiated (five 
versus seven) and several patients developed asymptomatic carotid artery occlusion 
before treatment (five versus nine), emphasising the importance of treating carotid 
stenosis as soon as possible after symptoms. 
The subgroup analyses were only exploratory in nature and will inform future analyses 
of combined data from the large trials.  The overall message from these analyses is that so 
far no subgroup of patients substantially benefiting from stenting instead of surgery 
could be identified.  It does suggest that carotid artery stenting may have a similar risk to 
endarterectomy in women, but that the intervention was more hazardous than 
endarterectomy in men.  The difference, which did not reach statistical significance, 
seemed to be largely explained by a higher risk of outcome events associated with 
endarterectomy in women than in men.   This finding is consistent with most large 
studies and was also seen in EVA-3S, in the pooled analysis of the major carotid 
endarterectomy trials, and in a systematic review of the published series (Rothwell et al. 
2004b; Bond et al. 2005; Mas et al. 2008).  Stenting seemed more hazardous, and 
endarterectomy less hazardous, in patients without treated hypertension at baseline than 
in patients with treated hypertension, but the reasons remain unclear.  However, a 
systematic review of predictors of stroke and death caused by carotid endarterectomy 
showed a similar increase in risk of stroke or death associated with hypertension (HR 
1.82, 95% CI 1.37 – 2.41, p < 0.0001) in accordance with our findings (Rothwell et al. 1997). 
In patients whose most recent event was an episode of amaurosis fugax the risk of 
stenting was smaller than the risk of surgery.  But interestingly, while the presence of a 
particular risk factor tended to increase the risk of carotid endarterectomy the same risk 
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factor tended to reduce the risk of stenting.  The observation that a treatment should 
become ‘safer’ in patients who because of their risk factor profile are thought to be at 
increased risk of intervention is somewhat counter-intuitive.  A possible explanation of 
this phenomenon may be that the inherent risk of stenting is much greater than the low 
risk of an outcome event in patients without risk factor than it is the case in patients with 
risk factor.  It somewhat supports the notion of stenting being more suitable for ‘high-
risk’ patients.  But the effect is not as large as it may have been hoped and certainly not 
large enough to tip the scale in favour of stenting.  This may change however, if 
individual patient data from the large trials are combined. 
It should be pointed out, that the term ‘high risk’ is very poorly defined.  Peter Rothwell 
pointed out in his comments on the long-term CAVATAS results that most patients who 
have undergone stenting for symptomatic carotid stenosis outside randomised trials 
would have met the inclusion criteria for the large trials (Rothwell 2009). 
ICSS, SPACE and EVA-3S formed a trio of clinical trials comparing carotid stenting and 
carotid endarterectomy in patients with symptomatic carotid stenosis.  They had very 
similar study protocols and were conducted at the same time.  Neither SPACE nor EVA-
3S reached their predefined sample size, albeit for different reasons (Mas et al. 2006; 
Ringleb et al. 2006).  The publication of SPACE and EVA-3S in 2006 sparked intense 
debate.  SPACE was very much in agreement with the Cochrane Review in not showing a 
significant difference between endovascular treatment and surgery, whereas EVA-3S was 
regarded as the “odd kid on the block”.  Much was made of the requirements for centres 
to join EVA-3S (Harjai et al. 2007; Naylor 2007; Qureshi 2007; Setacci et al. 2007; Beckett et 
al. 2008).  It was attempted to explain the high complication rate of stenting (9.6%) with 
the level of experience required from stenting personnel.  In hindsight, the focus should 
have been on the low complication rate following surgery. 
The findings of ICSS now vindicate EVA-3S.  The absolute risk difference between 
stenting and surgery for stroke, death, or procedural MI in ICSS is very similar although 
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smaller than that in EVA-3S (3.3% and 5.7%).  Both ICSS and EVA-3S stand out from 
other trials of stenting versus surgery with a comparably low complication rate following 
surgery (3.9% and 5.1%), which is approximately half that reported in ECST and 
CAVATAS (Farrell et al. 1998; Brown et al. 2001).  ICSS and EVA-3S are therefore more a 
testament to the safety improvements achieved in carotid endarterectomy over the years 
rather than a failure of carotid stenting as such.   
It is unclear why the often-evoked “improvements in stenting technology” such as the 
introduction of cerebral filter devices and a wealth of different stenting systems have 
thus far have not led to a clear improvement in outcome.  It could even be argued that 
rather than improving the safety of the procedure over the years the technological 
changes have done more harm than good.  This argument is supported by the lower 
complication rate following stenting in SPACE compared to EVA-3S and ICSS.  Roughly 
20% of patients in SPACE were treated with a protection device.  The use of protection 
devices was mandatory in EVA-3S and recommended in ICSS.  Interestingly, there was a 
higher rate of stroke in the patients treated with a protection device than those treated 
without in SPACE (Jansen et al. 2009).  ICSS also showed that protection devices had a 
higher complication rate than patients treated without protection device (Doig et al. 
2010).  
ICSS has confirmed suspicions raised by the Cochrane Review carried out in 2007 that 
surgery is superior to stenting in terms of short-term risk.  Carotid endarterectomy 
should remain the treatment of choice of symptomatic carotid stenosis.   
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12 The Impact of Small Vessel Disease on The Outcome of Invasive 
Treatment of Carotid Artery Stenosis 
12.1 Background 
The large clinical trials of surgery have demonstrated that invasive treatment of 
symptomatic carotid stenosis prevents recurrent stroke (Barnett et al. 1998; Farrell et al. 
1998; Rothwell et al. 2003).  To a lesser extent trials of carotid endarterectomy in 
asymptomatic patients have also shown a benefit of surgery over medical treatment 
alone in preventing stroke (Toole et al. 1995; Halliday et al. 2004).  However, while 
preventing stroke, surgery is itself a cause of stroke.  In the 30 days following 
endarterectomy, 6.7% of patients recruited in NASCET and 7.0% of patients recruited in 
ECST had a stroke or died, while of the patients randomised to the control group, only 
2.4% in NASCET and 0.2% in ECST had a stroke or died within 32 days after 
randomisation (Barnett et al. 1998; Farrell et al. 1998).   
In the asymptomatic trials the rate of operative stroke or death was somewhat lower in 
both groups but nevertheless stroke occurred following surgery: 2.3% of patients 
randomised in ACAS and 2.8% of patients enrolled in ACST had a stroke or died in the 
30-day period following carotid endarterectomy (Toole et al. 1995; Halliday et al. 2004).  
Only 0.4% of patients randomised to the control group in ACAS had a stroke or died in a 
similar time period following randomisation. 
The large stenting trials confirmed the findings of the surgical trials and in addition 
showed that stenting carried a similar risk of post-procedural stroke, and depending on 
the trial even a significantly higher risk than surgery (Eckstein et al. 2008; Mas et al. 2008; 
Brott et al. 2010; Ederle et al. 2010). 
It is not surprising that invasive treatment should carry a treatment-inherent risk.  There 
is no reason why Paracelsius’ axiom “Dosis sola venenum facit” (only the quantity makes 
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the poison) and the knowledge that there is no effect without side effect (“all things are 
poison and nothing is without poison”) should not apply to carotid endarterectomy or 
stenting.  It is one of the aims of research and clinical practice to strive to improve the 
safety of any procedure.  If factors contributing to the procedural risk could be identified 
and appropriate steps taken, safety may well be improved. 
White matter changes are a common finding on computed tomography (CT) and 
magnetic resonance imaging (MRI) of the brain.  They are prevalent in the elderly and 
seen particularly in patients with dementia and stroke (Pantoni et al. 1995; Streifler et al. 
1995; Tarvonen-Schroder et al. 1996; Pantoni et al. 1997; Leys et al. 1999).  The Framingham 
Heart Study has shown that severe cerebral white matter disease more than doubles the 
risk of future stroke (Debette et al. 2010).  Vladimir Hachinski and his colleagues first 
proposed the term leukoaraiosis as a purely descriptive term for the presence of patchy 
diffuse low density changes in the cerebral white matter (Hachinski et al. 1987). 
The pathophysiology of leukoaraiosis is complex and not entirely understood.  
Pathological studies have found enlarged perivascular spaces, gliosis, axonal loss, and 
myelin pallor in areas of leukoaraiosis (Caplan et al. 1978; Babikian et al. 1987).  Recent 
studies have not shown any correlation of leukoaraiosis with myelin loss demonstrated 
with Luxol Fast Blue (LFB) or immunohistochemical staining and myelin loss may not be 
the direct pathologic correlate of leukoaraiosis (Young et al. 2008; Auriel et al. 2010). 
Associated with areas of leukoaraiosis are changes in the structure of small perforating 
arteries and white matter changes can often be observed in patients with lacunar strokes 
(Wiszniewska et al. 2000).  The finding of vessel wall-thickening associated with 
leukoaraiosis indicates that structural abnormalities of cerebral vessels are associated 
with the development of leukoaraiosis (Auriel et al. 2010).  Increased vessel wall 
thickening and elevated immunoreactivity of hypoxia-inducible factors (HIF1α and 
HIF2α) in deep sub cortical white matter lesions were demonstrated in an unselected 
cohort of the elderly providing evidence that hypoxia may contribute to the development 
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of leukoaraiosis (Fernando et al. 2006).  This, together with a lack of association of 
leukoaraiosis with markers of systemic atherosclerosis, points towards longstanding 
haemodynamic hypoxia being the main cause for the development of leukoaraiosis 
(Auriel et al. 2010).   
Cross-sectional imaging of brain is useful in evaluating the extent of white matter 
changes.  A prevalence of leukoaraiosis between 4% and 44% using CT and up to 100% 
on MRI has been reported in stroke patients, the latter owing to its higher sensitivity and 
depending on patient selection (Streifler et al. 1995; Pantoni et al. 1997; Leys et al. 1999).  
The incidence of white matter changes increases with age and some changes are usual 
above the age of 40 years.  Other risk factors for the development of white matter changes 
include hypertension and leukoaraiosis is associated with cognitive impairment and 
dementia (Jeerakathil et al. 2004; Verdelho et al. 2010). 
Jonathan Streifler demonstrated that white matter changes were associated with a higher 
perioperative risk of stroke or death in patients assigned to carotid endarterectomy in 
NASCET (Streifler et al. 2002).  Patients with widespread white matter changes allocated 
to the control group also had an increased risk of stroke or death.  To date, the influence 
of white matter changes on the procedural risk of stroke and death in carotid stenting has 
not been investigated. 
The study described in this chapter was therefore carried out to investigate the influence 
of leukoaraiosis on the risk of procedural complications in a large patient group with 
recently symptomatic carotid disease. 
12.2 Methods 
12.2.1 Patients and Centre Requirements 
All patients included in this study were enrolled in the International Carotid Stenting 
Study (ICSS), which was described in detail in the previous chapter and the results of the 
main short-term analysis were published recently (Ederle et al. 2010).  ICSS is an 
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international multi-centre randomised clinical trial comparing carotid stenting and 
endarterectomy in patients with symptomatic carotid atheromatous disease.  All patients 
participating in ICSS provided written informed consent. 
 Patients were randomised at 50 centres in Europe, Canada, Australia and New Zealand 
with a team in place at each centre consisting of a neurologist or physician with a special 
interest in stroke medicine, a designated surgeon with experience in endarterectomy and 
an interventionist with expertise in carotid stenting.  Centres with little experience in 
either endarterectomy or stenting were enrolled as supervised centres and proctored 
until the Steering Committee was satisfied that a sufficient level of experience was 
achieved to carry out the procedure safely. 
Patients over the age of 40 years were eligible to be enrolled in ICSS if they had 
symptomatic atheromatous carotid artery disease greater than 50%, measured by 
NASCET criteria or a non-invasive equivalent imaging technique (Barnett et al. 1998).  
They had to be equally suitable for surgery and stenting and deemed in need of invasive 
treatment.  Patients were randomised using a computerised service provided by the 
Oxford Clinical Trials Service Unit. 
As part of the pre-treatment work up, brain imaging (CT or MRI) was carried out to 
exclude other pathology and serve as baseline for comparison with subsequent brain 
imaging.   
Patients were followed up by an independent neurologist or physician with an interest in 
stroke medicine one month after treatment, six months and annually after randomisation.  
Long-term follow-up is ongoing. 
All patients randomised in ICSS were eligible for the study of white matter changes.  
They were included in the analysis if baseline CT or MRI prior to study treatment was 
available at the Central Trial Office.  Patients were excluded if no baseline brain imaging 
was available or if the quality was poor. 
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12.2.2 Definition of Outcome Events 
Stroke was defined as an acute disturbance of focal neurological function with symptoms 
lasting more than 24 hours resulting from intracranial vascular disturbance.  Visual loss 
resulting from embolic or haemodynamic retinal ischaemia lasting more than 24 hours 
was included in this category.  Events leading to a modified Rankin score of 3 or greater 
for more than 30 days after onset were classified as disabling and the remaining events 
were classified as non-disabling.  Events leading to death within 30 days after onset were 
classified as fatal. 
Myocardial infarction was defined by the presence of a combination of two out of three of 
the following criteria: 
• Specific cardiac enzymes more than twice the upper limit of normal 
• A history of chest discomfort for at least half an hour 
• The development of specific abnormalities on a standard 12-lead ECG (e.g. Q 
waves) 
 A procedural event was defined as an event occurring within 30 days of treatment. 
12.2.3 Outcome Measures 
For the purpose of this study the main outcome measure was defined as: 
• Any stroke, death, or procedural MI  
This was also the main outcome measure of the short-term analysis of ICSS described in 
the previous chapter (Ederle et al. 2010).   
Additional outcome measures were defined prior to the analysis of data and excluded 
myocardial infarction: 
• Any stroke or death 
• Any stroke 
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• Disabling or fatal stroke 
Events were measured at 120 days after randomisation and analysed by intention to treat. 
12.2.4 Rating of White Matter Changes 
Anonymised diagnostic brain imaging prior to treatment were collected at the Central 
Trial Office.  Two investigators trained in the analysis of white matter changes and 
blinded to treatment and clinical outcome rated all images by consensus using the age-
related white matter changes (ARWMC) score first introduced and validated for the use 
in CT and MRI by Lars Wahlund and his colleagues (Wahlund et al. 2001). 
The degree of white matter disease was rated on a 4-point scale in different brain regions 
on T2-weighted and FLAIR MRI images or on CT images.  In patients in whom both 
imaging modalities had been carried out, MRI was chosen for rating white matter 
changes.   
White matter changes in the cerebral hemispheres and the brainstem were defined as 
poorly defined hyperintensities ≥ 5 mm along the maximum diameter on T2-weighted or 
FLAIR MRI images and areas of poorly defined hypodensity of 5 mm or more on CT.  
Changes in the basal ganglia were rated in the same manner.  The rating scale definitions 
are displayed in Table 12.1.  Infarcts were excluded. 
Five brain regions were scored in each patient separately in the left and right 
hemispheres: 
• The frontal area: This was the frontal lobe anterior to the central sulcus 
• The parieto-occipital area consisted of the parietal and occipital lobes in 
combination 
• The temporal area was the temporal lobe, with a line from the posterior part of 
the Sylvian fissure to the trigones of the lateral ventricles separating this area 
from the parieto-occipital area 
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• The infratentorial area included the brain stem and cerebellum 
• The basal ganglia included the striatum, globus pallidus, thalamus, external 
capsules and insula 
The total age-related white matter changes score was than obtained by adding the scores 
for each brain region.  Thus the total ARWMC score ranged from 0 to 30. 
Table 12.1 – ICSS-ARWMC: The Age-related white matter changes (ARWMC) rating scale for MRI and 
CT 
White matter lesions  
0 No lesions (including symmetrical, well-defined caps or bands) 
1 Focal lesions 
2 Beginning confluence of lesions 
3 Diffuse involvement of the entire region, with or without involvement of U fibres 
Basal ganglia lesions  
0 No lesions 
1 1 focal lesion (≥ 5 mm) 
2 > 1 focal lesion 
3 Confluent lesions 
 
In addition to the rating of white matter changes, the presence of established cerebral 
infarcts was noted. 
Due to the nature of the trial as an international multicentre trial different scanners and 
scanning protocols were used.  Studies available on film were rated using standardised 
diagnostic grade light boxes.  Digital imaging was reviewed using an open-source 
DICOM viewer software (OsiriX version 3.x, OsiriX Foundation, www.osirix-
viewer.com). 
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12.2.5 Hypothesis and Statistical Analysis 
The hypothesis for this study was that white matter changes are associated with an 
increased risk of an unfavourable outcome after stenting and carotid endarterectomy.  
The analysis of white matter changes was not pre-specified in the study protocol and no 
separate power calculation had been carried out. 
Because this was a subgroup analysis of a non-randomised comparison, baseline 
characteristics of patients allocated stenting and carotid endarterectomy were compared 
using the Mann-Whitney U-test for non-parametric variables and Chi-square tests for 
categorical variables.  The age-related white matter score in both groups was compared 
using the independent samples t-test.   
Some patients in ICSS did not receive their allocated treatment.  All randomised patients 
included in this study were compared in an intention-to-treat analysis based on 120 days 
of follow-up regardless of whether they received the allocated treatment or not. 
The overall 120-day risk of an outcome event was tested for the whole population 
(regardless of treatment allocation) using a Cox regression model with the age-related 
white matter score as continuous variable (i.e. intention to treat) to investigate the overall 
influence of white matter changes on the risk of procedural complications.  Subsequently, 
the cumulative incidences of the different outcome measures were estimated using log-
rank tests stratified by treatment using the age-related white matter score with cut-offs 
chosen at the 1st, 2nd, and 3rd quartile and dichotomised at the median.   
All analyses were adjusted for age to account for the fact that white matter changes are 
related to the age of the patient. 
12.3 Results 
12.3.1 Baseline Patient Data 
Baseline brain imaging prior to treatment was available in 1,051 patients enrolled in ICSS 
and included in this study (Figure 12.1).  Of the total number of patients enrolled in ICSS, 
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67% of the patients in the stenting group (n = 542) and 59% of the patients in the surgery 
group (n = 509) had suitable brain imaging.  Just over half of the scans had been carried 
out using CT (53% in the stenting group and 56% in the surgery group, p = 0.45).   
Figure 12.1 – ICSS-ARWMC: Trial profile 
 
The time between scan and treatment was significantly shorter in the stenting arm than 
in the surgery group (16 days versus 23 days, respectively, p < 0.0001). 
Baseline patient characteristics did not differ significantly between the two groups.  The 
risk factors generally thought to influence small vessel disease in particular such as age, 
hypertension, and hypercholesterolaemia were distributed equally in both groups. 
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Table 12.2 – ICSS-ARWMC: Patient characteristics at baseline per allocated treatment 
Data are number of patients (% of known data), unless otherwise indicated.  CEA, carotid endarterectomy; BP, blood 
pressure; SD, standard deviation.  *Degree of stenosis measured by NASCET method at randomising centre.  †If two 
events were reported on the same day, the more serious of the two was counted (stroke>retinal infarct>TIA>A 
fugax).  ‡P values are calculated using Fisher’s exact test or Pearson’s Chi-square test for categorical variables and the 
Mann-Whitney U-test for non-categorical variables (table continued on next page).   
  Stenting 
(n = 542) 
 CEA  
(n = 509) 
 P 
Value‡ 
CT scan  288 (53%)  285 (56%)  0.441 
Age (mean [SD], years)  70 [9]  70 [9]  0.753 
Sex       
Women  252 (30%)  251 (29%)  0.684 
Vascular risk factors       
Cerebral infarct on baseline scan  278 (51%)  252 (49%)  0.830 
Hypertension  384 (72%)  350 (69%)  0.340 
Systolic blood pressure (mean [SD], 
mmHg) 
 147.9 [25.2]  146.2 [23.4]  0.344 
Diastolic blood pressure (mean [SD], 
mmHg) 
 79.6 [12.4]  78.1 [12.5]  0.095 
Diabetes mellitus  120 (23%)  105 (21%)  0.491 
Hyperlipidaemia  338 (63%)  332 (66%)  0.476 
Cholesterol (mean [SD], mmol/L)  4.8 [1.2]  4.9 [1.3]  0.302 
Current smoker  120 (23%)  111 (22%)  0.881 
Past smoker  267 (50%)  262 (52%)  0.587 
Peripheral vascular disease  91 (17%)  78 (8%)  0.501 
Degree of symptomatic carotid stenosis*      0.252 
50-69%  70 (13%)  54 (11%)   
70-99%  472 (87%)  455 (89%)   
Degree of contralateral stenosis*      0.379 
<50%  365 (67%)  331 (65%)   
50-69%  78 (14%)  81 (16%)   
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  Stenting 
(n = 542) 
 CEA  
(n = 509) 
 P 
Value‡ 
70-99%  64 (12%)  74 (15%)   
Occluded  31 (6%)  21 (4%)   
Unknown  4 (1%)  2 (0.4%)   
Most recent ipsilateral event†      0.845 
Amaurosis fugax  84 (16%)  79 (16%)   
Transient ischaemic attack  175 (32%)  175 (34%)   
Ischaemic hemispheric stroke  262 (48%)  241 (47%)   
Retinal infarct  13 (2%)  9 (2%)   
Unknown  8 (2%)  5 (1%)   
Multiple ipsilateral symptoms prior to 
randomisation 
 221 (41%)  194 (38%)  0.413 
Ipsilateral stroke prior to most recent 
ipsilateral event 
 92 (17%)  68 (13%)  0.124 
Table 12.2 continued 
12.3.2 Age-related White Matter Changes Score 
The mean total age-related white matter changes score was similar in both groups (7.11 ± 
4.43 in the stenting group and 7.03 ± 4.62 in the surgery group, p = 0.637).  The 
distribution of ARWMC score in the different brain regions did not differ between the 
two treatment groups, with the frontal brain region being the most common site of small 
vessel disease (Table 12.3).   
Table 12.3 – ICSS-ARWMC: Rating scores (mean ± SD) according to location and treatment 
Data are mean ± SD.  CEA, carotid endarterectomy (table continued on next page). 
  Stenting 
(n = 542) 
 CEA  
(n = 509) 
 P 
Value* 
Frontal       
Ipsilateral  1.22 ± 0.71  1.19 ± 0.69  0.398 
Contralateral  1.15 ± 0.71  1.14 ± 0.70  0.569 
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  Stenting 
(n = 542) 
 CEA  
(n = 509) 
 P 
Value* 
Parieto-occipital       
Ipsilateral  1.04 ± 0.83  1.00 ± 0.80  0.356 
Contralateral  1.01 ± 0.83  0.94 ± 0.80  0.114 
Temporal       
Ipsilateral  0.23 ± 0.44  0.26 ± 0.45  0.340 
Contralateral  0.23 ± 0.43  0.25 ± 0.45  0.445 
Infratentorial       
Ipsilateral  0.20 ± 0.44  0.18 ± 0.43  0.497 
Contralateral  0.19 ± 0.44  0.19 ± 0.46  0.817 
Basal Ganglia       
Ipsilateral  0.94 ± 0.93  0.97 ± 0.91  0.996 
Contralateral  0.90 ± 0.89  0.92 ± 0.94  0.988 
Total ARWMC score  7.11 ± 4.43  7.03 ± 4.62  0.637 
Table 12.3 continued 
12.3.3 Analysis of ARWMC Score 
The ARWMC Score in the Population as a Whole 
Pooling both treatment groups together and adjusting for age, white matter disease as 
expressed by the total age-related white matter changes score was significantly associated 
with an increased the risk of stroke, death, or procedural MI at 120 days after 
randomisation.  The hazard ratio associated with an increase in ARWMC score of one 
point was 1.07 (95% CI 1.01 to 1.12, p = 0.019, Figure 12.2).  White matter disease was also 
significantly associated with an increased risk of stroke or death (HR 1.08, 95% CI 1.02 to 
1.14, p = 0.009), stroke (HR 1.07, 95% CI 1.01 to 1.14, p = 0.019) and disabling or fatal 
stroke (HR 1.10, 95% CI 1.01 to 1.20, p = 0.027, Figure 12.2). 
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Figure 12.2 – ICSS-ARWMC: Hazard ratios for total ARWMC score 
Shown are the hazard ratios for each outcome measure associated with a 1-point increase in ARWMC score.  HR, 
hazard ratio; CI, confidence interval; MI, myocardial infarction. 
 
The ARWMC Score in Quartiles per Treatment Group 
Stroke, Death, or Procedural Myocardial Infarction 
The cumulative incidence of stroke, death, or procedural myocardial infarction at 120 
days after randomisation increased with each quartile of total ARWMC score.  In the 
stenting group, the estimated cumulative incidence of stroke, death or procedural MI was 
5.4% (SE 2.1%) in patients in the 1st quartile, i.e. with an ARWMC score < 4 (6 events in 
112 patients), 3.8% (SE 1.5%, 6 events in 158 patients) in patients in the 2nd quartile 
(ARWMC score ranging from 4 to 6), 11.1% (SE 3.0%, 12 events in 108 patients) in 
patients in the 3rd quartile (ARWMC score ranging from 7 to 9), and 13.5% (SE 2.7%, 22 
events in 164 patients) in patients in the 4th quartile (ARWMC score ≥ 10).  This increase 
was statistically significant (log-rank p = 0.008).  In the surgery group, the cumulative 
incidence of stroke, death or procedural myocardial infarction at 120 days after 
randomisation was more evenly distributed between the four groups of ARWMC score 
and was estimated at 3.4% (SE 1.7%, 4 events in 119 patients), 4.3% (SE 1.7%, 6 events in 
141 patients), 4.8% (SE 2.1%, 5 events in 105 patients), and 6.3% (SE 2.0%, 9 events in 145 
patients) in the 1st, 2nd, 3rd, and 4th quartile of total ARWMC score respectively.  The 
increase in cumulative incidence in the surgery group was not statistically significant 
(log-rank p = 0.730, Figure 12.3). 
Outcome Measure! HR (95 % CI)! P value!
Stroke, death, or procedural MI! 1.07 (1.01 – 1.12)! 0.019!
Stroke or death! 1.08 (1.02 – 1.14)! 0.009!
Stroke! 1.07 (1.01 – 1.14)! 0.019!
Disabling or fatal stroke! 1.10 (1.01 – 1.20)! 0.027!
0.9! 1! 1.1! 1.2!
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Stroke or Death 
A similar result was obtained for the cumulative incidence of stroke or death 120 days 
after randomisation.  There was an increase in cumulative incidence in the stenting group 
from 5.4% (SE 2.1%, 6 events) in the 1st quartile to 13.5% (SE 2.7%, 22 events) in the 4th 
quartile (log=rank p = 0.008), while in the surgery group the cumulative incidence 
between quartiles of ARWMC score in the first quartile (2.5%, SE 1.4%, 3 events) and in 
the fourth quartile (5.6%, SE 1.9%, 8 events) was similar (log-rank p = 0.643, Figure 12.4). 
Stroke 
The pattern of a significant increase in cumulative incidence 120 days after randomisation 
with increasing quartile of total ARWMC score in the stenting group and more evenly 
balanced cumulative incidences in the quartiles of total ARWMC score in the surgery 
group was also observed for the separate analyses of stroke.  In the stenting group the 
cumulative incidence in the 1st quartile was 4.5% (SE 2.0%) and increased to 12.3% (SE 
2.6%) in the 4th quartile (p = 0.006).  In the surgery group there was a more modest and 
non-significant increase from 2.5% in the 1st quartile (SE 1.4%) to 4.9 (SE 1.8%) in the 4th 
quartile (p = 0.697, Figure 12.5). 
Disabling or Fatal Stroke 
The cumulative incidence of disabling or fatal stroke increased from 0.9% (SE 0.9%, 1 
event) in the 1st quartile to 6.1% (SE 1.9%, 10 events) in the stenting group (p = 0.018).  In 
the surgery group the cumulative incidence increased from 1.7% (SE 1.2%, 2 events) in 
the 1st quartile to 2.8% (SE 1.4%, 4 events) in the 4th quartile of ARWMC score (Figure 
12.6). 
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Figure 12.3 – ICSS-ARWMC: 120-day cumulative incidence of stroke, death or myocardial infarction per 
quartile of ARWMC score per treatment group 
Shown are Kaplan-Meier estimated cumulative incidences with their standard errors (vertical lines).  CAS, carotid 
stenting; CEA, carotid endarterectomy, ARWMC, age-related white matter score; N, number of patients; n, number of 
events. 
 
Figure 12.4 – ICSS-ARWMC: 120-day cumulative incidence of stroke or death per quartile of ARWMC 
score per treatment group 
Shown are Kaplan-Meier estimated cumulative incidences with their standard errors (vertical lines).  CAS, carotid 
stenting; CEA, carotid endarterectomy, ARWMC, age-related white matter score; N, number of patients; n, number of 
events. 
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Figure 12.5 – ICSS-ARWMC: 120-day cumulative incidence of stroke per quartile of ARWMC score per 
treatment group 
Shown are Kaplan-Meier estimated cumulative incidences with their standard errors (vertical lines).  CAS, carotid 
stenting; CEA, carotid endarterectomy, ARWMC, age-related white matter score; N, number of patients; n, number of 
events. 
 
Figure 12.6 – ICSS-ARWMC: 120-day cumulative incidence of disabling or fatal stroke per quartile of 
ARWMC score per treatment group 
Shown are Kaplan-Meier estimated cumulative incidences with their standard errors (vertical lines).  CAS, carotid 
stenting; CEA, carotid endarterectomy, ARWMC, age-related white matter score; N, number of patients; n, number of 
events. 
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Risk of Outcome by Treatment Group in the Upper and Lower 50th Percentile of 
ARWMC Score 
Stroke, Death, or Procedural Myocardial Infarction 
Patients allocated to stenting and a total ARWMC score of ≥ 7 (median) had a 
significantly higher risk of stroke, death, or procedural MI than those patients with a total 
ARWMC score of less than 7.  Stroke, death, or procedural MI occurred in 12 patients 
with an ARWMC score less than 7, and in 34 patients with an AWRMC score ≥ 7 in the 
stenting group.  The cumulative incidence 120 days after randomisation was 4.5% (SE 
1.3%) if the ARWMC score was less than 7 and 12.5% (SE 2.0%) with an ARWMC score ≥ 
7 (HR 2.32, 95% CI 1.18 to 4.56, p = 0.014, Figure 12.7).   
In the surgery group stroke, death, or procedural MI was recorded in 10 patients with an 
ARWMC score < 7 and in 14 patients with an ARWMC score ≥ 7.  The risk of the same 
outcome associated with a total ARWMC score ≥ 7 (5.7%, SE 1.5%) in patients allocated 
surgery was not significantly higher than the risk associated with a low ARWMC score 
(3.9%, SE 1.2%).  The hazard ratio was 1.48 (95% CI 0.62 to 3.56, p = 0.380). 
Stroke or Death 
The cumulative incidence of stroke or death was higher in patients allocated stenting 
with an ARWMC score in the upper 50 percentile, where it occurred in 34 patients 
(12.5%, SE 2.0%) than in patients with an ARWMC score in the lower 50 percentile, where 
stroke or death was recorded in 12 patients (4.5%, SE 1.3%, Figure 12.8).  The hazard ratio 
was 2.32 (95% CI 1.18 to 4.55, p = 0.014) and significantly favoured patients with a lower 
ARWMC score. 
No significant difference between patients with an ARWMC score in the lower and upper 
50 percentile was found for the risk of stroke or death in the surgery group (12 versus 8 
events, respectively).  The cumulative incidence was 3.1% (SE 1.1%) and 4.9% (SE 1.4 5), 
respectively (HR 1.84, 95% CI 0.70 to 4.84, p = 0.218). 
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Stroke 
The same pattern was observed for stroke.  In the stenting group there was a significant 
difference in cumulative incidence of stroke in patients with a ARWMC score less than 7 
compared to patients with an ARWMC score ≥ 7.  In the former group, 10 patients 
suffered a stroke (3.7%, SE 1.2%) while the same outcome was recorded in 32 patients in 
the latter group (11.8%, SE 2.0%, Figure 12.9).  The hazard ratio favoured the group of 
patients with a lower ARWMC score (HR 2.66, 95% CI 1.29 to 5.50, p = 0.008). 
In the surgery group no significant difference between patients with a low versus high 
ARWMC score was observed (ARWMC < 7: cumulative incidence 2.7%, SE 1.0%; 
ARWMC score ≥ 7: cumulative incidence 4.0%, SE 1.3%, hazard ratio 1.79, 95% CI 0.63 to 
5.11, p = 0.274). 
Disabling or Fatal Stroke 
Three patients who suffered a disabling or fatal stroke in the stenting group had an 
ARWMC score less than 7 compared to 12 patients with an ARWMC score ≥ 7 in the 
same treatment group suffering a disabling or fatal stroke (cumulative incidence 1.1%, SE 
0.6% versus 4.4%, SE 1.2%, Figure 12.10).  However, the hazard ratio showed no 
significant difference in the risk of disabling or fatal stroke in patients with a high or low 
ARWMC score (HR 2.72, 95% CI 0.76 to 9.94, p = 0.123). 
Similarly, in the surgery group the lower estimated cumulative incidence of disabling or 
fatal stroke in patients with an ARWMC score in the lower 50th percentile (1.9%, SE 0.9%) 
compared to patients with the ARWMC score in the upper 50th percentile (2.8%, SE 1.0%) 
was not associated with a significant difference in risk (HR 1.68, 95% CI 0.49 to 5.78, p = 
0.415). 
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Figure 12.7 – ICSS-ARWMC: Cumulative incidence of stroke, death or procedural MI according to extent 
of white matter changes 
Shown is the estimated 120-day Kaplan-Meier cumulative incidence in the stenting (top) and carotid endarterectomy 
group (bottom) with an age-related white matter changes (ARWMC) score < 7 and ≥ 7. 
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Figure 12.8 – ICSS-ARWMC: Cumulative incidence of stroke or death according to extent of white matter 
changes 
Shown is the estimated 120-day Kaplan-Meier cumulative incidence in the stenting (top) and carotid endarterectomy 
group (bottom) with an age-related white matter changes (ARWMC) score < 7 and ≥ 7. 
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Figure 12.9 – ICSS-ARWMC: Cumulative incidence of stroke according to extent of white matter changes 
Shown is the estimated 120-day Kaplan-Meier cumulative incidence in the stenting (top) and carotid endarterectomy 
group (bottom) with an age-related white matter changes (ARWMC) score < 7 and ≥ 7. 
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Figure 12.10 – ICSS-ARWMC: Cumulative incidence of disabling or fatal stroke according to extent of 
white matter changes 
Shown is the estimated 120-day Kaplan-Meier cumulative incidence in the stenting (top) and carotid endarterectomy 
group (bottom) with an age-related white matter changes (ARWMC) score < 7 and ≥ 7. 
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Test for Treatment Interaction with ARWMC Score 
The test for interaction between total ARWMC score and treatment showed that the 
increase in risk in patients with an ARWMC ≥ than 7 in patients allocated to stenting 
compared to patients allocated to surgery that was observed in all outcome measures as 
described above was not statistically significant different (Figure 12.11). 
Figure 12.11 – ICSS-ARWMC: Hazard ratios (stenting versus endarterectomy) and 95% confidence 
intervals for various outcome measures in patients with age-related white matter changes scores below 
and above (and including) the median 
P values are associated with treatment-covariate interaction tests.  ARWMC, age-related white matter changes; CAS, 
carotid stenting; CEA, carotid endarterectomy; MI, myocardial infarction; n, number of events; N, number of patients; 
HR, hazard ratio; CI, confidence interval. 
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12.4 Discussion 
This is the first time the influence of age-related white matter changes on the procedural 
risk of stenting compared to surgery has been investigated in a large group of patients 
randomised in a clinical trial.  The study showed that an increase in ARWMC score was 
associated with an increase in the risk of experiencing a procedural stroke, MI, or death.   
In particular, patients with an ARWMC score in the upper 50th percentile the risk of 
experiencing an outcome event was higher than in those patients with an ARWMC score 
in the lower 50th percentile.  This was more pronounced in patients who were 
randomised to stenting.  However, the test for interaction between treatment and 
ARWMC score showed that the increase in risk comparing carotid artery stenting and 
endarterectomy in patients in the lower 50th percentile was not significantly different than 
the risk comparing stenting and endarterectomy in patients in the upper 50th percentile.   
This study confirms findings by Jonathan Streifler and his colleagues in patients 
randomised in NASCET using a different rating method for white matter changes and 
who showed that the risk of perioperative stroke or death was associated with white 
matter changes (Streifler et al. 2002).  However, the big increase in risk in patients with an 
ARWMC score in the upper 50th percentile assigned to stenting is striking. 
The International Carotid Stenting Study found stenting to be associated with a higher 
risk of stroke, death, or procedural MI than surgery overall.  The increase in risk 
associated with white matter changes may have contributed to the overall findings of 
ICSS.   
Carotid Stenting is often carried out using cerebral filter devices that are designed to 
reduce the risk of embolisation to the brain.  The ICSS MRI sub-study has shown that the 
risk of small emboli detected as changes on DWI MRI but not resulting in clinical deficits 
was higher in the stenting group compared to the surgery group (Bonati et al. 2010b).  
Together with the findings of this white matter study it seems to suggest that although 
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these micro-emboli may be asymptomatic at the time they occur, they pave the way for 
delayed cerebrovascular symptoms.  This may be because of direct damage to blood 
vessels that directly lead to delayed symptoms.  It is also feasible that any damage caused 
by micro-emboli and detected only on DWI leaves the vasculature and brain vulnerable 
to any ischaemia in the future because it reduces the brain and vasculature’s ability to 
compensate for small brain ischaemia. 
Although the study was a randomised comparison, the patients included in the white 
matter study were a selected sub-group of patients who had prior imaging.  It is unlikely 
that this selection led to any bias, since the baseline characteristics were well matched 
between the two randomised groups in the white matter study and the white matter 
scores were also well balanced.  However, the fact that it was a selected group of patients 
means that the sample size was smaller, thus limiting the power of the comparison.  The 
number of outcome events in each group was small and the study was not designed to 
show small differences in risk associated with white matter changes.   
The cerebrovascular risk factor profiles in both treatment groups were similar, 
particularly age, the presence of hypertension and hypercholesterolaemia, which are all 
thought to play a role in the development of white matter changes.  This makes it less 
likely that the results can be attributed to differences in underlying risk factor profiles. 
The rating score used in this analysis was first proposed and validated for use in MRI 
and CT by Lars Wahlund and his colleagues (Wahlund et al. 2001).  The majority of brain 
imaging studies available in this comparison were acquired using CT and the extent of 
small vessel disease may be underestimated since the sensitivity of CT in detection white 
matter changes is lower than that of MR (Streifler et al. 1995; Pantoni et al. 1997; Leys et al. 
1999).  However, the proportion of CT studies in both treatment groups was similar and 
it is therefore unlikely to have introduced a significant bias in favour of one treatment. 
As pointed out above, not all patients enrolled into ICSS had baseline brain imaging prior 
to treatment available for analysis.  In many cases patients were referred for treatment 
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with the diagnosis of symptomatic carotid stenosis having been established elsewhere.  It 
was felt unethical to repeat the brain imaging in these cases and although efforts were 
made to obtain copies of the brain imaging carried out prior to randomisation this was 
not successful in all cases.  The study population available for the white matter changes 
study accounted for 60% of stroke, death, or procedural MI recorded in the entire ICSS 
population.  This shortcoming may have limited the applicability of the results.  While 
the estimated risk of stroke, death, or procedural MI in the entire ICSS population was 
exactly reproduced in the stenting group (8.5%), the estimated risk in the surgery group 
was slightly lower in this study population (4.7% compared to 5.2% in the entire ICSS 
population). 
Despite these shortcomings, the white matter changes study carried out as part of the 
International Carotid Stenting Study (ICSS) provides valuable insight in the risk 
associated with age-related white matter changes.  The study has confirmed earlier 
findings carried out in NASCET that white matter disease is associated with an increase 
in the procedural risk associated with carotid revascularisation of stroke or death or 
myocardial infarction, as well as stroke or death, stroke alone, and disabling or fatal 
stroke.  The risk of an outcome event appears to be particularly high in the upper 50th 
percentile of total ARWMC score (≥ 7) and while the increase in risk was bigger in 
patients assigned to stenting, the test for treatment interaction suggested that the increase 
in risk associated with stenting compared to endarterectomy was not significantly 
different between the group of patients with low ARWMC score of than and the group 
with scores greater than seven.  Nevertheless, the increase in risk of stroke or death 
comparing stenting and endarterectomy was small in patients with an ARWMC score of 
less than seven (4.5% vs. 3.1%) which may justify considering stenting as an alternative to 
carotid endarterectomy in certain patients.   
The pooled analysis of EVA-3S, SPACE, and ICSS has shown that age is an important 
predictor of risk of stenting (Bonati et al. 2010a).  CREST also found that the age of the 
patients affected treatment efficacy, in that older patients undergoing carotid artery 
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stenting had a greater risk of suffering an adverse event (Brott et al. 2010).  It is well 
documented that white matter disease becomes more prevalent with age (Breteler et al. 
1994).  The mean age of the patients was similar in both arms of the present study (70 ± 9 
years, p = 0.753), and the results therefore cannot be explained by differences in age in 
both treatment groups.  In a sub study of ICSS, the number of patients with new 
ischaemic lesions on DWI-MRI post treatment was three times higher in the stenting arm 
than in the carotid endarterectomy arm, with the majority of lesions not resulting in a 
corresponding neurological deficit (Bonati et al. 2010b).   
The pathophysiology of white matter changes is multi-factorial.  They are often 
associated with demyelination and axon loss (Grinberg et al. 2010).  Perivascular white 
matter lesions are frequently associated with both small and large vessel atherosclerotic 
disease (van Swieten et al. 1991; Chutinet et al. 2012).  It has been suggested that white 
matter lesions are a result of chronic white matter hypoperfusion and changes in the 
blood-brain barrier that together lead to white matter rarefaction (Pantoni et al. 1997; 
O'Sullivan et al. 2002; Black et al. 2009; Topakian et al. 2010).  White matter lesions are 
thought to be a risk factor for first ever and recurrent stroke (Fu et al. 2005; Enzinger et al. 
2007; Simoni et al. 2010). This association can be explained in part by shared risk factors 
such as hypertension and chronically ischaemic brain may be more likely to develop 
infarction when exposed to further ischaemia (Grueter et al. 2012).   
It was demonstrated using arterial spin-labeling MR perfusion that the extent of white 
matter lesions correlated with a reduction in cerebral blood flow (Bastos-Leite et al. 2008).  
Subjects with diffuse confluent white matter hyperintensities were found to have 
approximately 20% lower mean global cerebral blood flow than subjects with punctiform 
or beginning confluent white matter hyperintensities.   
But rather than being a risk factor in its own right, white matter disease identified on 
brain imaging is likely to be a marker of cerebrovascular disease reflecting the overall 
effects of individual cardiovascular risk factors (Jeerakathil et al. 2004).  A brain showing 
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signs of white matter disease and thereby demonstrating evidence of existing 
cerebrovascular disease may have less cerebrovascular reserve and be less able to cope 
with thrombotic material dislodged during carotid artery stenting, thus leading to stroke. 
This may explain the increased risk of procedural stroke, MI or death seen with 
increasing white matter changes overall, and in the stenting group in particular.
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13 Discussion, Recent Developments, and Outlook 
This thesis has described two major randomised clinical trials comparing endovascular 
treatment and endarterectomy in patients with symptomatic carotid artery stenosis, the 
Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS) and the 
International Carotid Stenting Study (ICSS) and has put the results of these two trials into 
context of other large randomised trials identified through a comprehensive Cochrane 
Review.  The research presented within the covers of this work spans almost 20 years of 
work by many collaborators in the field of carotid disease.  The main findings of the 
thesis will now be summarised with the main research questions in mind.  This will be 
followed by an outlook into the future of stroke research. 
13.1 Summary of Main Results 
CAVATAS was the first large trial that raised the possibility that endovascular treatment 
could be carried out with a similar short-term risk as carotid endarterectomy (Brown et al. 
2001).  This observation prompted other clinical trials that produced mixed results and 
failed to conclusively show endovascular treatment to be equivalent to surgery in terms 
of short-term risk (Naylor et al. 1998; Alberts 2001; Brooks et al. 2001; Yadav et al. 2004; 
Hoffmann et al. 2006; Mas et al. 2006; Ringleb et al. 2006).  Remarkable is the fact that none 
of these trials favoured endovascular treatment.   
The Cochrane Review carried out by this thesis’ author highlighted the uncertainty 
surrounding endovascular treatment compared to surgery for symptomatic carotid artery 
disease (Ederle et al. 2007a).  But it also highlighted how little consensus exists in the 
scientific community regarding terminology, choice of outcome events, length of follow 
up and presentation of data.  It is accepted that the length of follow up primarily depends 
on the availability of funding.  But why studies do not take into account other already 
published studies when writing up their own results, begs the question.  Providing data 
for the same time points as previously published studies alongside their own chosen time 
points and outcome measures would be easy and help to compare studies.  It is also very 
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unfortunate that some investigators included symptomatic and asymptomatic patients in 
the same trial without giving separate results for each group. The North American 
Carotid Revascularisation Endarterectomy vs. Stenting Trial (CREST) in particular 
suffered from the problem of combining both symptomatic and asymptomatic patients 
within a single study.  Given that all evidence points towards these groups responding to 
treatment quite differently, this can only be explained by the need to increase patient 
recruitment in order to meet the targets identified in the design stage of the trial.  This 
tends to unnecessarily muddy the waters and adds to the confusion and uncertainty 
surrounding best management of carotid artery disease.   
Research into the field culminated in the publication of the International Stenting Study 
(Ederle et al. 2010). The authors demonstrated that up to 120 days after randomisation the 
policy of carotid endarterectomy was associated with a significantly lower risk of stroke, 
death or procedural MI (5.1% vs. 8.5%), any stroke (4.0% vs. 7.7%) and any stroke or 
death (4.6% vs. 8.5%) compared to carotid stenting.  The absolute risk difference was 
small (3.4%), but the hazard ratio was significantly in favour of carotid endarterectomy 
(HR 1.73, 95% CI 1.18 to 2.52, p = 0.004).  In patients who received the allocated treatment 
the findings from the analysis including post-procedural events up to 30 days after 
treatment were very similar, suggesting that ICSS produced reliable and robust data.  
ICSS vindicated the results of the much-criticised EVA-3S study and together with 
SPACE accounts for almost 75% of patients contributing to the body of available 
evidence.  Little doubt should be remaining that carotid endarterectomy is superior to 
carotid stenting in the short-term.  What this result means for clinical practice, however, 
is less clear and will be explored further below. 
CAVATAS is the only trial with truly long-term follow up data.  It did not show a 
significant difference in the long term risk of disabling stroke or death, which was 
defined as the primary outcome measure (HR 1.02, 95% CI 0.79 to 1.32).  Reviewers of the 
long term CAVATAS paper made much of the primary outcome definition and argued 
that mortality unrelated to the procedure should not have been included in the analysis 
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(unpublished personal communication).  The reasons why this outcome has been chosen 
as the primary outcome measure have been set out in the relevant chapter and will not be 
repeated here.  Excluding non-procedural mortality made little difference to the overall 
result, it still did not tip the balance in favour of either treatment.  That none of the 
analyses favoured endovascular treatment is probably the more important message.  
Moreover, an extensive subgroup analysis comparing the risk of restenosis after either 
treatment points toward endovascular treatment as carrying a higher risk of restenosis 
greater than 70% and a higher rate of stroke associated with a high degree of restenosis.  
This makes it rather unlikely that, over the long term, stenting will be able to make up the 
ground it has lost in the initial 30 days after the procedure.  Particularly since the often-
cited improvements in stenting technology in terms of stent and guide wire design, 
which have become easier to use and deploy have thus far failed to translate into 
improvements in outcome.  
Endovascular treatment and medical care were compared in patients who were not 
suitable for surgery (Ederle et al. 2009b).  Unfortunately the trial only recruited a very 
small number of patients.  Nevertheless, it is the largest randomised dataset available to 
date.  Results of the trial were all associated with very large confidence intervals and one 
should refrain from forming firm conclusions from them.   
The reasons for being not suitable for surgery are very limited, particularly since carotid 
endarterectomy can be safely carried out under local anaesthesia, as shown by the 
General Anaesthesia versus Local Anaesthesia for carotid surgery trial (GALA) (Lewis et 
al. 2008).  Most patients today are likely to fulfil the inclusion criteria of the large trials 
(SPACE, EVA-3S, ICSS), a view shared and expressed by Peter Rothwell in a recent 
editorial in The Lancet Neurology (Rothwell 2009). 
A study was carried out as part of ICSS that investigated the influence of small vessel 
disease on the risk of various procedural outcome measures.  It showed that the risk of 
stroke, death, or procedural myocardial infarction up to 120 days after randomisation 
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was associated with small vessel disease in both the stenting and carotid endarterectomy 
group.  The risk was particularly high in patients with an age-related white matter 
changes score ≥ 7, which was the median score in this study.  The increase in risk 
associated with small vessel disease was greater in patients allocated stenting but the test 
for interaction between allocated treatment and ARWMC score showed that the increase 
in risk comparing carotid artery stenting and endarterectomy in patients in the lower 50th 
percentile was not significantly different than the risk comparing stenting and 
endarterectomy in the patients in the upper 50th percentile.  Still, this study adds to the 
misery for stenting and helps to explain why this treatment is not as good as surgery in 
preventing stroke. 
13.2 Recent Developments 
Since the publication of ICSS more relevant data has become available.  The Carotid 
Stenting Trialists’ Collaboration (CSTC) was set up to perform a prospective meta-
analysis of SPACE, EVA-2S, and ICSS and published their results in 2010 (Bonati et al. 
2010a).  It confirmed that stenting carried a significantly greater short-term risk of stroke 
or death than carotid endarterectomy.  The absolute risk difference was 3% after 120 days 
and the analysis showed a relative risk increase of 50%. The results of ICSS (4% absolute 
risk increase for the same outcome) are broadly in line with the pooled meta-analysis.  
The risk associated with stenting was strongly dependent on age and doubled in patients 
older than 70 years while remaining similar in those patients younger than 70 years 
(Figure 13.1).  The risk of stroke or death associated with carotid endarterectomy was 
similar in both age groups (Bonati et al. 2010a).  
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Figure 13.1 – CSTC: Treatment risk ratios of any stroke or death within 120 days of randomisation by 
age (both continuous and by age groups) 
Analysis was by intention to treat. Blue dots and vertical bars represent treatment risk ratios and 95% confidence 
intervals, respectively, adjusted for source trial for each age group, with endarterectomy (CEA) as the reference group, 
plotted on a log scale at the mean age in each group.  The continuous risk ratios by age (line) and 95% confidence 
intervals (dashed lines) were calculated by use of a binominal regression model containing treatment, continuous age, 
and their interaction, adjusted for source trial.  CAS, carotid stenting.  Reprinted from (Bonati et al. 2010a) with 
permission from Elsevier. 
 
The North American Carotid Revascularisation Endarterectomy vs. Stenting Trial 
(CREST) published its results in 2010.  The trial included both symptomatic and 
asymptomatic patients. Overall, the reported risk of the composite primary endpoint of 
peri-procedural stroke, myocardial infarction, or death and post-procedural ipsilateral 
stroke after a median 2.5 years was similar in the stenting and endarterectomy groups 
(Brott et al. 2010).  The CREST investigators concluded that stenting and endarterectomy 
were equivalent.  It must be emphasised that this conclusion depends on the fact that, 
unlike in the European trials, patients were systematically screened for myocardial 
infarction. The reported myocardial infarction rates following carotid endarterectomy 
were much higher than reported in other trials, which did not screen for MI.  On the 
other hand, MRI was not used to screen patients for cerebral infarction.  ICSS showed 
that about three times more patients receiving carotid stenting than those undergoing 
carotid endarterectomy had new ischaemic lesions on DWI on post treatment MR scans 
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(Bonati et al. 2010b).  The investigators have thus used double standards, on the one hand 
screening for (clinically silent) MI but not screening for (clinically silent) strokes.  This in 
addition to the fact, that symptomatic patients were included alongside asymptomatic 
patients leaves CREST open to criticism.  
Nevertheless, the risk of any peri-procedural stroke or death or post-procedural 
ipsilateral stroke was significantly higher in the stenting group compared to surgery (6% 
vs. 3.2%, hazard ratio 1.89, 95% CI 1.11 – 3.21, p = 0.02) in CREST, thus confirming the 
results of ICSS and, as shown in Figure 13.2, broadly in line with the European trials 
(Amarenco et al. 2010). 
Figure 13.2 – CREST, EVA-3S, ICSS, and SPACE: Individual and pooled relative risks of death and of 
combined stroke and death within 30 days of randomisation 
Pooled relative risks (RR) were calculated with fixed-effects model.  Data for EVA-3S, SPACE, and ICSS were extracted 
from per-protocol analysis of Carotid Stenting Trialists’ Collaboration meta-analysis (Bonati et al. 2010a).  CEA, carotid 
endarterectomy; CAS, carotid stenting.  *Sensitivity analysis excluding subgroup of asymptomatic patients enrolled in 
CREST.  Reprinted from (Amarenco et al. 2010) with permission from Elsevier. 
 
1!0.1! 0.2! 1! 2!0.5! 5! 10!
CEA worse! CAS worse!
CAS (n/N)! CEA (n/N)! RR (95 % CI)!
All-cause death!
EVA-3S! 2/260! 3/257! 0.66 (0.11 – 3.91)!
SPACE! 6/591! 3/567! 1.92 (0.48 – 7.64)!
ICSS! 11/828! 4/821! 2.73 (0.87 – 8.53)!
CREST! 9/1262! 4/1240! 2.71 (0.68 – 7.17)!
Overall effect: p = 0.04 (heterogeneity: p = 0.61, I2 = 0 %)! 1.96 (1.04 – 3.72)!
Any stroke or death!
EVA-3S! 25/260! 10/257! 2.47 (1.21 – 5.04)!
SPACE! 44/591! 35/567! 1.21 (0.79 – 1.85)!
ICSS! 61/828! 28/821! 2.16 (1.40 – 3.34)!
CREST! 55/1262! 29/1240! 1.86 (1.20 – 2.90)!
Overall effect: p = 0.0001 (heterogeneity: p = 0.19, I2 = 37.1 %) ! 1.78 (1.40 – 2.25)!
Sensitivity analysis*: p = 0.0001 (heterogeneity: p = 0.19, I2 = 36.9 %)! 1.77 (1.38 – 2.26)!
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13.3 Translating Trial Results Into Clinical Practice 
The findings of this thesis raise the question what this means for clinical practice.  The 
results of ICSS are applicable to the current practice of carotid stenting at most vascular 
centres.  The participating centres were representative of academic centres with 
substantial experience of treating carotid stenosis and had to show a high standard of 
practice before they could join the trial.  The main lesson to be drawn for day-to-day 
clinical care of patients with symptomatic patients is that carotid endarterectomy is and 
should remain the treatment of choice in patients with symptomatic carotid stenosis.  
However, several points need be borne in mind.  While the definite result of stenting 
carrying a significantly higher risk than surgery with respect to short-term events cannot 
be disputed, the differences between the treatments were small and neither procedure 
has been shown to be risk-free.   
The Department of Health, the National Health Service in the United Kingdom and 
health authorities elsewhere are promoting the participation of patients in the decision-
making process (Department of Health 2009) and patients are encouraged to take a more 
active role in their clinical care. This requires a well-informed patient and informed 
decisions by patients judged to have the capacity to consent should be respected.  This is 
not limited to the choice of hospital and doctor but extends to having a choice in what 
treatment they receive, even if that represents an in the eyes of the medical profession 
‘unwise’ choice such as to forego carotid endarterectomy in favour of stenting (or not 
have invasive treatment at all).  In light of these new realities it must be kept in mind that 
the absolute risk difference between stenting and endarterectomy is small.  Moreover, the 
vast majority of patients will not experience any complications at all.  ICSS provided 
robust data on the risk of stenting for the first time and patients can now be informed 
about risks of benefits of both carotid endarterectomy and carotid stenting.  Patients may 
well decide that the absolute difference in risk is not large enough to keep them from 
opting for what on the face of it remains the riskier option. 
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By no means should stenting be routinely carried out in place of endarterectomy.  The 
author of this thesis argues that there is room for carotid stenting as an alternative 
treatment.  Careful patient selection is paramount in order to avoid strokes caused by 
unnecessary procedures.  The best safe-guard for avoiding unnecessary and potentially 
dangerous procedures and identifying the patients in need of treatment is a multi-
disciplinary team led by a neurologist or physician with a special interest in stroke 
medicine, a surgeon with experience in carotid surgery and a neuro-radiologist with 
experience in angiography and stenting. The main point of contact for patients should be 
the neurologist or physician with a special interest in stroke medicine who is normally 
not directly involved in the delivery of either treatment and thus has no vested interest 
and is in a position to advise patients free of bias.  This advise should start with pointing 
out that carotid endarterectomy is the treatment of choice for the treatment of 
symptomatic carotid artery stenosis.  It should also contain reference to stenting and its 
risks and benefits.  Patients not expressing a preference after receiving all relevant 
information should normally undergo carotid endarterectomy.  The decision not to have 
any invasive treatment should be respected, as should the wish for stenting.  A high-class 
centre specialising in treating patients with carotid stenosis should therefore strive to 
have carotid stenting in their armoury in order to accommodate patients unwilling or 
unable to undergo surgery.  Almost 2% of the patients allocated to surgery crossed over 
to stenting in ICSS.  The ICSS study population was in a highly selected population 
thought to be equally suitable for surgery and stenting.  The number of patients who turn 
out not to be suitable for surgery is bound to be higher in the wider population. 
It has been suggested that only centres that are able to demonstrate a very low 
complication rate should be allowed to carry out stenting. However, it is unlikely that 
any individual centre will be able to achieve sufficient numbers to provide this data.  
After all, ICSS required 1700 patients to show a statistically significant difference between 
treatments.  Moreover, the ICSS centres with a high caseload were no better than the 
overall ICSS result despite their claims that this was the case (author’s unpublished 
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observation).  It may be argued that none of the investigators in ICSS had sufficient 
experience.  Suggested requirements to achieve technical competence to perform carotid 
artery stenting range from ten supervised carotid stenting procedures to at least 75 
supervised carotid stenting procedures with a minimum of 50 procedures per year to 
maintain competence (Barr et al. 2003; Rosenfield et al. 2005; Cremonesi et al. 2006).  It has 
been suggested that it may take active carotid artery stenting units up to 2 years before 
the stroke/death rates fall below 5% (Smout et al.).  It is questionable that prospective 
stenters should practise on patients to gain the necessary experience when surgeons 
achieve better results with less experience. 
13.4 Scope for Further Research 
The need for careful patient selection has been emphasised.  Currently, the decisions to 
treat are based on rather crude instruments.  The main points taken into consideration are 
the time since symptoms and the degree of stenosis.  Evidence from coronary artery 
disease and carotid research suggests that the risk of stroke associated with carotid 
disease is determined by more than just the degree of stenosis.  This presents an avenue 
for future research and researchers have been successful in linking plaque pathology and 
stroke.  Jonathan Gillard’s group in Cambridge have contributed a large body of work 
using various imaging modalities of carotid plaque (U-King-Im et al. 2004; Tang et al. 
2008; U-King-Im et al. 2008; Patterson et al. 2009; Sadat et al. 2009; Tang et al. 2009).  Their 
work adds to findings of other investigators that different plaque components contribute 
to the plaque’s stability, correspond to histological findings and are associated with 
stroke (Spagnoli et al. 2004; Ouhlous et al. 2005; Clarke et al. 2006; Redgrave et al. 2006). 
Researchers are only in recent years beginning to understand the significance of very 
small areas of bleeding in the brain that can be picked up by special MRI techniques 
(microbleeds).  They are thought to be associated with stroke (Werring et al. 2004; 
Werring et al. 2005; Werring 2007; Gregoire et al. 2010) and may increase the procedural 
risk of stenting and carotid endarterectomy.  Further research in this field may help to 
improve the safety of invasive carotid treatment. 
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Improving the safety of carotid endarterectomy and stenting is only one side of the 
medal, though.  Given that carotid endarterectomy was established as the treatment of 
choice at a time when medical treatment of cerebrovascular risk factors was still in its 
infancy, the question if invasive treatment is superior to current medical therapy at all 
remains. An exploratory study has been set up to compare carotid endarterectomy to 
modern conservative medical therapy of carotid stenosis and should shed light on this 
question. 
While extensive research has been carried out in the field of carotid artery stenosis, many 
questions surrounding prevention of stroke and treatment of carotid artery stenosis 
remain to be answered and many avenues for future research still exist. 
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Appendix 1 – CAVATAS collaborators 
Centres randomising patients with carotid stenosis between surgery and endovascular 
treatment and individual investigators. Centres marked with an asterisk (*) also randomised 
patients between endovascular treatment and medical care in CAVATAS-MED. 
Australia 
*Austin and Repatriation Medical Centre, Heidelberg: CF Bladin, GA Donnan, G Fell, G 
Fitt, J Royle 
Royal Melbourne Hospital: S Davis, R Gerraty, P Mitchell 
*Royal Perth Hospital: MA Goodman, GJ Hankey, MS Khangure, MM Lawrence-Brown, 
J Linto, W McAuliffe, FJ Prendergast, K Siennarine, EG Stewart-Wynne 
Canada 
*Ottowa General Hospital: S Grahovac, W Morrish, N Pageau, CE Pringle, DM Richard 
Finland 
*Kuopio University Hospital: H Manninen, J Sivenius, T Saari 
Germany 
Heinrich Heine University, Düsseldorf: J Malms, L Reiher, M Siebler 
Italy 
*Policlinico St Marco, Bergamo-Zingonia: G Belloni, M Porta 
Spain 
*Hospital Clinic I Provincial, Barcelona: A Chamorro, N Vila, V Riambau, F Vazquez 
Hospital Universitario Virgen del Rocio, Sevilla: F Boza, JL Garcia Rodríguez, A Gil 
Peralta, A González, JR González Marcos, A Mayol Deya J Rauno 
Switzerland 
*University Hospital, Basel: EC Kirsch, PA Lyrer, JA Rem 
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Centre Hospitalier Universitaire Vaudois, Lausanne: J Bogousslavsky, A Uske 
United Kingdom 
*Royal Hallamshire and Northern General Hospitals, Sheffield: JD Beard, TJ Cleveland, 
C Doyle, PA Gaines, A Sivaguru, GS Venables 
*Atkinson Morley’s and St George’s Hospitals, London: MM Brown, T Buckenham, A 
Clifton, D Colquhoun, F Crawley, PW Leopold, T Loosemore, DJH McCabe, A 
Pereira, J Rogers, R S Taylor 
*The Walton Centre, Liverpool: TP Enevoldson, G Gilling-Smith, P Harris, T Nixon 
King’s College, London: P Baskerville, T Cox, S Fraser, M Jeffrey, H Markus, J Molloy 
Royal London, London: P Butler, J Dick, F Frankel 
*Western General Hospital, Edinburgh: A Bradbury, D Collie, JA Murie, CV Ruckley, 
PAG Sandercock, D Schultz, R J Sellar, J Wardlaw 
Withington Hospital, Manchester: RJ Ashleigh, CN McCollum, P O’Neill 
Newcastle General Hospital: A Gholkar, AD Mendelow , TJ Walls 
University Hospital of Wales, Cardiff: H Angus-Leppan, S Halpin, J Hughes, I Lane, M 
Wiles, AM Wood 
Gloucestershire Royal Hospital: PA Birch, JJ Earnshaw, GN Fuller, B Heather, K Poskitt, 
AJ Tottle 
*Queen’s Medical Centre, Nottingham: DT Hope, D Jefferson, N McConachie 
Queen Elizabeth Neuroscience Centre, Birmingham: M Duddy, MTE Heafield, RK 
Vohra
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Appendix 2 – The Carotid and Vertebral Artery Transluminal 
Angioplasty Study Protocol1 
Protocol Summary 
Introduction: One of the major preventable causes of stroke is thromboembolism from 
stenosis of the carotid or vertebral arteries. Clinical trials have shown that carotid surgery 
is a benefit in preventing further strokes in patients with recently symptomatic severe 
carotid stenosis. However, surgery also carries a significant morbidity. Percutaneous 
transluminal angioplasty (PTA) has become an established treatment for coronary and 
peripheral vascular disease. Preliminary results suggest that PTA of carotid and vertebral 
stenosis also has an acceptable complication rate and may provide an alternative to 
surgery. PTA typically requires only a short hospital stay and has the advantage of 
avoiding the risks of general anaesthesia as well as the discomfort and cost of surgery. 
The Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) is an 
international multicentre randomised trial, which has been established to evaluate 
angioplasty in patients with cerebrovascular disease. 
Aims:  1)  To determine the risks and benefits of carotid and vertebral angioplasty. 
2) To compare the risks and benefits of carotid and vertebral angioplasty 
with surgical treatment in patients who are eligible for surgery or best 
medical treatment alone in patients ineligible for surgery. 
Centre Requirements: A neurologist with an interest in cerebrovascular diseases: a 
vascular surgeon or neurosurgeon with expertise in carotid endarterectomy: a radiologist 
with training in neuroradiology and the techniques of angioplasty. (Prior experience of 
carotid or vertebral angioplasty is not required as this will be an entirely new procedure 
at most centres) 
Inclusion Criteria: Stenosis of the internal or common carotid or vertebral artery suitable 
for percutaneous transluminal balloon dilation and/or stenting. Patients also suitable for 
surgery are randomised between angioplasty and surgery. Patients unsuitable for 
surgery are randomised between percutaneous transluminal techniques and medical 
                                                           
1 The CAVATAS protocol (September 1996) is reproduced in an abridged version 
in this thesis. 
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treatment alone. All patients have the best medical treatment, whatever their 
randomisation group. The majority of patients should have relevant symptoms with six 
months but asymptomatic patients may be randomised if treatment is considered 
appropriate. 
Grey Area: Individual centres need only randomise patients in their own "grey area" eg 
an individual centre might only randomise patients not fit for surgery between 
angioplasty and medical treatment, or only patients with vertebral artery stenosis. 
Randomisation: Randomisation is by a simple telephone call to the randomisation centre 
at the Clinical Trials Unit, Oxford. Randomisation is stratified within each centre and 
balanced within the treatment groups. 
Angioplasty Protocol: Angioplasty will be carried out by percutaneous transluminal 
interventional techniques, including the use of balloon dilation catheters and/or stents. 
Patients will be pre treated with an antiplatelet agent and anticoagulated with heparin 
during the procedure and for a minimum of 24 hours afterwards. An antiplatelet agent 
will be continued throughout the follow up. 
Follow-up: Patients will be followed up at one month, six months and then at yearly 
intervals to determine the incidence of stroke and death. Where possible, patients will be 
followed up using ultrasound and/or angiography to determine the rate of restenosis. 
Trial Organisation: The trial is organised on behalf of the collaborators by the central 
office at St George's Hospital Medical School, University of London. A distinguished 
monitoring committee have been established. 
Funding: The British Heart Foundation has supported the initial period of the study. 
From June 1994 CAVATAS will be funded for a period of 3 years by the National Health 
Service Executive Research & Development Programme on Cardiovascular Disease and 
Stroke. 
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Background 
Carotid artery stenosis and stroke: Stroke is an important cause of death and disability. 
Considerable effort has therefore been focused on identifying the causes of stroke with a 
view to preventive treatment. Atheromatous disease of the carotid and vertebral arteries 
is an important cause of ischaemic strokes, most of which result from embolism of 
thrombus formed on ulcers or stenosis to more distal branches. The mechanisms 
involved in thrombus formation at these sites are uncertain, but the risks are partly 
proportional to the degree of stenosis, the presence of ulceration and possibly the 
occurrence of haemorrhage within the atheromatous plaque,1 A smaller proportion of 
strokes may result from haemodynamic ischaemia distal to severe arterial stenosis or 
occlusion. In younger patients other causes of arterial stenosis, such as fibromuscular 
dysplasia or dissection may be relevant. 
Many strokes occur unheralded, but about 20% are proceeded by transient ischaemic 
attacks (TIA) or minor strokes which recover without significant disability. These events 
provide the opportunity for therapeutic intervention if stenosis is detected, to prevent a 
further catastrophic major stroke. The risk of stroke following a TIA is about 8% in the 
first year and then 5% per annum,2 but in patients with severe carotid stenosis the risk in 
medically treated patients increases to as high as 28% over 2 years3. 
There is a strong association between carotid atherosclerosis and cardiovascular disease, 
particularly coronary heart disease4. Asymptomatic carotid stenosis may therefore also be 
detected during the course of routine screening of patients with ischaemic heart disease 
or peripheral vascular disease. The risks of stroke occurring in patients with carotid 
stenosis who have not had previous cerebrovascular symptoms are lower than patients 
who have had TIAs, other things being equal. In one study the annual risk of stroke in 
asymptomatic patients with severe carotid stenosis was 3.4%5. The published trials have 
not lent strong support to the policy of routine carotid surgery for asymptomatic 
stenosis6,7. Prophylactic surgical treatment is therefore not usually recommended in 
asymptomatic patients, at least in Europe, although the results of the ongoing 
asymptomatic carotid surgery trials in progress are awaited with interest. However, in 
patients with severe asymptomatic carotid stenosis, major surgery such as coronary 
artery bypass grafting, increases the risks of stroke at the time of surgery up to four times 
normal8. Treatment of severe asymptomatic carotid stenosis to reduce the risk of stroke 
can therefore be justified prior to coronary artery by pass or other major surgery. 
Conventional treatment of carotid artery stenosis: The optimum treatment of carotid 
artery stenosis is uncertain. Aspirin therapy is of undoubted benefit in patients who have 
had TIAs, but at best only prevents 25% of embolic strokes that would otherwise have 
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occurred and cannot be expected to prevent haemodynamic stroke9. Anticoagulation has 
not been shown to be of any greater benefit. Consequently, a considerable portion of 
strokes cannot be prevented by current medical treatment. Carotid endarterectomy 
therefore continues to be considered as an addition to medical therapy, with the aim of 
removing atheromatous sources of thrombo-embolism and/or improving cerebral 
perfusion pressure. Until recently the value of carotid endarterectomy was disputed, 
because of concern about the risks of the procedure10, 11. The reported rate of death or 
major stroke following carotid endarterectomy in earlier studies varied from 2% to 
21%,12,13 with an average combined mortality and stroke risk estimated at around 6%14. 
However, the recent results of the European Carotid Surgery Trial (ECST)15 and the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET)3 have 
convincingly demonstrated the benefits of carotid endarterectomy in preventing stroke in 
medically fit patients with carotid stenosis of greater than 70%. The ECST also showed 
that surgery confers no significant benefit if the stenosis is less than 30%, but the value of 
surgery remains uncertain in patients with stenosis of between 30 and 69%. Despite the 
overall benefits of carotid endarterectomy in the ECST there was still a significant risk of 
stroke or death resulting from surgery of 7.5%. Carotid endarterectomy also risks 
significant morbidity from myocardial infarction, particularly in patients who have 
ischaemic heart disease or severe hypertension16. There are also anaesthetic hazards, such 
as pulmonary embolism, and minor morbidity from the surgical incision, such as cranial 
nerve palsyl3. A disadvantage of surgery in the UK is that treatment may be delayed by 
several weeks, during which time a devastating stroke may occur. 
Vertebral artery stenosis and stroke: A significant percentage of strokes within the 
vertebro-basilar territory result from vertebral artery stenosis or occlusion. Surgery is 
rarely considered for vertebral artery disease because of its technical difficulty, but some 
cases appear to be ideal candidates for PTA17. The natural history of vertebral artery 
stenosis and the value of PTA at this site are uncertain and therefore warrant further 
study. 
Percutaneous angioplasty: Following the introduction of percutaneous transluminal 
angioplasty (PTA) by Dotter and Judkins in 1964, PTA has become established in the 
treatment of peripheral, renal and coronary vascular disease. The success rate in these 
situations approaches 90%, with serious complications occurring in less than 5% of 
procedures18,19. PTA has the advantage that the procedure is brief, does not require a 
surgical incision and can be performed under local anaesthesia. It was therefore logical to 
extend the procedure to the carotid arteries, but initially this was not recommended 
because of anxiety about the risks of cerebral embolism resulting from the procedure19,20. 
However, reports appeared of successful dilation of common carotid stenosis through an 
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arteriotomy2l and then by PTA22. Fibromuscular dysplasia of the internal carotid artery 
and of other brachiocephalic arteries was also successfully treated by PTA22-26. With 
increasing experience, several case reports and series of PTA for atherosclerotic stenosis 
of the internal carotid have appeared, suggesting that the procedure might be safer than 
previously suggested (see Table). By 1995 a total of 447 patients with atherosclerotic 
internal carotid stenosis and a smaller number with vertebral artery stenosis treated by 
PTA have been reported, with an observed stroke rate associated with the procedure of 
less than 5%27-41. The precise risks of the carotid PTA are as yet undefined, but this 
preliminary experience suggests that the risks of stroke are comparable to those of 
carotid endarterectomy. 
Potential hazards of PTA: 
• Cerebral embolism due to dislodgement of atheromatous material or thrombus 
from the vessel wall is the most serious risk of PTA. The risk of embolisation may 
be reduced by avoiding patients with angiographic evidence of thrombus within 
the artery, by pre-treatment with Aspirin and by anticoagulation at the time of 
the procedure. Embolism or occlusion may also occur from thrombus formed on 
the damaged intima after PTA. Anticoagulation and/or antiplatelet agents 
should therefore be continued after the procedure. 
• Haemodynamic cerebral ischaemia may occur during the temporary occlusion of 
the internal carotid artery by the inflated balloon. Cerebral damage from 
haemodynamic ischaemia can be avoided by limiting the period of balloon 
inflation to a maximum of 40 seconds. In selected cases, the fall in perfusion 
pressure can be minimised by injecting oxygenated arterial blood through the 
lumen of the catheter during balloon inflation. 
• Contrast reactions. 
• Haemorrhage and/or pseudo-aneurysm formation at the arterial puncture site. 
• Reflex bradycardia and hypotension may result from the inflation of the balloon 
in the region of the carotid sinus. This can be controlled by Atropine therapy. 
• A reflex local arterial spasm may occasionally be induced by stretching the 
carotid artery. This can be controlled by a local infusion of an appropriate 
pharmacological agent. 
• Transient neck pain and ipsilateral frontal headache occur occasionally and may 
be the result of stretching of the carotid artery. 
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• Arterial rupture may occur. This is very uncommon. 
The mechanism by which PTA results in an increase in vessel diameter involves the 
development of splits in the intima and plaque, and sometimes in the underlying media. 
Arterial dissection in some cases is therefore an inevitable consequence of successful 
PTA, but is usually limited to the area of balloon dilation. 
Restenosis is a well-recognised disadvantage of PTA at other sites where symptoms such 
as angina are caused by a reduction in flow. However, restenosis may not be so 
disadvantageous after carotid or vertebral PTA unless it leads to emboli or complete 
occlusion. The preliminary results of carotid PTA suggest patency rates at I year of 
around 84%.35 Restenosis may possibly be prevented by the use of antiplatelet agents. 
Table summarising known risks of angioplasty for atheromatous carotid artery 
stenosis  
 N Minor non-disabling Stroke Major Stroke 
Bockenheimer & Mathias 198327 3 0 0 
Wiggli & Gratzl 198328 2 0 0 
Tsai et al 198629 6 0 0 
Freitag et al 198731 11 0 0 
Theron et al 199033 13 0 0 
Kachel et al 199134 37 0 0 
Munari et al 199235 44 3 1 
Eckert et al 199436 53 0 1 
Mathias 199437 166 1  
Gil-Peralta 199538 62 0 3 
Brown et al 199539 50 1 2 
TOTAL 447 5 
(1.1%) 
10 
(2.2%) 
 
Trial proposal: The preliminary experience suggests that PTA of the carotid and 
vertebral arteries is technically feasible and has considerable advantages over 
endarterectomy in terms of avoiding the risks of general anaesthesia and surgical 
incision. The incidence of cerebral embolism seems in the small series to date comparable 
with that of carotid endarterectomy and possibly better. PTA also has major advantages 
over endarterectomy in terms of resource allocation and patient comfort. The procedure 
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is technically simple and there is immediate ascertainment of any neurological 
complications since the patient remains conscious throughout. In addition, PTA provides 
an option for the treatment of patients who are not fit for surgery. 
Encouraged by these preliminary results, a formal international multi centre scientific 
prospective randomised trial of carotid and vertebral artery percutaneous transluminal 
angioplasty (CAVATAS) has been established with a defined protocol to determine more 
fully the success rate, risks, benefits, and indications for the procedure. To demonstrate a 
benefit, careful investigation and selection of patients before the procedure and non-
invasive investigation during follow up will be essential. If the low complication rate is 
confirmed, PTA will provide a valuable new therapy for the management of 
cerebrovascular disease. 
Aims of CAVATAS 
1. To determine the risks and benefits of carotid and vertebral angioplasty. 
2. To compare the risks and benefits of carotid and vertebral angioplasty with 
surgical treatment in patients eligible for surgery or best medical treatment alone 
in patients ineligible for surgery. 
Secondary aims are: 
1. To evaluate the use of different guide wires, predilation and dilation catheters, 
including cerebral protection balloons and the use of stents. 
2. To identify risk factors for angioplasty and surgery, e.g. calcified plaques. 
3. To determine the recurrence rate of stenosis following angioplasty and surgery. 
Protocol of Investigation 
Central Office: The study will be organised on behalf of the collaborators by a central 
office at St George's Hospital Medical School, University of London. The central office 
will be responsible for protocol design, data collection and analysis of the results but will 
consult with the collaborators at the annual investigators meeting and as necessary at 
other times. 
Participating Centre Requirements: Patients entered into the study will be seen prior to 
randomisation and during follow up by a designated neurologist or physician with an 
interest in cerebrovascular disease. Centres randomising to carotid endarterectomy will 
have a designated vascular surgeon or neurosurgeon with expertise in carotid 
endarterectomy, available to assess eligibility and who will personally carry out all the 
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carotid endarterectomy operations within the study. PTA will be carried out by a 
designated radiologist of consultant status, who has had training in neuroradiology and 
the techniques of angioplasty. (Prior experience of cerebrovascular angioplasty is not 
required as this will be an entirely new procedure at most new centres). Participating 
centres will be required to submit curriculum vitaes of the principal investigators and 
satisfy the credentials subcommittee that they have appropriate experience and expertise 
to join the study. New centres will be encouraged to obtain training in cerebrovascular 
PTA techniques at one of the active CAVATAS centres and will be requested to invite 
one of the radiologists from an experienced centre to attend the first few PTA procedures 
at the new centre. 
Inclusion criteria: Patients will be eligible for inclusion in the study if angiography 
demonstrates unilateral or bilateral stenosis of the common carotid artery, carotid 
bifurcation, external carotid artery, internal carotid artery or extracranial vertebral artery 
considered suitable for percutaneous transluminal balloon dilation and/or stenting. 
Patient groups: Two groups of patients will be studied and randomised separately: 
1. Patients eligible for surgery: Patients with carotid or vertebral artery stenosis, 
which the clinician and the patient would be happy to treat by either surgery or 
percutaneous transluminal techniques.  
Patients eligible for surgery will be randomised in equal numbers to surgery or 
angioplasty. 
2. Patients ineligible for surgery: Patients considered inappropriate candidates for 
surgery with carotid or vertebral stenosis, which the clinician and the patient 
would be happy to treat by percutaneous transluminal angioplasty or medical 
treatment. 
Patients ineligible for surgery will be randomised in equal numbers to 
angioplasty or best medical treatment alone. 
All the patients randomised to interventional treatment will have the best medical 
treatment in addition to PTA or surgery, which should include control of hypertension, 
diabetes and hypercholesterolaemia, and an antiplatelet agent or anticoagulant as 
appropriate. 
Grey area: Patients should only be randomised if the investigator is uncertain which of 
the alternatives is the best treatment for that patient at that time. Individual centres need 
only randomise patients in their own "grey area". This allows centres to only randomise 
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patients who they are happy to treat by angioplasty. In an individual centre this might 
mean only randomising patients who were not fit for surgery between angioplasty and 
medical treatment or in another centre only vertebral artery disease. Each centre will 
provide a written policy statement defining their grey area. 
Angiographic features: Suitability for PTA will be a matter for individual judgement by 
the collaborating radiologists, but guidelines will be issued during the course of the 
study if any particularly high risk factors emerge. At least 30% linear diameter stenosis 
should be present. Stenosis due to atherosclerosis, fibromuscular dysplasia, webs or post 
surgical fibrosis may be included. 
Eligibility for carotid endarterectomy: 
Severe carotid stenosis: Following the results of the ECST and NASCET otherwise fit 
patients with appropriate symptoms or signs and 70% or greater carotid stenosis 
(using the ECST criteria) will normally be randomised between surgery and PTA 
in group I if an experienced vascular surgeon is available. If no suitable surgeon is 
available or the patient refuses surgery, then patients with severe stenosis can be 
randomised between PTA and medical treatment in Group 2. 
Moderate carotid stenosis: The benefits of carotid endarterectomy remain uncertain in 
patients with moderate stenosis of between 30 and 69%. Patients with moderate 
stenosis considered suitable for surgery can be randomised within CAVATAS 
between surgery and PTA. If a patient with moderate stenosis is considered 
ineligible for surgery but the investigator is uncertain whether PTA or medicine 
alone would be the best treatment for the patient, then the patient should be 
randomised between PTA and medicine. 
Ineligibility for surgery: Patients randomised between PTA and medicine may include: 
(a) patients at high risk from surgery because of ischaemic heart disease, poorly 
controlled hypertension, liver disease, decompensated diabetes mellitus or other 
medical risk factor. 
(b) patients with anatomical factors making surgery difficult or impossible, such as a 
high site of carotid stenosis or a rigid neck or inaccessible vertebral artery stenosis. 
(c) patients refusing surgery. 
Symptoms: It is anticipated that the majority of the patients considered for PTA will have 
had appropriate cerebrovascular symptoms or signs of embolic and haemodynamic 
cerebral ischaemia within 6 months of randomisation. However, asymptomatic patients 
310 
or patients with more distant symptoms may be randomised if intervention is considered 
appropriate by the Clinician, e.g. major surgery, such as cardiac by pass, is planned. 
Patients with recent symptoms will be randomised separately asymptomatic patients. 
Disease of more than one artery: Patients who, at the time of randomisation, or 
subsequently, develop indications for treatment of more than one carotid or vertebral 
artery, may have more than one artery treated if clinically indicated as follows: 
If two or more arteries are suitable for PTA, the patient should be randomised for 
the artery, which is to be treated first. All the arteries to be treated at the same time 
or subsequently should then receive the same treatment (PTA, surgery or medical 
treatment alone) allocated by randomisation. 
If only one artery is suitable for PTA and this artery requires treatment first, 
then the patient should be randomised first. After treatment of this artery as 
randomised, the patient may have surgical treatment of other arteries not suitable 
for PTA. 
If the artery to be treated first is only suitable for surgery and is not suitable for 
PTA, surgery should be carried out first and the patient randomised between PTA 
and surgery (or medical treatment alone) for the second artery when the patient is 
fit for the second procedure. 
As a general principle, patients can only be randomised in the study once. 
Exclusion criteria: The following will be absolute exclusion criteria: 
1. Unwilling or unable to give informed consent. 
2. Thrombus present on preliminary angiography. 
3. Major stroke with no useful recovery of function within the territory of the 
treatable artery. 
4. Intracranial stenosis beyond the skull base. 
5. Stenosis unsuitable for PTA or stenting. 
Non-randomised patients: Each centre will provide baseline data and the reason for non-
randomisation on all patients who are under the care of a collaborating clinician and 
receive carotid surgery or PTA outside the trial at that centre 
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Consent: Written witnessed informed consent will be obtained from all patients, who 
will be given a written explanation of the study and its aims. 
Age range: Not specified. 
General investigations: All patients should have routine haematology (FBC, platelets) 
and biochemical blood tests, (renal function, blood sugar, cholesterol), ECG, chest x ray 
and cranial CT or MRI scan prior to randomisation. In appropriate symptomatic patients, 
echocardiography should be performed to detect cardiac sources of emboli. 
Ultrasound Doppler imaging: Where possible, linear measurements of vessel diameter 
and peak systolic flow will be recorded and the morphology and degree of calcification of 
the stenosing atheromatous plaque assessed using ultrasound Doppler imaging prior to 
randomisation and during follow up to allow the anatomical results and patency rates to 
be compared. 
All patients randomised for accessible carotid stenosis will have ultrasound 
measurements to assess patency at one year as a minimum and then at yearly intervals if 
possible. The same standardised ultrasound criteria circulated by the Central Office will 
be used at all centres to assess the degree of stenosis. 
Cerebrovascular reactivity: In centres where transcranial Doppler is available, 
cerebrovascular reactivity may be recorded by measuring the increase in the velocity of 
blood flow occurring during the inhalation of carbon dioxide in both middle cerebral 
arteries before and after treatment, but is not essential to the protocol. 
Angiography: Bilateral selective carotid or vertebral angiography (DSA) will be 
performed prior to randomisation to confirm the suitability of the lesion for carotid 
endarterectomy and/or PTA and to detect significant disease distal to the carotid 
bifurcation or vertebral artery. At least two views of the diseased area should be taken. 
Angiography will be carried out to assess the success of the PTA at 6 to 12 months after 
the procedure in selected centres. Individual centres may randomise carotid patients after 
magnetic resonance angiography (MRA) or intravenous DSA and duplex ultrasound 
without conventional angiography if both investigations agree by arrangement with the 
central CAVATAS Office and the centre has been able to demonstrate the accuracy of 
their ultrasound by audit. Patients randomised to PTA after MRA and ultrasound alone 
in whom preliminary angiography as part of the PTA procedure demonstrates a lesion 
unsuitable for PTA may cross over to surgery or medicine as appropriate. If MRA and 
ultrasound results differ in an individual patient then DSA should be performed prior to 
randomisation. 
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Randomisation: Patients will be randomised by a telephone call to the randomisation 
centre at the Clinical Trials Unit, Oxford. The telephone call to the randomisation centre 
may be made from the angiography suite in appropriate cases if prior consent has been 
obtained and if it is desired to proceed immediately to PTA at the same session if 
randomised. Alternatively, the investigators may wish to discuss the angiograms to 
confirm the appropriateness of the lesion for surgery and/or PTA prior to randomisation, 
in which case PTA can be carried out at a separate session if so randomised. In any case, 
the allocated treatment should be instituted as soon as practical after randomisation. 
Randomisation between the different groups will be balanced within each Centre. 
Angioplasty protocol: Angioplasty will be carried out using percutaneous transluminal 
interventional techniques, including the use of balloon dilation and/or stents. Where 
appropriate cerebral protection catheters may be used at individual centres, but are not 
required by the protocol. Details of the technique and catheter design will be left to the 
preference of individual participating radiologists to allow flexibility according to 
individual preference and variation in arterial anatomy. Stents may be used at the 
discretion of the individual radiologist. Premedication, atropine and the use of local 
anaesthetic will be discretionary. As a guide, maximum balloon diameter when inflated 
should not exceed the estimated normal arterial diameter. Hand held inflation without 
monitoring of pressure is acceptable. Continuous infusion of oxygenated blood through a 
central catheter lumen during balloon inflation may be used during the treatment of 
patients with severe bilateral disease or severely impaired haemodynamic reserve, if 
measured. The number of balloon inflations will normally be limited to a maximum of 3 
and the duration of individual inflation limited to a maximum of 30 seconds, to minimize 
haemodynamic cerebral ischaemia. Two catheters (the second inserted into the common 
carotid artery to enable visualisation of the stenosis after angioplasty) may be used. 
Anticoagulation regime: All patients randomised to PTA will be pre treated with Aspirin 
(minimum dose 150 mg) or an alternative anti platelet agent if preferred for at least 24 
hours prior to PTA. Immediately prior to balloon inflation, the patients will be anti 
coagulated with intra arterial or intravenous Heparin, 5000 units, (or Warfarin continued 
if already anti-coagulated). Anti-coagulation will be continued for a minimum of 24 
hours after PTA, unless contraindicated. Aspirin or an alternative anti platelet agent will 
then be continued throughout the period of follow up. 
Monitoring: During the procedure simple neurological examination will be repeated, as 
frequently during PTA as practical during the procedure. This can be performed by any 
trained member of staff, e.g. radiology nurse, and should comprise assessment of at least 
speech and limb movement. The value of continuous monitoring of cerebral blood flow 
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in the middle cerebral artery ipsilateral to the procedure using transcranial Doppler 
sonography will be assessed during the study, but is not essential to the protocol. ECG 
and BP will also be monitored. 
Follow up: Patients will be carefully followed up by a neurologist or physician to record 
the presence of new symptoms and neurological signs at one month after procedure or 
randomisation if randomised to medical care, and then at six months, one year and then 
yearly intervals after randomisation for at least 5 years. Follow up CT or MRI should be 
performed in patients who have new neurological symptoms. In individual centres, 
ultrasound and/or angiography will be carried out at 12 months after randomisation in 
all angioplasty patients to assess patency rates. (see above) 
Restenosis: Restenosis will only be treated by further PTA or surgery if the patient has 
relevant new symptoms. Asymptomatic restenosis will not be an indication to retreat the 
lesion as the risk of disabling symptoms after restenosis is unknown. 
Cross-overs: Patients who have further symptoms after technically successful PI'A will 
have the option of further PTA, anticoagulation or cross over to surgery if significant 
carotid stenosis is present on further investigation. Cross-overs to surgery and 
angioplasty will be avoided unless clinically essential. Patients ineligible for surgery 
allocated to medical treatment, who have further symptoms after randomization will 
have the option of anticoagulation or cross over to PTA if anticoagulation is not effective, 
but cross over in this Group will be avoided if possible. Patients in whom PTA fails to 
dilate the artery for technical reasons will have the option of proceeding to early surgery 
if appropriate. 
Analysis: The results in symptomatic patients with carotid and vertebral artery disease 
will be analysed separately, as will the results in patients eligible or ineligible for surgery. 
Results will be analysed by decade of severity of stenosis. The following will be analysed 
both immediately after PTA and during the follow up period: 
1. Risks of PTA: Complications and neurological symptoms, including TIAS, 
stroke and death occurring during and within 30 days after the procedure. The 
primary analysis will assess the rates of ipsilateral disabling stroke or death 
within 30 days of treatment. Disabling stroke will be defined as "needing help as 
a result of the stroke from another person to perform everyday activities" lasting 
for 30 days or more after the onset of stroke. 
2. Clinical Benefits: Period after randomisation free of disabling stroke or death.  
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3. Anatomical Benefits: Alteration in luminal diameter, blood flow velocity, 
cerebrovascular reactivity, flow characteristics and plaque morphology, where 
measured. 
4. Statistical Analysis: The main statistical comparisons will be made between the 
primary event rates of disabling stroke and/or death in patients randomised to 
surgery, PTA or medical treatment alone. Sub group analysis will compare 
patients eligible with those ineligible for surgery, recently symptomatic and 
asymptomatic (or distantly symptomatic) patients and different degrees of 
stenosis. 
Analysis of crossovers will be by intention to treat. A separate efficacy analysis will be 
carried out on patients who have had successful angioplasty. 
Recruitment Numbers: The study plans to recruit a total of 400 symptomatic patients 
with carotid artery disease (approximately 200 of whom should have received PTA). An 
analysis will be published at this stage. At current recruitment rates we predict that 
recruitment of 400 patients will have be achieved by the summer of 1997. 
Monitoring Committee: The Monitoring Committee will assess the progress of the study 
at regular intervals and consist of an independent neurologist, medical statistician and 
one other member. During the period of intake to the study, interim analyses of mortality 
and of any other information that is available on major endpoints (including serious 
adverse events believed to be due to treatment) will be supplied, in strict confidence, to 
the chairman of the Data Monitoring Committee, along with any other analyses that the 
Committee may request. In the light of these analyses, the Data Monitoring Committee 
will advise the chairman of the Steering Committee if, in their view, the randomised 
comparisons in CAVATAS have provided both (i) "proof beyond reasonable doubt" that 
for all, or for some, specific types of patients, one particular treatment is clearly indicated 
or clearly contraindicated in terms of a net difference in outcome, and (ii) evidence that 
might reasonably be expected to influence materially patient management. Appropriate 
criteria of proof beyond reasonable doubt cannot be specified precisely, but a difference 
of at least 3 standard deviations in an interim analysis of a major endpoint may be 
needed to justify halting, or modifying, the study prematurely. This criterion has the 
practical advantage that the exact number of interim analyses is of little importance, and 
so no fixed schedule is proposed. 
Publication: Individual participating centres may report their own technical experience 
of angioplasty during the study, but should not identify individual patients randomised 
in CAVATAS and should not make direct comparison with the results in patients 
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randomised to surgery or medicine. Copies of any abstracts or articles including data 
from patients in CAVATAS should be sent to the Central Office. Publication of the results 
of CAVATAS will be prepared by the Central Office and circulated to participating 
centres for comment prior to submission of the manuscript for publication under the 
authorship of all the CAVATAS collaborators. 
Funding: The British Heart Foundation has supported the initial period of the study. 
From June 1994 CAVATAS will be funded for a period of 3 years by the National Health 
Service Executive Research & Development Programme on Cardiovascular Disease and 
Stroke. 
Ethical Committee Approval and Indemnity: 
Individual centres are expected to obtain local ethical committee approval for the study. 
If the local ethics committee approves the study and the patient agrees to enter the study 
after reading the patient information sheet (which explains the risk of stroke) and signs 
the consent form, then the study in the United Kingdom should be protected by the 
National Health Service indemnity which should defend the collaborators against 
allegations of negligence. In overseas centres it is hoped that a collaborator's own 
malpractice insurance policy, or that of his institution, would provide cover on the same 
basis. We are not able to provide no fault compensation for a patient who has a stroke or 
other mishap as a result of angioplasty or surgery in the trial as we believe that such 
events are equally likely to happen to eligible patients if they are treated outside the trial. 
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Appendix 3 – Cochrane Search Strategy 
1. carotid artery diseases/ or carotid artery thrombosis/ or carotid stenosis/ 
2. carotid arteries/ or carotid artery, common/ or carotid artery, external/ or carotid 
artery, internal/ 
3. constriction, pathologic/ 
4. 2 and 3 
5. (carotid adj5 (stenosis or thrombo$ or disease$ or narrow$ or plaque$ or arterioscler$ 
or atheroscler$)).tw. 
6. 1 or 4 or 5 
7. angioplasty/ or angioplasty, balloon/ or angioplasty, balloon, Laser-assisted/ 
8. Balloon Dilatation/ 
9. Stents/ 
10. (angioplasty or stent$ or endovascular).tw. 
11. (balloon adj5 (dilat$ or catheter$)).tw. 
12. ((endoluminal or transluminal) adj5 repair$).tw. 
13. 7 or 8 or 9 or 10 or 11 or 12 
14. 6 and 13 
15. Randomized Controlled Trials/ 
16. random allocation/ 
17. Controlled Clinical Trials/ 
18. control groups/ 
19. clinical trials/ or clinical trials, phase i/ or clinical trials, phase ii/ or clinical trials, 
phase iv/ 
20. double-blind method/ 
21. single-blind method/ 
22. Therapies, Investigations/ 
23. Research Design/ 
24. Randomized controlled trial.pt. 
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25. Controlled clinical trial.pt. 
26. clinical trial.pt 
27. random$.tw. 
28. (controlled adj5 (trial$ or stud$)).tw. 
29. (clinical$ adj5 trial$).tw 
30. ((control or treatment or experiment$ or intervention or surgical) adj5 (group$ or 
subject$ or patient$)).tw. 
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw. 
32. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or 
manage$)).tw. 
33. (singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$).tw. 
34. (coin adj5 (flip or flipped or toss$)).tw. 
35. latin square.tw. 
36. versus.tw. 
37. controls.tw. 
38. or/15-37 
39. 14 and 38 
40. limit 39 to humans 
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Appendix 3 – Odds Ratios for the Outcome Measures Chosen In the 
Cochrane Review Calculated With the Random Effects Model 
The ends of the lines are the 95% confidence intervals (CI). The analyses are based on 
published results. The large diamond represents the odds ratio and 95% CI of the 
combined data. The summary estimate statistic is calculated using a Mantel-Haenszel 
random effects model, the centre of the diamond is the point estimate and its width the 
95% CI. The χ2 test indicates the strength of evidence for heterogeneity. N is the total 
number of patients in each treatment group and n is the number of outcome events. Df 
indicates the degrees of freedom. 
Figure 14.1 – Cochrane Review: Meta-analysis of death or any stroke within 30 days after treatment 
(random effects model) 
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Figure 14.2 – Cochrane Review: Meta-analysis of disabling stroke or death within 30 days after treatment 
(random effects model) 
 
Figure 14.3 – Cochrane Review: Meta-analysis of death within 30 days after treatment (random effects 
model) 
!"#$% &'$()*+,#-*.
'/0
!#.12,*-
'/0
3$$+45*"2(46.*'$(78
9:4;4<=
>?21@"
6;8
3$$+45*"2(46.*'$(78
9:4;4<=
ABAC ABC C CA CAA
D?2,?+"?.4C99E !"# !$"%&'($")#*'%%+"&,-,.!! $.!%
<FGFHF!4IAAC %&", !"$/'($"+%*'%",,-!0.%+% !+.%+,
J?'"#,K%46+%7L"B84IAAC !"0 $",!'($"$!*'#"&$-$.+, !.+!
1234'567'82427692:2;4<'=8;>3?@A72'B'+"!0*'C5'B'#*'D'B'$")$'
1234'567'6E27AFF'2552=4'G'B'$"/0*'D'B'$")$
!FMMN=5&4IAAO !$") $"+0'($"!0*'!"&+-).!0# #.!0#
PF<F!!4IAAQ $"$ :64'234;HAIF2$.!$ $.!$
!MF<&4IAAQ )+"0 !"%+'($"#!*'%"%%-%/.+&& %%.+/)
&GFRS!4IAAQ !!") %"%#'($"0&*'#")0-&.%0+ ).%0%
H("*-469:4;4<=8 CAABA CBIA4TABEAU4CBEAVQA/CS:W O9/CSS9
X*)(#.+4?'$()*+,#-*. X*)(#.+4+#.1?.%
!"#$% &'$()*+,#-*.
'/0
!#.12,*-
'/0
3$$+45*"2(46.*'$(78
9:4;4<=
>?21@"
6;8
3$$+45*"2(46.*'$(78
9:4;4<=
ABAC ABC C CA CAA
D?2,?+"?.4C99E !"! #$%&'(%)*+,-'!.// !./0
<FGFHF!4IAAC 10"2 /"34&5!"6/7&8"/693.060 :.061
J?'"#,K%46+%7L"B84IAAC :"2 !"1/&5!"!/7&3"2!9!.61 /.6/
;'(%&<$=&>'%'=$?'#')%@&A>)B(CD+='&E&0"037&F<&E&:7&G&E&!"82&
;'(%&<$=&$H'=+--&'<<'A%&I&E&!"!/7&G&E&/
!FMMN=5&4IAAO /3"1 !":2&5!"!27&0"3190./83 :./83
PF<F!!4IAAQ !"! #$%&'(%)*+,-'!./! !./!
!MF<&4IAAQ 02"/ /"00&5!"117&:"6396.622 :.64:
&GFRS!4IAAQ /6"3 !"88&5!"//7&1"2890.086 1.080
H("*-469:4;4<=8 CAABA CBAA4TABO9U4IBAOVCQ/CS:W CQ/CSS9
X*)(#.+4?'$()*+,#-*. X*)(#.+4+#.1?.%
324 
Figure 14.4 – Meta-analysis of stroke within 30 day after treatment (random effects model) 
 
Figure 14.5 – Cochrane Review: Meta-analysis of cranial neuropathy within 30 days after treatment 
(random effects model) 
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Figure 14.6 – Cochrane Review: Meta-analysis of death or neurological complications within 30 days after 
treatment (random effects model) 
 
Figure 14.7 – Cochrane Review: Meta-analysis of death or stroke or myocardial infarction within 30 days 
after treatment (random effects model) 
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Figure 14.8 – Cochrane Review: Meta-analysis of death, stroke, cranial neuropathy or myocardial 
infarction within 30 days after treatment (random effects model) 
 
Figure 14.9 – Cochrane Review: Meta-analysis of death or stroke during follow-up (random effects 
model) 
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Figure 14.10 – Cochrane Review: Meta-analysis of death occurring more than 30 days after treatment 
(random effects model) 
 
Figure 14.11 – Cochrane Review: Meta-analysos of stroke occurring more than 30 days after treatment 
(random effects model) 
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Figure 14.12 – Cochrane Review: Meta-analysis of protected versus unprotected endovascular treatment 
(random effects model) 
 
Figure 14.13 – Cochrane Review: Death or stroke occurring more than 30 days after endovascular 
treatment or randomisation (random effects model) 
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Appendix 5 – ICSS collaborators 
Centres randomising patients with carotid stenosis between surgery and stenting and 
individual investigators. Numbers in square brackets are patients randomised 
Australia  
Box Hill Hospital (Monash University), Melbourne [25]: C Bladin (Neurologist), Dr B 
Beiles, Dr G Fell, M Grigg (Surgeons), C Clifford (Surgeon and Interventionist), G 
New (Interventionist) 
Monash Medical Centre, Clayton [26]: PG Than, S Bower (Neurologists), M Holt, W 
Chong (Interventionists), R Bell, A Saunder (Surgeons) 
Repatriation General Hospital, Daw Park, Adelaide [6]: D Schultz (Neurologist), B 
Stanley, R Scroop (Interventionist), B Stanley (Surgeon and Interventionist), R 
Foreman (Surgeon) 
Austin Health, Heidelberg [46]: B Chambers, G Donnan, H Dewey (Neurologists) M 
Brooks, D Clark, M Molan (Interventionists), N Roberts (Surgeon and 
Interventionists), A Chan, M Hoare, G Fell, A Roberts, P Chu (Surgeons) 
The Royal Hobart Hospital, Hobart [18]: S Walker (Surgeon), D Stary, A Beasley 
(Interventionists), D Dunbabin (Stroke Physician) 
Royal Melbourne Hospital, Melbourne [57]: S Davies (Neurologist), N Atkinson, B 
Allard, W Cambell, P Field, P Milne (Surgeons), B Tress, P Mitchell, B Yan 
(Interventionists) 
Princess Alexandra Hospital, Brisbane [48]: T McGahan, A Wong (Neurologists), J Quinn 
M Ray, S Gett, P Woodruff (Surgeons), D Leggett (Interventionist)  
Belgium 
University Hospital Antwerp, Antwerp [10]: J Hendriks, P Cras (Neurologists), O 
d'Archambeau (Interventionist), P Van Schil (Surgeon) 
Imelda Ziekenhuis, Bonheiden [3]: L DeJaegher (Neurologist), P Peeters, J Verbist 
(Surgeons and Interventionists) 
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AZ Sint-Jan Brugge-Oostende, Campus Brugge, Brugges [18]: G Vanhooren 
(Neurologist), Jan De Letter (surgeon & Interventionist) 
Cliniques Universitaires St Luc, Bruxelles [1]: A Peters (Neurologist), V Lacroix, P 
Astarci (Surgeons), F Hammer, R Verhels 
AZ St Blasius, Dendermonde [5]: M Bosiers (Surgeon and Interventionist), E van 
Buggenhout (Neurologist), K Deloose (Surgeon and Interventionist) 
Canada 
Foothills Medical Centre, Calgary [4]: M Hill (Neurologist), W Morrish, M Hudion, W 
Hu (Interventionists), G Sutherland, J Wong (Surgeons) 
CHUM Notre-Dame Hospital, Montreal [30]: D Roy (Interventionist), S Lanthier, S 
Lanthier, N, Daneault, L-H Lebrun (Neurologist), A Weill, F Guilbert, J raymond, G 
Soulez, V Oliva, M-F Giroux, J-F Blair, JL Caron (Surgeons) 
Finland 
Helsinki University Central Hospital, Helsinki [33]: M Kaste (Neurologist), M Skalej 
(Interventionist), Z Halloul (Surgeon) 
Germany 
Otto von Guericke University, Magdeburg [9]: M Görtler (Neurologist), M Skalej 
(Interventionist), Z Halloul (Surgeon) 
Ireland 
Beaumant Hospital, Dublin [4]: J Moroney (Neurologist), J Thornton, P Brennan 
(Interventionists), A Leahy, C Kelly (Surgeons) 
New Zealand 
Auckland City Hospital, Auckland [40], J Stewart (Interventionist), PA Barber 
(Neurologist), A Holden (Interventionist), A Hill, R Bourchier (Surgeon) 
Norway 
Rijkshospitalet University Hospital, Oslo [16]: SJ Bakke (Interventionist), M Skjelland 
(Neurologist), K Krohg-Sørensen (surgeon), B Tennøe (Interventionist) 
Poland 
Institute of Psychiatry and Neurology (2nd Department of Neurology & Department of 
Neuroradiology) & Medical University of Warsaw (2nd Department of General, 
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Vascular and Oncological Surgery), Warsaw [20]: A Czlonkowska, J Jedrzewska 
(Neurologists), J Polanski, P Bialek, Z Biejat (Surgeons), A Kobayashi, W Czepiel, M 
Lelek, A Dowzenko (Interventionists) 
Slovenia 
University Medical Centre, Ljubljana [12]: B Zvan (Neurologist), Z Milosevic 
(Interventionist), J Kirbis (Surgeon) 
Spain 
Hospital Clinic, Barcelona [18]: A Chamorro (Neurologist), J Blasco, L San Roman, J 
Macho (Interventionists), V Riambau (Surgeon), V Obach (Neurologist) 
Parc Taulí Sabadell Hospital, Barcelona [33]: D Canovas (Neurologist), Jordi Estela 
(Neurologist), J Perendreu, J Branera (Interventionist), A Gimenez Gaibar  (Surgeon) 
Sweden 
Malmö University Hospital, Malmö [67]: A Gottsater (Neurologist), K Ivancev 
(Interventionist) T Maetzsch (Surgeon), B Sonesson, K Björses (Surgeons and 
Interventionists) 
Sodersjukhuset, Stockholm [55]: P Konrad (Surgeon), T-B Kall (Neurologist), J Formgren, 
M Delle, N Nyman (Interventionists), P Gillgren, R Takolander, B Berg (Surgeons) 
The Karolinska Institute, Stockholm [5]: N Wahlgren (Neurologist), T Andersson, M 
Soderman (Interventionists), J Malmstedt, C Wahlgren (Surgeons) 
Switzerland 
University Hospital Basel, Basel [94]: P Lyrer, ST Engelter, LH Bonati, F Fluri, 
(Neurologists), E-W Radue, AL Jacob, S Wetzel (interventionists), P Stierli, M Wasner 
(Surgeons) 
University Hospital of Geneva, Geneva [16]: R Sztajzel (Neurologist), A Kalangos, N 
Murith (Surgeons), K Lovblad, D Ruefenacht (Interventionists), Christophe Bonvin 
Centre Hospitalier Universitaire Vaudois, Lausanne [12]: P Michel, S Binaghi 
(Interventionist), P Ruchat (Surgeon), L Hirt (Neurologist) 
The Netherlands 
Academic Medical Centre, Amsterdam, Amsterdam [56]: PJ Nederkoorn, YB Roos 
(Neurologists), J Reekers (Interventionist), M Koelemaij (Surgeon) 
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UMC St Radboud, Nijmegen [13]: LJ Schultze Kool, FE De Leeuw (Neurologists), JD 
Blankensteijn, JA van der Vliet (Surgeons) 
Erasmus Medical Centre, Rotterdam [75]: PJ Koudstaal (Neurologist), JM Hendriks, 
MRHM van Sambeek, HJM Verhagen, H van Urk (Surgeons), PMT Pattynama, LC 
van Dijk (Interventionists) 
Isala Klinieken, Zwolle [14]: P Van den Berg (Neurologist), B van Hasselt 
(Interventionist), F de Beer, D Zeilstra (Surgeons) 
The Haga Teaching Hospitals, The Hague [45]: A Mosch, R Keunen, SF de Bruijn  
(Neurologists), CMA Bruijninckx, B Knippenberg, J Wever (Surgeons), H van 
Overhagen , F Treurniet, L van Dijk (interventionists) 
Medical Centre Haaglanden, The Hague [3]: J Boiten (Neurologist), G Lyklama a 
Nyeholt, B van der Kallen (Interventionists), A de Vries, A de Mol van Otterloo 
(Surgeons) 
University Medical Centre, Utrecht [270]: LJ Kapelle (Neurologist), GAP de Kort, TH Lo, 
WPThM Mali (Interventionists), F Moll, H Verhagen, GJ de Borst (Surgeons), HB van 
der Worp (Neurologist) 
United Kingdom 
Birmingham Heartlands Hospital, Birmingham [11]: RA Shinton (Neurologist), P Crowe 
(Interventionist), A Bradbury, M Gannon, L Papp, JM Scriven, T Wilmink (Surgeons), 
Scriven (Neurologist) 
North Bristol NHS Trust, Frenchay Hospital, Bristol [13]: N Baldwin (Stroke Physician), 
L Jones, M Thornton (Interventionists), T Baker, D Mitchell, E Munro (Surgeons) 
Addenbrookes Hospital, Cambridge [5]: P Martin (Neurologist), N Higgins 
(Interventionist), PJ Kirkpatrik, K Varty (Surgeons) 
Western Infirmary, Glasgow [5]: J Moos (Interventionist), KR Lees (Neurologist), RD 
Edwards (Interventionist), AJ MacKay, P Rogers (Surgeons) 
Liverpool Royal Infirmary [21] and The Walton Centre, Liverpool [7]: G Gilling-Smith 
(Surgeon), DA Gould, RG McWilliams, H-C Nasser, PL Harris, JA Brennan 
(Surgeons), JP Enevoldsen, R White (Neurologists) 
University College Hospital, London [51]: MM Brown (Neurologist), R Jaeger, S Brew, J 
Brookes (Interventionists), C Bishop, N Kitchen (Surgeons) 
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Royal Free Hospital, London [1]: G Hamilton (Surgeon), D McCabe (Neurologist), A 
Platts, J Tibballs, N Davis (Interventionists), D Baker (Surgeon) 
St. Mary’s Hospital, Imperial College Healthcare NHS Trust, London [13]: J Chataway 
(Neurologist), M Hammady (Interventionist), I Malik (Cardiologist/Interventionist), 
Nick Cheshire, J Wolfe, M Jenkins, R Gibbs (Surgeons) 
St George’s University of London and St George’s NHS Healthcare Trust, London [58]: 
H Markus, A Pereira (Neurologists), G Cloud (Stroke Physician), A Belli, A Clifton, R 
Morgan (Interventionists), A Halliday, A Thompson, R McFarland (Surgeons) 
Manchester Royal Infirmary, Manchester [2]: G Subramanian (Stroke Physician), KG 
Prakash (Neurologist), F Serracino-Inglott (Surgeon and Interventionist), JV Symth, 
MG Walker (Surgeons) 
University Hospital of South Manchester, Wythenshawe, Manchester [58]: C McCollum 
(Neurologist), P O'Neill (Stroke Physician), GE Gamble (Neurologist), R Ashleigh, S 
Butterfield (Interventionists), A Nasim, J Wong (Surgeons) 
Newcastle Acute Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne [108]: P 
Dorman, SA Dixit, S Louw, M Davis, H Rodgers. (Neurologists) G Ford, A Dyker 
(Stroke Physicians), A Golkar, S Macdonald, J Rose, V Jayakrishnan, R Jackson 
(Interventionists), D Mendelow, G Stansby, M Wyatt, D Lambert, T Lees, M Clarke 
(Surgeons) 
Lancashire Teaching Hospitals NHS Trust, Preston [2]: DM Seriki (Interventionist), R 
Guta, S Punekar (Neurologists), S D'Souza (Interventionist), A Egun, G Thomson 
(Surgeons) 
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield [151]: G Venerables 
(Neurologist), J Beard, D Dodd, R Lonsdale, R Nair, A Nassef, S Nawaz (Surgeons), P 
Gaines, T Cleveland (Interventionists)
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Appendix 6 – The International Carotid Stenting Study Protocol2 
Protocol Summary 
Background: Clinical trials have shown that carotid surgery prevents stroke but also has 
significant morbidity. Stenting has become an established alternative treatment for 
coronary and peripheral vascular disease and has the advantage of avoiding general 
anaesthesia and neck incision. In July 1997, randomisation was completed in the Carotid 
and Vertebral Artery Transluminal Angioplasty Study (CAVATAS). The results did not 
show a difference in the major risks or benefits of carotid angioplasty and surgery, but 
the trial did show that both methods still carry a significant risk of causing a stroke. 
Techniques of carotid angioplasty have improved and stenting is increasingly used. The 
International Carotid Stenting Study (ICSS or CAVATAS 2) is a follow-on study to 
CAVATAS designed as an international, multicentre, randomised trial, which will 
evaluate stenting of carotid artery stenosis in patients with cerebrovascular disease. 
Centre requirements: A neurologist or physician with an interest in stoke; a surgeon 
with expertise in carotid endarterectomy and an interventionalist with expertise in 
carotid angiography and the techniques of angioplasty and stenting.  
Inclusion criteria: Symptomatic atheromatous carotid stenosis, > 50% by NASCET 
criteria, suitable for stenting and surgical endarterectomy. 
Treatments: Patients will be randomised in equal proportions to be treated by carotid 
endarterectomy or stenting. New design of stents, filters and protection devices will be 
incorporated into the study to allow tracking of new technology if approved by the 
Steering Committee. Surgery can be performed with local or general anaesthesia. 
Sample size:  N = 1500 patients from fully enrolled centres. Sample size calculations 
show that the 95% confidence intervals will be ± 3.0 percentage points for the outcome 
measure of 30 day stroke, myocardial infarction and death rate and ± 3.3 percentage 
points for the outcome measure of death or disabling stroke during follow-up.  
Primary outcome measure: Long term survival free of disabling stroke. 
Secondary outcome measures: Any stroke, myocardial infarction or death within 30 days 
of treatment, treatment-related cranial nerve palsy or haematoma. Stenosis (>70%) and 
occlusion on ultrasound follow-up. Transient ischaemic attack. Stroke during follow-up. 
Further treatment procedure. Quality of life and economic measures.  
                                                           
2 The ICSS protocol v3.2 is reproduced in an abridged version in this thesis. 
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Background 
Stroke is the major cause of acquired adult physical disability and is responsible for 12% 
of all deaths in the UK. Reducing the burden of stroke is one of the priorities of the recent 
government white paper, Saving Lives: Our Healthier Nation. In Europe alone, there are 
approximately one million new cases of stroke a year. Atherosclerotic stenosis of the 
carotid artery is an important cause of stroke, which may be heralded by a transient 
ischaemic attack (TIA) or minor stroke, which recovers without serious disability. The 
risk of recurrent stroke in recently symptomatic patients with severe carotid stenosis is as 
high as 28% over two years. The European Carotid Surgery Trial (ECST) and the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) have demonstrated 
convincingly that this risk is reduced significantly by carotid endarterectomy.1,2 Carotid 
surgery has therefore become a standard treatment for these patients. However, the trials 
showed a significant risk of stroke or death resulting from surgery of between 6 and 8%. 
Surgery also caused significant morbidity from myocardial infarction during the general 
anaesthetic used in most centres and minor morbidity, including cranial nerve palsy and 
wound haematoma from the incision. An increasing number of surgeons are performing 
carotid endarterectomy under local anaesthesia in the belief that it reduces the risks, 
although there is currently little evidence to support this practice, until the data from the 
General Anaesthesia versus Local Anaesthesia for Carotid Endarterectomy (GALA) trial 
are reported. 
Stenting is a new method of treating carotid stenosis, which has evolved from the 
technique of percutaneous transluminal angioplasty (PTA). Stenting avoids some of the 
hazards of surgery and has become an established treatment for peripheral and coronary 
artery stenosis. Stenting is less invasive than carotid endarterectomy and has advantages 
in terms of patient comfort, because the procedure avoids an incision in the neck, and is 
usually conducted under local anaesthesia. Hospital stay need only be for 24 hours after 
treatment if uncomplicated. When given the choice, stenting is preferred by many 
patients. On the other hand, stenting does not remove atheromatous plaque, has not been 
shown to prevent stroke and may have an unacceptable incidence of restenosis. We 
therefore propose a multicentre randomised trial to compare carotid stenting with carotid 
surgery. 
Previous work in the field 
 Percutaneous transluminal angioplasty: A number of groups have published series of 
patients with carotid stenosis treated by PTA. The cumulative total of patients in these 
series is over 1000, with a reported major complication rate of less than 5% at the time of 
the procedure.3 These data suggested that carotid PTA has a similar risk to carotid 
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surgery, but the results could not be taken as definitive because none of the data were 
from randomised trials. We therefore started a randomised trial, known as the Carotid 
and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) in l992. We 
completed randomisation in July 1997. 
Results of CAVATAS: 560 patients were entered, from 24 centres in the UK, Australia, 
Canada, Finland, Germany, Italy, Spain, Switzerland, and the USA. Patients with carotid 
stenosis suitable for surgery were randomised between PTA (n=251) and carotid surgery 
(n=253). Patients with carotid stenosis unsuitable for surgery (n=40) and patients with 
vertebral artery stenosis (n=16) were separately randomised between PTA and medical 
care alone. The number of patients in these last 2 groups was too small to form any firm 
conclusions. The analysis has therefore been restricted to the 504 patients with carotid 
stenosis randomised between PTA and surgery.4 Baseline variables were well matched. 
Almost all patients had severe stenosis (mean 86%). The 30-day outcome events were 
almost identical in the two groups with a rate of death or any stroke lasting more than 7 
days of 10.0% after angioplasty and 9.9% after surgery, giving a hazard ratio of 1.01 
(95%CI:0.56,1.81) (NS). Analysis of the other risks of treatment has confirmed that PTA 
was safer than surgery in terms of minor morbidity. Cranial or peripheral nerve palsy 
was reported in 9% of surgical patients, but not in any PTA patients (p<0.0001). 
Haematoma requiring operation or prolonging hospital stay was reported in 7% of 
surgical patients compared with 1% of PTA patients (p<0.0015). PTA also appeared safer 
than surgery with regard to perioperative myocardial infarction, which occurred in 0.8% 
of surgical patients, but not in any PTA patients. Survival analysis from randomisation 
showed no difference in outcome events of ipsilateral stroke and any disabling stroke or 
death during follow up for up to 3 years with very few events in either arm after the 
treatment period, suggesting that both treatments were equally effective at preventing 
stroke. However, 19% of PTA patients had stenosis of >70% or occlusion by ultrasound 
criteria at 12 months after randomisation compared to 5% of surgical patients (p<0.0001). 
Restenosis was not associated with new symptoms, but long-term follow up is limited 
Causes and timing of stroke in CAVATAS: The cause of stroke within 30 days of first 
treatment in CAVATAS was cerebral infarction in 22 patients in the PTA group and 20 
patients in the surgery group. Primary cerebral haemorrhage caused the other three 
strokes in the PTA group and 2 strokes in the surgery group. All but one stroke was 
ipsilateral to the randomised artery. Suprisingly, a significant proportion of these 
treatments related strokes were delayed after the day of treatment. Eight (36%) of the 
strokes in PTA patients occurred between the second and 21st day after treatment. 
Delayed stroke was also found in 6 (27%) of the surgical group between the third and 10th 
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day after operation. Delayed stroke may account for the relatively high rate of 30-day 
morbidity in CAVATAS at 10% compared to 7.5% in ECST and 5.8% in NASCET. 
Carotid stenting: Stents suitable for carotid use have only become available recently. The 
CAVATAS Steering Committee decided to allow the use of stents at the discretion of the 
interventionist. Stents were used in 55 patients randomised to PTA, usually as a 
secondary procedure i.e. after initial balloon dilation. The indication for using a stent in 
these cases was usually an inadequate angiographic result and in some cases stents were 
deployed because of stroke at the time of full balloon inflation, as a ‘bail-out’ procedure. 
Only one stroke occurred at the time of stent deployment (1.8%), although there were a 
small number of delayed strokes after stenting.  
The need for a trial of carotid stenting: It would be inappropriate to use the results of 
CAVATAS to propose the widespread introduction of PTA for the treatment of carotid 
stenosis as an alternative to surgery, because the 95% confidence interval surrounding 
the 10% risk of any stroke within 30 days of treatment in the surgical and angioplasty 
groups is ± 5%. Nevertheless, the results support the need for further randomised 
studies. The interventional technique used to treat carotid stenosis has evolved over the 7 
years since we started CAVATAS, from the use of simple inflatable balloon catheters at 
the beginning of the trial to the increasing use of stenting towards the end of the trial. 
Initially stents were used only as a secondary procedure after full balloon inflation for 
inadequate results or complications of treatment. The desire to prevent these 
complications and superior early results in stented patients has led to the increasing use 
of the technique of primary stenting in which the intention is to deploy a stent in every 
patient before dilation (but after pre-dilatation to allow the atraumatic passage of the 
stent) of the artery5. Primary stenting is now accepted as best practice5 and has become 
the radiological technique of choice for carotid stenosis, replacing balloon angioplasty. 
Advantages of carotid stenting: The majority of major strokes after carotid PTA are the 
result of dissection of the carotid artery at the time of balloon inflation with subsequent 
thrombosis. It is believed that stenting is safer than simple balloon angioplasty because 
embolisation, dissection and closure of the carotid artery are less likely to occur.6,7 The 
subgroup analysis of stented patients in CAVATAS is consistent with this suggestion. 
The adverse consequences of dissection are minimised, because the stent maintains 
laminar flow across the stenosis and seals the site of dissection, preventing a free intimal 
flap. In addition, the stent mesh limits the size of any thrombus or atheromatous debris 
that may be dislodged from the plaque at the time of dilation of the artery. Superior 
dilation achieved by stenting compared with balloon angioplasty may also reduce the 
rate of stroke in the early post-treatment period. In the coronary circulation, stenting has 
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been shown to produce superior outcomes compared with balloon angioplasty.8,9 
Individual case series suggest that carotid stenting has a similar rate of procedural stroke 
to that of carotid surgery,6,7 while a recent registry reported a total of 2,048 patients from 
24 centres undergoing carotid stenting with a complication rate of stroke and death 
within 30 days of treatment of 5.8%.10 
Disadvantages of carotid stenting: Although acceptable safety at the time of stenting has 
been suggested by the case series and registry data, stenting has not been subjected to a 
randomised trial in comparison to conventional surgical treatment and has not been 
demonstrated to prevent stroke, which is the aim of treatment. Stenting does not remove 
atheromatous plaque and stents may stimulate neo-intimal hyperplasia. In the long term 
it is likely that the rate of restenosis will be greater after stenting than after carotid 
surgery, which could well result in an unacceptable rate of long-term stroke recurrence. 
There is an important need to establish the efficacy of carotid stenting in comparison to 
surgery before the technique is widely introduced without adequate trial based evidence.        
Antiplatelet therapy: In cardiological practice, ischaemic complications during coronary 
stenting have been shown to be significantly reduced by using a combination of two 
antiplatelet agents, ticlopidine and aspirin. In one coronary trial, stent thrombosis was 
reduced from 3.6% in patients assigned aspirin alone down to 0.5% in patients assigned 
aspirin and ticlopidine.11 A recently completed trial has shown that similar results with 
less risk of side effects can be achieved during coronary stenting by using the 
combination of clopidogrel with aspirin.12 It is likely that this combination would also 
reduce the risks of stroke during carotid stenting. A pilot study is currently being carried 
out at one of the centres to establish the safety of the combination of clopidogrel and 
aspirin given before and for 30 days after carotid stenting. It is likely that this will 
become standard therapy. Most surgeons currently believe that combination antiplatelet 
therapy during surgery is hazardous because of excess bleeding. 
Economic and quality of life considerations: Quality of life and general health status were 
assessed in CAVATAS using the SF36 and EuroQol EQ-5D questionnaires. These showed 
a similar quality of life for patients randomised to either treatment. Operating and 
radiology suite costs were similar in a sample of patients at two UK centres, but surgery 
was associated with a longer hospital stay and greater use of ITU beds. Surgery was 
therefore considerably more expensive than angioplasty (mean difference £946).13 
However, the mean cost of an angioplasty increased from £1086 to £1864 if a stent was 
used. The use of stents in every case is therefore likely to increase the costs of stenting 
close to that of surgery, but this might be counterbalanced by performing carotid stenting 
as a day case procedure. Surgical length of stay is also declining. Follow up costs might 
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be very different if restenosis is more frequent in one arm. Economic analysis will 
therefore be an important component of ICSS. 
Aims of ICSS 
To compare the risks, benefits and cost effectiveness of a treatment policy of referral for 
carotid stenting compared with referral for carotid surgery. 
Trial design  
ICSS is an international, multicentre, randomised, controlled, open, prospective clinical 
trial comparing carotid surgery with carotid stenting. 
Participating centre requirements 
Each centre must have a neurologist or physician with an interest in stroke who will see 
patients prior to randomisation and for follow up. Carotid endarterectomy must be 
carried out by designated surgeons with expertise in the operation. Carotid stenting will 
be carried out by designated consultant interventionists with expertise in carotid 
angiography and the techniques of angioplasty and stenting. Good collaboration between 
the neurologists, surgeons and interventionists is essential and centres should have 
regular neurovascular meetings. Attendance at training sessions in carotid stenting 
provided by credentialing centres will be required for all interventionists prior to 
participation. Participating centres will be required to submit curriculum vitae for all 
participating clinicians and an audit of recent carotid surgery and PTA/stenting results. 
An accreditation committee will decide if they have appropriate experience and expertise 
to join the study. As a guide, surgeons and interventionists will be expected to show a 
stroke and death rate within 30 days of treatment, consistent with the centres in ECST 
who had an average rate of 7.0% with a 95% confidence interval of 5.8 to 8.3%.1 Surgeons 
will be expected to have performed a minimum of 50 carotid operations with a minimum 
annual rate of at least 10 cases per year. Interventionists will similarly be expected to 
have performed a minimum of 50 stenting procedures, of which at least 10 should be in 
the carotid territory. Centres where there is little or no experience of carotid stenting may 
join ICSS for a probationary period in order to gain the minimum experience of ten 
carotid stenting procedures required to join the trial fully. The results in patients 
randomised during the probationary period will be analysed separately. 
All centres will have to provide proof of Ethical Committee Approval for the study 
before commencing randomisation.  
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Probationary centres  
Probationary centres will be required to fulfil all the other requirements for entry, but 
will not have to provide audited data on ten carotid stenting procedures initially. 
Probationary centres will randomise patients within the ICSS protocol between surgery 
and stenting. Individual interventionists who are not able to satisfy the credentialing 
requirements will be identified as probationary investigators. Stenting procedures carried 
out during the probationary period must be proctored by an experienced carotid 
interventionist, until the proctor is satisfied that the interventionist(s) at the centre can 
satisfactorily carry out procedures unproctored. Probationary interventionists will 
become fully enrolled in ICSS when both the proctor is satisfied that the interventionist 
can perform procedures unsupervised and the interventionist has 10 or more successfully 
completed cases in the trial, with an acceptable complication rate. When an investigator 
has done sufficient successful procedures, the trial office will get comments from the 
relevant proctor, and then have any decision to promote the investigator or centre signed 
off by the chair of steering committee. 
Proctoring  
Proctors for probationary centres will be approved by the accreditation committee in 
consultation with the probationary centre via the central ICSS office. Probationary centres 
may suggest an appropriate proctor, but he or she will require prior approval from the 
accreditation committee, based on review of the proctor’s experience of carotid stenting. 
It is the responsibility of the probationary interventionist to make contact with an 
approved ICSS proctor and to ensure a convenient date is organised for the stenting 
procedure at which the proctor can be present.  Copies of the relevant radiology should 
be available for the proctor for review prior to starting the stenting procedure. This 
should be done prior to randomisation if there was any doubt about the suitability of the 
patient for stenting. In the event of a centre requiring proctoring for surgery the same 
procedure will apply. 
It is the responsibility of the probationary interventionist and the proctor in discussion to 
ensure the lesion is appropriate for treatment (e.g. sufficiently severe), that the patient 
has received appropriate premedication (e.g. a combination of clopidogrel and aspirin) 
and that the lesion is suitable for stenting. They should agree the type, range and sizes of 
equipment required and the probationary interventionist should ensure that this 
equipment is available to complete the procedure. If any of these conditions are not met, 
the procedure should be abandoned and if appropriate rescheduled for another occasion. 
Catheter or arch angiography is not required in ICSS prior to randomisation if the centre 
does not routinely perform angiography prior to treatment.  However, the centre 
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interventionist, the proctor and the patient should be aware that if preliminary 
angiography at the time of planned stenting shows a lesion which is not suitable for 
stenting, the procedure should be abandoned and the patient referred for surgery, or 
continued medical management.  This type of cross over is envisaged in the trial design.  
Where a centre has an adequately qualified surgeon and interventionist they may 
supervise surgeons and interventionists at the same centre whose experience would not 
initially qualify them for the trial until they have gained sufficient experience.  These new 
investigators must enrol with the central ICSS office (see participating centre 
requirements). 
Inclusion criteria  
• Symptomatic, extracranial, internal or bifurcation, atheromatous carotid artery 
stenosis that is suitable for both stenting and surgery and is deemed by the 
randomising clinician to require treatment.  
• The severity of the stenosis of the randomised artery should be at least 50% (as 
measured by NASCET method or non-invasive equivalent). 
• Symptoms must have occurred in the 12 months before randomisation. It is 
recommended that the time between symptoms and randomisation should be 
less than 6 months, but patients with symptoms occurring between 6 and 12 
months may be included if the randomising physician considers treatment 
indicated.  
• The patient must be clinically stable following their most recent symptoms 
attributable to the stenotic vessel.  
• Patients must be willing to have either treatment, be able to provide informed 
consent, and be willing to participate in follow up.   
• Patients must be able to undergo their allocated treatment as soon as possible 
after randomisation.  
• Any age greater than 40 may be included. There is no upper age limit. 
• Patients should only be randomised if the investigator is uncertain which of the 
two treatments is best for that patient at that time.  
Exclusion criteria 
• Patients refusing either treatment. 
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• Patients unable or unwilling to give informed consent. 
• Patients unwilling or unable to participate in follow up for whatever reason. 
• Patients who have had a major stroke with no useful recovery of function within 
the territory of the treatable artery. 
• Patients with a stenosis that is known to be unsuitable for stenting prior to 
randomisation because of one or more of: 
• Tortuous anatomy proximal or distal to the stenosis 
• Presence of visible thrombus 
• Proximal common carotid artery stenotic disease 
• Pseudoocclusion (‘string sign’). 
• Patients not suitable for surgery due to anatomical factors e.g. high stenosis, rigid 
neck. 
• Patients in whom it is planned to carry out coronary artery bypass grafting or 
other major surgery within 1month of carotid stenting or endarterectomy. 
• Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, 
fibromuscular disease or neck radiotherapy.  
• Previous carotid endarterectomy or stenting in the randomised artery. 
• Patients in who common carotid artery surgery is planned. 
• Patients medically not fit for surgery. 
• Patients who have a life expectancy of less than two years due to a pre-existing 
condition, e.g. cancer. 
Non-randomised patients 
An anonymised log will be kept of patients undergoing treatment for carotid stenosis by 
the trial investigators but not randomised at the participating centres. Patients 
undergoing stenting but not randomised should also be included on a suitable registry, 
such as EUROCAST. 
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Consent 
Written witnessed, informed consent will be obtained from all patients and a copy must 
be retained by the randomising centre. All patients will be provided with a written 
explanation of the study. 
Randomisation 
Randomisation will be by a telephone call or fax to a computerised service provided by 
the Oxford Clinical Trials Service Unit. Randomisation will be stratified by centre with 
minimisation of the main risk factors and balanced between the arms. Patients who need 
treatment of both carotid arteries will only be randomised for the carotid artery to be 
treated first. Patients can only be randomised once. 
Investigations before randomisation 
The following investigations are required: Routine haematology (FBC, platelets), blood 
biochemistry (renal function, blood sugar, cholesterol), chest x-ray, ECG, brain CT or MRI 
scans. The brain scan is required to exclude other pathology, to identify existing infarcts 
and to provide a baseline reference against which any subsequent infarction or 
haemorrhage can be assessed. Copies of the CT or MRI scans should be sent to the ICSS 
office. 
Carotid imaging 
Mandatory investigation is required for entry into the study to confirm the presence and 
severity of the ipsilateral stenosis and to assess contralateral carotid disease. The 
following are acceptable: 
1. Arch arteriogram showing both carotid bifurcations,  
2. Selective catheter carotid angiography showing the randomised carotid artery 
with non-invasive investigation of the contralateral carotid bifurcation. 
3. Bilateral magnetic resonance carotid angiograms together with a concordant 
ultrasound scan.  
4. Bilateral spiral CT angiograms together with a concordant ultrasound scan.  
5. Bilateral duplex and Doppler ultrasound scan, only if this is standard practice to 
treat on the basis of ultrasound alone in individual centres and the centre has 
been able to provide proof of the reliability of their ultrasonographic imaging 
through clinical audit. 
The following data from the pre-randomisation imaging will be sent to the Central Office 
for review: 
1. A copy of the written reports of the studies. 
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2. A film copy of the view of the vessel to be treated showing the stenosis at its 
most severe. 
3. A film copy of the view of the contralateral vessel showing any stenosis at its 
most severe. 
4. Velocity data from the ultrasound examination. 
Patients who are randomised to stenting after ultrasound or other non-invasive 
investigation, in which subsequent angiography, prior to stenting, reveals one or more 
exclusion criteria should be treated by surgery, if appropriate, or medical care only if 
surgery is not appropriate (e.g. because the stenosis is less than 50%). These patients will 
continue follow up in the trial and will be analysed on an intention to treat basis. A 
similar approach should be taken to patients randomised to surgery in whom 
contraindications to surgery emerge after randomisation. 
Ultrasound 
Ultrasound study of the carotid artery to be treated will be performed at or before 
randomisation, at one month after treatment and then annually after randomisation in all 
patients. The following information is required for each study: Peak systolic velocity of 
internal carotid artery (PSV ICA), end diastolic velocity of internal carotid artery (EDV 
ICA), peak systolic velocity of common carotid artery (PSV CCA). The accuracy of 
individual ultrasound laboratories will be audited by comparing the pretreatment 
ultrasound examination against catheter angiography films, which will be available in 
patients randomised after angiography and in all the patients treated by stenting. 
Baseline data 
Baseline data collected at randomisation will include demographic data; existing medical 
risk factors; neurological symptoms including an assessment of disability using the 
Modified Rankin Scale; current antiplatelet therapy and blood pressure. Films and/or 
reports of pre-randomisation imaging as detailed above and in all cases the results of 
Doppler ultrasound as detailed below are required to allow assessment of any 
subsequent stenosis. 
Baseline assessment  
Patients will be seen by the study neurologist or physician interested in stroke prior to 
randomisation to confirm suitability for the study. 
Stenting protocol 
Stenting will be carried out as soon as possible after randomisation using percutaneous 
transluminal interventional techniques from the femoral, brachial or common carotid 
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artery by a designated interventional consultant using an appropriate stent. A cerebral 
protection system should be used whenever the operator thinks one can be safely 
deployed. Stents and other devices used in the trial must be CE marked and approved by 
the Steering Committee. Pre-medication will be discretionary. The combination of aspirin 
and clopidogrel is recommended as the antiplatelet regime of choice to cover the period 
of stenting and for a minimum of 4 weeks afterwards. Intra procedural heparin is 
mandatory at a dose determined by the operator, post procedural heparin may be given 
according to clinical requirements. Patients should be monitored for changes in their 
neurological status and heart rate throughout the procedure. If femoral or brachial access 
is being used a long sheath introducer or a guiding catheter is placed in the common 
carotid artery allowing pre-dilation and stent placement under direct arteriographic 
imaging. Atropine, or a similar agent, must be administered prior to stent deployment to 
counteract any effects on the carotid artery baroreceptors, which could lead to severe 
bradycardia and / or asystole. Virtually all patients will require pre-dilatation of the 
stenosis by balloon angioplasty prior to stent deployment. This will minimise the embolic 
load caused by passage of the endoluminal stent through the stenosis. The size of the pre-
dilatation balloon will be determined by the size of the delivery system being used. 
Further balloon dilation of the stent will usually be required to ensure apposition of the 
stent against the arterial wall.  Angiographic images showing the stenosis at its most 
severe prior to stenting and the same view and any other view that demonstrates the 
maximum residual stenosis after stenting must be sent to the Central Office. Details of the 
procedure, including all peri-procedural complications, drug therapy and devices used in 
the procedure, must be reported and the stenting and cerebral protection technical data 
sheet returned to the trial Central Office. 
Endarterectomy protocol 
Endarterectomy is to be done as soon as possible after randomisation by a designated 
consultant surgeon who has been approved by the Credentials Committee. It is to be 
carried out using whichever procedures are standard at the individual centre, including 
the use of local or general anaesthesia, shunts or patches as required by the operating 
surgeon. Standard or eversion endarterectomy may be performed. 
Reporting of suspected problems with surgical or stenting techniques at individual 
centres 
If the local investigator, or other member of the team, at a trial centre has concern about 
the outcome of their trial procedures, they should inform the ICSS trial office, which will 
organise a blinded assessment of the relevant outcome events. This will be submitted by 
the central office to the chairman of the data monitoring committee who may recommend 
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further action, such as suspending randomisation at the centre. Similarly, the database 
manager at the trial office will monitor outcome events and if there are two consecutive 
deaths or three consecutive major events at a single centre within 30 days of treatment in 
the same arm of the study, then assessment of the events will be triggered. A cumulative 
major event or death rate of more than 10% over 20 cases would also trigger careful 
assessment of the relevant outcome events.  
Medical treatment  
All patients will receive best medical care including antiplatelet therapy or 
anticoagulation (when appropriate) and control of medical risk factors such as 
hypertension, smoking and hyperlipidaemia before treatment and throughout the period 
of follow up. 
Prevention of thrombosis 
Therapy to prevent thrombosis during or soon after surgery or stenting will be 
prescribed according to standard practice in each centre. This may include heparin, 
dextran, aspirin, dipyridamole, ticlopidine, clopidogrel, or a combination of aspirin and 
another antiplatelet agent. Glycoprotein IIb/IIIa antiplatelet receptor antagonists will not 
be used routinely. 
Follow up 
Patients will be followed up by a neurologist or a physician interested in stroke at the 
participating centres at 30 days after treatment, 6 months after randomisation and then 
annually after randomisation. All post-procedural complications occurring within thirty 
days after the procedure will be reported to the central office at the 30 day follow up. At 
each visit, levels of stroke related disability will be assessed using the modified Rankin 
Scale and any relevant outcome events will be notified to the Central Office. A Doppler 
ultrasound will be used to measure carotid arterial diameter to assess patency at one 
month after treatment and then annually after randomisation. In addition, ultrasound re-
examination and CT or MRI scan should be performed in-patients who have any 
transient ischaemic events and / or stroke during follow up.  The duration of follow up 
will be a minimum of 5 years (or until termination of the trial if earlier).  At the 5 year 
follow up, patients will be asked if they are willing to continue follow up, in which case 
annual follow up will continue up to a maximum of 10 years from randomisation. 
Sample size calculations and recruitment 
The planned sample size is 1500. We do not anticipate any large difference in the 
principal outcome between surgery and stenting. We propose to estimate this difference 
and present a confidence interval for difference in 30-day death, stroke or myocardial 
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infarction and for three-year survival free of disabling stroke or death. For 1500 patients, 
the 95% confidence interval will be the observed difference ± 3.0 percentage points for the 
outcome measure of 30 day stroke, myocardial infarction and death rate and ± 3.3 
percentage points for the outcome measure of death or disabling stroke over three years 
follow up. However, the trial will have the power to detect major differences in the risks 
of the two procedures, for example if stenting proves to be much riskier than surgery or 
associated with more symptomatic restenosis. The difference detectable with power 80% 
are 4.7 for 30 day outcome and 5.1 percentage points for survival free of disabling stroke. 
Similar differences are detectable for secondary outcomes. We expect to achieve this 
recruitment within 6 years. 
Principal research questions to be addressed 
Primary analysis 
• What is the difference in the long-term rate of fatal or disabling stroke in any 
territory of patients with severe symptomatic stenosis after randomisation to a 
policy of carotid stenting compared to surgery? 
Secondary analysis 
• What are the differences in mortality and morbidity within 30 days of carotid 
stenting compared to surgery? 
• What is the rate of symptomatic and asymptomatic restenosis after carotid 
stenting compared to surgery? 
• What are the differences in the rate of ipsilateral stroke during follow-up after 
carotid stenting compared to surgery? 
• What is the cost-effectiveness of carotid stenting compared to surgery? 
• What are the risk factors for stroke within 30 days and during long term follow 
up (including those related to age, gender, symptoms, imaging, centre and 
technique)? 
Outcome events  
• Any stroke or death. 
• Transient ischaemic attack. 
• Myocardial infarction within 30 days of treatment.  
• Cranial nerve palsy within 30 days of treatment. 
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• Haematoma caused by treatment requiring surgery, transfusion or prolonging 
hospital stay. 
• Stenosis greater than 70% or occlusion during follow up. 
• Further treatment of the randomised artery by interventional radiology 
techniques or surgery after the initial attempt. 
• Quality of life, health status and Health Service costs (see paragraph below). 
Outcome event reporting  
Outcome events will be documented in detail by the investigating centre, censored after 
receipt at the central office to remove clues as to the treatment received, and then 
adjudicated by an independent neurologist. Patients suffering stroke should have a CT or 
MRI brain scan as soon as possible after the event. A film copy of this, together with a 
film copy of the pre-randomisation scan (if done) should be submitted together with a 
report of the event. The event report should include copies of discharge summaries; 
death certificates and post mortem results if relevant. Deaths of UK patients will be 
tracked by flagging patients against the UK Registry of Births and Deaths. Disability after 
stroke and cranial nerve palsy will be assessed 30 days and six months after treatment or 
onset, using the Modified Rankin scale. Duration of symptoms will be recorded and 
outcome events will be classified as disabling if the Rankin score is 3 or more at six 
months. 
Learning curve 
Carotid stenting is a new procedure, while the techniques of carotid surgery are well 
established. It is likely that there will be a learning curve for carotid stenting and the 
results may improve with experience during the trial. However, we believe it is better 
that carotid stenting should be performed as part of a randomised clinical trial at this 
stage of its development, because this will ensure careful assessment and follow up of all 
patients treated in the trial and supervision from the Data Monitoring and Ethics 
Committee ensures that continuing treatment with the new technique remains ethical. 
The influence of the early part of the learning curve for carotid stenting will be limited by 
careful training of individual interventionists. The total experience of carotid PTA and 
stenting of individual interventionists will be recorded prior to entry into the trial. This 
will allow the average duration of the learning curve to be analysed, taking into account 
the current experience of the individual interventionists. This information may have 
implications for interpretation of the results of the trial and for the future training and 
supervision of the procedure. Similarly, there may be improvements in individual 
surgical or anaesthetic techniques during the trial. 
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Effect of changes in technology during the course of the study 
The field of carotid stenting is an area of fast changing technology. The protocol does not 
at present specify the type or manufacturer of the stents or protection devices to be used, 
but devices to be used in the trial will be CE marked and approved by the Steering 
Committee who will expect a peer reviewed report of device safety. More than one 
device may be recommended to allow the interventionist to tailor the choice of stent to 
the individual stenosis and to use new designs of stent or protection devices if 
appropriate. The protocol will not specify the technique to be used during carotid 
surgery. Decisions about the use of shunts or specific suture materials will be left to the 
individual surgeon. Local or general anaesthesia will be allowed in both arms. Technical 
details of surgical and stenting technique, including the manufacturer and type of stent 
used, the use of local or general anaesthesia, and the use of antithrombotic agents, will be 
recorded. The analysis will include a subgroup comparison of different techniques in 
both arms and the data will be presented to the DMC meetings to ensure that no one 
technique is significantly inferior to another. Randomisation will use a computer 
programme to minimise variation between centres and over time, so that equal numbers 
of patients will be entered into the stenting and surgery arms before and after any change 
in practice. 
Health service research issues 
If the trial confirms the hypothesis that carotid stenting and surgery are equivalent in 
terms of the major risks of stroke and death, then the choice between the two procedures 
will be determined primarily by differences between the two procedures in other 
outcomes e.g. the disadvantage of a scar or cranial nerve palsy, or the effects of surgery 
on health related quality of life. If these differences are minor, the choice between the 
procedures will be made primarily on economic grounds. The effects of cranial nerve 
palsy may be detected by a minor increase in the disability score, but it is not easy to 
assess the effect of these outcomes during follow up on clinical examination alone. 
Quality of life and health status will therefore be assessed using the EuroQol (EQ5D) 
questionnaire14 to compare patients’ feeling of well-being, health and quality of life before 
and after stenting or surgery at one month, six months and annual follow up. The results 
will be analysed blind to treatment arm. The first questionnaire will be completed at the 
time of randomisation and subsequent questionnaires at each follow-up visit. The 
investigator performing randomisation or follow-up should ensure the patient completes 
the EQ5D at the same time. The English language version of the EQ5D has been modified 
to record the date on which it is completed and the patients trial number. Those centres 
using versions in other languages should also record the date and trial number on each 
completed form.  If patients are too disabled to complete the questionnaires themselves, 
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the patient’s carer may complete them. The EQ5D should be returned to the central office 
with the other trial forms. 
Information on hospital resource use during the treatment and follow up, including the 
type and manufacturer of the devices employed in carotid stenting procedures, will be 
collected to measure treatment costs and estimate the costs of stroke and any 
consequences of restenosis (e.g. retreatment) during follow up. Unit costs will be 
obtained from a sample of representative centres.  The costs of stroke caused by 
treatment are a major component of the total cost of treatment, and therefore have a 
major influence on cost effectiveness. As the additional length of stay in hospital 
resulting from stroke largely drives these costs, the prospective collection of length of 
stay data will be designed to capture the stroke-related data in addition to direct 
operative stay. The economic evaluation will address cost-effectiveness and cost-utility 
(cost per QALY). The latter will be estimated from patients’ responses to the EuroQol 
(EQ-5D) questionnaires using the York MVH tariff. Uncertainty regarding specific 
parameters within the analysis will be subjected to a sensitivity analysis, and uncertainty 
around the point estimate of the cost utility ratio will be represented using cost-
effectiveness acceptability curves. To inform the economic analyses, the preferences of 
potential patients and clinicians between carotid endarterectomy and carotid stenting 
given various differences in outcomes will be explored using the technique of conjoint 
analysis (discrete choice experiments).  A sample of members of the general population 
(matched to the ICSS patients) and clinicians will be asked to complete a questionnaire 
after completion of randomisation, informed by the preliminary safety results.  
Preliminary work, structuring and piloting the conjoint analyses, will be undertaken 
earlier. 
Stenosis after treatment 
Patency of the carotid artery will be monitored by Doppler ultrasound at a minimum of 
30 days after treatment and then annually after randomisation. Restenosis should only be 
treated by further angioplasty or surgery if the patient has relevant new symptoms. 
Restenosis is usually the result of smooth muscle hypertrophy or neo-intimal 
hyperplasia, rather than recurrence of atherosclerosis and hence may not cause embolic 
stroke. Asymptomatic restenosis will not be an indication to retreat the lesion because the 
risk of disabling symptoms after restenosis is not known. 
Crossovers 
Crossovers before any attempt to treat the randomised artery by the allocated treatment 
will be avoided unless clinically essential, because the trial data will be analysed by 
intention to treat. Patients who are randomised to stenting after ultrasound or other non-
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invasive investigation, in whom subsequent angiography prior to stenting, reveals one or 
more exclusion criteria should be treated by surgery, if appropriate, or medical care only 
if surgery is not appropriate (e.g. because the stenosis is less than 50%). These patients 
will continue follow up in the trial and will be analysed on an intention to treat basis. A 
similar approach should be taken to patients randomised to surgery in whom 
contraindications to surgery emerge after randomisation. Patient refusal of the treatment 
to which they are randomised can be minimised by careful consent. Patients requiring re-
treatment because of further symptoms should be re-treated with whichever treatment is 
most appropriate. This is also the case if the non-randomised carotid artery requires 
treatment. Patients in whom an attempt at stenting fails may proceed to early surgery if 
appropriate and vice versa. 
Data analysis 
The data will be analysed by intention to treat using standard statistical tests by the trial 
statistician. The analyses will compare the treatment groups with respect to the length of 
time before treatment failure (i.e. occurrence of an outcome event) by means of the 
Mantel-Haenszel chi-squared test and Kaplan-Meier survival curves. Secondary analysis 
will compare the proportions of outcome events within 30 days of treatment. All analyses 
will be adjusted for centre and predetermined risk factors. Subgroup analyses will 
examine risk factors for outcome events and will examine the influence of different 
devices, surgical techniques and experience within the trial. Results at probationary 
centres will be analysed separately.  The results of any interim data analysis will remain 
confidential to the trial statistician and Data Monitoring Committee until after 
completion or early discontinuation of the trial. Investigators and the Steering Committee 
will remain blind until such point. 
Publication 
Publication of the results of ICSS will be prepared by the Central Office and circulated to 
participating centres for comment prior to submission of the manuscript for publication 
on behalf of all the ICSS collaborators. 
Ethical Committee approval 
Multicentre Research Ethics Committee approval will be sought in the UK. In addition, 
individual centres are expected to obtain local ethical committee approval for the study.  
Data Monitoring Committee 
The safety aspects of the trial will be overseen by a Data Monitoring Committee 
consisting of an independent neurologist, medical statistician surgeon and 
interventionist. The progress of the study will be assessed at regular intervals determined 
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by the Data Monitoring Committee. During the period of intake to the study, interim 
analyses of mortality and of any other information that is available on major endpoints 
(including serious adverse events believed to be due to treatment) will be supplied, in 
strict confidence, to the chairman of the Data Monitoring Committee, along with any 
other analyses that the Committee may request. In the light of these analyses, the Data 
Monitoring Committee will advise the chairman of the Steering Committee if, in their 
view, the randomised comparisons in ICSS have provided both (i) "proof beyond 
reasonable doubt" that for all, or for some, specific types of patients, one particular 
treatment is clearly indicated or clearly contraindicated in terms of a net difference in 
outcome, and (ii) evidence that might reasonably be expected to influence materially 
patient management. Appropriate criteria of proof beyond reasonable doubt cannot be 
specified precisely, but a difference of at least 3 standard deviations in an interim analysis 
of a major endpoint may be needed to justify halting, or modifying, the study 
prematurely. This criterion has the practical advantage that the number of interim 
analyses is of little importance.  
Steering Committee 
Steering Committee Committee, consisting of individuals participating in and 
independent of the trial with experience in stroke medicine, neurology, vascular surgery, 
vascular radiology, interventional neuroradiology, health economics, clinical trials and 
statistics, will oversee the management of the trial. 
Trial organisation 
The study will be organised on behalf of the collaborators by the central office, located at 
the UCL Institute of Neurology in London. The office will be responsible for protocol 
design, data collection and management, and analysis of the results in consultation with 
the Steering and Data Monitoring Committees, but will consult with the collaborators at 
an annual meeting and at other times as necessary. Communication with investigators 
will also take place via a regular newsletter and the trial website. 
Payments to centres 
While funding is available, the Lead Institution (UCL Institute of Neurology, London) 
will pay the participating centres a one-off payment of £100 for each patient randomised 
patient for whom correctly filled-out randomisation, technical data and one month 
follow-up forms have been received. Participating centres must invoice to the Lead 
Institution within 6-months of receipt of this revised protocol and thereafter 6 monthly in 
arrears. The Lead Centre may vary or terminate such payments in the future in 
accordance with budgetary needs and will inform the participating centre of such 
changes as they occur. 
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Indemnity 
ICSS is an academic trial performed as a collaborative effort for the benefit of patients, 
and is not performed for, or on behalf of an industry sponsor. The trial compares two 
existing forms of treatment currently used in many hospitals. The various devices 
approved for use in the trial are not investigational devices and are required by the 
protocol to be marketed and already in use in the carotid artery as recognised by the CE 
mark. Hence, the trial is not an industry sponsored test of a new treatment with 
unknown hazards. The trial protocol anticipates that some patients may be harmed 
inadvertently as a result of treatment in the trial. Indeed, the determination of the rate of 
these adverse outcome events is a major aim of the trial. However, we believe that the 
risks of these adverse events will be outweighed by the benefits of treatment in either 
arm of the trial. The trial protocol does not subject patients to hazards that the patient 
would not have encountered if they had received the trial treatments outside the context 
of the trial in routine practice. Hence, the organisers of the trial cannot take responsibility 
for any harm occurring to patients as a result of partaking in the trial. Individual 
investigators and hospitals are required to take responsibility for the occurrence of any 
adverse events in the same way as they would do if the treatments were performed 
outside the trial. 
Website  
The trial website contains updated information about the trial together with 
downloadable copies of the protocol, trial data collection forms, newsletters and contact 
information. The names of the collaborating centres will be included on the website. The 
website address is www.cavatas.com and all the pages are accessible to the public, 
patients and collaborators alike without a password. At present, the data collection forms 
cannot be completed on line. 
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Definitions of Outcome Events 
• Transient ischaemic attack (TIA): An acute disturbance of focal neurological 
function with symptoms lasting less than 24 hours attributed to cerebrovascular 
disease. 
• Transient monocular blindness (Amaurosis fugax): Acute total or partial loss of 
vision in one eye with recovery within 24 hours attributed to vascular disease. 
This will be included as a variety of TIA. 
• Stroke: An acute disturbance of focal neurological function with symptoms 
lasting more than 24 hours resulting from intracranial vascular disturbance. It 
must be established whether the cause is infarction or haemorrhage (primary 
intracranial or subarachnoid). Visual loss resulting from embolic or 
haemodynamic retinal ischaemia lasting more than 24 hours will be included 
within the category of stroke. 
• Myocardial Infarction: Two of the following have to be documented: specific 
cardiac enzymes more than twice the upper limit of normal, a history of chest 
discomfort for at least half an hour, or the development of specific abnormalities 
(e.g. Q waves) on a standard 12 lead electrocardiogram. 
• Cranial Nerve Palsy: weakness or sensory impairment in the distribution of one 
of the cranial nerves attributed to treatment. 
• Haematoma: bleeding attributed to the treatment of carotid narrowing requiring 
new surgery, transfusion or prolonging hospital stay. 
• Disabling Outcome Events: disability after stroke and cranial nerve palsy will be 
assessed using the Modified Rankin scale (defined below). Outcome events will 
be classified as disabling if the Rankin score is 3 or greater for more than 30 days 
after onset. The Rankin scale will be recorded at one and six months after 
treatment and then at annual follow up. Investigators will be asked to estimate 
the Rankin scale at one and six months after onset of new stroke when they see 
the patient more than 6 months after onset of stroke. 
• Recovered strokes: in patients who make a full recovery from stroke or other 
outcome events, the duration from onset to full recovery will be recorded in 
days. 
• Modified Rankin Scale: The following modified Rankin scale will be used to 
assess residual disability from stroke at randomisation to establish a baseline 
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level of disability and at every follow up visit to assess the severity of any 
subsequent stroke: 
0 Asymptomatic. 
1 Non-disabling symptoms which do not interfere with lifestyle. 
2 Minor disability - symptoms which lead to some restriction of lifestyle  
but do not interfere with the patient’s capacity to look after themselves. 
3 Moderate disability – symptoms which significantly interfere with lifestyle 
or prevent totally independent existence, but able to walk without assistance. 
4 Moderately severe disability – symptoms which clearly prevent independent 
existence, unable to walk without assistance, although the patient does not 
need constant attention day and night. 
5 Severely disabled – totally dependent requiring constant attention day and 
night. 
6 Dead. 
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